
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:91a5880f-2711-461e-9d6e-108d0526bb27,g:a0103916-348c-4ecd-b1a4-0a8fdd2852a9,d:75d4456fb1ed409bb59167bcf5c6f56b--><meta http-equiv="Content-Type" content="text/html">


<title>alpn-20211231</title><div style="display:none"><ix:header><ix:hidden><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityCentralIndexKey" id="fact-identifier-0" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl80L2ZyYWc6OGQ5MmMwZTc4NGI0NGFjMmE0ODc2NTg4YmM4YmU5MjQvdGFibGU6NGNjNTg5NWE4OGY5NDc4ZGEzYzYxOWMxOWQwYWM0NjcvdGFibGVyYW5nZTo0Y2M1ODk1YTg4Zjk0NzhkYTNjNjE5YzE5ZDBhYzQ2N18zLTEtMS0xLTI2NjM1_2d0de862-d739-4f5a-8dee-6242b36dee9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001626199</ix:nonnumeric></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="fact-identifier-1" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl80L2ZyYWc6OGQ5MmMwZTc4NGI0NGFjMmE0ODc2NTg4YmM4YmU5MjQvdGFibGU6NGNjNTg5NWE4OGY5NDc4ZGEzYzYxOWMxOWQwYWM0NjcvdGFibGVyYW5nZTo0Y2M1ODk1YTg4Zjk0NzhkYTNjNjE5YzE5ZDBhYzQ2N181LTEtMS0xLTI2NjM1_9298d4ca-d410-49d7-bac8-d22a14cf8b34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="fact-identifier-2" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl80L2ZyYWc6OGQ5MmMwZTc4NGI0NGFjMmE0ODc2NTg4YmM4YmU5MjQvdGFibGU6NGNjNTg5NWE4OGY5NDc4ZGEzYzYxOWMxOWQwYWM0NjcvdGFibGVyYW5nZTo0Y2M1ODk1YTg4Zjk0NzhkYTNjNjE5YzE5ZDBhYzQ2N182LTEtMS0xLTI2NjM1_5e996824-51a0-4b0c-bdbf-70db9f037dd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="fact-identifier-3" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl80L2ZyYWc6OGQ5MmMwZTc4NGI0NGFjMmE0ODc2NTg4YmM4YmU5MjQvdGFibGU6NGNjNTg5NWE4OGY5NDc4ZGEzYzYxOWMxOWQwYWM0NjcvdGFibGVyYW5nZTo0Y2M1ODk1YTg4Zjk0NzhkYTNjNjE5YzE5ZDBhYzQ2N183LTEtMS0xLTI2NjM1_ad7ab920-90df-42c3-97b7-56f147909795" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_091ece9d-39cf-4ec6-b31a-e859f676634f">http://www.alpineimmunesciences.com/20211231#CollaborationMember</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_0e8d6efb-e8ab-4715-88e6-68781f569926">http://www.alpineimmunesciences.com/20211231#CollaborationMember</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_92f831ac-72b6-420b-a93c-169263491fdc">http://www.alpineimmunesciences.com/20211231#CollaborationMember</ix:nonnumeric><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzQyMzc_f6dd7d1f-e6bd-4216-a7b6-14c223c6ef62">P3Y</ix:nonnumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="alpn-20211231.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9560243c66fa4c3d8cfe1f6fe7c7fc2b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib0f82a3fb6db4e4786f6fe47fcebfbbe_I20220307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i963ab54fb1c14a5c9f6b44f38e016825_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc5e0f908c041b189c9615068048458_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i919043086e3049048a17c0e6de073a2f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4ce683b38c4ba9a752ad0990e7db31_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c61c72b207f4822b0f8726675195e4f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ad74a5fab448fa94b0294c0c03a645_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa3867bf696240f9af9d3129e941f0ee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8071de4bb91440b9adb67a4f284b30fe_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99cb38eebbf14566811523dbafb7634d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i256db623b464499499272de9a09fe475_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i91d44d4b51814547bc7e3b442fcff7b0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15d2b0e22559474b8985b59136c58e26_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie14bab752cfe496c895327a2fcb47e59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ed7c537c77e4e78919fdf840dabfb19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e4b53c25b064cbdb61c73329f9d373d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id40267d2fb5a4cb592c161a53fb6c50a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb34f9836454ee4b95587a80586d219_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a21cddc36c40df81368c4056b6ce3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3cc09431f82641ca94d297afdc885945_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i243f35162d6f4ed7a415269f539b04e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id3e587cdd7ab4aa0ab733f9cfbc155fb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba0ddb9b77924e6096476453a17bb2a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4edcf137dc74d3f8eeab9ad1ea23448_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aed5ad924d745e0a110878651454bf4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0c2b383b84d40e58fa0f67af121be49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2648eabdbd140f5974b595477aca5ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i707070799aba47bbbf2bacf54dcf8436_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1fe4f6c096224997bdc46005a9f39525_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaec48ff876724e438f733dcf4f37690b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9e466bd5f39940ba920dcf1ddf259781_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i75d81b01f697461cb4c519a3d2969ed3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74040b977c504756ac1b5616db85814d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef03a0a954a4cb28f082b2a2bd77dba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3769092a6f2e4a09bab7b6cb75d25c62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e587f3abecf433193c20c1bb12350a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>alpn:segment</xbrli:measure></xbrli:unit><xbrli:context id="i3122bde756bb405da9845b0b4487e083_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24fe921914f34cc882da3945c9ad85cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i364f36976add441091096711347137c1_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e6f753d91fb4814bccc6c4706af2805_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9d3c61b57ce24a41bdf082b485b48a9e_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-07-01</xbrli:startdate><xbrli:enddate>2020-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i795c5e13955e498abdbdcd24bf7fc219_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic36dad9700ed425c910c0c97b97eb15c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i12569b1fee504a8b803f445721db26f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1ee8e3f455b4c7ab91aba027b3db616_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id3fed388f6ee430ea4f84b9776b51a5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3b02939f14340fdbe39ab5b7f6969ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i96ba1ec08180409aba13f53843f88603_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idccd5aaa47fe4bfa85f50ff3adf5e175_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alpn:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i782ef4bf21d14891ac5cb6726bb3f733_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alpn:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic227d35d6112472495b45a85c929140e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alpn:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i334c78b1bed8469a9dfb31129440ffde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1646109f1204cd68f023c88a1e22901_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a34d14730364f2089358509b6c6e251_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i658455ca7f404340acb649949f14bfb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f44a1b35c14402a0cfb87615de07a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7ffc09728149089985212baf293ad7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d32d5fe12b641829dad30499431b82b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefb6ee89584f4fd887ae10408d3487f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d64fb4c1544495a5e0a6fcf0b6e8e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibed046730d564d47bb4885ab0051af84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d6a976adc64b91b2621f028a4d3d07_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4807bd0acb44a5b9307c98748f7ef66_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9141ca2bcbe64bfb885d1dfae8aa3439_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdfb42ef083744e7a20a93a0c8c6ff53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6fd8694e2f04147863afe58bfc4314e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4d0b6fd1994501b7ce5646ed902dde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica69f81c0ede414ea292931d80ed1ef8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ced17734a944d3bd430e2451263ae9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481ddd50b9d64bb695304ca870715b27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77aaca15b9f8439ca646dac552bb0018_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6421e10a56a348f0a007ffa6e931a374_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88591b5adc104f998fe815b011629dcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia663e0df8fd74120a4788d77e90ac526_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc58f79a169438590808f9b221ae586_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03fa31b49fd4f8a91745ea634c73f08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8150d9fab84031b0c0f2067c50b126_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90a98074ae246abb7d17c75e56556e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba26f7978ab46908f569d30a877c023_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e5dde8cd214c64ae36080fe04efda5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie36b74e37fdd4372a7a5f38e68c38503_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4223d7cb5bc440ba61cd2a7dbd019a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b46f4d303c04132b6c19f6eeb3dd6a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aff9044035a41e3920e055df6c75993_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64252761e6d44205991db3cd2c1470be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0755487af112435b8d7d8cfac801d1cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">alpn:CorporateDebtSecuritiesAndCommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6e9f7d4b5342448544c11860e093f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i390feb44b2ac4712b2fae153aa1e274a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie24fdbc2559c481b82a63532a0a82f91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia731b73192204033a92ad47db122bf32_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61ddc1e316434e84b1326d82b3e39515_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e27e9c1efce41d2a4a50ebf8478bc90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief221263101442d5b984c00cdc0175c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297ad02942cb436cb66fd0344a78c95b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083b717b3e6849a9abad4799efac640c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf472bbf7fde4eaaaaa52bb42e5283d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a0ddfb5549d426e9d11b7347a03e9b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73042143305f4b2d8eb75ee413683cda_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-02-01</xbrli:startdate><xbrli:enddate>2018-02-28</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5a92caa4df7494d86fa7ffb7621152c_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-06-01</xbrli:startdate><xbrli:enddate>2018-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa55a2e4dc214bc593f1a6e45e171b1f_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-06-01</xbrli:startdate><xbrli:enddate>2019-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9d001249bd54a16b1d98d98076401b0_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:LaurelVentureCapitalLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">alpn:GSNORMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieae2ee4376514631bd2f88324fddebf2_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:OriginalAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-12-01</xbrli:startdate><xbrli:enddate>2016-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib5248356bea14293ab5f6128546160c1_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:OriginalAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2016-12-01</xbrli:startdate><xbrli:enddate>2016-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d1d5568c7fa4b9a87aefbdcd38391ed_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b68bced6acb4558a8e16e5a7d47bedb_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>alpn:tranche</xbrli:measure></xbrli:unit><xbrli:context id="i0f311401c86845e3a26ee4f56456d389_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2b4a12df2c0b40a2aa808a1c3245ab40_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:OriginalAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idfffa9b897014a0da1f1784b26577c5c_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-03-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7812e6c89eb44d39911f5e0226410fc4_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheThreeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i238b2644cec24ef2a1b9cef4c5171a1f_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>alpn:installment</xbrli:measure></xbrli:unit><xbrli:context id="i623358c6ce04441781af218ea4ed34db_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:OriginalAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebe8391caf35418db8897242b7f86588_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf5e45b2c94e4166b9a05797103db792_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia5477c8a4eb6487d9f392c189830c10d_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3a982b848ef4abcbd8740c7c00cb8a6_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89214fd22b344936ab289722a0c30e0e_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbef58a54523456282dba402b270de92_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cad8f970b62489086fb35513bc32430_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheOneMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06fbdb85dd6245d6b21ed18d69c3e19b_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">alpn:TermLoansTrancheTwoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i596b561952cf4ea4be7acd5e19c607d7_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LineOfCreditFacilityAxis">alpn:SiliconValleyBankMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b2d9c5c1a524d7ab30e7127baa2a19b_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-01</xbrli:startdate><xbrli:enddate>2019-08-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9318da7258ad48f9ac24e4a77fd86292_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">alpn:TermLoansMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678d4957aa5b4bb89cfb502af5f764d5_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c21bce11c2749e2aab827f627b0abcb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease_term_type"><xbrli:measure>alpn:lease_term_type</xbrli:measure></xbrli:unit><xbrli:context id="i72e961c3079340f8a18bd09a4f4e2b08_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-03-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i21a965cf6f0d416a99915433235d717d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d55851d588457b8af381d6826d0e52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="candidate"><xbrli:measure>alpn:candidate</xbrli:measure></xbrli:unit><xbrli:unit id="program"><xbrli:measure>alpn:program</xbrli:measure></xbrli:unit><xbrli:context id="i22b150e5f4b549dca8129cd7c110db03_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-12-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5251479cf79c49749c959a3b7df6aca3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i151315902722437a8ad49cfe34610af5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibcd9d7ab1c6244d2b2c93079e85f636b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3454a020ba504a65bb403cbb8792e1de_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:UpfrontPaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i152d7cb06f574ef185e7df19b538c207_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020be8c887b846768ee393edf4d0af2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:UpfrontPaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5cdcf2ae8e447ea4ff3d9c718d0caa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:PremiumPaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84b2b262f0c4ee2bae1e3ecff18cadd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:HorizonMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i062134b2fef643f594d8f17b4a7c78e9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:UpfrontLicensePaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dddb55d8ff54aae89296bb009468029_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a691e7bc9e346ee9c27fcfc724ebecb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9a7edca16b44cab64b32238668d6a8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment"><xbrli:measure>alpn:payment</xbrli:measure></xbrli:unit><xbrli:context id="i093ea9e497144471b54a7dc0652275ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id7db5daf1ecb4d9a9ea71684f2be918e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b719a349b5747a8834254f8d6fffb75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AbbVieMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0cfe61a076402a941cf3ce5b7540a0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:UpfrontLicensePaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i779979eacbe54b72937d4fab02c71731_D20190701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:UpfrontLicensePaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-07-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifa5fddd88c3e48fe8ff8dbe605960a7f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:ResearchSupportPaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5500833b9eaf473abf2f636d5c30f7af_D20190701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">alpn:ResearchSupportPaymentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-07-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i345f1436aeb944a782c69c7d697fb4d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a75c47adacc45d1bf2c0a53c190fe55_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if536e7e2d9ca4f7a8557f2c51d4e5f08_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f141abe10344389a58347647e70766b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dec84da2bb344a08dd21b61ee6a2864_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">alpn:AdaptimmuneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib88192ff637346c6adfd814116ed19aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89883447444d43b880147da6b2fd98ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1aca4a3f0af543bdb4d112a177a7741c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1f3650c42a4d00908cfbed80c1ee4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f983a058be47afbb58ce562b1c4d6c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5a15a858b3243bfbb2174b597e839b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b626fbf80d34ac084167087599ad148_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia37a014b4a1643b5a5b9a82861705114_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:SharesAvailableForFutureStockGrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida43dc13312a46108b9a1cc6ec681ffa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:SharesAvailableForFutureStockGrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d0ebb9da1143a2aff58659fd34ff3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3def57b944b455183938bc50142ac8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b327bcfa98a40eb91977c3449fc1f7a_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4519e0cf9f5a4d29831defb5a0bdf860_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7147d6c86994e1c9b650f6ee79fcd0d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a05e8d545af4e86a1a2bfe82cb175ef_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib35141db54104f6d85ffff605e75fe41_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieebacfd44c9b4102a8eb72c9991f2e71_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:ExchangeWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29eb1f5a55ba460d93ee7d27fba0bb17_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifcefc03f1e124d9bbe7d55bffac1f72a_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-07-01</xbrli:startdate><xbrli:enddate>2020-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i91a19ea89ef747edb76c57033ac240ce_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a12320f064d4eb7ad11d98b1d6406ff_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b02509e21fe45ef8444933f3cf33999_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-07-01</xbrli:startdate><xbrli:enddate>2020-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i101c599b3b8246bdbc84e94f5abf0fbd_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:PrefundedWarrantUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="warrant"><xbrli:measure>alpn:warrant</xbrli:measure></xbrli:unit><xbrli:context id="i293473c00f0f4e6b8f7c85b5b0dec6de_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:PrefundedWarrantUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f3968ad1b82430eaa805a7b7154b755_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:PrefundedWarrantUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-07-01</xbrli:startdate><xbrli:enddate>2020-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i794d5118016b40dbbd0610e5dd3e4ecf_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80adb87431ed4df1ac1d1748f2389a3a_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:A2019UnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7376a713e8824a83b2c48abf564c1be2_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f4be439d1e42caba8e3d7a6219cab6_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b418204263c4b8ea69d175de06bb545_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:CommonUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie30e212db6cb40799cad98f14bc8696d_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i007148e03dd84205a1a6b6b3bbe00984_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">alpn:CowenCoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:SalesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-07-01</xbrli:startdate><xbrli:enddate>2021-07-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i92f975219deb422cab650fbc8f47a58a_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:LegacyPlanCancellationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i319952407da944169e6a39afab11abb1_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-06-01</xbrli:startdate><xbrli:enddate>2020-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3b6d3569bb984c1b81f2fb89e7012f6f_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-06-01</xbrli:startdate><xbrli:enddate>2018-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i68fc51cabc7a4b9f9a3c96c70ed15458_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-06-01</xbrli:startdate><xbrli:enddate>2018-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i76e8d3957f4e470691a8e3f87306f2b9_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:TwoThousandAndEighteenPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-01-01</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib8be91d9d31c487bb0337b4b034a9e7c_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94bbbbf5ff2445589142fe551b2539c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:IncentiveStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e5aa97b39d04aae95d242dd56165164_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">alpn:StockPlan2018StockPlan2015AndEquityIncentivePlan2015Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f7052f9f1934696b3a10648c61ff1d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8896a776a6e944f6a4c6f4ffd48be081_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id0b9f3a08f6e445e807288f2baa56edb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i74885c002f184c33b1b02b9b2e01ebee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1eaf7070bec4465887796348dc4e160e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i15197c79e7fc4158aca6c067db846ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:ShareBasedPaymentArrangementOptionAndRestrictedStockUnitsRSUsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie62ad91d10bc4fe4a4e201b2525409b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i340c17cd1eea4f6a995433fc3a407d0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i20e72b63f886405e9244810f0fabe4c0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22001bdad5d845b79c4c231a67c25caf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i77ab615ab1bb47629a6c3ef4f7221a13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i09e5e8720481494d800c23fb60f91e5e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a3777ec15ed4679ab515eeddca493ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2d270ec08c748fa85ed7d59442baec1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22cbaa79a99e44f28f042370da6cdcf2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if44ed21dacff4c85827cdfea8ea78958_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:EmployeesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9bb1471e612840b880517cee850835a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97eab3dab8ef46fea30ead9b87fcff96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia832c77a80ba48e6baa3930ff9c1d7f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id2151a39d8864da591888605c608654d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i367ab12b77d04395a7f2a515b8c68b0c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-01-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i79aaff2fa4d84a01ab4feb086666d7e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">alpn:NonEmployeesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i577d5843a4f74cb2bbcec261be5d6d4f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">alpn:BeforeJanuary12018Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadf8aefc9b9a4e28bae5dccfc69dd77e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">alpn:BeforeJanuary12018Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1f107ab72d4110a5e915a7f041b1f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">alpn:BeforeJanuary12018Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i585c2562ce674120b62d30847e189adc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">alpn:AfterJanuary12018Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce1e29137a74b5bafb32effd358f488_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">alpn:AfterJanuary12018Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d2f911cf0e487dab40fd6658396735_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxPeriodAxis">alpn:AfterJanuary12018Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43fa42d2304d44a58722229d29c67a48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48656f99e5a945c1857a4e605d7f5e2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c91e71c8fc454dbca0620bea64ea0c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee75049cfece4bb491b857c973622337_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5e81dc1b884809b82fecca810b65fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c40c23209da440fac6f64dc973f7914_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0184f3a0824e486d8c8bb1c1dcf3ee8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7372e514e8e45f19127e257f82cbd72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafcf19971b8d49fbaf8dcd14cb3233d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a59584cefcd451891ad490590ce1e9e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">alpn:NivalisTherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8decf993a445a1b3d01f6914b305e0_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2021SecurityPurchasesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i68b5b7144bc845a7b7e702990f1139fd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2021SecurityPurchasesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f1ad68d3fab4425afdbf0d151e4af91_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockAndCommonStockWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2021SecurityPurchasesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i466a64b6d0a7497e9142d4a02fd6c42c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockAndCommonStockWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:OwnershipAxis">alpn:AlpineImmuneSciencesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2021SecurityPurchasesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433869c2192449498bb8e2059fa6ee05_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:ExchangeOfStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-09-01</xbrli:startdate><xbrli:enddate>2021-09-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06c6336b2fd648c58cb6ff26ceb0bec0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">alpn:ExchangeWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:ExchangeOfStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">alpn:PrefundedWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id10fcca6dd424b65a308430ebbc6a412_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockAndCommonStockWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:OwnershipAxis">alpn:AlpineImmuneSciencesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9be77689b7604ed0a6842a08b5bc1cea_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2019SecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e8a974826dd41e1bcdbabb957b91c43_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2019SecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockWarrantMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic061b92b614844538355b5488516f87d_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockAndCommonStockWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2019SecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-01-01</xbrli:startdate><xbrli:enddate>2019-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9cd1403bd64f4ad1bf977722324b29fb_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001626199</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">alpn:CommonStockAndCommonStockWarrantsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:OwnershipAxis">alpn:AlpineImmuneSciencesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">alpn:A2019SecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentType" id="fact-identifier-4" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTMy_2b557a8b-44a1-44ba-a8d9-205feccec8a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="fact-identifier-5" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6MjYxNGM0ZGZlYTgyNDdlZTlhMWUxMGQ0NTFkNjVlMGEvdGFibGVyYW5nZToyNjE0YzRkZmVhODI0N2VlOWExZTEwZDQ1MWQ2NWUwYV8wLTAtMS0xLTI2NjM1_c2e10b7b-c55b-409f-a83b-d23f67dc4934" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="fact-identifier-6" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8xNjQ5MjY3NDQ0ODI5_119d4482-abeb-4dc5-a79e-32907f859581" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="fact-identifier-7" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8xNjQ5MjY3NDQ0ODI5_322ff4af-7d91-4eb0-8df5-f908a7ab7ecb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">December 31</ix:nonnumeric></span>, 2021</ix:nonnumeric></span> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="fact-identifier-8" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6MTBhM2YxMTEwYzk1NDE4ZmFkYTA0ZmVlMWRlNDUzYmYvdGFibGVyYW5nZToxMGEzZjExMTBjOTU0MThmYWRhMDRmZWUxZGU0NTNiZl8wLTAtMS0xLTI2NjM1_51e852ce-185e-497f-9d94-ddfdf6e97b61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934 FOR THE TRANSITION PERIOD FROM&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TO &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number&nbsp;<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityFileNumber" id="fact-identifier-9" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTI3_d7dcf0fb-ca4c-4fa4-b839-b01f6f69ace7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-37449</ix:nonnumeric></span> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityRegistrantName" id="fact-identifier-10" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTI4_8329d961-212a-4f0e-8584-564cbe498d7c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ALPINE IMMUNE SCIENCES, INC.</ix:nonnumeric></span> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its Charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:23.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="fact-identifier-11" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF8wLTAtMS0xLTI2NjM1_43ab67c7-5b9d-4185-8d7e-c47384363661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Delaware</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="fact-identifier-12" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF8wLTItMS0xLTI2NjM1_35d39e58-b290-43f2-9beb-3afef78af844" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20-8969493</ix:nonnumeric></span></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(I.R.S. Employer<br>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="fact-identifier-13" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF8zLTAtMS0xLTI2NjM1_a7df24ff-c00d-47b5-803b-dc0d2238b361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">188 East Blaine Street</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="fact-identifier-14" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF8zLTEtMS0xLTI2NjM1_d25d2e10-10ee-4306-90d0-c91bfa619382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite 200</ix:nonnumeric></span></span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="fact-identifier-15" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF8zLTItMS0xLTI2NjM1_37d6df77-29fd-4175-9416-3e65a5fb7b23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98102</ix:nonnumeric></span></span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="fact-identifier-16" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF80LTAtMS0xLTI2NjM1_099cdcd9-78a6-48db-8c0a-93ed32b731d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Seattle,</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="fact-identifier-17" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NzMzNTc5MGViNzA5NDQwZDhlOTQ0YzFlNmIxMzRiZDgvdGFibGVyYW5nZTo3MzM1NzkwZWI3MDk0NDBkOGU5NDRjMWU2YjEzNGJkOF80LTEtMS0xLTI2NjM1_3f01ba9e-d322-4bc2-914b-44667c860246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">WA</ix:nonnumeric></span></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrants telephone number, including area code: (<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:CityAreaCode" id="fact-identifier-18" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTI5_25c32c80-1b7a-41fa-9d83-b641524162a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">206</ix:nonnumeric></span>)&nbsp;<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:LocalPhoneNumber" id="fact-identifier-19" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTMw_528c337c-3f6e-4c04-9fec-fb5f54961a46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">788-4545</ix:nonnumeric></span> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&nbsp;12(b) of the Act:</span></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:Security12bTitle" id="fact-identifier-20" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NGE0YjhmNjEwMGMyNDc1MmIwOGYxNzRiNjEzMmE4YzEvdGFibGVyYW5nZTo0YTRiOGY2MTAwYzI0NzUyYjA4ZjE3NGI2MTMyYThjMV8xLTAtMS0xLTI2NjM1_404af7ab-c287-422f-99ed-9fe0340a4f6b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, par value $0.001 per share</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:TradingSymbol" id="fact-identifier-21" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NGE0YjhmNjEwMGMyNDc1MmIwOGYxNzRiNjEzMmE4YzEvdGFibGVyYW5nZTo0YTRiOGY2MTAwYzI0NzUyYjA4ZjE3NGI2MTMyYThjMV8xLTEtMS0xLTI2NjM1_6cfd5e4a-a7f0-4ccc-80a9-3398e0b79f18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ALPN</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="fact-identifier-22" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6NGE0YjhmNjEwMGMyNDc1MmIwOGYxNzRiNjEzMmE4YzEvdGFibGVyYW5nZTo0YTRiOGY2MTAwYzI0NzUyYjA4ZjE3NGI2MTMyYThjMV8xLTItMS0xLTI2NjM1_b0222277-ac8a-4638-8736-b2c60804f1c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The Nasdaq Stock Market LLC</ix:nonnumeric></span></span></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&nbsp;12(g) of the Act: None</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.&nbsp;Yes&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="fact-identifier-23" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTMz_819acda1-b406-4a54-a481-90fb32d571a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span>&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d) of the Act.&nbsp;Yes&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="fact-identifier-24" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTI0_5272cc6b-d08e-4e51-8f80-2931fd967774" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span>&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="fact-identifier-25" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTM0_24242725-b389-4056-a292-12280bda638f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;No&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit such files).&nbsp;<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="fact-identifier-26" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTM1_ca371681-7f4e-4b33-bd02-49e46e41381b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;No&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:2pt"><span><br></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&nbsp;accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="fact-identifier-27" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6YmZiOGQxNTU3NWY1NDZiZTk1ZjNjMzYzOGZlMDdmNmYvdGFibGVyYW5nZTpiZmI4ZDE1NTc1ZjU0NmJlOTVmM2MzNjM4ZmUwN2Y2Zl8yLTAtMS0xLTI2NjM1_bb921b79-c83e-4018-9d1c-eeeb00b6c5ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&nbsp;reporting&nbsp;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="fact-identifier-28" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6YmZiOGQxNTU3NWY1NDZiZTk1ZjNjMzYzOGZlMDdmNmYvdGFibGVyYW5nZTpiZmI4ZDE1NTc1ZjU0NmJlOTVmM2MzNjM4ZmUwN2Y2Zl8yLTYtMS0xLTI2NjM1_1a5da133-a1f3-4e3e-b811-e53505eaa52c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="fact-identifier-29" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGFibGU6YmZiOGQxNTU3NWY1NDZiZTk1ZjNjMzYzOGZlMDdmNmYvdGFibGVyYW5nZTpiZmI4ZDE1NTc1ZjU0NmJlOTVmM2MzNjM4ZmUwN2Y2Zl80LTItMS0xLTI2NjM1_c4c6e26d-5657-4475-9268-21bdb25e3959" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its managements assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.<span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="fact-identifier-30" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTI1_38e7ab2e-9395-413a-baec-5420c20ef425" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;Yes&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="fact-identifier-31" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTMx_1a85216c-4301-47e6-8e1f-e561811e302f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&nbsp;No&nbsp;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on the Nasdaq Stock Market on June 30, 2021, was approximately $<span><ix:nonfraction unitref="usd" contextref="i9560243c66fa4c3d8cfe1f6fe7c7fc2b_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-32" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8yNjgz_ceffe706-fa75-4480-a671-65e97835755d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104.8</ix:nonfraction></span> million. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant, have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of the registrants common stock outstanding as of March&nbsp;7, 2022 was <span><ix:nonfraction unitref="shares" contextref="ib0f82a3fb6db4e4786f6fe47fcebfbbe_I20220307" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-33" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMDc3_27e29dcf-2160-457d-bd0f-5affc1bd53cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,294,434</ix:nonfraction></span>.</span></div><div><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="fact-identifier-34" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xL2ZyYWc6MjIzZGU2Y2ZiMjkyNDNmYjg5OWIyMjlkOWNjMzc0ZTYvdGV4dHJlZ2lvbjoyMjNkZTZjZmIyOTI0M2ZiODk5YjIyOWQ5Y2MzNzRlNl8zMTI2_534d8f55-3cad-49f1-b5a6-5cff339c952e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Portions of the Registrants Definitive Proxy Statement relating to the 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission subsequent to the date hereof, are incorporated by reference into Part III of this Report. Such Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days following the end of the Registrants fiscal year ended December 31, 2021.</ix:nonnumeric></span> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_13" tabindex="18">Summary Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_13" tabindex="18">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_13" tabindex="18">Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_1617" tabindex="18">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_16" tabindex="18">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">Item&nbsp;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_22" tabindex="18">Item&nbsp;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_22" tabindex="18">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_22" tabindex="18">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_61" tabindex="18">Item&nbsp;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_61" tabindex="18">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_61" tabindex="18">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_64" tabindex="18">Item&nbsp;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_64" tabindex="18">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_64" tabindex="18">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_67" tabindex="18">Item&nbsp;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_67" tabindex="18">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_67" tabindex="18">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_70" tabindex="18">Item&nbsp;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_70" tabindex="18">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_70" tabindex="18">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_73" tabindex="18">PART&nbsp;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_76" tabindex="18">Item&nbsp;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_76" tabindex="18">Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_76" tabindex="18">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_79" tabindex="18">Item&nbsp;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_79" tabindex="18">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_79" tabindex="18">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_82" tabindex="18">Item&nbsp;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_82" tabindex="18">Managements Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_82" tabindex="18">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_106" tabindex="18">Item&nbsp;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_106" tabindex="18">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_106" tabindex="18">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_109" tabindex="18">Item&nbsp;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_109" tabindex="18">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_109" tabindex="18">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_112" tabindex="18">Item&nbsp;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_112" tabindex="18">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_112" tabindex="18">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_115" tabindex="18">Item&nbsp;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_115" tabindex="18">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_115" tabindex="18">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_118" tabindex="18">Item&nbsp;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_118" tabindex="18">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_118" tabindex="18">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_1690" tabindex="18">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_1690" tabindex="18">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_1690" tabindex="18">96</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_121" tabindex="18">PART&nbsp;III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_124" tabindex="18">Item&nbsp;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_124" tabindex="18">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_124" tabindex="18">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_127" tabindex="18">Item&nbsp;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_127" tabindex="18">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_127" tabindex="18">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_130" tabindex="18">Item&nbsp;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_130" tabindex="18">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_130" tabindex="18">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_133" tabindex="18">Item&nbsp;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_133" tabindex="18">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_133" tabindex="18">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_136" tabindex="18">Item&nbsp;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_136" tabindex="18">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_136" tabindex="18">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_139" tabindex="18">PART&nbsp;IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_142" tabindex="18">Item&nbsp;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_142" tabindex="18">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_142" tabindex="18">98</a></span></div></td></tr></tbody></table></div><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this report, unless otherwise stated or as the context otherwise requires, references to Alpine, the Company, we, us, our and similar references refer to Alpine Immune Sciences, Inc. All rights reserved. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NEON-1," "NEON-2," "Synergy," and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report also contains registered marks, trademarks, and trade names of other companies. All other trademarks, registered marks, and trade names appearing in this report are the property of their respective holders. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those highlighted in the section of this report captioned Risk Factors. The following is a summary of the principal risks we face:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to us. If these companies develop technologies or therapeutic candidates more rapidly than we do, or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">To date, our revenue has been primarily derived from our collaboration agreements, and our success will be dependent, in part, on our collaborators efforts to develop our therapeutic candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If third parties on which we depend to conduct our clinical or preclinical studies, or any future clinical trials, do not perform as expected, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed, which may result in materially adverse effects on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expenses, and present significant distractions to our management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we may be unable to successfully commercialize any such future products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The COVID-19 coronavirus could adversely impact our business, including our clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We depend on our information technology systems and any failure of these systems could harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are an early stage biopharmaceutical company with a history of losses, we expect to continue to incur significant loses for the foreseeable future, we may never achieve or maintain profitability, and we have a limited operating history that may make it difficult for investors to evaluate the potential success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we are not able to obtain and enforce patent protection for our technology, including therapeutic candidates, therapeutic products, and platform technology, development of our therapeutic candidates and platform, and commercialization of our therapeutic products may be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may license patent rights from third-party owners or licensees. If such owners or licensees do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We or our licensors, collaborators, or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development of our therapeutic candidates and commercialization of our therapeutic products, or put our patents and other proprietary rights at risk.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we fail to comply with our obligations under any license, collaboration, or other agreements, we may be required to pay damages and could lose intellectual property rights necessary for developing and protecting our technology, including our platform technology, therapeutic candidates, and therapeutic products, or we could lose </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain rights to grant sublicenses, either of which could have a material adverse effect on our results of operations and business prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our therapeutic candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our stock price may be volatile, and an active, liquid, and orderly trading market may not develop for our common stock. As a result, stockholders may not be able to resell shares at or above their purchase price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our officers and directors, and their respective affiliates, have a controlling influence over our business affairs and may make business decisions with which stockholders disagree and which may adversely affect the value of their investment.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_1617"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the safe harbor created by those sections. In some cases you can identify these statements by forward-looking words such as believe, may, will, estimate, continue, anticipate, intend, could, would, project, plan, expect, or similar expressions, or the negative or plural of these words or expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other forward-looking information. These statements relate to our future plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. These forward-looking statements include, but are not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our ability to identify, develop and commercialize additional products or product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our estimates regarding our expenses, revenues, anticipated capital requirements and our needs for additional financing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our ability to obtain funding for our operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the implementation of our business model and strategic plans for our business and technology;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the timing of the commencement, progress and receipt of data from any of our preclinical and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the expected results of any preclinical or clinical trial and the impact on the likelihood or timing of any regulatory approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology and product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the anticipated impact of the COVID-19 pandemic on our business, research and clinical development plans and timelines and results of operations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the therapeutic benefits, effectiveness and safety of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">the rate and degree of market acceptance and clinical utility of any future products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our ability to maintain and establish collaborations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our ability to achieve milestones in our current and any future collaborations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our expectations regarding market risk, including interest rate changes;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our expectations regarding the sufficiency of our cash and cash equivalents to fund operations for at least the next 12 months;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">developments relating to our competitors and our industry; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">our expectations regarding licensing, acquisitions and strategic operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this report in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_22" tabindex="18">Part I, Item 1A. Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, and elsewhere in this report. Forward-looking statements are based on our managements beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments, except as required by law.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;In addition, statements that we believe and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br></span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to treat cancer and autoimmune and inflammatory diseases. Our approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. We believe our strategies are capable of meaningfully modulating the human immune system and significantly improving outcomes in patients with serious diseases. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Autoimmune/Inflammatory Diseases</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALPN-101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases. Preclinical studies with acazicolcept have demonstrated efficacy in models of systemic lupus erythematosus, or SLE, Sjgrens syndrome, or SjS, arthritis, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, uveitis, and graft versus host disease. We have evaluated acazicolcept in a Phase 1 healthy volunteer study and initiated patient dosing in Synergy, a global, randomized, double-blind, placebo-controlled Phase 2 study of acazicolcept in adults with moderate-to-severe SLE. In June 2020, we entered into an Option and License Agreement with AbbVie Ireland Unlimited Company, or AbbVie, which grants AbbVie an exclusive option to take an exclusive license to acazicolcept. Through December&nbsp;31, 2021, we have received $105.0&nbsp;million in upfront and pre-option exercise development milestones as part of the Option and License Agreement with AbbVie, or the AbbVie Agreement. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALPN-303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Engineered using our proprietary directed evolution platform, ALPN-303 potently inhibits the pleiotropic B cell cytokines B cell activating factor (BAFF, BLyS) and a proliferation inducing ligand (APRIL), which play key roles in B cell development, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">differentiation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and survival, and together contribute to the pathogenesis of multiple autoimmune diseases such as SLE and many other autoantibody-related inflammatory diseases. Data presented at the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting demonstrated that ALPN-303 inhibits the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as anti-BAFF and anti-APRIL monoclonal antibodies. In addition, ALPN-303 has been well-tolerated in preclinical models and exhibited superior pharmacokinetics and pharmacodynamics over wild-type TACI-Fc counterparts, including superior serum exposure, suppression of T-dependent antibody production, and/or serum immunoglobulins in mice and/or cynomolgus monkeys. A first-in-human, Phase 1 study of ALPN-303 in healthy volunteers was initiated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the fourth quarter of 2021, with top-line results targeted by mid-2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This randomized, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303 administered intravenously and subcutaneously. We are planning to initiate patient-based studies in the second half of 2022 including SLE, and possibly other autoantibody-related diseases in other therapeutic areas.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into an exclusive license and collaboration agreement, or the Horizon Agreement, with Horizon </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ireland DAC, or Horizon, for the development and commercialization of up to four preclinical candidates generated from our unique discovery platform for autoimmune and inflammatory diseases. Under the terms of the agreement, Horizon made an upfront payment to us of $25.0 million as well as an equity investment for which they paid $15.0 million, a 25 percent premium to the 30-day volume-weighted average share price as of December 9, 2021. In addition, we are eligible to receive up to $381.0 million per program, or approximately $1.5 billion in total, in future success-based payments related to development, regulatory and commercial milestones as well as tiered royalties on global net sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immuno-oncology</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead oncology program is ALPN-202, or davoceticept, a conditional CD28 costimulator and dual checkpoint </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inhibitor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intended for the treatment of cancer. Preclinical in vivo data have demonstrated monotherapy efficacy in tumor models superior to approved therapies. In June 2020, we initiated NEON-1, a Phase 1 monotherapy dose escalation and expansion study in patients with advanced malignancies. Initial data from NEON-1 were presented at the 2021 American Society of Clinical Oncology (ASCO) Virtual Meeting demonstrating that davoceticept was well-tolerated as of the cutoff date (April 22, 2021) with evidence of peripheral T cell modulation consistent with CD28 agonism. In addition, although most enrolled participants had tumors considered classically non-responsive to immunotherapies, the majority derived clinical benefit as defined as a best outcome of stable disease or better. Completion of dose escalation for NEON-1 and initiation of expansion cohorts is anticipated in the first half of 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 2021, we announced a collaboration and supply agreement with Merck to evaluate the safety and efficacy of davoceticept in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase 1 dose escalation and expansion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The clinical trial, NEON-2, was initiated in June 2021and is currently subject to a partial clinical hold. As discussed further below, on March 7, 2022, we announced that the FDA placed a partial clinical hold on the NEON-2 trial in response to the death of a study participant in the NEON-2 trial. The participants death was attributed to cardiogenic shock, considered by the treating physicians as likely related to immune-mediated myocarditis, or possibly infection. Participants who are currently enrolled in the NEON-2 trial may continue to receive davoceticept and pembrolizumab, although no new participants may be enrolled until the partial clinical hold is resolved. This partial clinical hold does not affect the ongoing NEON-1 clinical trial of davoceticept as monotherapy (NCT04186637).</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> scientific platform has also generated immune modulatory proteins with the potential of improving engineered cellular therapies such as chimeric antigen receptor T cells, T cell receptor-engineered T cells, and tumor infiltrating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lymphocytes</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> May 2019, we signed a collaboration and license agreement with Adaptimmune Therapeutics plc, or Adaptimmune, to develop next-generation SPEAR T cell products which incorporate our secreted and transmembrane immunomodulatory protein (termed SIP and TIP) technology. We intend to continue to leverage our existing pipeline and platform to actively explore and evaluate potential value-creating partnering opportunities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> goal is to discover and develop modern therapies to treat patients with serious conditions such as cancer and autoimmune/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflammatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diseases. To achieve our goals, we intend to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">aggressively move our lead autoimmune/inflammatory program acazicolcept through clinical development as part of the AbbVie Agreement, including conducting Synergy, our Phase 2 study for the treatment of SLE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">aggressively move our second autoimmune/inflammatory program ALPN-303 through a Phase 1 study in healthy volunteers and into patient-based studies for the treatment of B cell mediated autoimmune/inflammatory diseases;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">aggressively move our lead oncology program davoceticept through clinical development for the treatment of cancer, and;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maximize the value of our pipeline and platform via potential partnering activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Pipeline</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a diverse pipeline of novel therapies, as shown in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below. </span></div><div style="margin-top:12pt;text-align:center"><img alt="alpn-20211231_g1.jpg" style="height:318px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g1.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g1.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Scientific </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">tform</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> human immune system is a complex network of biological processes and structures evolved to protect humans from external infections and harmful changes of internal cells. Within the immune system, proteins play a key role in a variety of essential functions, including recognition of foreign and self-antigens, cell adhesion and trafficking, and modulation of cellular activity through costimulatory or inhibitory signaling. Our scientific platform seeks to develop novel therapeutics by engineering native, or so-called wild-type, proteins with unique properties that may benefit patients with cancer or inflammatory diseases. We have focused our efforts to-date on two major protein superfamilies that play critical roles in the regulation of immune cell signaling and activity: the immunoglobulin superfamily, or IgSF, and the tumor necrosis factor (receptor) superfamily, or TNFSF/TNFRSF. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IgSF is the largest family of adhesion, costimulatory (activating), and inhibitory (blocking) proteins found on the surface of immunological, neurological, and other human cell types. These cell surface and soluble molecules are broadly involved with recognition of antigens, assisting in the formation of the immune synapse, and performing costimulatory, coinhibitory, and cytokine receptor signaling functions. This family includes many well-known targets, such as those seen in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the IgSF protein family members may be particularly valuable because many IgSF proteins naturally bind multiple binding partners, also referred to as counterstructures. Acazicolcept and davoceticept are both derived from members of the IgSF.</span></div><div style="margin-top:10pt;text-align:center"><img alt="alpn-20211231_g2.jpg" style="height:158px;margin-bottom:5pt;vertical-align:text-bottom;width:404px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g2.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g2.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TNFSF/TNFRSF proteins are expressed broadly in the immune system and play a critical role in immune cell signaling and </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proliferation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. TNFSF/TNFRSF members are composed of 48 unique proteins that are structurally similar and are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">characterized by their ability to bind to trimeric tumor necrosis factors (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Members of the TNFSF/TNFRSF include many clinically relevant targets with applications in both autoimmune disease and immuno-oncology (e.g., CD40, TACI, BCMA, 4-1BB, TNF). </span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The TNF Superfamily</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g3.jpg" style="height:196px;margin-bottom:5pt;vertical-align:text-bottom;width:500px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g3.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g3.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 3</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientists create engineered proteins from IgSF members (variant immunoglobulin domains, or vIgDs) and TNFSF/TNFRSF members (variant TNF domains, or vTDs). We use directed evolution, which is an iterative scientific engineering </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purposefully conducted to modify an IgSF and TNFSF/TNFRSF protein for a desired therapeutic function. The potential to create therapies capable of working within a formed immune synapse, forcing a synapse to occur, or preventing a synapse from occurring are important, novel attributes of our scientific platform.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> illustrates the process of directed evolution in our scientific platform. Our scientists utilize yeast display protein library strategies to identify variants of wild-type proteins with desired binding characteristics. We start with a wild-type IgSF or TNFSF/TNFRSF protein and then enter a cycle of library generation and yeast display. Flow cytometry or other methods are used to sort for yeast clones displaying variants with desired binding characteristics. Biologic and biophysical assays of purified proteins assess biological function and manufacturing characteristics. The end product is an optimized vIgD or vTD. Additional cycles can be carried out by building next generation libraries from the output of prior libraries to result in further optimization.</span></div><div style="margin-top:12pt;text-align:center"><img alt="alpn-20211231_g4.jpg" style="height:282px;margin-bottom:5pt;vertical-align:text-bottom;width:589px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g4.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g4.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 4</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific platform is generally able to improve upon native IgSF or TNFSF/TNFRSF activity regardless of whether natural binding </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affinity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is weak or strong. When starting affinity is very weak, techniques employed by our scientists have accomplished several thousand-fold increases in binding affinity with sometimes as few as two library generation cycles. Even when starting affinity is very high, our scientific platform can still improve binding affinities. The same general strategies can be used when the desired therapeutic profile requires reduced affinity compared to the wild-type protein. We have applied our scientific platform to several IgSF and TNFSF/TNFRSF protein targets.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our vIgDs and vTDs are highly flexible. In many cases, a single affinity-maturation campaign can result in multiple domains suitable for use in the formats such as those illustrated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 5 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and further described below.</span></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g5.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:500px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g5.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g5.jpg"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 5</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">vIgD-Fc</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">or vTD-Fc</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A vIgD- or vTD-Fc fusion protein is the simplest format. Our lead autoimmune/inflammatory program, acazicolcept, and lead oncology program, davoceticept, are both examples of vIgD-Fc formats. ALPN-303 is an example of a vTD-Fc format. The engineered vIgD or vTD protein is fused to an Fc backbone. Combining vIgDs or vTDs with antibody Fc domains to make Fc fusion </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proteins</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potentially allows for better expression, facilitates purification, and improves pharmacokinetic (dosing) properties. Fc fusion proteins are a standard format in the industry, with examples such as etanercept, abatacept, and belatacept. A vIgD- or vTD-Fc could potentially be administered intravenously, subcutaneously, topically, or via other methods of delivery.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Enhancement</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scientific</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform has also generated immune modulatory proteins with the potential of improving engineered cellular therapies, such as CAR-Ts, TCR-Ts, or TILs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acazicolcept, a</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Dual</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ICOS/CD28 Antagonist for Autoimmune/Inflammatory Diseases</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead autoimmune/inflammatory disease program, acazicolcept, is an Fc fusion protein of a human inducible T cell costimulator ligand, or ICOSL, vIgD designed to inhibit simultaneously the CD28 and ICOS T cell costimulatory pathways (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This vIgD is fused to an effectorless Fc backbone and is intended for the potential treatment of autoimmune/</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflammatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diseases. Notably, acazicolcept is not a bispecific antibody construct. A traditional bispecific might be constructed of one domain binding ICOS and one domain binding CD28. Instead, acazicolcept makes use of a novel single vIgD domain capable of binding both ICOS and CD28 engineered by our scientists using our proprietary scientific platform.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g6.jpg" style="height:291px;margin-bottom:5pt;vertical-align:text-bottom;width:566px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g6.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g6.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 6</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been long recognized to be required for nave T cell activation. The therapeutic inhibitors of the CD28 pathway (e.g., abatacept, CTLA4-Ig; and belatacept, a second generation CTLA4-Ig) have proven valuable for the treatment of some inflammatory arthritis conditions (rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis) and for the prevention of renal allograft rejection or graft versus host disease. However, therapeutic blockade of the CD28 pathway, primarily as studied with abatacept, has not been successful in several other inflammatory diseases (e.g., Crohns disease, lupus nephritis, multiple sclerosis) despite extensive evidence implicating T cells in disease pathogenesis and evidence of clinical biological activity. This suggests an additional pathogenic costimulatory pathway(s) remains unaddressed.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICOS is part of the CD28 costimulatory family of molecules, including PD-1, CD28, and CTLA-4. ICOS is related to CD28, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in contrast, is poorly expressed in nave T cells. ICOS is, however, rapidly induced upon T cell activation. It appears to be a dominant costimulatory pathway in at least some effector or pathogenic T cells, such as potentially in the absence of CD28. Elevated levels of ICOSexpressing T cells have been described in an increasing number of autoimmune/inflammatory diseases, correlating with disease activity. At the same time, inhibition of ICOS is effective in several preclinical inflammatory disease models. The ICOS pathway may therefore represent a major costimulatory pathway, nonredundant with CD28, and highly relevant to autoimmune/inflammatory diseases.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have performed a number of preclinical experiments demonstrating acazicolcept is active in both </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> models, several of which are described below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A potent immunomodulator of diseased cells</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acazicolcept inhibits cytokine production from human peripheral blood mononuclear cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> more potently than single </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (abatacept, or CTLA4-Ig) or ICOS (prezalumab, or anti-ICOSL mAb) pathway inhibitors alone or in combination (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g7.jpg" style="height:220px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g7.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g7.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 7</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sjgrens Syndrome Model</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sjgren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s syndrome is an autoimmune disease in which immune cells attack the glands that produce saliva and tears, as well as other internal organs. In an animal model of salivary gland inflammation (sialoadenitis), a key organ manifestation of Sjgrens syndrome, acazicolcept appeared more efficacious in reducing the incidence and severity of sialadenitis as compared to abatacept or wild-type ICOSL-Fc alone or in combination. These data were presented at the 2019 annual meeting of the ACR. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 8)</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g8.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:350px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g8.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g8.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 8</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemic Lupus Erythematosus Model</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acazicolcept has demonstrated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efficacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a preclinical model of SLE, a multiorgan autoimmune disease that that can lead to serious organ complications and death. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which evaluated acazicolcept in a bm12 inducible model of SLE, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with acazicolcept reduced serum titers of anti-dsDNA autoantibodies throughout the study compared to Fc control treatment. These data were presented at the 2019 annual meeting of the ACR. We evaluated acazicolcept in a Phase 1 healthy volunteer study and in the second quarter of 2021 initiated patient dosing in Synergy, a global, randomized, double-blind, placebo-controlled Phase 2 study of acazicolcept in adults with moderate-to-severe SLE.</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g9.jpg" style="height:213px;margin-bottom:5pt;vertical-align:text-bottom;width:425px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g9.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g9.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 9</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arthritis Model</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shows data from an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collagen-induced arthritis model. This model is designed to test a drugs ability to reduce inflammatory signals thought to play a role in rheumatoid arthritis, psoriatic arthritis, and other types of inflammatory arthritis </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the data presented at the 2019 annual meeting of the American College of Rheumatology, acazicolcept was superior to abatacept, a drug approved by the FDA to treat rheumatoid, psoriatic, and juvenile idiopathic arthritis.</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g10.jpg" style="height:213px;margin-bottom:5pt;vertical-align:text-bottom;width:425px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g10.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g10.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 10</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Xenograft GVHD Model</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acazicolcept has been studied in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mouse model of GVHD, a damaging and potentially fatal inflammatory disease frequently observed following allogeneic stem cell and/or bone marrow transplant treatments for cancer or other serious diseases. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> results represented in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> show acazicolcept had superior survival when dosed three times per week for four weeks compared to belatacept (an FDA-approved drug for prevention of renal allograft rejection - a type of inflammation-related rejection process analogous to GVHD. Belatacept is a more potent variant of abatacept, which is FDA-approved for the prevention of GVHD). In fact, 100% of acazicolcept multi-dose treated animals across three different dose levels survived. Animals given only a single dose of acazicolcept performed comparably to animals treated with belatacept dosed 3x/week for four weeks, demonstrating the potency and efficacy of acazicolcept in this disease model.</span></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g11.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:425px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g11.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g11.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 11</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of acazicolcept Program Preclinical Data</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientists and collaborators have demonstrated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical studies that acazicolcept:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">demonstrates a lower incidence and severity of sialadenitis, a model of Sjgrens syndrome, as compared to abatacept or wild-type ICOSL-Fc alone or in combination;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">reduces levels of pathogenic anti-dsDNA autoantibodies compared to an Fc control in an animal model of SLE; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">reduces disease severity and delays disease onset time relative to control in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> arthritis model with activity superior to abatacept, an FDA-approved drug for rheumatoid, psoriatic, and juvenile idiopathic arthritis;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">improves survival compared to belatacept in a humanized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mouse GVHD model;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">demonstrates control of colitis in an animal model of inflammatory bowel disease, or IBD; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">shows improved disease scores in an animal model of multiple sclerosis, or MS, compared to abatacept.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acazicolcept Clinical Development</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1 study of acazicolcept in healthy volunteers (NCT03748836). This study was designed to </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the safety and tolerability of single and multiple ascending intravenous and/or subcutaneous doses of acazicolcept. In addition, pharmacokinetics, pharmacodynamics and exploratory biomarkers were evaluated to help determine acazicolcepts potential for the treatment of autoimmune/inflammatory diseases. Results of the study were presented at the 2020 European Alliance of Associations for Rheumatology (EULAR) E-Congress and published in the peer-reviewed journal Clinical Translational Science (doi:10.1111/cts.12983). The first-in-human study randomized 96 healthy adults to receive single or multiple, intravenous or subcutaneous, placebo or acazicolcept at doses ranging from 1 g/kg to 10 mg/kg. At all dose levels, acazicolcept was well-tolerated, with no severe adverse events, clinically-significant immunogenicity events, or evidence of cytokine release. Pharmacokinetics and pharmacodynamics (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) exhibited desirable dose dependence, with increasing doses corresponding to increasing duration of complete, or near-complete target saturation, as well as inhibition of antibody responses to keyhole limpet hemocyanin, or KLH, immunization. </span></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g12.jpg" style="height:453px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g12.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g12.jpg"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 12</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">u</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pported by these results, and as part of the AbbVie Agreement, we initiated Synergy, an international, double-blind placebo-controlled Phase 2 study of acazicolcept in patients with SLE in mid-2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Davoceticept, a Conditional CD28 Costimulator and Dual PD-L1/CTLA-4 Inhibitor for Oncology</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immune checkpoint blockade using inhibitors of the cytotoxic T-lymphocyte antigen 4, or CTLA-4, or programmed death 1, or </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PD-1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pathways have been therapeutically successful for a wide variety of malignancies, dramatically altering the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment paradigm in oncology. However, the majority of patients treated with an inhibitor of CTLA-4, PD-1, or programmed death-ligand 1, or PD-L1, fail to respond or develop resistance, indicating that additional strategies to improve anti-tumor immunity and responses remain needed to improve outcomes. Because immune checkpoints like PD-1 and CTLA-4 appear to suppress anti-tumor immune responses in part by inhibiting the activating signals mediated by cluster of differentiation 28, or CD28 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), next generation immunotherapeutic strategies may substantially improve anti-tumor responses by activating a T cell (co-)stimulatory pathway(s) while also inhibiting a checkpoint pathway(s). Preferably, such activity might be focused primarily within the tumor microenvironment to limit potential systemic immune activation and toxicity.</span></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g13.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g13.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g13.jpg"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 13</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Davoceticept is an Fc fusion protein of a modified human cluster of differentiation 80, or CD80, vIgD designed to block the inhibitory immune checkpoints PD-L1 and CTLA-4, and to provide PD-L1-dependent T cell activation via CD28 costimulatory </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">receptor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As illustrated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 14</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, davoceticept binds PD-L1 expressed on the tumor, blocking PD-L1/PD-1 interactions. Localized to the tumor, davoceticept is able to provide a CD28 signal to T cells (PD-L1-dependent CD28 costimulation). Additionally, davoceticept binds CTLA-4 expressed on T cells and blocks CTLA4-CD80/CD86 interactions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:6pt;text-align:center"><img alt="alpn-20211231_g14.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g14.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g14.jpg"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 14</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> assays, we have characterized and validated the three primary mechanisms of action of davoceticept: conditional CD28 </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costimulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and dual PD-L1/CTLA-4 inhibition (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Importantly, CD28 costimulation with davoceticept requires both T cell receptor, or TCR, signaling and expression of PD-L1 on the antigen presenting cell, or APC. PD-L1 dependent T cell costimulation is a unique and key attribute of davoceticept which we believe may limit the risk for systemic toxicity while providing potent anti-tumor activity. </span></div><div style="margin-top:10pt;text-align:center"><img alt="alpn-20211231_g15.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g15.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g15.jpg"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 15</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Davoceticept </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also been validated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tumor models. In a mouse model where mice were implanted with MC38 mouse colon cancer tumors transfected with human PD-L1, davoceticept as a monotherapy demonstrated superior tumor control compared to durvalumab, an FDA-approved anti-PD-L1 monoclonal antibody (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g16.jpg" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g16.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g16.jpg"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Figure 17</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tumor-free</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> mice in the davoceticept arm were re-challenged with additional tumors, they continued to be tumor free despite no additional doses of davoceticept. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of davoceticept or durvalumab on various components of the immune system were compared using a technique called RNA sequencing in the tumor model. This technique generates a display of inflammatory gene signatures where green represents lower or no upregulation of inflammatory genes and red represents higher upregulation of inflammatory genes. For the treatment of cancer, it is thought the more upregulation of the immune system - indicated by higher upregulation of inflammatory genes - potentially results in better outcomes for patients. As seen in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, davoceticept upregulates a broader variety of different inflammatory genes connected with several different types of immune cells compared to durvalumab.</span></div><div style="margin-top:10pt;text-align:center"><img alt="alpn-20211231_g17.jpg" style="height:111px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g17.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g17.jpg"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Figure 18</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of davoceticept Preclinical Data</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have demonstrated in preclinical studies that davoceticept:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">exhibits three primary mechanisms of action: conditional CD28 costimulation and dual PD-L1/CTLA-4 inhibition;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">improves tumor control in a human PD-L1 transduced mouse model of colon cancer compared to the FDA approved anti PD-L1 therapeutic durvalumab; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">demonstrates a more robust intra-tumor inflammatory signature in the mouse colon cancer model than durvalumab, potentially indicating superior immune system upregulation to fight cancer; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">has the potential to be used as a monotherapy or in combination with standard of care chemotherapy or checkpoint only inhibition.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Davoceticept Clinical Development</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we initiated enrollment in NEON-1, our Phase 1 study in patients with advanced malignancies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEON-1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enrolls adults with advanced solid tumors or lymphoma refractory or resistant to standard therapy, including </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">checkpoint</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> inhibitors when indicated. Measurable disease is required for most participants, as are an ECOG status of 0 to 2 and adequate hematological, renal, and hepatic function. Safety endpoints include dose-limiting toxicities, adverse events, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circulating cytokines. Objective responses will be assessed by RECIST v1.1 for solid tumors and Lugano criteria for lymphoma. Pharmacokinetics and pharmacodynamics will also be evaluated. More information is available at www.clinicaltrials.gov (NCT04186637).</span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><img alt="alpn-20211231_g18.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:636px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g18.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g18.jpg"></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 19</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial data from NEON-1 were presented at the 2021 ASCO Virtual Meeting demonstrating that davoceticept was well-tolerated as of the cutoff date (April 22, 2021) with evidence of peripheral T cell modulation consistent with CD28 agonism. In </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, although most enrolled participants had tumors considered classically non-responsive to immunotherapies, the majority derived clinical benefit as defined as a best outcome of stable disease or better (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of dose escalation for NEON-1 and initiation of monotherapy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expansion cohorts, initially cutaneous melanoma and PD-L1+ (non-melanoma) tumors, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is anticipated in the first half of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g19.jpg" style="height:308px;margin-bottom:5pt;vertical-align:text-bottom;width:636px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g19.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g19.jpg"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 20</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we announced a collaboration and supply agreement with Merck to evaluate the safety and efficacy of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">davoceticept</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase 1 dose escalation and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expansion study. The clinical trial, NEON-2, was initiated in June 2021. More information for both NEON-1 (NCT04186637) and NEON-2 (NCT04920383) is available at www.clinicaltrials.gov.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 7, 2022, we announced that the FDA placed a partial clinical hold on the NEON-2 trial evaluating davoceticept in combination with pembrolizumab in adults with advanced malignancies. This partial clinical hold was prompted by report of a death of a study participant in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and ipilimumab, and had received a single dose each of davoceticept and pembrolizumab. The participants death was attributed to cardiogenic shock, considered by the treating physicians as likely related to immune-mediated myocarditis, or possibly infection. We are working closely with the FDA, Merck, the study Safety Monitoring Committee, and the study investigators to further understand this event and to evaluate the appropriate safety precautions before we resume enrollment of additional participants. Participants who are currently enrolled in the NEON-2 trial may continue to receive davoceticept and pembrolizumab, although no new participants may be enrolled until the partial clinical hold is resolved. This partial clinical hold does not affect the ongoing NEON-1 clinical trial of davoceticept as monotherapy (NCT04186637). </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPN-303, a Dual B Cell Cytokine Antagonist for B Cell-Mediated Autoimmune/Inflammatory Diseases</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">autoimmune</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diseases. Engineered using our proprietary directed evolution platform, ALPN-303 is an Fc fusion protein of a human transmembrane activator and CAML interactor, or TACI, variant TNFR domain, or vTD, that potently inhibits the pleiotropic B cell cytokines BAFF and APRIL. It mediates significantly improved combined BAFF and APRIL inhibition in vitro and enhanced pharmacokinetic and immunomodulatory properties in vivo, as compared to wild-type, or WT, TACI-Fc molecules. BAFF and APRIL are TNF superfamily members that bind TACI, BCMA, and/or BAFF-R on B cells and together support B cell development, differentiation, and survival. Their co-neutralization dramatically reduces B cell survival and function, including antibody production, whereas inhibition of either BAFF or APRIL alone mediates only modest effects (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). B cell targeting therapies like the WT TACI-Fc fusions atacicept and telitacicept have demonstrated promising clinical potential in B cell-related diseases like SLE but have not yet clearly exhibited long-term and/or complete disease remissions. ALPN-303, with enhanced inhibitory activity against BAFF &amp; APRIL, could further improve clinical outcomes.</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g20.jpg" style="height:328px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g20.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g20.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 21</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data on ALPN-303 presented at the ACR Convergence 2021 Annual Meeting demonstrated that ALPN-303 inhibited the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as anti-BAFF and anti-APRIL monoclonal antibodies. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 22</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ALPN-303 inhibited BAFF- and APRIL-mediated signaling in vitro with significantly lower IC50 values than WT TACI-Fc, anti-BAFF mAb, and anti-APRIL mAb comparators.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g21.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g21.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g21.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 22</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administration of ALPN-303 rapidly and significantly reduced key B lymphocyte subsets including plasma cells, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">germinal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> center, and follicular B cells in a KLH immunization mouse model (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 23</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:9pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g22.jpg" style="height:324px;margin-bottom:5pt;vertical-align:text-bottom;width:425px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g22.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g22.jpg"></div><div style="margin-top:9pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 23</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, treatment with ALPN-303 potently suppressed anti-dsDNA auto antibodies, proteinuria, sialoadenitis, kidney lesions, and renal immune complex deposition in the (NZBxNZW)F1 lupus model (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 24</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span><br></span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g23.jpg" style="height:343px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g23.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g23.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 24</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALPN-303 has been well-tolerated in nonclinical studies (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and exhibited superior pharmacokinetics and pharmacodynamics than wild-type TACI-Fc counterparts, including superior serum exposure and pharmacodynamic reduction of serum immunoglobulins in mice and/or cynomolgus monkeys (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Based on these data, we believe that ALPN-303 </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">represents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an attractive development candidate for the treatment of multiple autoimmune and inflammatory diseases, including SLE and other autoantibody-mediated diseases.</span></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g24.jpg" style="height:222px;margin-bottom:5pt;vertical-align:text-bottom;width:675px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g24.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g24.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 25</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><img alt="alpn-20211231_g25.jpg" style="height:278px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" data-src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g25.jpg" src="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-20211231_g25.jpg"></div><div style="margin-top:6pt;text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 26</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ALPN-303 Clinical Development</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in a first-in-human, Phase 1 study of ALPN-303 in healthy volunteers began in the fourth quarter of 2021, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> top-line results targeted by mid-2022. This randomized, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303 administered intravenously and subcutaneously. We are planning to initiate patient-based studies in the second half of 2022 including SLE, and possibly other autoantibody-related diseases in other therapeutic areas.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Research Programs</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our acazicolcept, davoceticept, and ALPN-303 programs, we have a number of other research efforts </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">underway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to address cancer and autoimmune/inflammatory diseases that we intend to continue to develop either internally or together with a partner. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnerships</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> addition to advancing programs internally, we continue to seek partners who can bring therapeutic area experience, development expertise, commercialization capabilities, and funding to maximize the potential of our existing programs and scientific platform.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Horizon (December 2021)</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the Horizon Agreement, pursuant to which we granted to Horizon rights to one of our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical biologic therapeutic programs, or the Existing Program, and agreed to collaborate with Horizon in the discovery, research and preclinical development of up to three additional autoimmune and inflammatory disease programs for other designated biological targets, or the Research Programs, and products arising from the Existing Program and the Research Programs, or the Agreement Products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Existing Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We granted to Horizon an exclusive, worldwide, royalty-bearing, sublicensable license under our intellectual property rights for the development, manufacture and commercialization of Agreement Products associated with the Existing Program, or the Existing Program Products, for all applications; however, Horizon has agreed not to pursue the Existing Program </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for oncology. In addition, we granted to Horizon a non-exclusive license to access our libraries of proteins and molecules for research, discovery and identification of additional compounds meeting the agreed criteria (subject to certain exceptions, including compounds reserved by us from the libraries, as set forth in the Horizon Agreement) which would be included in Horizons license.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will conduct our activities under the Existing Program and deliver compounds meeting the agreed criteria pursuant to one or more deliverables plans as mutually agreed by the parties. In addition, Horizon will pay us for the costs and expenses of conducting such activities under the deliverables plans.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research Programs</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Horizon Agreement, during a limited research term, we will conduct, together with Horizon, up to three Research </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for specified biological targets selected by Horizon (subject to certain exceptions, including targets reserved by us) to discover proteins and molecules with specified attributes and biological functions, pursuant to a mutually agreed research plan for each such Research Program. Each party has the right to reserve certain targets and to replace such reserved targets or reserve more targets (up to a fixed number) through a gatekeeper mechanism. We will deliver certain compounds meeting the agreed criteria for each Research Program as mutually agreed upon by the parties. Horizon will pay us for the costs and expenses for conducting its activities under the Research Programs. As agreed between the parties, Horizon will own the inventions and intellectual property developed from the Research Programs or otherwise associated with the Agreement Products arising therefrom.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties will establish a joint research committee composed of an equal number of representatives from each of Alpine </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Horizon, which will, among other responsibilities, oversee and govern the Existing Program and the Research Programs and review and approve research plans. The parties will also form a joint patent committee comprised of one or two representatives of each party to discuss strategy and facilitate communication and coordination for prosecution and maintenance of the relevant patents under the Horizon Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development, Manufacture, Regulatory and Commercialization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Horizon will have the sole right and responsibility for the development, manufacturing, regulatory and commercialization of all </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Agreement Products. We will provide Horizon reasonable assistance and cooperation. In addition, we have agreed during the term of the Horizon Agreement not to conduct or enable any third party to conduct the development, manufacture or commercialization of certain competing products as set forth therein.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transaction, Horizon made an upfront payment to us of $25.0 million as well as an equity </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for which they paid $15.0 million, a 25 percent premium to the 30-day volume-weighted average share price as of December 9, 2021.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> addition to the upfront payment and equity consideration, Horizon has agreed to make milestone payments to us upon our achievement of certain preclinical, clinical and regulatory and commercialization milestones, up to an aggregate amount of $381.0 million per program, or approximately $1.5 billion in total, if all milestones are met.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Horizon has further agreed to pay the Company royalties based on future net sales of the Agreement Products. For the Existing Program, such royalty percentages range from a mid-single digit percentage to a low double-digit percentage of net sales, with the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty rate depending on the aggregate net sales. For each Research Program, such royalty percentages are in a range of mid-single digit percentages of net sales, with the specific royalty rate depending on the aggregate net sales. Horizons obligations to pay royalties with respect to an Agreement Product and country will expire after specific criteria for such Agreement Product in such country including it no longer being covered by valid claims of applicable patent rights in such country, or the Royalty Term. Royalty payments are subject to reduction in specified circumstances, including expiration of patent rights, biosimilar competition, or Horizon is required to make payments to a third party with respect to an Agreement Product.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Horizon Agreement remains in effect until the expiration of the Royalty Term for all </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Products. The Horizon Agreement is subject to customary termination provisions including termination by a party for the other partys uncured, material breach. Additionally, Horizon may terminate the Horizon Agreement with specified prior notice in its entirety or on a Program-by-Program basis, for any or no reason.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the event of certain terminations of the Horizon Agreement, at our request, the parties will negotiate one or more licenses for us to develop, manufacture and commercialize terminated Agreement Products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Horizon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Agreement includes certain other customary terms and conditions, including mutual representations and warranties, indemnification and confidentiality provisions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with AbbVie (June 2020)</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June 2020, we entered into the AbbVie Agreement, which grants to AbbVie an exclusive option to take an exclusive license </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acazicolcept</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or the License Option.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the terms of the AbbVie Agreement we granted to AbbVie an exclusive option to obtain an exclusive, royalty-bearing, sublicensable license to certain intellectual property rights for the research, development and commercialization of acazicolcept and any other molecule owned or controlled by us that binds to or directly modulates or targets ICOS at certain agreed-upon levels, or the Compounds, on a worldwide basis for all human and non-human diagnostic, prophylactic and therapeutic uses, subject to certain exceptions set forth in the AbbVie Agreement. The License Option is immediately exercisable and will expire 90 days following our delivery of the data package described below to AbbVie, subject to certain exceptions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or the HSR Act, if required.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the AbbVie Agreement, AbbVie paid us a nonrefundable upfront payment of $60.0 </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash. If AbbVie exercises its License Option, they will pay a one-time cash payment of $75.0 million.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment and License Option payment, AbbVie has agreed to make cash payments upon our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">achievement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of certain development milestones, the Alpine Development Milestones, prior to the exercise of the License Option as set forth in a written development plan, up to an aggregate amount of $75.0 million. In the second quarter of 2021, we achieved $45.0 million of the Alpine Development Milestones. Following the exercise of the License Option, AbbVie has agreed to make cash payments of up to $205.0 million upon AbbVies achievement of certain development and commercial milestones and additional cash payments of up to $450.0 million upon AbbVies achievement of certain sales-based cash milestones. AbbVie has further agreed to pay royalties from a high-single digit percentage to a low double-digit percentage of net sales of any pharmaceutical product that contains a Compound, or a Licensed Product, with the specific royalty rate depending on the aggregate net sales. AbbVies obligations to pay royalties with respect to a Licensed Product and country will expire upon the latest of the expiration of the last to expire valid patent claim applicable to such Licensed Product in such country, 10 years from the first commercial sale of the Licensed Product in such country, and the expiration of regulatory exclusivity for such Licensed Product in such country. Royalty payments are subject to reduction in specified circumstances, including expiration of patent rights, if average net sales decrease by a certain percentage after the introduction of a generic product, or if AbbVie is required to pay amounts to a third party in order commercialize a Licensed Product in a particular country.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development Activities</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the exercise of the License Option, we will conduct acazicolcept development efforts as per a development plan </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for, among other things, the generation of a data package in order for AbbVie to evaluate exercising the License Option and an itemized budget for such activities, including all activities reasonably necessary to conduct a Phase 2 clinical study of acazicolcept for the treatment of systematic lupus erythematosus; all non-clinical activities; and all CMC activities agreed to under the development plan. We will be fully responsible for all costs incurred to conduct our activities, provided that, AbbVie may be responsible for increased costs under the development plan in connection with certain material amendments agreed upon with AbbVie.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the exercise of the License Option, we will be solely responsible, at our sole cost and expense, for preparing, filing and maintaining regulatory documentation, which AbbVie will be entitled to access and review. We will also be responsible for any and all correspondence with the applicable regulatory authorities and for maintaining all data related to acazicolcept. We will be solely responsible, at our sole cost and expense, for manufacturing the compounds necessary to complete the development activities consistent with the development plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parties will establish a joint governance committee, or JGC, composed of an equal number of representatives from each of Alpine and AbbVie, which will, among other responsibilities, coordinate and oversee the development activities, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approve amendments to the development plan and discuss interactions with regulatory authorities. The chairperson of the JGC will be appointed by AbbVie. AbbVie may disband the JGC, at its sole discretion, following the exercise of the License Option.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercialization</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon AbbVies exercise of the License Option, AbbVie and its affiliates will be solely responsible, at AbbVies sole cost and expense, for the development, manufacture, commercialization, and regulatory compliance of any Licensed Product. Following exercise of the License Option, AbbVie shall use commercially reasonable efforts to develop and seek regulatory approval for one of the compounds in one indication in each of the United States and one of the United Kingdom, Germany, France, Spain, or Italy, or the Major Markets, and, following receipt of any such regulatory approval, commercialize the compound in such country.</span></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Changes in Control</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will notify AbbVie immediately upon the closing of any change in control (as defined in the AbbVie Agreement) during the term of the AbbVie Agreement. Following the delivery of such notice, AbbVie may, in its sole and absolute discretion, elect to continue the AbbVie Agreement subject to certain modifications as set forth in the AbbVie Agreement, including the assumption by AbbVie of responsibility to perform certain activities previously assigned to us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Term and Termination</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the AbbVie Agreement shall terminate either: (i) in the event that the License Option is not exercised by AbbVie, the first day following the last day of the License Option exercise period; or (ii) in the event that the License Option is exercised by AbbVie, the date of the expiration of the last Royalty Term for the last Licensed Product.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both us and AbbVie may terminate the AbbVie Agreement upon written notice in the event of a material breach by the other party that has not been cured within a 90-day cure period. However, if the uncured material breach is with respect to AbbVies obligation to use commercially reasonable efforts to obtain regulatory approval for and commercialize a Licensed Product with respect to any Major Market (but not all Major Markets), then we will only be entitled to terminate the AbbVie Agreement with respect to such Major Market(s). Both AbbVie and us may also terminate the AbbVie Agreement upon written notice if the other party voluntarily or involuntarily files for bankruptcy or insolvency, makes an assignment for the benefit of creditors, has a receiver or trustee appointed over substantially all of such other partys property, proposes or is party to any dissolution or liquidation, or admits in writing its inability generally to meet such other partys obligations as they fall due in the general course.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie may terminate the AbbVie Agreement in its entirety or on a country-by-country basis, for any or no reason, by providing at least 90 days prior written notice to us. AbbVie may also terminate the AbbVie Agreement upon notice to us if (i) either we or AbbVie receives a second request for additional information under the HSR Act, provided AbbVies notice of termination is delivered within ten business days after AbbVie becomes aware of such request or receives notice from us regarding such request or (ii) the License Option has not been exercised or clearance under the HSR Act, if required, has not occurred within 180 days of submission of the parties request for such clearance, provided AbbVies notice of termination is delivered within ten business days after the end of such 180-day period.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the termination of the AbbVie Agreement in its entirety for any reason, all licenses and other rights granted (i) to AbbVie by us and (ii) to us by AbbVie shall terminate. Upon termination in certain circumstances, AbbVie has agreed to grant to us licenses to certain intellectual property that is reasonably necessary, and that was actually used by AbbVie for the development, manufacturing or commercialization of the terminated products, to research, develop and commercialize the terminated products in the terminated countries.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In lieu of terminating the AbbVie Agreement in connection with an uncured material breach or the bankruptcy or insolvency of the Company, AbbVie may alternatively elect to continue the AbbVie Agreement subject to certain modifications, including that AbbVie will be entitled to conduct activities allocated to us under the Development Plan, subject to reimbursement by us for AbbVies out-of-pocket expenses in connection with such activities. If AbbVies right to terminate in connection with an uncured material breach or the bankruptcy or insolvency of the Company arises before exercise of the License Option, then the License Option exercise payment amount will be reduced by half and the amount of any then-unearned milestone payments will be reduced by half. If AbbVies right to terminate arises after exercise of the License Option, then the amount of any then-unearned milestone payments will be reduced by 25%.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AbbVie Agreement includes certain other customary terms and conditions, including mutual representations and warranties, indemnification and confidentiality provisions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Adaptimmune Therapeutics (May 2019)</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a collaboration and license agreement with Adaptimmune, or the Adaptimmune Agreement, to develop next-generation SPEAR T cell products which incorporate our secreted and transmembrane immunomodulatory protein (termed SIP and TIP) technology. We and Adaptimmune will collaborate on a specified number of programs to develop SIP and TIP candidates with tailored affinities and modulatory activities that may enhance the anti-tumor responses seen with Adaptimmunes SPEAR T cells. For each program, Adaptimmune has an option to take a worldwide exclusive license for development and commercialization of SPEAR T cell products incorporating the developed SIP or TIP candidate for the treatment of cancer. Under the terms of the collaboration agreement, Adaptimmune provided an upfront payment and will provide research funding for ongoing programs. In addition, we may be eligible for downstream development and commercialization milestones up to $288.0 million, if all pre-specified milestones for each program are achieved. In addition, we are eligible to receive low-single digit royalties on worldwide net sales of the applicable products. In February 2022, Adaptimmune selected an additional research program, triggering a $1.0&nbsp;million upfront payment, which will be recorded as deferred revenue upon receipt and recognized to revenue based on employee hours contributed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established in-house non-current good manufacturing practices, recombinant protein generation capabilities enabling our scientific platform, including validation of new scientific discoveries in vitro and in vivo. Having protein production capabilities in-house allows more rapid progression for vIgDs and vTDs generated by our scientific platform.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have chosen U.S.-based contract drug substance and U.S. and Australian drug product manufacturers for our initial current good manufacturing practices, or cGMP, clinical trial supplies of acazicolcept, davoceticept and ALPN-303. We believe these contract manufacturers particular expertise in protein production, analytical development and fill/finish provide us with the capability to meet rapid timelines encompassing the development of production cell-lines to manufacturing of clinical trial quantities of the biopharmaceutical product.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have successfully completed two cGMP manufacturing campaigns for acazicolcept and one cGMP campaign each for davoceticept and ALPN-303 and believe we have produced sufficient quantities of drug product necessary to execute our stated Synergy, NEON-1, NEON-2, and ALPN-303 Healthy volunteer clinical trials. We have not yet manufactured any of our proteins at commercial scale. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the highly competitive sector of biotechnology and pharmaceuticals and in the subsector of immune modulation. This subsector has undergone tremendous technological advancement over the last decade due to advancements in understanding the role of the immune system across multiple therapeutic areas, including oncology and autoimmune/inflammatory disease. While we believe our novel technology platform, discovery programs, knowledge, experience, and scientific resources offer competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, public and private research institutions, and others.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products we successfully develop and commercialize will face competition from currently approved therapies and new therapies potentially available in the future.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies we compete against may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, our competitors include companies developing therapies with the same target(s) as acazicolcept, davoceticept and ALPN-303 as well as companies building novel platforms to generate immunomodulatory multi-specific antibody or non-antibody-based targeting proteins, particularly in the area of oncology or autoimmunity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the risk factor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to us. If these companies develop technologies or therapeutic candidates more rapidly than we do, or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A of this report for more discussion of the effects of competition and competitors on our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acazicolcept Program Competitors (ICOSL/CD28)</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competitors listed below have programs targeting either ICOS or CD28 (or one of their ligands) for autoimmune and inflammatory diseases. To our knowledge, there are currently no competitors with a single molecule targeting ICOS and CD28 simultaneously.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an anti-BAFF, anti-ICOSL bispecific antibody being developed by Amgen, Inc. (rozibafusp alfa (AMG570/MEDI0700));</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an anti-CD28 monoclonal antibody fragment being developed by OSE ImmunoTherapeutics SA and Veloxis Pharmaceuticals Inc., a subsidiary of Asahi Kasei (FR104); </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an anti-CD28 peptide being developed by AtoxBio, Inc. (reltecimod (AB-103));</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an anti-CD28 monoclonal antibody being development by TheraMAB (TAB08); and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">CTLA-4-Fc fusion proteins targeting CD80 and CD86 being marketed Bristol Myers Squibb (abatacept and belatacept).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Davoceticept Program Competitors</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous clinical trials for immuno-oncology products used as a single agent or in combination. One of the potentially novel attributes of the davoceticept program is that it has exhibited conditional CD28 costimulation and dual checkpoint inhibition in a single molecule interacting with multiple immune targets.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of additional multi-target compounds for immuno-oncology are highlighted below. To our knowledge, there are currently no competitors with a single molecule capable of dual PD-L1/CTLA-4 antagonism and PD-L1-dependent CD28 agonism.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">wild-type CD80-Fc being developed by Five Prime Therapeutics, Inc., which was purchased by Amgen Inc. (FPT155);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific antibodies being developed by Regeneron targeting tumor specific antigens and CD28 (REGN5678 anti-PSMAxCD28, REGN5668 anti-MUC16xCD28, and REGN7075 anti-EGFRxCD28);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">trispecific antibodies being developed by Sanofi (CD3xCD38xCD28) (SAR442257) and SAR443216 (CD3xCD28xHER2);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bifunctional fusion protein composed of monoclonal antibody against PD-L1 fused to the extracellular domain of human transforming growth factor-, or TGF-, receptor II being developed by EMD Serono, Inc. (bintrafusp alfa, or M7824);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bifunctional fusion protein composed of PD-1 and OX40L developed by Shattuck Labs, Inc. (SL-279252);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific fusion protein targeting 4-1BBL and PD-1 being developed by Shattuck Labs, Inc. (SL-279137);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific fusion protein targeting 4-1BB and PD-L1 being developed by Pieris Pharmaceuticals, Inc. and Servier Laboratories (PRS-344/S095012);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody targeting 4-1BB and PD-L1 being developed by Genmab A/S and BioNTech SE (GEN1046);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">trispecific monoclonal antibody/fusion targeting 4-1BB and PD-L1 being developed by Numab Therapeutics AG and CStone Pharmaceuticals Co., Ltd. (NM021/NM21-1480);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody targeting 4-1BB and PD-L1 being developed by Merus NV and Incyte Corporation (MCLA-145);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific antibody 4-1BB and PD-L1 being developed by Inhibrx, Inc. and Elpiscience Biopharma Ltd. (INBRX-105);</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody targeting 4-1BB and PD-L1 being developed by F-star Biotechnology Ltd. (FS-222);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific fusion protein targeting 4-1BB and PD-L1 being developed by Kahr Medical Ltd., (DSP105);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody/fusion protein targeting 4-1BB and PD-L1 being developed by ABL, Inc., and I-Mab Biopharma Co., Ltd. (ABL503/TJ-L14B);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody targeting PD-L1 and LAG-3 being developed by F-star Biotechnology Ltd. (FS118);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibodies being developed by Xencor, Inc. including XmAb808 targeting CD28 and B7-H3, Vudalimab/XmAb20717 targeting CTLA-4 and PD-1, XmAb841/XmAb22841 targeting CTLA-4 and LAG-3, XmAb104/XmAb23104 targeting PD-1 and ICOS, and additional preclinical CD28 bispecific antibody programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific constructs called DARTs being developed by Macrogenics Inc., including Tebotelimab (MGD013) targeting PD-1 and LAG-3 and Lorigerlimab MGD019) targeting PD-1 and CTLA-4;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">DARPin therapeutic candidate targeting 4-1BB and FAP being developed by Molecular Partners AG and Amgen, Inc (MP0310/AMG 506);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody targeting 4-1BB and FAP being developed by Tesaro, Inc., which was purchased by GlaxoSmithKline plc, targeting PD-1 and LAG-3;F. Hoffmann-La Roche AG (RO7122290);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">bispecific monoclonal antibody targeting 4-1BB and HER-2 being developed by Pieris Pharmaceuticals, Inc. (cinrebafusp alfa or PRS-343); </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">small molecule antagonists being developed by Aurigene Ltd. and Curis, Inc., including CA-170 targeting PD-L1 and VISTA and CA-327 targeting PD-L1 and TIM-3;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">various combinations of separate anti PD-1/L1 and anti-CTLA-4 monoclonal antibodies; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">various combinations of separate anti PD-1/L1 and costimulatory monoclonal antibodies such as OX-40, 4-1BB, and others.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ALPN-303 Program Competitors</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The competitors listed below have programs targeting either the TACI, BCMA, or BAFF pathway for autoimmune disease. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Anti-BAFF antibody marketed by GSK plc (belimumab);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">TACI-Fc being developed by Vera Therapeutics (atacicept);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">TACI-Fc being developed by RemeGen Ltd. (telitacicept (RC18));</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Anti-BAFF-R IgG1 being developed by Novartis AG (Ianalumab (VAY736));</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Anti-APRIL antibody being developed by Visterra, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. (sibeprenlimab (VIS649));</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Anti-BAFF, anti-ICOSL bispecific antibody being developed by Amgen, Inc. (rozibafusp alfa (AMG570/MEDI0700)); </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Anti-APRIL antibody being developed by Chinook Therapeutics, Inc. (BION-1301); and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a recombinant Fc fusion protein designed to block BAFF and APRIL cytokines being developed by Aurinia Pharmaceuticals Inc. (AUR200).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Platform Competitors</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multifunctional therapeutic protein platforms potentially competitive with our platform include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Amgen Inc. (BiTE): fusion proteins consisting of two single-chain variable fragments to link T cells to tumors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Macrogenics, Inc. (DART): Dual-Affinity Re-Targeting and Trident technology platforms bind multiple targets with a single molecule; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Xencor, Inc. (XmAb Bispecific): Optimized Fc domains for improved potency, half-life and stability;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Zymeworks, Inc. (Azymetric): Proprietary amino acid modifications to facilitate interaction of distinct heavy chains;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Pieris Pharmaceuticals, Inc. (Anticalin): Engineered proteins derived from natural lipocalins found in blood plasma; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Compass Therapeutics, LLC (Targeted Immunomodulation, StitchMabs): Antibody discovery targeting the tumor-immune synapse;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Harpoon Therapeutics, Inc.: TriTAC (Tri-specific T cell Activating Construct) contain CD3 binding domain, half-life extension domain, and antigen-binding domain;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Shattuck Labs, Inc.: Agonist Redirected Antibody platform claimed to bind tumor-necrosis factor (TNF) and checkpoint targets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Ablynx NV (Nanobody), purchased by Sanofi Pharma, Inc.: Platform technology of single-domain, heavy-chain antibody fragments derived from camelidae (e.g., camels and llamas);</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Regeneron, Inc.: VEGF Trap and VelociSuite antibody technology platforms;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Five Prime Therapeutics, Inc., purchased by Amgen Inc.: Proprietary protein library and rapid protein production and testing platform; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Merus N.V. (Merus Multiclonics including Biclonics and Triclonics): Discovery, screening, and identification platform for bispecific and trispecific antibodies.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific platform and substantially all our intellectual property have been developed internally. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, our patent portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 47 granted patents and over</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 155</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Several of our initial patent applications are directed to our scientific platform itself. Other patent applications in our portfolio are directed to various target domains and research programs under development. Each of these patent applications is solely owned by us. As we continue the development of our scientific platform and target vIgDs, we intend to continue pursuing intellectual property protection for these technologies.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in-licensed some intellectual property and trade secret materials on a non-exclusive basis. To date, such non-exclusive in-licenses are solely related to commercially-available cell lines involved in the manufacture of our vIgD programs. To date, no other intellectual property related to our scientific platform has been in-licensed.&nbsp;We have out-licensed two programs under our TIP/SIP technology to Adaptimmune on an exclusive basis. Additionally, pursuant to the AbbVie Agreement, we have granted AbbVie an exclusive option to purchase an exclusive worldwide license to acazicolcept. If AbbVie exercises the License Option, AbbVie will take over the future development and commercialization. Finally, pursuant to the Horizon Agreement, we have granted Horizon an exclusive license of certain intellectual property and have entered into a collaboration for the development and commercialization of up to four preclinical candidates generated from Alpines unique discovery platform. These candidates include previously undisclosed multi-specific fusion protein-based therapeutic candidates for autoimmune and inflammatory diseases. No other out-licenses have been made. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not believe our technology infringes any intellectual property rights owned by third parties, we are aware of one or more patents and patent applications that may relate to our technology. Third parties may assert claims against us alleging infringement of their intellectual property rights regardless of whether their allegations have merit. Allegations of infringement could harm our reputation, may result in the expenditure of significant resources to defend and resolve such allegations, and could require us to pay monetary damages if we are found to have infringed any third-party intellectual property rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements on the clinical development, manufacture, marketing, and distribution of therapeutic candidates. These agencies and other federal, state, and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, and export and import of therapeutic candidates and products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drugs, medical devices, and biologic products under the Federal Food, Drug, and Cosmetic Act, or FFDCA, its implementing regulations and other laws, including, in the case of biologics, the Public Health </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service Act. Our potential therapeutic candidates and products will be subject to regulation by the FDA as biologics. Biologics require the submission of a Biologics License Application, or BLA, and approval by the FDA before being marketed in the U.S. None of our therapeutic candidates have been approved by the FDA for marketing in the U.S., and we currently have no BLAs pending. If we fail to comply with applicable FDA or other requirements at any time during the product development process, clinical testing, the approval process, or after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDAs refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal prosecution. Any FDA enforcement action could have a material adverse effect on us. The process required by the FDA before biologic therapeutic candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">completion of extensive preclinical laboratory tests, preclinical animal studies, and formulation studies all performed in accordance with the FDAs current good laboratory practice, or cGLP, regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">submission to the FDA of an Investigational New Drug, or IND, application which must become effective before human clinical trials in the U.S. may begin;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">submission to the FDA of a BLA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP regulations; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">FDA review and approval of the BLA prior to any commercial marketing, sale, or shipment of the therapeutic product.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain any approvals for our therapeutic candidates will be granted on a timely basis, if at all.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a therapeutic candidate is identified for development, it enters the preclinical testing stage. Preclinical studies include laboratory evaluations of protein chemistry, formulation, and stability, as well as studies to evaluate toxicity in animals. The results of the preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. Currently, the IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may result in the FDA not allowing the clinical trials to commence or not allowing the clinical trials to commence on the terms originally specified in the IND. A separate submission to an existing IND must also be made for each successive clinical trial conducted during drug development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the therapeutic candidate to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND. For each medical center proposing to conduct a clinical trial, an institutional review board, or IRB, must also review and approve a plan for any clinical trial before it can begin at that center and the IRB must monitor the clinical trial until it is completed. The FDA, an IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive Good Clinical Practice requirements, including the requirements for informed consent.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical research performed in the U.S. in support of a BLA must be authorized in advance by the FDA under the IND regulations and procedures described above. However, a sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA so long as the clinical trial is conducted in compliance with an international guideline for the ethical conduct of clinical research known as the Declaration of Helsinki and/or the laws and regulations of the country or countries in which the clinical trial is performed, whichever provides the greater protection to the participants in the clinical trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of BLA submission and approval, clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Phase 1 clinical trials are initially conducted in a limited population of subjects to test the therapeutic candidate for safety, dose tolerance, absorption, metabolism, distribution, and excretion in healthy humans or, on occasion, in patients with severe problems or life-threatening diseases to gain an early indication of its effectiveness.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Phase 2 clinical trials are generally conducted in a limited patient population to evaluate preliminary efficacy of the therapeutic candidate for specific targeted indications in patients with the disease or condition under study, evaluate dosage tolerance and appropriate dosage, determine a dosage schedule, and identify possible adverse effects and safety risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Phase 3 clinical trials are commonly definitive efficacy studies of the experimental medication. Phase 3 trials are typically conducted when Phase 2 clinical trials demonstrate a dose range of the therapeutic candidate is effective and has an acceptable safety profile. Phase 3 clinical trials are generally undertaken with large numbers of patients, such as groups of several hundred to several thousand, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded patient population at multiple, geographically-dispersed clinical trial sites.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may condition approval of a BLA on the sponsors agreement to conduct additional post-approval clinical trials to further assess the biologics safety and effectiveness after BLA approval. Such post-approval clinical trials are typically referred to as Phase 4 clinical trials.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the chemistry and physical characteristics of the biologic and finalize a process for manufacturing the biologic in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the therapeutic candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the therapeutic candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, as a result of the COVID-19 pandemic, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, the FDA has issued guidance on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including certain reporting requirements, and additional guidance on the good manufacturing practice considerations for responding to COVID-19 infection and other topics. We may be required to make further adjustments to our clinical trials or business operations based on current or future guidance and regulatory requirements as a result of the COVID-19 pandemic.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics License Applications</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies and of the clinical trials, together with other detailed information, including extensive manufacturing information and information on the chemistry, pharmacology, clinical pharmacology, and the clinical effects of the biologic, are submitted to the FDA in the form of a BLA requesting approval to market the biologic for one or more specified indications. The FDA reviews a BLA to determine, among other things, whether a biologic is safe, pure, and potent and whether the facility in which the biological product is manufactured, processed, packed, or held meets standards designed to assure the biological product continues to be safe, pure, and potent.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been accepted for filing, by law the FDA will review the application and respond to the applicant, but the review process may be significantly delayed by FDAs requests for additional information or clarification. Under the Prescription Drug User Fee Act, the FDA evaluates a standard original BLA submission within the first 60 days of its receipt to determine if it is sufficiently complete to conduct a full review, and the FDA has a goal of responding to the submission within ten months of the 60-day filing date, but this timeframe is often extended. The FDA may refer the application to an advisory committee for review, evaluation, and/or recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The FDA may deny approval of a BLA if the applicable statutory and regulatory criteria are not satisfied, or for any reason, or it may require additional clinical data. Even if such data are submitted, the FDA may ultimately decide the BLA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret data. Once the FDA approves a BLA, or supplement thereto, the FDA may withdraw the approval if ongoing regulatory requirements are not met or if safety problems are identified after the biologic reaches the market. Where a withdrawal may not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">be appropriate, the FDA still may seize existing inventory of such biologic or require a recall of any biologic already on the market. In addition, the FDA may require testing, including Phase 4 clinical trials and surveillance programs to monitor the effect of approved biologics which have been commercialized. The FDA has the authority to prevent or limit further marketing of a biologic based on the results of these post-marketing programs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may also seek approval of its therapeutic candidates under programs designed to accelerate FDA review and approval of BLAs. For instance, a sponsor may seek FDA designation of a therapeutic candidate as a fast track product. Fast track products are those products intended for the treatment of a serious or life-threatening disease or condition and which demonstrate the potential to address unmet medical needs for such diseases or conditions. If fast track designation is obtained, the FDA may initiate review of sections of a BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the remaining information. In some cases, a fast track product may be approved on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments, under the FDAs accelerated approval program. Approvals of this kind typically include requirements for appropriate post-approval confirmatory clinical trials to validate the surrogate endpoint or otherwise confirm the effect of the clinical endpoint.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established a new category of drugs referred to as breakthrough therapies that may be subject to accelerated approval. A sponsor may seek FDA designation of a drug candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutic candidates may also be eligible for priority review, or review within a six-month timeframe from the 60-day filing date, if a sponsor provides sufficient clinical data demonstrating its therapeutic candidate provides a significant improvement compared to marketed products. Even if a therapeutic candidate qualifies for one or more of these programs, the FDA may later decide the therapeutic candidate no longer meets the conditions for qualification or that the period for FDA review or approval will be lengthened. When appropriate, we intend to seek fast track designation and/or accelerated approval for our biologics. We cannot predict whether any of our therapeutic candidates will obtain a fast track and/or accelerated approval designation and, if so, whether such designation will be maintained or rescinded by FDA, or the ultimate impact, if any, of the fast track or the accelerated approval process on the timing or likelihood of FDA approval of any of our proposed biologics.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the biologic, including changes in indications, labeling, or manufacturing processes, equipment, or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require us to develop additional data or conduct additional preclinical studies and clinical trials.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an application, the FDA will inspect the facility or the facilities at which the biologic product is manufactured and will not approve the product unless cGMP compliance is satisfactory. The FDA may also inspect the sites at which the clinical trials were conducted to assess their compliance and will not approve the biologic unless compliance with Good Clinical Practice requirements is satisfactory.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing and approval processes require substantial time, effort, and financial resources, and each may take several years to complete. The FDA may not grant approval on a timely basis, or at all. Even if we believe a clinical trial has demonstrated safety and efficacy of one of our therapeutic candidates for the treatment of a disease, the results may not be satisfactory to the FDA. Preclinical and clinical data may be interpreted by the FDA in different ways, which could delay, limit, or prevent regulatory approval. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals which could delay or preclude us from marketing our therapeutic candidates. The FDA may limit the indications for use or place other conditions on any approvals restricting the commercial application of the products. After approval, certain changes to the approved biologic, such as adding new indications, change in personnel, manufacturing changes, or additional labeling claims, are subject to further FDA review and approval. Depending on the nature of the change proposed, a BLA supplement which may require additional studies to evaluate the effect of such change on the identity, strength, quality, purity, or potency of the product as they may relate to the safety or effectiveness of the productmust be filed and approved before the change may be implemented. As with new BLAs, the review process for BLA supplements may be delayed by the FDA through requests for additional information or clarification.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe any of our therapeutic products approved as a biological product under a BLA might qualify for a 12-year period of exclusivity currently permitted by the Biologics Price Competition and Innovation Act, or BPCIA. Specifically, the BPCIA established an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The new abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be submitted by an applicant until four years after the date the reference product was first licensed and cannot be approved by the FDA until 12 years after the original branded product was first licensed under a BLA. There is a risk the U.S. Congress could amend the BPCIA to significantly shorten this exclusivity period or the FDA will not consider our therapeutic candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. The BPCIA is complex and is only beginning to be interpreted and implemented by the FDA and the courts. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes operating to limit the scope or length of exclusivity afforded by the BPCIA could have a material adverse effect on the future commercial prospects for our biological products. In addition, foreign regulatory authorities may also provide for exclusivity periods for approved biological products or for abbreviated pathways for follow on biological products. For example, biological products in Europe may be eligible for a 10-year period of exclusivity.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to therapeutic candidates intended to treat a rare disease or condition, which is generally a disease or condition affecting fewer than 200,000 individuals in the U.S. or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation the cost of developing and making available in the U.S. a therapeutic candidate for this type of disease or condition will be recovered from sales in the U.S. for that therapeutic candidate. Orphan drug designation must be requested before submitting a marketing application for the therapeutic for that particular rare disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The FDA may revoke orphan drug designation, and if it does, it will publicize the drug is no longer designated as an orphan drug. If a therapeutic candidate with orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the therapeutic candidate is entitled to orphan product exclusivity, which means the FDA may not approve any other applications to market the same therapeutic candidate for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same therapeutic candidate as defined by the FDA or if our therapeutic candidate is determined to be contained within the competitors therapeutic candidate for the same indication or disease.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the therapeutic candidate in children. The FDA may not issue a Written Request for studies on unapproved or approved indications where it determines information relating to the use of a therapeutic candidate in a pediatric population, or part of the pediatric population, may not produce health benefits in that population. In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for most therapeutic candidates and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or New Drug Applications, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDAs, BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the therapeutic candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the therapeutic candidate is safe and effective. The sponsor or the FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or additional safety or effectiveness data needs to be collected before the pediatric studies begin. The FDA must send a noncompliance letter to any sponsor that fails to submit the required assessment, keep a deferral current, or fails to submit a request for approval of a pediatric formulation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any biologics manufactured or distributed by us or our collaborators pursuant to FDA approvals would be subject to continuing regulation by the FDA, including recordkeeping requirements and reporting of adverse experiences associated with the product. Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements upon us and third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. Our company cannot be certain it or its present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements. If our company or its present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA may halt our clinical trials, require us to recall a drug from distribution, or withdraw approval of the BLA for the therapeutic product.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A company can make only those claims relating to safety and efficacy approved by the FDA. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. Physicians may prescribe legally available biologics for uses not described in the products labeling and different from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers communications regarding off-label use.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, Congress passed the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, which we refer to as the ACA, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry, and impose additional policy reforms. The ACA contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes, and fraud and abuse, impacting existing government healthcare programs and resulting in the development of new programs, including Medicare payment for performance initiatives, and improvements to the physician quality reporting system and feedback program. The Affordable Care Act also does, among other things, the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Increases pharmaceutical manufacturer rebate liability under the Medicaid Drug Rebate Program due to an increase in the minimum basic Medicaid rebate on most branded prescription drugs, and the application of Medicaid rebate liability to drugs used in risk-based Medicaid managed care plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Expands the 340B Drug Pricing Program to require discounts for covered outpatient drugs sold to certain childrens hospitals, critical access hospitals, freestanding cancer hospitals, rural referral centers, and sole community hospital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Requires pharmaceutical companies to offer discounts on brand-name drugs to patients who fall within the Medicare Part D coverage gap, commonly referred to as the Donut Hole.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Requires pharmaceutical companies to pay an annual non-tax-deductible fee to the federal government based on each companys market share of prior year total sales of branded drugs to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs, and Department of Defense.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Establishes the Patient-Centered Outcomes Research Institute to identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Establishes the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services, or CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the sale, marketing, coverage, and reimbursement of products regulated by the CMS or other government agencies. In addition to new legislation, CMS regulations and policies are often revised or interpreted by the agency in ways significantly affecting our business and our products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, in June 2021, the United States Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial condition and results of operations. Complying with any new legislation or changes in healthcare regulation could be time-intensive and expensive, resulting in material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, at the federal level, in 2020, the HHS and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, importation of prescription drugs from Canada and other countries, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of the rules implemented during the Trump administration. As a result, the Biden administration and HHS have delayed the implementation or published rules rescinding some of these Trump-era policies. In January 2021, President Biden also issued an executive order to initiate a special enrollment period for people to obtain health insurance coverage through the ACA marketplace, and instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, among others. Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. Additionally, in July 2021, the Biden administration released an executive order, Promoting Competition in the American Economy, with multiple provisions aimed at prescription drugs. In response to Bidens executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Although no legislation or administrative actions have been finalized to implement these principles, Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases and allowing Medicare to negotiate pricing for certain drugs. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products candidates. We cannot be sure to what extent these and future legislative and regulatory efforts, whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDAs approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate, if approved, is prescribed or used.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, political, economic, and regulatory influences are subjecting the health care industry in the U.S. to fundamental change. Initiatives to reduce the federal budget and debt and to reform health care coverage are increasing cost-containment efforts. We anticipate federal agencies, Congress, state legislatures, and the private sector will continue to review and assess alternative health care benefits, controls on health care spending, and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for, or the amounts federal and state governments will pay for, health care products and services, which could also result in reduced demand for our products or additional pricing pressures, and limit or eliminate our spending on development projects and affect our ultimate profitability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-Party Payor Coverage and Reimbursement</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the U.S., sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers and other organizations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid Drug Rebate Program, which is part of the federal Medicaid program, a program for financially needy patients, among others, requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturers outpatient drugs furnished to Medicaid patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for a pharmaceutical product to receive federal reimbursement under Medicare Part B, part of the federal Medicare program covering outpatient items and services for the aged and disabled, and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program, a federal program requiring manufacturers to provide discounts to certain safety-net providers. The required 340B discount on a given product is calculated based upon certain Medicaid Drug Rebate Program metrics reported by the manufacturer.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a particular branded product on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. However, under Medicare Part D - Medicares outpatient prescription drug benefit - there are protections in place to ensure coverage and reimbursement for oncology products and all Part D prescription drug plans are required to cover substantially all anti-cancer agents. Furthermore, a payors decision to provide coverage for a product does not imply an adequate reimbursement rate will be available. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product approved for sale, we may need to pursue compendia listings or conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, in addition to the costs required to obtain regulatory approvals. Our drug candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover an approved product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the research, manufacturing, distribution, sale and promotion of drug products are subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state attorneys general, and other state and local government agencies.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval of our products, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing strategies. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws affecting our ability to operate include, but are not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration (a term interpreted broadly to include anything of value, including, for example, gifts, discounts, and credits), directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal health care program, such as the Medicare and Medicaid programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid, or other third-party payors that are false or fraudulent, or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money owed to the federal government;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">provisions of HIPAA,&nbsp;prohibiting knowingly and willfully executing a scheme to defraud any health care benefit program and making false statements relating to health care matters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the federal transparency laws, including the federal Physician Payment Sunshine Act, which was part of the Affordable Care Act, requiring applicable manufacturers of certain drugs and biologics, among other covered medical products for which payment is available under Medicare, Medicaid or the Childrens Health Insurance Program, with certain exceptions, to track and report annually certain payments and other transfers of value they </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">make to covered recipients, including U.S. physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors, other health care professionals (such as nurse practitioners and physician assistants, among others) and teaching hospitals, as defined by law, as well as physicians and physicians immediate family members ownership and investment interests in the applicable manufacturer, which are subsequently made publicly available in a searchable format on the CMS Open Payments website; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state transparency reporting and compliance laws, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA broadened the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C.  1320a-7b. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the ACA provides the government may assert a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act or the civil monetary penalties statute. Many states have adopted laws similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the U.S. federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. We may also be subject to additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement with a governmental entity to resolve allegations that we have violated these laws. To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-approval requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees share a passion for meaningful work and are committed to solving the most complex problems in creating immunotherapies to treat cancer and autoimmune and inflammatory diseases. Our culture is guided by our core values of innovative thinking, collaboration, flexibility, bias for action, and healthy debate. As of December&nbsp;31, 2021, we had 85 employees, of which 67 are engaged in research and development activities and 18 in general and administrative. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we provide competitive compensation and benefits for our personnel and that our compensation and benefit packages are designed to attract and retain highly qualified personnel essential to our business. In addition to salary compensation, our compensation includes new equity grants, a 401(k) retirement plan, healthcare and insurance benefits and a flexible paid time off policy.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to diversity, equity and inclusion. We recruit the best qualified employees regardless of gender, ethnicity or other protected traits and it is our policy to comply with all applicable laws related to discrimination in the workplace.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, in response to the COVID-19 pandemic, we continue to provide many employees with the ability to work from home and have implemented additional safety and infection prevention measures including enhanced cleaning, additional personal protective equipment, testing, and contact tracing protocols for employees who have transitioned back to critical work on site.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 24, 2017, Alpine Immune Sciences, Inc., or Private Alpine, completed its business combination with Nivalis Therapeutics, Inc., a publicly held company. In connection with the merger, Nivalis Therapeutics, Inc. changed its name to Alpine Immune Sciences, Inc. Nivalis Therapeutics, Inc. was incorporated in Delaware in March 2007.&nbsp;Alpine Immune Sciences, Inc. (prior to its business combination with Nivalis Therapeutics, Inc.) was incorporated in Delaware on December 30, 2014.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office is located at 188 East Blaine Street, Suite 200, Seattle WA, 98102. Our telephone number is (206) 788-4545. Our website is www.alpineimmunesciences.com. Information contained in, or that can be accessed through, our website is not a part of, and is not incorporated into, this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> should carefully consider the following risk factors, in addition to the other information contained in this Annual Report on Form 10-K, including </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_82" tabindex="18">Managements Discussion and Analysis of Financial Condition and Results of Operations</a></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> included in Part II, Item 7, and our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_148" tabindex="18">consolidated financial statements and related notes</a></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. If any of the events described in the following risk factors and the risks described elsewhere in this report occurs, our business, operating results and financial condition could be seriously harmed. Our Risk Factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part. This report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_25"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Pipeline and Product Development</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of innovative therapeutic treatments based on our technology is unproven and may not result in marketable products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> plan to develop novel protein-based immunotherapies in part via our proprietary directed evolution platform for the treatment of cancer and autoimmune/inflammatory diseases. The potential to create therapies capable of working within and/or modulating an immune synapse, forcing a synapse to occur, or preventing a synapse from occurring is an important, novel attribute of the majority </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our approaches. However, the scientific research forming the basis of our efforts to develop therapeutic candidates based on our platform is relatively new. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our platform is both preliminary and limited.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relatively</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> few therapeutic candidates based on immunoglobulin superfamily, or IgSF, domains, or tumor necrosis factor receptor super family, or TNFRSF, domains, have been tested in humans. We may discover the therapeutic candidates developed using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> scientific platform do not possess certain properties required for the therapeutic candidate to be effective. We currently have only limited data to suggest we can introduce these necessary therapeutic properties into variant Ig domain, or vIgD or variant TNF(R) domain, or vTD, based therapeutic candidates. In addition, vIgDs or vTDs may demonstrate different chemical and pharmacological properties in human subjects or patients than they do in laboratory studies. Even if our programs have successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective, or harmful ways. While we continue to evaluate our vIgDs and vTDs preclinically and clinically, the risk profile in humans is still being fully assessed. Undesirable side effects that may be caused by our therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete clinical trials or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. As a result, we may never succeed in developing a marketable therapeutic, we may not become profitable, and the value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we believe that the FDA has little prior experience with vIgDs or vTDs, which may increase the complexity, uncertainty, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> length of the regulatory approval process for our therapeutic candidates. Our company and our current collaborators, or any future collaborators, may never receive approval to market and commercialize any therapeutic candidate. Even if our company or a collaborator obtains regulatory approval, the approval may be for disease indications or patient populations not as broad as we intended or desired or may require labeling, including significant use or distribution restrictions or safety warnings. Our company or a collaborator may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If therapeutic candidates we develop using our scientific platform prove to be ineffective, unsafe, or commercially unviable, our entire platform and pipeline would have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market may not be receptive to our therapeutic products based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of therapeutic products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if approval is obtained for a therapeutic candidate, we may not generate or sustain revenue from sales of the therapeutic product due to factors such as whether the therapeutic product can be sold at a competitive price and otherwise accepted in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Therefore, any revenue from sales of the therapeutic product may not offset the costs of development. The therapeutic candidates we are developing are based on new technologies and therapeutic approaches. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment based on our therapeutic products, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable coverage or reimbursement for, any therapeutic products developed by our company, our existing collaborator, or any future collaborators. Market acceptance of our therapeutic products will depend on, among other factors:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of our receipt of any marketing and commercialization approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the terms and scope of any approvals and the countries in which approvals are obtained;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the safety and efficacy of our therapeutic products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the prevalence and severity of any adverse side effects associated with our therapeutic products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the prevalence and severity of any adverse side effects associated with therapeutics of the same type or class as our therapeutic products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">relative convenience and ease of administration of our therapeutic products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the willingness of patients to accept, and the willingness of physicians to prescribe, any new methods of administration;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the success of our physician education programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the availability of adequate government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the willingness of patients to pay out-of-pocket in the absence of coverage by government and third-party payors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the pricing of our products, particularly as compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our ability to compliantly and effectively market and sell our products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of market introduction of our therapeutic products as well as alternative treatments; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">availability of alternative effective treatments for the disease indications our therapeutic products are intended to treat and the relative risks, benefits, and costs of those treatments.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our development focus, these risks may increase to the extent this field becomes more competitive or less favored in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> marketplace. Additional risks apply in relation to any disease indications we pursue which are classified as rare diseases and allow for orphan drug designation by regulatory agencies in major commercial markets, such as the United States, European Union, and Japan. Because of the small patient population for a rare disease, if pricing is not approved or accepted in the market at an appropriate level for an approved therapeutic product with orphan drug designation, such drug may not generate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enough</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue to offset costs of development, manufacturing, marketing, and commercialization despite any benefits received from the orphan drug designation, such as market exclusivity, assistance in clinical trial design, or a reduction in user fees or tax credits related to development expense. Market size is also a variable in disease indications classified as rare. Our estimates regarding potential market size for any rare indication may be materially different from what we discover to exist at the time we commence commercialization, if any, for a therapeutic product, which could result in significant changes in our business plan and have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a therapeutic product with orphan drug designation subsequently receives the first FDA approval for the indication for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> it has </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> designation, the therapeutic product is entitled to orphan product exclusivity, which means the FDA may not approve any other applications to market the same therapeutic product for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic products for seven years if a competitor obtains approval of the same therapeutic product as defined by the FDA or if our therapeutic product is determined to be within the same class as the competitors therapeutic product for the same indication or disease.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we may apply for designation of a therapeutic product as an orphan drug for the treatment of a specific </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indication</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the European Union before the application for marketing authorization is made. Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show its therapeutic product is safer, more effective, or otherwise clinically superior to the orphan-designated therapeutic product. The respective orphan designation and exclusivity frameworks in the United States and in the European Union are subject to change, and any such changes may affect our ability to obtain EU or U.S. orphan designations in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products on the market and all of our therapeutic candidates are in early stages of development. Our ability </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> achieve and sustain profitability depends on obtaining regulatory approval and Institutional Review Board, or IRB, approval to conduct clinical trials at particular sites, obtaining regulatory approvals to market our therapeutic candidates and successfully commercializing our therapeutic candidates, either alone or with third parties, such as our collaborators. Before obtaining regulatory approval for the commercial distribution of our therapeutic candidates, we or a collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our therapeutic candidates. Preclinical testing and clinical trials are expensive, difficult to design and implement, can take many years to complete, and are uncertain as to outcome. For example, we are currently advancing the development of acazicolcept, davoceticept and ALPN-303; however, even </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the significant investment of time and funding to advance these product candidates, we cannot guarantee that our clinical and preclinical development efforts will be successful. The start or end of a clinical study is often delayed or halted due to delays in or failure to obtain regulatory approval to commence the study, delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or CROs, or clinical trial sites, delays in or failure to obtain IRB approval at each site, changing regulatory requirements, manufacturing challenges, clinical sites or CROs deviating from the trial protocol or failing to comply with regulatory requirements or meet contractual obligations, slower than anticipated patient enrollment, changing standards of care, availability or prevalence of use of a comparative therapeutic or required prior therapy, clinical outcomes, failure of patients to complete the trial or return for post-treatment follow-up, or financial constraints. For instance, delays or difficulties in patient enrollment or difficulties in retaining trial participants can result in increased costs, longer development times, or termination of a clinical trial. Clinical trials of a new therapeutic candidate require the enrollment of a sufficient number of patients, which may include patients who are suffering from the disease the therapeutic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the eligibility criteria for the clinical trial, the age and condition of the patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, and the availability of effective treatments or competing academic and other clinical trials for the relevant disease.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapeutic candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for therapeutic candidates is high due to scientific feasibility, safety, efficacy, changing standards of medical care, and other variables. The novelty of our platform may mean our failure rates are higher than historical norms. The results from preclinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or early clinical trials of a therapeutic candidate may not predict the outcome of later phase clinical trials of the therapeutic candidate, particularly in immuno-oncology and autoimmune/inflammatory disorders. We will have to conduct additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our proposed indications to verify the results obtained to date in our preclinical and clinical studies and to support any future regulatory submissions. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the FDA, an IRB, an independent ethics committee, or other applicable regulatory authorities may suspend clinical trials of a therapeutic candidate at any time for various reasons, including a belief that subjects participating in such trials are being exposed to unacceptable health risks or adverse side effects. Similarly, an IRB or ethics committee may suspend a clinical trial at a particular trial site. We may not have the financial resources to continue development of, or to enter into collaborations for, a therapeutic candidate if we experience any problems or other unforeseen events delaying or preventing clinical development or regulatory approval of, or our ability to commercialize, therapeutic candidates, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">negative or inconclusive results from our clinical trials, or the clinical trials of others for therapeutic candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our therapeutic candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">serious drug-related side effects experienced in the past by individuals using therapeutics similar to our therapeutic candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in submitting IND applications or clinical trial applications, or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators or IRBs to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">conditions imposed by the FDA or comparable foreign authorities, such as the European Medicines Agency, or EMA, regarding the scope or design of our clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in enrolling research subjects in clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">high drop-out rates of research subjects;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inadequate supply or quality of therapeutic candidate or therapeutic candidate components, or materials or other supplies necessary for the conduct of our clinical trials, including those owned, manufactured, or provided by companies other than ours;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater than anticipated clinical trial costs, including the cost of any approved drugs used in combination with our therapeutic candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">poor effectiveness of our therapeutic candidates during clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays and changes in regulatory requirements, policies, and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">varying </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interpretations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agencies.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and operational resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly important for us due to the breadth of potential product candidates and indications that we intend to utilize with our clinical development strategy. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical trials and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates showing promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. We have evaluated acazicolcept in a Phase 1 healthy volunteer trial and previously initiated a Phase 1b/2 study of acazicolcept in patients with steroid-resistant or steroid-refractory active acute graft-versus-host disease, or SR-aGVHD. We terminated this Phase 1b/2 SR-aGVHD </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2020. Our Phase 2 study in SLE will materially increase our anticipated research and development spending. SLE is a challenging indication and a number of trials conducted by other companies have failed after significant investment of time and funding. We cannot predict whether our efforts in this indication will be successful. If we are unsuccessful, it is unlikely that AbbVie would exercise its option for acazicolcept pursuant to our option and license agreement and, as a result, we would not receive the option payment pursuant to this agreement and we would not be eligible for future milestones and royalties. In addition, we have initiated our Phase 1 studies of davoceticept as well as our Phase 1 study of ALPN-303 in healthy volunteers. We will have to conduct additional preclinical studies and human trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether Phase 1, Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our therapeutic candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed by necessary </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down multiple times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees. In response to the COVID-19 public health emergency, the FDA has postponed some inspections and continues to conduct mission-critical inspections on a case-by-case basis, or, where possible to do so safely, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has resumed prioritized domestic inspections, such as pre-approval and surveillance inspections. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDAs inability to complete required inspections for their applications. While the FDA continues to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA Good Manufacturing Practices, the FDA may not be able to continue its current inspection pace or be unable to complete required inspections during the review period, or the review timelines could be extended. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, or if global health or other concerns continue to prevent the FDA or other regulatory authorities from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducting</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> their regular inspections, reviews, or other regulatory activities in a timely manner, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter delays or difficulties enrolling patients in our clinical trials and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including supply chain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruptions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, staffing shortages and other business and economic disruptions resulting from geopolitical actions, including war and terrorism, natural disasters, including earthquakes, typhoons, floods and fires, as well as other disruptions resulting from the impact of public health factors, including the COVID-19 pandemic, business disruptions of our strategic partners, third-party manufacturers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suppliers</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other third parties upon which we rely. The timely completion of clinical trials in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until completion of treatment and adequate follow-up. The enrollment of patients depends on many factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Inabili</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ty to enroll, or delay in enrollment of, patients due to outbreaks and public health crises, such as the COVID-19 global pandemic, as further described under Risk Factors  Risks Related to COVID-19 and Other Health Epidemics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The patient eligibility criteria defined in the protocol;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The perceived risks and benefits of the product candidate being studied;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The size of the patient population required for analysis of the trials primary endpoints;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The proximity of patients to trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The design of the trial;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our ability to obtain and maintain patient consent;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Geopolitical events in countries where we have or seek to have clinical trial sites;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Reporting of the preliminary results of any of our clinical trials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The risk that patients enrolled in clinical trials will drop out of the trials before completion of treatment and adequate fo</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llow-up.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigation sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sites</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Geopolitical events in countries where we have or seek to have clinical trial sites can also negatively impact our ability to enroll patients in our trials.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we had intended to open trial sites in Russia for both our ongoing Synergy trial and our planned Phase 2 trial in SLE with ALPN-303. Following the start of the Russia-Ukraine conflict, we have decided to abandon our plans to open these sites.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although no sites in Russia had been opened, we must revise our plans and locate alternative trial sites in order to achieve targeted enrollment numbers for these trials.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any resulting delays in patient enrollment may increase our costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials that involve cancer patients with significant co-morbidities are associated with increased risks as such participants may be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> susceptible to safety and toxicity risks. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as safety and toxicity monitoring may be complicated and difficult to manage, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or another factors, especially in oncology subjects who may suffer from other medical conditions and take other medications. Such risks are increased in clinical trials that evaluate combination therapies. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If serious adverse events or undesirable side effects arise, we could be required to suspend, delay, or halt our clinical trials and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorities</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could deny approval or require us to limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Side effects that are observed during the trial, whether treatment related or not, could also affect patient recruitment for future trials or the ability of enrolled patients to complete the trial or result in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product liability claims.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if serious adverse events or undesirable side effects are identified during development or after approval and are determined to be attributed to any of our product candidates, we may be required to develop Risk Evaluation and Mitigation Strategies, or REMS, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may harm our business, financial condition and prospects significantly. As discussed further in the risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below, FDA placed a partial clinical hold on the NEON-2 trial evaluating davoceticept in combination with Mercks pembrolizumab in adults with advanced malignancies. This partial clinical hold was prompted by the death of a study participant in the NEON-2 trial. We are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">working</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> closely with the FDA, Merck, the Safety Monitoring Committee, and the study investigators to further understand this event. FDA must lift the partial clinical hold before we can continue to enroll additional patients in this study. We can provide no assurances that FDA will lift the partial clinical hold for this study, or will do so in a timely manner. At this time, the full extent of this event on the NEON-2 trial is unclear. </span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development of product candidates in combination with other therapies could expose us to additional risks.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development of any of our product candidates in combination with one or more other therapies that have either been approved or not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities could expose us to additional risks, as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapies may increase the rate of serious or unexpected adverse events, which could result in a clinical hold as well as pre-approval and post-approval restrictions by the FDA or other regulatory authorities on the proposed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therapy, including narrowing of the indication, warnings, additional safety data collection and monitoring procedures, and REMS, even if the cause of such serious or unexpected adverse events are not directly attributed to our product candidate. Any of these events or restrictions could have a material adverse effect on our business, development of our product candidates, delay our regulatory approval, and decrease the market acceptance and profitability of our product candidate if approved for a combination therapy. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not be able to market and sell any product candidate in combination with any unapproved therapies that do not ultimately obtain marketing approval. If the FDA, EMA or other comparable foreign regulatory authorities do not approve or revoke their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of other therapies used in combination therapies, or if safety, efficacy, commercial adoption, manufacturing or supply </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> arise with the therapies we choose to evaluate in combination with any of our product candidate, we may be unable to obtain approval of or successfully market any one or all of the product candidates we develop. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> existing approved therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revoke approval of the other therapy used in combination with any of our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our own products being removed from the market or being less successful commercially.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the third-party providers of therapies or therapies in development used in combination with our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 7, 2022, we announced that the FDA placed a partial clinical hold on the NEON-2 trial evaluating davoceticept in combination with Mercks pembrolizumab in adults with advanced malignancies. This partial clinical hold was prompted by the death of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> participant in the NEON-2 trial. The participant had choroidal melanoma previously treated with nivolumab and ipilimumab, and had received a single dose each of davoceticept and pembrolizumab. The participants death was attributed to cardiogenic shock, considered by the treating physicians as likely related to immune-mediated myocarditis, or possibly infection. We are working closely with the FDA, Merck, the Safety Monitoring Committee, and the study investigators to further understand this event and to evaluate the appropriate safety precautions before we resume enrollment of additional participants. Participants who are currently enrolled in the NEON-2 trial may continue to receive davoceticept and pembrolizumab, although no new participants may be enrolled until the partial clinical hold is resolved. We can provide no assurances that FDA will lift the partial clinical hold for this study, or will do so in a timely manner. This partial clinical hold does not affect the ongoing NEON-1 clinical trial of davoceticept as monotherapy (NCT04186637). </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> this time, it is unclear what FDA will require before the partial hold can be removed or the full impact of this event. To the extent the FDA requires additional safety data to be collected in the NEON-2 trial, impose further or more stringent exclusion criteria, expand the size of the trial, or impose other restrictions or changes to our study protocol, or prolong the partial clinical hold for any reason, our clinical plans for the combination therapy would be delayed substantially and incur additional costs, which could have an adverse effect on our business, financial condition, results of operations and growth prospects. We may encounter further challenges with enrollment. If we fail to meet the additional requirements set by the FDA for resolving the partial clinical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hold</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we may be required to abandon the development of davoceticept in combination with pembrolizumab. Continued safety concerns could cause the FDA and other regulatory authorities or the IRB to terminate the NEON-2 trial, narrow the indication or impose other restrictions in the labeling even if we obtain regulatory approval for the combination therapy, such as implementation of REMS and addition of a black box warning, among other measures, any of which could decrease the demand, market acceptance and profitability of the combination therapy.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from entities that have developed or may develop therapeutic candidates for our target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to us. If these companies develop technologies or therapeutic candidates more rapidly than we do, or their technologies, including delivery technologies, are more effective, our ability to develop and successfully commercialize therapeutic candidates may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the highly competitive sector of biotechnology and pharmaceuticals and in the subsector of immune </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modulation</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This subsector has undergone tremendous technological advancement over the last decade due to advancements in understanding the role of the immune system across multiple therapeutic areas, including oncology and autoimmune/inflammatory disease. While we believe our novel technology platform, discovery programs, knowledge, experience, and scientific resources offer competitive </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advantages</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, public and private research institutions, and others.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products we successfully develop and commercialize will face competition from currently approved therapies and new therapies potentially </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> competitiveness of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we compete against may have significantly greater financial resources and expertise in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. For additional information regarding our competitors and the competitive landscape, please refer to the section of this report titled Business  Competition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales, and supply </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or experience than we have. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including safety and effectiveness, ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, timing and scope of regulatory approvals, availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position of our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products could present superior treatment alternatives, including by being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. Competitors could also recruit our employees, which could negatively impact our ability to execute our business plan.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We believe our development programs and platform have a particular mechanism of action, but this mechanism of action has not been proven conclusively.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific platform is novel, and the underlying science is not exhaustively understood nor conclusively proven. In particular, the interaction of vIgDs with the immune synapse, the ability of vIgDs to slow, stop, restart, or accelerate immune </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responses</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the ability of vIgD </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">domains</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to interact with multiple counter structures is still largely theoretical. Graphical representations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proposed mechanisms of action of our therapies, the size, actual or relative, of our therapeutics, and how our therapeutics might interface with other cells within the human body, inside the immune synapse, or inside the disease and/or the tumor microenvironment are similarly theoretical and not yet conclusively proven. The lack of a proven mechanism of action may adversely affect our ability to raise sufficient capital, complete preclinical studies, adequately manufacture drug product, obtain regulatory clearance for clinical trials, gain marketing approval, or conclude collaborations, or interfere with our ability to market our product to patients and physicians or achieve reimbursement from payors.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to present our data in scientific journals or at scientific conferences could adversely impact our business and stock price.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time submit data related to our research and development activities in peer-reviewed scientific publications or apply to present data related to our research and development activities at scientific or other conferences. We have no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">control</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over whether these submissions or applications are accepted. Even if accepted for a conference, we have no control over whether presentations at scientific conferences will be accepted for oral presentation, poster presentation, or abstract publication only. Even when </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accepted</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for publication, we have no control over the timing of the release of the publication. Rejection by publications, delays in publication, rejection for presentation, or a less-preferred format for a presentation may adversely impact our stock price, ability to raise capital, and business.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be affected by adverse scientific publications or editorial or discussant opinions.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time publish data related to our research and development activities in peer-reviewed scientific </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">publications</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or present data related to our research and development activities at scientific or other conferences. Editorials or discussants unrelated to us may provide opinions on our presented data unfavorable to us. In addition, scientific publications or presentations may be made which are critical of our science or research or the field of immunotherapy in general. This may adversely affect our ability to raise necessary capital, complete clinical and preclinical studies, adequately manufacture drug product, obtain regulatory clearance for clinical trials, or approval for marketing, or interfere with our ability to market our product to patients and physicians or achieve reimbursement from payors.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_28"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To date, our revenue has been primarily derived from our collaboration agreements, and our success will be dependent, in part, on our collaborators efforts to develop our therapeutic candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on our collaborators efforts to develop our therapeutic candidates and, historically, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revenue</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been primarily derived from our agreements with collaborators. For example, in June 2020, we entered into the AbbVie Agreement for the development of acazicolcept and in December 2021, we entered into the Horizon Agreement pursuant to which we granted to Horizon rights to one of our existing preclinical biologic therapeutic programs and we and Horizon agreed to collaborate in the discovery, research and preclinical development of up to three additional autoimmune and inflammatory disease programs for other designated biological targets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the AbbVie Agreement, we received an upfront payment of $60.0 million in cash and are eligible </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> receive up to $75.0 million in development milestones (of which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$45.0&nbsp;million was achieved in the second quarter of 2021)</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an additional $75.0 million if </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exercises its option with respect to acazicolcept following our completion of certain development activities, additional development, commercial and sales-based milestones up to an aggregate of $655.0 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalties on any future net sales. Pursuant to the AbbVie Agreement, we will conduct certain development activities under a development plan that provides for, among other things, the generation of a data package in order for AbbVie to evaluate exercising its exclusive option, including all activities reasonably necessary to complete our Phase 2 study of acazicolcept in SLE. If we successfully complete these activities, AbbVie may not exercise its option, which would make achievement of future milestones and receipt of future royalties unattainable. If AbbVie exercises its option, our realization of additional milestones and royalty payments will depend upon the efforts of AbbVie. If AbbVie fails to develop, obtain regulatory approval for, or ultimately commercialize acazicolcept or if AbbVie terminates the collaboration, our business, financial condition, results of operations, and prospects could be materially and adversely affected. For additional information regarding the AbbVie Agreement, please refer to the Partnerships section within </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">Item 1. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">Business</a></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this report. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Horizon Agreement, we received an upfront payment of $25.0 million as well as an equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which they paid </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million. We are also eligible to receive milestone payments upon our achievement of certain preclinical, clinical and regulatory and commercialization milestones, up to an aggregate amount of $381.0 million per program, or approximately $1.5 billion in total, if all milestones are met, as well as royalties on future product sales. Pursuant to the Horizon Agreement, we will conduct certain research activities under a research program; however, even if we successfully perform our obligations under the Horizon Agreement, there is no certainty that Horizon will continue the development of any of the programs, or, if development is continued, if such programs will ultimately succeed and receive regulatory approval. Horizon will have discretion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and directing its efforts and resources for future development activities and, if approval is obtained, commercialization and marketing of the approved drug. As a result, there can be no assurances that we will achieve additional milestones pursuant to the Horizon Agreement. For additional information regarding the Horizon Agreement, please refer to the Partnerships section within </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">Item 1. B</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_19" tabindex="18">usiness</a></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this report.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaborations may </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> result in reduced royalty revenues if we are unable to obtain and maintain patent protection, as well as if we are unable to obtain patent term extension, for therapeutic candidates or products developed under our agreements with collaborators. In the event of expiration or invalidation of patents covering a therapeutic candidate or product, for example, our collaborators may be entitled to a significant decrease in royalty revenues owed to us under the agreements. Invalidation of patents and failure to obtain patent term extension for one or more patents in our portfolio may occur as a result of factors beyond our control due to the complex legal and factual questions surrounding pharmaceutical and biotechnology patents. If we are unable to obtain and maintain patent protection, or if we unable to obtain patent term extension for therapeutic candidates or products developed under our agreements with collaborators, our revenue derived from our collaborators may be less than the full amount anticipated, and our business, financial condition, results of operations, and growth prospects could be materially harmed.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued advancement of our other product candidates and other development efforts depends, in part, upon the efforts of AbbVie, Horizon, and our other current or future collaborators. If our collaborators do not dedicate sufficient resources to the development of product candidates that are the subject of our agreements, such product candidates may never be successful and we may be ineligible to receive additional milestone payments or royalties pursuant to the terms of our arrangements, which could have a material adverse impact on our financial results and operations. Even if we and our collaborators dedicate sufficient resources to our collaboration agreements, neither we nor our collaborators may be effective in obtaining approvals for any therapeutic candidates or, if approved, the successful commercialization of any approved products. Collaborators may change their strategic focus or pursue alternative technologies after entering into a collaboration agreement with us, which could result in reduced, delayed or no revenue to us. Disputes regarding collaboration agreements, including disputes pertaining to ownership of intellectual property, may also arise and if we and our collaborators are unable to resolve such disputes, litigation proceedings may occur, which could further delay development programs, create uncertainty as to ownership of intellectual property rights, distract management from other business activities and generate substantial expenses, any of which could materially and negatively impact our business.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties on which we depend to conduct our clinical or preclinical studies, or any future clinical trials, do not perform as expected, fail to satisfy regulatory or legal requirements, or miss expected deadlines, our development program could be delayed, which may result in materially adverse effects on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on third-party clinical investigators, CROs, clinical data management organizations, and consultants to design, conduct, supervise, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">monitor</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials and preclinical studies of our therapeutic candidates and may do the same for future clinical trials. Because we rely on third parties to conduct preclinical studies or clinical trials, we have less control </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the timing, quality, compliance, and other aspects of preclinical studies and clinical trials than we would if we conducted all preclinical studies and clinical trials on our own. These investigators, CROs, and consultants are not our employees and we have limited control over the amount of time and resources they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw their time and resources away from our programs. The third parties with which we contract might not be diligent, careful, compliant, or timely in conducting our preclinical studies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. Further, if any of our relationships with third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their expected duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials, or meet expected deadlines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical development programs could be delayed and otherwise adversely affected. In all events, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are responsible for ensuring each of our preclinical studies and clinical trials is conducted in accordance with the general investigational plan and protocols for the trial and with legal, regulatory and scientific standards. The FDA and certain foreign regulatory authorities, such as the EMA, require preclinical studies to be conducted in accordance with applicable Good Laboratory Practices, or GLPs, and clinical trials to be conducted in accordance with applicable FDA regulations and Good Clinical Practices, or GCPs, including requirements for conducting, recording, and reporting the results of preclinical studies and clinical trials to assure data and reported results are credible and accurate and the rights, integrity, and confidentiality of clinical trial participants are protected. Our reliance on third parties we do not control does not relieve us of these responsibilities and requirements. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Any such event could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, switching or adding additional CROs involves additional cost and requires management time and focus. There is also a natural transition period when a new CRO commences work. As a result, delays may occur, which could </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impact our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter such challenges or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delays</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply partners, our supply of clinical trial materials may become limited or interrupted or may not be of satisfactory quantity or quality, and our dependence on these third parties may impair the advancement of our research and development programs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established in-house recombinant protein generation capabilities for producing sufficient protein materials to enable a portion of our current preclinical studies. We rely on third-party supply and manufacturing partners to supply the materials, components, and manufacturing services for a portion of preclinical studies and also rely on such third parties for all our clinical trial drug supplies. We do not own manufacturing facilities or supply sources for such components and materials for clinical trial supplies and our current manufacturing facilities are insufficient to supply such components and materials for all of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies. Certain raw materials necessary for the manufacture of our therapeutic products, such as cell lines, are available from a single or limited number of source suppliers on a purchase order basis. There can be no assurance our supply of research and development, preclinical study, and clinical trial drugs and other materials will not be limited, interrupted, restricted in certain geographic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of satisfactory quality or quantity, or continue to be available at acceptable prices. In particular, any replacement of our therapeutic substance manufacturer could require significant effort and expertise and could result in significant delay of our preclinical or clinical activities because there may be a limited number of qualified replacements. In addition, disruptions to ports and other shipping infrastructure, due in part to the impact of the ongoing COVID-19 pandemic, may result in shortages or delays impacting the availability of materials and other supplies, which could negatively impact our manufacturers, suppliers and other third parties on whom we rely. While we have not yet suffered any direct, material negative impacts from these ongoing supply chain disruptions, we cannot be certain that we will not be impacted, which could increase our costs or negatively impact our development timelines.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing process for a therapeutic candidate is subject to FDA and foreign regulatory authority review, and the facilities used by our contract manufacturers to manufacture our therapeutic candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our marketing application(s) to the FDA. Suppliers and manufacturers must meet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with cGMP regulations or other regulatory standards. In the event any of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our suppliers or manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing, or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may experience shortages resulting in delayed shipments, supply constraints, and/or stock-outs of our products, be forced to manufacture the materials alone, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our therapeutic candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual and intellectual property restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors may increase our reliance on such manufacturer or require us to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a license from such manufacturer in order to have another third party manufacture our therapeutic candidates. If we are required to change manufacturers for any reason, we will be required to verify the new manufacturer maintains facilities and procedures complying with quality standards and with all applicable regulations. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop therapeutic candidates in a timely manner, within budget, or at all.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any therapeutic </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for therapeutic candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our therapeutic candidates successfully. Our, or a third partys, failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including as a result of:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an inability to initiate or continue preclinical studies or clinical trials of therapeutic candidates under development;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delay in submitting regulatory applications, or receiving regulatory approvals, for therapeutic candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the loss of the cooperation of a collaborator;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">subjecting manufacturing facilities of our therapeutic candidates to additional inspections by regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">requirements to cease distribution or to recall batches of our therapeutic candidates; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">in the event of approval to market and commercialize a therapeutic candidate, an inability to meet commercial deman</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As product candidates progress from preclinical studies to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, materials and processes, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent purity, identity, potency, quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and could affect planned or other clinical trials conducted with product candidates produced using the modified manufacturing methods, materials, and processes. This could delay completion of clinical trials and could require non-clinical or clinical bridging and comparability studies, which could increase costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize therapeutic candidates, impact our cash position, increase our expenses, and present significant distractions to our management.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> time to time, we consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases or divestitures, and out- or in-licensing of therapeutic candidates or technologies. In particular, we intend to evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or pharmaceutical companies. The competition for collaborative partners is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on suboptimal terms for us, and ultimately may not maximize value for our stockholders. In addition, we may be unable to maintain any new or existing collaboration if, for example, development or approval of a therapeutic candidate is delayed, sales of an approved therapeutic product do not meet expectations, or the collaborator terminates the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> would entail numerous operational and financial risks, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">exposur</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e to unknown liabilities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">disruption of our business and diversion of our managements time and attention in order to manage a collaboration or develop acquired therapeutic candidates, or technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">higher than expected collaboration, acquisition, or integration costs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">write-downs of assets, or incurring impairment charges or increased amortization expenses; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business or impairment of relationships with key suppliers, manufacturers, or customers of any acquired business due to ch</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anges</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to retain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of any acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance we will undertake or successfully complete any transactions of the nature described above, any transactions we do complete may be subject to the foregoing or other risks and have a material </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adverse</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> effect on our business, results of operations, financial condition, and prospects. Conversely, any failure to enter any collaboration or other strategic transaction beneficial to us could delay the development and potential commercialization of our therapeutic candidates and have a negative impact on the competitiveness of any therapeutic candidate reaching market.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Ability to Commercialize Product Candidates</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our therapeutic candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we may be unable to successfully commercialize any such future products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing, or distribution capabilities or experience. If any of our therapeutic candidates are approved, we will need to develop internal sales, marketing, and distribution capabilities to commercialize such products, which may be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial, legal, and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration, and compliance capabilities. If we rely on third parties with such capabilities to market our approved products, or decide to co-promote products with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we will be able to enter into such arrangements on acceptable, compliant terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved therapeutic. If we are not successful in commercializing any therapeutic approved in the future, either on our own or through third parties, our business, financial condition, results of operations, and prospects could be materially and adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company, our therapeutic candidates, our suppliers, and our contract manufacturers, distributors, and contract </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> laboratories are subject to extensive regulation by governmental authorities in the European Union, the United States, and other countries, with regulations differing from country to country.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if we receive marketing and commercialization approval of a therapeutic candidate, we and our third-party service providers will be subject to continuing regulatory requirements, including a broad array of regulations related to establishment registration and product listing, manufacturing processes, risk management measures, quality and pharmacovigilance systems, post-approval clinical studies, labeling and packaging, advertising and promotional activities, record keeping, distribution, adverse event reporting, import and export of pharmaceutical products, pricing, sales, and marketing, and fraud and abuse requirements.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the FDA strictly regulates manufacturers promotional claims of drug products. In particular, a drug product may not be promoted by manufacturers for uses that are not approved by the FDA, as reflected in the FDA-approved labeling, although healthcare professionals are permitted to use drug products for off-label uses. The FDA, the Department of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Justice, the Inspector General of the Department of Health and Human Services, among other government agencies, actively enforce the laws and regulations prohibiting manufacturers promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including large civil and criminal fines, penalties, and enforcement actions. The FDA has also imposed consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed for companies that engaged in such prohibited activities. If we cannot successfully manage the promotion of our approved product candidates, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to submit safety and other post market information and reports, and are subject to continuing regulatory review, including in relation to adverse patient experiences with the product and clinical results reported after a product </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> made commercially available, both in the United States and in any foreign jurisdiction in which we seek regulatory approval. The FDA and certain foreign regulatory authorities, such as the EMA, have significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FDA also has the authority to require a REMS plan either before or after approval, which may impose further requirements or restrictions on the distribution or use of an approved therapeutic. The EMA now routinely requires risk management plans, or RMPs, as part of the marketing authorization application process, and such plans must be continually modified and updated throughout the lifetime of the product as new information becomes available. In addition, the relevant governmental authority of any EU member state can request an RMP whenever there is a concern about the risk/benefit balance of the product.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturers and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inspection</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturers or facilities, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will have limited control over compliance with applicable rules and regulations by such manufacturers.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or our collaborators, manufacturers, or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we may be subject to, among other things, fines, warning and untitled letters, clinical holds, a requirement to conduct additional clinical trials, delay or refusal by the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA or foreign regulatory authorities to approve pending applications or supplements to approved applications, suspension, refusal to renew or withdrawal of regulatory approval, product recalls, seizures, or administrative detention of products, refusal to permit the import or export of products, operating restrictions, inability to participate in government programs including Medicare and Medicaid, and total or partial suspension of production or distribution, injunction, restitution, disgorgement, debarment, civil penalties, and criminal prosecution.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Imposed price controls may adversely affect our future profitability.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most countries, the pricing of prescription drugs is subject to governmental control. In these countries, pricing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic, and regulatory developments may further complicate pricing and reimbursement negotiations, and pricing negotiations may continue after reimbursement has been obtained.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical trial or other studies comparing the cost-effectiveness of our therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations, or prospects could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> business may become subject to economic, political, regulatory and other risks associated with international operations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to risks associated with conducting business internationally, including our use of foreign clinical trial sites. Some of our suppliers, collaborators and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">economic instability or weakness, including inflation, reduced growth, diminished credit availability, weakened consumer confidence or increased unemployment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">sociopolitical instability in particular foreign economies and markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">difficulties in compliance with non-U.S. laws and regulations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in non-U.S. regulations and customs, tariffs and trade barriers, including any changes that China may impose as a result of political tensions between the United States and China;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in non-U.S. currency exchange rates and currency controls;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities outside the United States; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Personnel and Operations</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise substantial additional funds to advance development of our therapeutic candidates, and we cannot guarantee we will have sufficient funds available in the future to develop and commercialize our current or future therapeutic candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise substantial additional funds to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities to us. We have used substantial funds to develop our therapeutic candidates and will require significant funds to conduct further research and development, preclinical testing, and clinical trials of our therapeutic candidates, to seek regulatory approvals for our therapeutic candidates, and to manufacture and market products, if any are approved for commercial sale. As of December&nbsp;31, 2021, we had $215.4&nbsp;million in cash and cash equivalents, restricted cash, and investments. Based on our current operating plan, we believe our available cash and cash equivalents, and investments will be sufficient to fund our planned level of operations, including anticipated capital expenditures, for at least the next 12 months. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with successful development of our therapeutic candidates are highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. To execute our business plan, we will need, among other things:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to obtain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">necessary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">test,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture, and market our therapeutic candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to build and maintain a strong intellectual property portfolio and avoid infringing intellectual property of third parties;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to establish and maintain successful licenses, collaborations, and alliances;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to satisfy the requirements of clinical trial protocols, including patient enrollment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to establish and demonstrate the clinical efficacy and safety of our therapeutic candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to obtain regulatory approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to manage our spending as costs and expenses increase due to preclinical studies, clinical trials, regulatory approvals, manufacturing scale-up, and commercialization;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to obtain additional capital to support and expand our operations; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">to market our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to achieve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and use by the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">community</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in general.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain necessary funding on a timely basis or on acceptable terms, we may have to delay, reduce, or terminate our research and development programs, preclinical studies, or clinical trials, if any, limit strategic opportunities, or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements with collaborators or others requiring us to relinquish rights to some of our technologies or therapeutic candidates we would otherwise pursue on our own. We do not expect to realize revenue from product sales, or royalties in the foreseeable future, if at all. Our revenue sources are, and will remain, extremely limited unless and until our therapeutic candidates are clinically tested, approved for commercialization, and successfully marketed.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity securities, debt, and payments received under our collaboration agreements. We will be required to seek additional funding in the future and intend to do so through a combination of public or private equity offerings, debt financings, credit and loan facilities, research collaborations, and license agreements. Our ability to raise additional funds from these or other sources will depend on financial, economic, and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. For example, in January 2019, we issued in a private placement 4,706,700 shares of common stock and warrants to purchase an additional 1,835,610 shares of common stock for gross proceeds of approximately $25.3 million. In July 2020, we issued in a private placement 5,139,610 shares of common stock, prefunded warrants to purchase 790,710 shares of common stock and warrants to purchase an additional 1,779,096 shares of common stock&nbsp;for gross proceeds of approximately $60.0 million. In September 2021, we issued in a private placement 6,489,357 shares of common stock and prefunded warrants to purchase an additional 3,191,487 shares of common stock for gross proceeds of approximately $91.0 million. In December 2021, in connection with the Horizon Agreement, we sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 951,980 shares of our common stock to Horizon for which they paid $15.0&nbsp;million.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We also have a sales agreement in place with Cowen and Company, LLC, or Cowen, to sell up to $75.0 million of our common stock from time to time through an at the market equity offering under which Cowen will act as sales agent.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of a liquidation or insolvency, debt holders would be repaid before holders of equity securities receive any distribution of corporate assets. Our failure to raise capital or enter into such other arrangements within a reasonable timeframe would have a negative impact on our financial condition, and we may have to delay, reduce, or terminate our research and development programs, preclinical or clinical trials, or undergo reductions in our workforce or other corporate restructuring activities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> are </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">an</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> early stage biopharmaceutical company with a history of losses, we expect to continue to incur significant losses for the foreseeable future, we may never achieve or maintain profitability, and we have a limited operating history that may make it difficult for investors to evaluate the potential success of our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage immunotherapy company, with a limited operating history, focused on developing treatments for autoimmune/inflammatory diseases and cancer. Since inception, we have devoted our resources to developing novel protein-based immunotherapies primarily using our proprietary directed evolution platform, which converts native immune system proteins into potential differentiated, multi-targeted therapeutics designed to modulate the immune system. We have had significant operating losses since inception. For the year ended December&nbsp;31, 2021, our net loss was $50.3 million. Substantially all of our losses have resulted from expenses incurred in connection with our research programs and from general and administrative costs associated with our operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inflationary pressure could adversely impact our financial results. Our operating costs have increased, and may continue to increase, due to the recent growth in inflation.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our technologies and therapeutic candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of therapeutic candidates based on novel technologies.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically generated revenue primarily from the receipt of research funding and upfront and other payments under our collaboration agreements. We have not generated, and do not expect to generate, any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, and the regulatory approval process for therapeutic candidates. The amount of future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, our or our existing collaborators, or any future collaborators, successfully developing therapeutic candidates, obtaining regulatory approvals to market and commercialize therapeutic candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third-party alternatives for any approved product, and raising sufficient funds to finance business activities. If we or our existing collaborators, or any future collaborators, are unable to develop and commercialize one or more of our therapeutic candidates or if sales revenue from any therapeutic candidate receiving approval is insufficient, we will not achieve profitability, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">patient</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim, preliminary or topline data from clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or preliminary data from clinical trials that we may conduct may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Interim or preliminary data also remains subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or preliminary data should be viewed with caution until the final data are available. Adverse differences between interim, preliminary or topline data and final data could significantly harm our reputation and business prospects. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, preliminary, interim and topline data are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become available when patients mature on study, patient enrollment continues or as other ongoing or future clinical trials with a product candidate further develop. Past results of clinical trials may not be predictive of future results. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically more extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. Similarly, even if we are able to complete our planned and ongoing preclinical studies and clinical trials of our product candidates according to our current development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory approval.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management and other specialized personnel, including Mitchell H. Gold, M.D., our Executive Chairman and Chief Executive Officer, Stanford Peng, M.D., Ph.D., our President and Head of Research and Development, and Paul Rickey, our Senior Vice President and Chief Financial Officer.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and materially harm our business, financial condition, results of operations, and prospects. The relationships our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our therapeutic candidates and technologies, and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. We do not maintain key person life insurance policies on any of our management team members or key employees. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical, and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation, and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities, and other organizations, including significant competition in the Seattle employment market.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As our therapeutic candidates advance into clinical trials, we may experience difficulties in managing our growth and expanding our operations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in therapeutic development and very limited experience with clinical trials of therapeutic candidates. As our therapeutic candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory, and manufacturing capabilities or contract with other organizations to provide these capabilities for us. For example, as we continue enrollment in our Phase 2 study in SLE and continue with the development of our other product candidates, we will need to hire additional personnel in clinical operations. We also must manage relationships with collaborators or partners, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, and management controls, reporting systems, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business entails a significant risk of product liability and our inability to obtain sufficient insurance coverage could harm our business, financial condition, results of operations, or prospects.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing, and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an investigation by certain regulatory authorities, such as FDA or foreign regulatory authorities, of the safety and effectiveness of our products, our manufacturing processes and facilities, or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of managements time and our resources, substantial monetary awards to trial participants or patients, and a decline in our valuation. We currently have product liability insurance we believe is appropriate for our stage of development and may need to obtain higher levels of product liability insurance prior to marketing any therapeutic candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims with a potentially material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include, but is not limited to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">intentional failures to comply with FDA or U.S. health care laws and regulations, or applicable laws, regulations, guidance, or codes of conduct set by foreign governmental authorities or self-regulatory industry organizations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a provision of inaccurate information to any governmental authorities such as FDA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">noncompliance with manufacturing standards we may establish;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">noncompliance with federal and state healthcare fraud and abuse laws and regulations; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">noncompliance with the U.S. Foreign Corrupt Practices Act (the FCPA) and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a failur</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to report</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accurately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a failure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to disclose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unauthorized activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to us.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws, regulations, guidance and codes of conduct intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws, regulations, guidance statements, and codes of conduct may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive program, health care professional, and other business arrangements. As our business is heavily regulated, it involves significant interaction with government officials, including potentially officials of non-U.S. governments. Additionally, in many countries, healthcare providers are employed by the government, and the purchasers of biopharmaceuticals are government entities. As a result, our dealings with are subject to regulation and such healthcare providers and employees of such purchasers may be considered foreign officials as defined in the FCPA. Recently, the Securities and Exchange Commission, or SEC, and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology companies. We also may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations and if we fail to comply with these laws and regulations, we may face significant penalties, finds and/or denial of certain export privileges.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions, including debarment or disqualification of those employees from participation in FDA regulated activities and serious harm to our reputation. This could include violations of provisions of the U.S. federal Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union General Data Protection Regulation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, regulations, guidance or codes of conduct. Furthermore, we may be held liable under the FCPA and similar laws in other jurisdictions for the corrupt or other illegal activities of our employees, our third-party business partners, representatives and agents, even if we do not explicitly authorize such activities. If any such governmental investigations or other actions or lawsuits are instituted against us, and we are not successful in defending such actions or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines, exclusion from government programs, or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which may be expensive and restrict how we conduct business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party manufacturers activities and our own activities involve the controlled storage, use and disposal of hazardous and flammable materials, including the components of our pharmaceutical product candidates, test samples and reagents, biological materials and other hazardous compounds. We and our manufacturers are subject to federal, state, local, and foreign laws and regulations governing the use, generation, manufacture, storage, handling, and disposal of these hazardous materials. Although we believe our safety procedures for handling and disposing of these materials and waste products comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental injury or contamination from the use, storage, handling, or disposal of hazardous materials. In the event of an accident, state, or federal or other applicable authorities may curtail our use of these materials and/or interrupt our business operations. In addition, if an accident or environmental discharge occurs, or if we discover contamination caused by prior operations, including by prior owners and operators of properties we acquire, we could be liable for cleanup obligations, damages, and fines. If such unexpected costs are substantial, this could significantly harm our financial condition and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with governmental regulations regarding the treatment of animals used in research could increase our operating costs, which would adversely affect the commercialization of our technology.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Welfare Act, or AWA, is the federal law covering the treatment of certain animals used in research. Currently, the AWA imposes a wide variety of specific regulations governing the humane handling, care, treatment, and transportation of certain animals by producers and users of research animals, most notably relating to personnel, facilities, sanitation, cage size and feeding, watering, and shipping conditions. Third parties with whom we contract are subject to registration, inspections, and reporting requirements under the AWA. Furthermore, some states have their own regulations, including general anti-cruelty legislation, which establish certain standards in handling animals. Comparable rules, regulations, and or obligations exist in many foreign jurisdictions. If we or our contractors fail to comply with regulations concerning the treatment of animals used in research, we may be subject to fines and penalties and adverse publicity, and our operations could be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location and any events affecting this location may have material adverse consequences.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current operations are located in facilities situated in Seattle, Washington. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, power outage, telecommunication failure, or other natural or man-made accidents or incidents resulting in our company being unable to fully utilize the facilities, may have a material adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our therapeutic candidates, or interruption of our business operations. As part of our risk management policy, we maintain insurance coverage at levels we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you the amounts of insurance will be sufficient to satisfy any damages and losses or that the insurance covers all risks. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial position, results of operations, and prospects.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be affected by litigation and government investigations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time receive inquiries and subpoenas and other types of information requests from government authorities and others and we may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests, and legal proceedings is difficult to predict, defense of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">litigation claims can be expensive, time-consuming and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, costs, and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash and cash equivalents, in fixed income and other marketable securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, we had $215.4 million in cash and cash equivalents, restricted cash, and investments. We expect to invest our excess cash in fixed income and other marketable securities. These investments are subject to general credit, liquidity, market and interest rate risks. We may realize losses in the fair value of these investments, an inability to access cash in these investments for a potentially meaningful period, or a complete loss of these investments, which would have a negative effect on our financial statements.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be materially affected by changes to fiscal and tax policies. Negative or unexpected tax consequences could adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017, or TCJA, enacted in December 2017, as modified by the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, enacted in April 2020, significantly changed the U.S. Internal Revenue Code. Such changes include a reduction in the corporate tax rate and limitations on certain corporate deductions and credits, among other changes. We have generally accounted for changes related to the TCJA in accordance with our understanding of the legislation and guidance available as of the date of this filing as described in more detail in our financial statements and will continue to monitor and assess the impact of the federal legislation on our business and the extent to which various states conform to the newly enacted federal tax law. In addition, adverse changes in the financial outlook of our operations or further changes in tax laws or regulations could lead to changes in our valuation allowances against deferred tax assets on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which could materially affect our results of operations.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nivalis pre-merger net operating loss carryforwards and certain other tax attributes are likely subject to limitations. The pre-merger net operating loss carryforwards and certain other tax attributes of Alpine and of the combined organization may also be subject to limitations as a result of ownership changes resulting from the merger.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, a corporation that undergoes an ownership change is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards, or NOL carryforwards, to offset future taxable income. In general, an ownership change occurs if the aggregate stock ownership of certain stockholders, generally stockholders beneficially owning five percent or more of a corporations common stock, applying certain look-through and aggregation rules, increases by more than 50 percentage points over such stockholders lowest percentage ownership during the testing period, generally three years. Nivalis may have experienced ownership changes in the past and may experience ownership changes in the future. In addition, the closing of the merger in 2017 likely resulted in an ownership change for Nivalis. It is likely that, due to the method by which limitations on the utilization of NOL carryforwards are calculated, we will not be able to utilize any of Nivalis NOL carryforwards and certain other tax attributes. It is also possible that Alpines NOL carryforwards and certain other tax attributes may be subject to limitation as a result of ownership changes in the past and/or the closing of the merger. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of Alpines, or any of Nivalis NOL carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our debt instruments may restrict our ability to pursue our business strategies.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our term loan agreement requires us, and any debt financing we may obtain in the future may require us, to comply with various covenants that limit our ability to, among other things:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">dispose of assets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">complete mergers or acquisitions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">incur indebtedness;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">encumber assets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">pay dividends or make other distributions to holders of our capital stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">make specified investments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">engage in any new line or business; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">engagement in certain transactions with our affiliates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These restrictions could inhibit our ability to pursue our business strategies.&nbsp;If we default under our term loan agreement, including a material adverse change in our business, operations or condition (financial or otherwise), and such event of default is not cured or waived, the lenders could terminate commitments to lend and cause all amounts outstanding with respect to the debt to be due and payable immediately, which in turn could result in cross defaults under other debt instruments. Our assets and cash flow may not be sufficient to fully repay borrowings under our outstanding debt instruments if some or all of these instruments are accelerated upon a default. We may incur additional indebtedness in the future. The debt instruments governing such indebtedness could contain provisions that are as, or more, restrictive than our existing debt instruments. If we are unable to repay, refinance or restructure our indebtedness when payment is due, the lenders could proceed against the collateral granted to them to secure such indebtedness or force us into bankruptcy or liquidation.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to COVID-19 and Other Health Epidemics</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 coronavirus could adversely impact our business, including our clinical trials.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of coronavirus, SARS-CoV-2, the causative agent of coronavirus disease 2019, or COVID-19, was first reported. Since then, SARS-CoV-2 has spread globally, including countries in which we have planned or active clinical trial sites. We have experienced and will likely continue to experience disruptions that could severely impact our business and clinical trials, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">elays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in receiving approval from local regulatory authorities and ethics committees to initiate our planned clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">refusal </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the FDA to accept data from clinical trials whose conduct has been affected by the COVID-19 outbreak, such as due to missing data.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic. The FDA has also published other COVID-19-related industry guidance, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including updates to previous guidance documents, regarding Good Manufacturing Practices, remote interactive evaluations of drug manufacturing and bioresearch monitoring facilities, and drug product manufacturing and supply chain inspections, among others. It is possible that additional governmental action will be taken to address the COVID-19 pandemic. The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, including new regulatory requirements and changes to existing regulations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. For example, with the increased availability of vaccines in North America and certain countries around the world, the rate of additional COVID-19 infections and hospitalizations declined in certain locations for periods of time, resulting in relaxed restrictions and a general reopening of the economy and travel across many jurisdictions, however some jurisdictions continue to maintain or reimpose restrictions in view of increased hospitalization rates and cases due to COVID-19 variants. While certain of these developments are positive, reduced vaccine availability, resistance to vaccination by certain persons or ineffectiveness of vaccines against certain variants may result in increasing infection and hospitalization rates, which could be further complicated by the emergence of more virulent or infectious variants of the virus.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to health epidemics and other outbreaks, which could significantly disrupt our operations and/or business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely impacted by the effects of the COVID-19 outbreak originating in China, or by other epidemics. Our supply chain for raw materials, drug substance or drug product is worldwide, including China, and accordingly could be subject to disruption. There may be restrictions on the export or shipment of raw materials, drug substance or drug product that could materially delay our business or clinical trials.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our research and development efforts are also conducted globally, for example the NEON-1 clinical trial and ALPN-303 healthy volunteer study include investigative sites in Australia and our Synergy trial includes investigative sites in Korea and Poland. A health epidemic or other outbreak, including the current COVID-19 outbreak, may materially and adversely affect our business, financial condition and results of operations. The extent to which the outbreak impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak and the actions to contain the outbreak or treat its impact, among others.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Cybersecurity</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer security or data privacy breaches or incidents or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations. </span></div><div><span><br></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems, and those of our third-party CROs, other contractors (including sites performing clinical trials) and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches and incidents from inadvertent or intentional actions by our employees, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including supply chain cyber-attacks or the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure or lead to the loss, destruction, alteration, prevention of access to, disclosure, or dissemination of, or damage or unauthorized access to, our data (including trade secrets or other confidential information, intellectual property, proprietary business information, and personal information) or data that is processed or maintained on our behalf, or other assets, which could result in financial, legal, business and reputational harm to us. Companies have experienced an increase in phishing and social engineering attacks from third parties in connection with the COVID-19 pandemic, and the increase in remote working further increases security threats. To the extent that any disruption or security incident were to result in any loss, destruction, unavailability, alteration, disclosure, or dissemination of, or damage or unauthorized access to, our applications, any other data processed or maintained on our behalf or other assets, or for it to be believed or reported that any of these occurred, we could incur liability, financial harm and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reputational damage and the development and commercialization of our product candidates could be delayed. We cannot assure you that our data protection efforts and our investment in information technology, or the efforts or investments of CROs, consultants or other third parties, will prevent significant breakdowns or breaches in systems or other cyber incidents that cause loss, destruction, unavailability, alteration or dissemination of, or damage or unauthorized access to, our data and other data processed or maintained on our behalf or other assets that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Further, any such event that leads to loss, damage, or unauthorized access to, or use, alteration, or disclosure or dissemination of, personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notifications and follow-up actions related to a security breach or incident could impact our reputation and cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We expect to incur significant costs in an effort to detect and prevent security breaches and incidents, and we may face increased costs and requirements to expend substantial resources in the event of an actual or perceived security breach or incident. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security incident were to result in any loss, destruction, or alteration of, unavailability of, or damage or unauthorized access to, our data or other information that is processed or maintained on our behalf, or inappropriate disclosure of or dissemination of any such information, or if any of these were perceived or reported to have occurred, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption in or, failure or security breach or incident of or impacting our systems or third-party systems where information important to our business operations or commercial development is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. </span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems could face serious disruptions adversely affecting our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines, and connection to the Internet, face the risk of systemic failure potentially disruptive to our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems, or those of third parties that perform services or supply materials to us, could cause interruptions in our collaborations with our partners and delays in our research and development work.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facility is located in Seattle, Washington. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major flood, blizzard, fire, earthquake, power loss, terrorist activity, pandemics or other disasters and do not have a recovery plan for such disasters. Also, our contract development and manufacturing organizations and suppliers facilities are located in multiple locations where other natural disasters or similar events which could severely disrupt our operations, could expose us to liability and could have a material adverse effect on our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_46"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain and enforce patent protection for our technology, including therapeutic candidates, therapeutic products, and platform technology, development of our therapeutic candidates and platform, and commercialization of our therapeutic products may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our technology, including platform technology and therapeutic candidates and products, methods used to manufacture our therapeutic candidates and products, and methods for treating patients using our therapeutic candidates and products, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights, and to operate without infringing upon the proprietary rights of others. Our scientific platform and substantially all of our intellectual property have been developed internally. As of December&nbsp;31, 2021, our patent portfolio consists of 47 granted patents and over </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending patent applications. We may not be able to apply for patents on certain aspects of our technology, including therapeutic candidates and products, in a timely fashion or at all. Any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing therapeutics and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, any of our issued or granted patents will not later be found to be invalid or unenforceable, or any issued or granted patents will include claims sufficiently broad to cover our technology, including platform technology and therapeutic candidates and products, or to provide meaningful protection from our competitors. Moreover, the patent position of pharmaceutical and biotechnology companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent our current and future technology, including platform technology and therapeutic candidates and products, are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely impact our competitive position in the market.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Patent offices may be affected by COVID-19 or other health epidemic shut-downs, resulting in, for example, non-essential administrative tasks being delayed or eliminated. This could affect patent rights, including the partial or complete loss of patent rights in jurisdictions such as the USPTO and international patent offices. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. Further, the standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical patents. As such, we do not know the degree of future protection we will have on our technology, including platform technology and therapeutic candidates and products. While we will endeavor to try to protect our technology, including platform technology and therapeutic candidates and products, with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive, and sometimes unpredictable, and we can provide no assurances our technology, including our platform technology, therapeutic candidates and products, will be adequately protected in the future against unauthorized uses or competing claims by third parties.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, recent and future changes to the patent laws and to the rules of the USPTO or other foreign patent offices may have a significant impact on our ability to protect our technology, including therapeutic candidates and products, and enforce our intellectual property rights. For example, the Leahy-Smith America Invents Act enacted in 2011 involves significant changes in patent legislation. In addition, we cannot assure that court rulings or interpretations of any court decision will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, there also may be uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO, or made in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability. Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter partes review, revocation, nullification, or derivation action in court or before patent offices or similar proceedings before or after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the pending, allowed or granted claims thus attacked or may lose the allowed or granted claims altogether. Our patent risks include that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">others may, or may be able to, make, use, offer to sell, or sell compounds that are the same as or similar to our therapeutic candidates and products but that are not covered by the claims of the patents we own or license;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we or our licensors, collaborators, or any future collaborators may not be the first to file patent applications covering certain aspects of our technology, including our platform technology, therapeutic candidates and products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">others may independently develop similar or alternative technology or duplicate any of our technology without infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a third party may challenge our patents and, if challenged, a court may not hold that our patents are valid, enforceable, or that a third party is infringing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a third party may challenge our patents in various patent offices and, if challenged, we may be compelled to limit the scope of our pending, allowed or granted claims or lose the allowed or granted claims altogether;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">any issued patents we own or have licensed may not provide us with any competitive advantages, or may be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the patents of others could harm our business; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our competitors could conduct research and development activities in countries where we do not or will not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in major commercial markets where we do not or will not have enforceable patent rights.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may license patent rights from third-party owners or licensors. If such owners or licensors do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, or if they retain or license to others any competing rights, our competitive position and business prospects may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely upon intellectual property rights licensed from third parties to protect our technology, including platform technology and therapeutic candidates and products. To date, we have in-licensed some intellectual property on a non-exclusive basis relating to commercially-available cell lines involved in the manufacture of our vIgD programs; however, we may also license additional third-party intellectual property in the future, to protect our technology, including intellectual property relating to our platform technology and therapeutic candidates and products. Our success will depend in part on the ability of our licensors to obtain, maintain, and enforce patent protection for our licensed intellectual property, in particular those patents to which we have secured exclusive rights. Our licensors may elect not to prosecute, or may be unsuccessful in prosecuting, any patent applications licensed to us. Even if patents issue or are granted, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies infringing these patents, or may pursue litigation less aggressively than we would. Further, any additional licenses we enter into may be non-exclusive and we may not be able to obtain exclusive rights, which would potentially allow third parties to develop competing products or technology. Without protection for, or exclusive right to, any intellectual property we may license, other companies might be able to offer substantially identical or similar product(s) for sale, which could adversely affect our competitive business position and harm our business prospects. In addition, we may need to sublicense any rights we have under third-party licenses to current or future collaborators or any future strategic partners. Any impairment of these sublicensed rights could result in reduced revenue under or result in termination of an agreement by one or more of our collaborators or any future strategic partners.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our platform technology and therapeutic candidates and products for an adequate amount of time.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States and abroad, if all maintenance fees/annuity fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date. The protection a patent affords is limited. Even if patents covering our products are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to protect our patent intellectual property rights throughout the world.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining a valid and enforceable issued or granted patent covering our technology, including therapeutic candidates and products, in the United States and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology, including our platform technology and therapeutic candidates and products, to develop their own products, and further, may commercialize such products in those jurisdictions and export otherwise infringing products to territories where we have not obtained patent protection. In certain instances, a competitor may be able to export otherwise infringing products in territories where we will obtain patent protection. In jurisdictions outside the United States where we will obtain patent protection, it may be more difficult to enforce a patent as compared to the United States. Competitor products may compete with our future products in jurisdictions where we do not or will not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly relating to biopharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the Patent Cooperation Treaty, or PCT, is usually filed within twelve months after the priority filing, at times with a United States filing. Based on the PCT filing, national and regional patent applications may be filed in various international jurisdictions, such as in Europe, Japan, Australia, Canada, and the United States. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before they are granted. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that, depending on the country, various scopes of patent protection may be granted on the same therapeutic candidate, product, or technology. The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors, collaborators, or any future strategic partners may become subject to third-party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development of our therapeutic candidates and commercialization of our therapeutic products, or put our patents and other proprietary rights at risk.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors, licensees, collaborators, or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold harmless our licensors, licensees, or collaborators for damages arising from intellectual property infringement by us. If we or our licensors, licensees, collaborators, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, licensees, collaborators, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to or from us. If we fail to obtain a required license, we or our licensee or collaborator, or any future licensee or collaborator, may be unable to effectively market therapeutic products based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our managements attention. Some of our competitors may be able to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not believe our technology infringes the intellectual property rights of others, we are aware of one or more patents or patent applications that may relate to our technology, and third parties may assert against our products alleging infringement of their intellectual property rights regardless of whether their claims have merit. Infringement claims could harm our reputation, may result in the expenditure of significant resources to defend and resolve such claims, and could require us to pay monetary damages if we are found to have infringed the intellectual property rights of others.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to initiate legal proceedings against a third party to enforce a patent covering our technology, including therapeutic candidates and products, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, patent ineligibility, lack of novelty, lack of written description, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology, including our platform technology and therapeutic candidates and products. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology, including our platform technology and therapeutic candidates and products, if competitors design around our protected technology, including our platform technology and therapeutic candidates and products, without legally infringing our patents or other intellectual property rights.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible we have failed to identify relevant third-party patents or applications. For example, patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our technology, including our platform technology and therapeutic candidates and products, could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our technology, including our platform technology and therapeutic candidates and products. Third-party intellectual property rights holders may also actively bring infringement claims against us. We cannot guarantee we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable, and time-consuming litigation and may be prevented from, or experience substantial delays in, marketing our technology, including therapeutic candidates and products. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing our technology, including a therapeutic product, held to be infringing. We might, if possible, also be forced to redesign therapeutic candidates or products so we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources we would otherwise be able to devote to our business.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration, or other agreements, we may be required to pay damages and could lose intellectual property rights necessary for developing and protecting our technology, including our platform technology, therapeutic candidates, and therapeutic products, or we could lose certain rights to grant sublicenses, either of which could have a material adverse effect on our results of operations and business prospects.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell or offer to sell products covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensors rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on future sales of licensed products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in therapeutic products we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize therapeutic products, we may be unable to achieve or maintain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any therapeutic candidate or product we may develop, our business may be materially harmed.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upon the timing, duration, and specifics of any FDA marketing approval of any therapeutic candidate or product we may develop, one or more of our or in-licensed U.S. patents may be eligible for limited patent term extension under the Drug </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">only</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and growth prospects could be materially harmed.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for certain aspects of our technology, including platform technology and therapeutic candidates and products, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants obligating them to maintain confidentiality and assign their inventions to us. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We also cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Enforcing a claim in the event of a party illegally disclosing or misappropriating a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject both in the United States and outside the United States to various regulatory schemes regarding requests for the information we provide to regulatory authorities, which may include, in whole or in part, trade secrets or confidential commercial information. While we are likely to be notified in advance of any disclosure of such information and would likely object to such disclosure, there can be no assurance our challenge to the request would be successful.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be in the future subject to claims we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees or consultants former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages, may be prohibited from using some of our research and development and may lose valuable intellectual property rights or personnel.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees were previously employed at universities or biotechnology or pharmaceutical companies, including our current and potential competitors. We may receive correspondence from other companies alleging the improper use or disclosure, and have received, and may in the future receive, correspondence from other companies regarding the use or disclosure, by certain of our employees who have previously been employed elsewhere in our industry, including with our competitors, of their former employers trade secrets or other proprietary information. Responding to these allegations can be costly and disruptive to our business, even when the allegations are without merit, and can be a distraction to management. We may be subject to claims in the future that our employees have, or we have, inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending current or future claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, personnel, or the ability to use some of our research and development. A loss of intellectual property, key research personnel, or their work product could hamper our ability to commercialize, or prevent us from commercializing, our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be materially and adversely affected.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. Any trademark litigation could be expensive. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be materially and adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may independently develop similar or superior technology.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance others will not independently develop, or have not already developed, similar or more advanced technologies than our technology or that others will not design around, or have not already designed around, aspects of our technology or our trade secrets developed therefrom. If third parties develop technology similar or superior to our technology, or they successfully design around our current or future technology, our competitive position, business prospects, and results of operations could be materially and adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breaches of our internal computer systems, or those of our contractors, vendors, or consultants, may place our patents or proprietary rights at risk.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of clinical or preclinical data or data from any future clinical trial involving our technology, including therapeutic candidates and products, could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or other exposure of data may interfere with our ability to protect our intellectual property, including trade secrets, and other information critical to our operations. We have experienced in the past, and may experience in the future, unauthorized intrusions into our internal computer systems, including portions of our internal computer systems storing information related to our platform technology, therapeutic candidates and products, and we can provide no assurances that certain sensitive and proprietary information relating to one or more of our therapeutic candidates or products has not been, or will not in the future be, compromised. Although we have invested significant resources to enhance the security of our computer systems, there can be no assurances we will not experience additional unauthorized intrusions into our computer systems, or those of our CROs, vendors, contractors, and consultants, that we will successfully detect future unauthorized intrusions in a timely manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business prospects. Payments related to the elimination of ransomware may materially affect our financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of HIPAA, as amended by HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union General Data Protection Regulation, and financial penalties may also apply.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_49"></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, may be unable to commercialize our therapeutic candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our therapeutic candidates are subject to extensive governmental regulations relating to, among other things, research, development, testing, manufacture, quality control, approval, labeling, packaging, promotion, storage, record-keeping, advertising, distribution, sampling, pricing, sales and marketing, safety, post-approval monitoring and reporting, and export and import of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be completed successfully in the United States and in many foreign jurisdictions before a new therapeutic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain, and subject to unanticipated delays. We have not obtained regulatory approval for any therapeutic candidates, and it is possible none of the therapeutic candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling them.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA as well as foreign regulatory authorities, such as the EMA. The time required to obtain FDA and foreign regulatory approvals is unpredictable but typically takes many years following the commencement of clinical trials, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depending upon the type, complexity, and novelty of the therapeutic candidate, and at the substantial discretion of the regulatory authorities. The standards the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, who could delay, limit, or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, future legislation or administrative action, or from changes in the policy of FDA or foreign regulatory authorities during the period of product development, clinical trials, and regulatory review by the FDA or foreign regulatory authorities. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign, regulations, guidance, or interpretations will be changed, or what the impact of such changes, if any, may be.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the therapeutic candidates we are developing may represent a new class of therapeutics, we are not aware of any definitive policies, practices, or guidelines that the FDA or its foreign counterparts have established in relation to these drugs. While we believe the therapeutic candidates we are currently developing are regulated as new biological products under the Public Health Service Act, or PHSA, the FDA could decide to regulate them or other products we may develop as drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA. The lack of policies, practices, or guidelines may hinder or slow review by the FDA or foreign regulatory authorities of any regulatory filings we may submit. Moreover, the FDA or foreign regulatory authorities may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our therapeutic candidates. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therapeutic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> candidates could fail to receive regulatory approval for many reasons, including the following: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a therapeutic candidate is safe and effective for its proposed indication; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may be unable to demonstrate that a therapeutic candidates clinical and other benefits outweigh its safety risks; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the data collected from clinical trials of our therapeutic candidates may not be sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the particular therapeutic candidate for which we are seeking approval. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process, and in determining when or whether regulatory approval will be obtained for any of our therapeutic candidates. Even if we believe the data collected from preclinical and clinical trials of our therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or in the product labeling or be subject to other restrictions. Regulatory authorities also may impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the therapeutic. In addition, the FDA has the authority to require a REMS plan as part of the approval of a BLA or NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria, and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the therapeutic and affect coverage and reimbursement by third-party payors.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing, marketing authorization, pricing, and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for certain of our products, our competitors may sell products to treat the same conditions and our revenue may be reduced.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a therapeutic product with orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the therapeutic product is entitled to orphan product exclusivity, which means the FDA may not approve any other applications to market the same therapeutic product for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, we may apply for designation of a therapeutic candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made. In the European Union, the EMAs Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Sponsors of orphan drugs in the European Union can enjoy economic and marketing benefits, including reduction of fees or fee waivers and up to ten years of market exclusivity for the approved indication unless another applicant can show its therapeutic product is safer, more effective, or otherwise clinically superior to the orphan-designated therapeutic product. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek orphan drug designation from the FDA and the EMA for certain of our product candidates. However, we may never receive such designation. Even if we are able to obtain orphan designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, regulatory authorities may subsequently approve the same drug with the same active moiety for the same condition if they conclude that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process. In addition, orphan drug exclusivity could block the approval of one of our therapeutic candidates if a competitor obtains approval of the same therapeutic product as defined by the FDA before we do, or if our therapeutic candidate is determined to be within the same class as the competitors therapeutic product for the same indication or disease. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The respective orphan designation and exclusivity frameworks in the United States and in the European Union are subject to change, and any such changes may affect our ability to obtain EU or U.S. orphan designations in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our existing or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we or such other parties could be subject to enforcement actions, which could adversely affect our ability to develop, market, and sell our therapeutics and may harm our reputation.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not currently have any products on the market, once we begin commercializing our therapeutic candidates, if approved, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal, state, and foreign governments of the jurisdictions in which we conduct our business. Healthcare providers, physicians, and third-party payors play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud, abuse, and other healthcare laws and regulations constraining the business or financial arrangements and relationships through which we market, sell, and distribute the therapeutic candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering, or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. In addition, the government may assert a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">state all-payor fraud laws, which impose criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">HIPAA, HITECH, and their implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates performing certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the federal Physician Payment Sunshine Act and its implementing regulations, also referred to as Open Payments, require applicable manufacturers of pharmaceutical and biological drugs, among other covered medical products, reimbursable under Medicare, Medicaid, or Childrens Health Insurance Programs to track and report to the CMS certain payments and transfers of value made in the previous year, including but not limited to, consulting fees, travel reimbursements, and research grants made to cover recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding physicians and their immediate family members ownership and investment interests in the applicable manufacturer, with limited exceptions; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">analogous and similar state and foreign laws and regulations, such as, state anti-kickback and false claims laws potentially applicable to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; and some state laws require pharmaceutical companies to comply with the pharmaceutical industrys voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement, or other government programs, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare and Medicaid, any of which could adversely affect our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause our company to incur significant legal expenses and could divert our managements attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time, and resources.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our current or future collaborators, manufacturers, or service providers fail to comply with applicable federal, state, or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market, and sell our therapeutics successfully and could harm our reputation and lead to reduced acceptance of our therapeutics by the market. These enforcement actions include, among others:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">adverse regulatory inspection findings;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">warning or untitled letters;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">voluntary product recalls with public notification or medical product safety alerts to healthcare professionals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">restrictions on, or prohibitions against, marketing our therapeutics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">restrictions on, or prohibitions against, importation or exportation of our therapeutics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">suspension of review or refusal to approve pending applications or supplements to approved applications;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">exclusion from participation in government-funded healthcare programs;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">exclusion from eligibility for the award of government contracts for our therapeutics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">FDA debarment;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">suspension or withdrawal of therapeutic approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">seizures or administrative detention of therapeutics;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">injunctions; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">restitution, disgorgement of profits, or civil and criminal penalties and fines.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of our therapeutic candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies of the FDA or similar regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and biologics and spur innovation, but it is still being implemented and its ultimate implementation is unclear. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our therapeutic candidates may not obtain or maintain regulatory approval, and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or executive or administrative action, either in the United States or abroad. The FDAs and other regulatory authorities policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. It is difficult to predict how current and future legislation, executive actions, and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business, our clinical development, and the FDAs and other agencies ability to exercise their regulatory authority, including FDAs pre-approval inspections and timely review of any regulatory filings or applications we submit to the FDA. To the extent any legislative or executive actions impose constraints on FDAs ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any therapeutics we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices, or healthcare reform initiatives, thereby harming our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations governing marketing approvals, pricing, coverage, and reimbursement for new drugs and biologics vary widely from country to country. Many countries require approval of the sale price of a drug before it can be marketed. In many </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a product in a particular country but then be subject to price regulations delaying our commercial launch of the product and negatively impacting the revenues we are able to generate from the sale of the product in that country.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any therapeutics successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. However, there may be significant delays in obtaining coverage for newly-approved therapeutics. Moreover, eligibility for coverage does not necessarily signify a therapeutic will be reimbursed in all cases or at a rate covering our costs, including research, development, manufacture, sale, and distribution costs. Also, interim payments for new therapeutics, if applicable, may be insufficient to cover our costs and may not be made permanent. Thus, even if we succeed in bringing one or more therapeutics to the market, these products may not be considered cost-effective, and the amount reimbursed for any of them may be insufficient to allow us to sell them on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness, coverage prospects, potential compendia listings, or the likely level or method of reimbursement, if covered. It is equally difficult for us to predict how Medicare coverage and reimbursement policies will be applied to our products in the future, and coverage and reimbursement under different federal healthcare programs are not always consistent. Medicare reimbursement rates may also reflect budgetary constraints placed on the Medicare program.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement rates. These coverage policies and limitations may rely, in part, on compendia listings for approved therapeutics. Our inability to promptly obtain relevant compendia listings, coverage, and adequate reimbursement from both government-funded and private payors for new therapeutics we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products, and our financial condition.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the efforts of governments and third-party payors to contain or reduce the cost of healthcare, and legislative and regulatory proposals to broaden the availability of healthcare, will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A number of legislative and regulatory changes in the healthcare system in the United States and other major healthcare markets have been proposed, and such efforts have expanded substantially in recent years. These developments could, directly or indirectly, affect our ability to sell our products, if approved, at a favorable price. In addition, third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates, and other concessions to reduce the prices for therapeutics. If the price we are able to charge for any therapeutics we develop, or the reimbursement provided for such products, is inadequate, our return on investment could be adversely affected. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to health reform legislation and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, are working with various healthcare providers to develop, refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries, including the Bundled Payments for Care Improvement Initiative, the Comprehensive Primary Care Initiative, the Duals Demonstration, and other models. The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any future reimbursement we may receive for approved therapeutics administered by such organizations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in recent years, the U.S. Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures. For example, as a result of the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015, an annual 2% reduction to Medicare payments that took effect in 2013 and will remain in effect through 2031, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2022, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. These across-the-board spending cuts could adversely affect our future revenues, earnings, and cash flows.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, in 2020, HHS and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of the rules implemented during the Trump administration. As a result, the Biden administration and HHS have delayed the implementation or published rules rescinding some of these Trump-era policies. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. In July 2021, the Biden administration released an executive order, Promoting Competition in the American Economy, with multiple provisions aimed at increasing competition for prescription drugs. In response to this executive order, the HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering legislation that, if passed, could have significant impact on prices of prescription drugs covered by Medicare, including limitations on drug price increases. The impact of these legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry as a whole is unclear. Any reduction in reimbursement from Medicare or other government programs may result in a reduction in payments from private payors. Additionally, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. The impact of legislative, executive, and administrative actions of the Biden administration on us and the biopharmaceutical industry as a whole is unclear. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare industry is heavily regulated in the U.S. at the federal, state, and local levels</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and in other jurisdictions in which we may conduct trials or other activities, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a healthcare company, our operations, clinical trial activities, and interactions with healthcare providers will be subject to extensive regulation in the United States, particularly if we receive FDA approval for any of our products in the future, and we may be subject to laws and regulations in other jurisdictions as we conduct clinical trials or engage in other activities in foreign jurisdictions. For example, if we receive FDA approval for a therapeutic for which reimbursement is available under a federal healthcare program, it would be subject to a variety of federal laws and regulations, including those prohibiting the filing of false or improper claims for payment by federal healthcare programs, prohibiting unlawful inducements for the referral of business reimbursable by federal healthcare programs, and requiring disclosure of certain payments and other transfers of value made to covered recipients in the previous year, including U.S.-licensed physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding certain physicians and their immediate family members ownership and investment interests in the applicable manufacturer, with limited exceptions. If our past or present operations, or those of our contractors or agents who conduct business on our behalf, are found to be in violation of any of these laws, we could be subject to enforcement action, government investigation, civil and criminal penalties, which could hurt our business, operations, and financial condition. It is not always possible to identify and deter misconduct by parties we may contract with, including employees, contractors, collaborators, CROs, and suppliers, and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, some state laws prohibit, among other offenses, knowingly and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying, concealing, or covering up a material fact or making any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for items or services under a health care benefit program. We may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with respect to such information. Additionally, many states have enacted similar laws imposing more stringent requirements on entities like us. Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial condition and results of operations. Complying with new regulatory requirements and changes in the laws and regulations will increase our compliance cost and exposure to potential liability.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the collection and use of health data in the EU is governed by the General Data Protection Regulation, or GDPR, which extends the geographical scope of EU data protection law to non-EU entities under certain conditions and imposes substantial obligations upon companies and new rights for individuals.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, state and foreign laws may apply generally to the privacy and security of information we maintain, and may differ from each other in significant ways, thus complicating compliance efforts, as discussed in the risk factor below titled, Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conducting and/or enrolling patients in our current or future clinical trials, we are subject to restrictions relating to privacy, data protection and data security and may be subject to additional restrictions as our clinical operations expand. For example, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, or EU, including personal health data, is subject to the GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches (initially to supervisory authorities and, if the breach is serious enough, to individuals), and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to 20 million or 4% of annual global revenues, whichever is greater, for the most serious of violations. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Certain aspects of cross-border data transfers under the GDPR are uncertain as the result of legal proceedings in the EU, including a July 2020 decision by the Court of Justice for the European Union, or CJEU, that invalidated the EU-U.S. Privacy Shield and, to some extent, called into question the efficacy and legality of using standard contractual clauses (SCCs). To address certain concerns of the CJEU, the European Commission issued revised SCCs in June 2021. Regulatory guidance and other developments relating to cross-border personal data transfers, including the necessity of putting in place those revised SCCs and the UK SCCs, as discussed below, may increase the complexity of transferring personal data across borders and may require us to engage in additional contractual negotiations and to modify our policies and practices relating to the transfer and other processing of personal data. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the vote in the United Kingdom, or UK, in favor of exiting the EU, referred to as Brexit, has created uncertainty with regard to data protection regulation in the UK. The Data Protection Act of 2018, which implements and complements the GDPR, achieved Royal Assent on May 23, 2018 and is now effective in the UK along with a version of the GDPR referred to as the UK GDPR. Collectively, the Data Protection Act of 2018 and the UK GDPR authorize significant fines, up to the greater of 17.5 million or 4% of global turnover, and expose us to two parallel regimes and other potentially divergent enforcement actions for certain violations.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, aspects of data protection in the UK remain uncertain. On June 28, 2021, the European Commission issued an adequacy decision under the GDPR and the Law Enforcement Directive, pursuant to which personal data generally may be transferred from the EU to the UK without restriction; however, this adequacy decision is subject to a four-year sunset period, after which the European Commissions adequacy decision may be renewed, and this decision may be revoked or modified in the interim.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on February 2, 2022, the UKs Information Commissioners Office issued new standard contractual clauses to support personal data transfers out of the UK. If approved by the UK Parliament, these standard contractual clauses become effective March 21, 2022, and we may, in addition to other impacts, experience additional costs associated with increased compliance burdens and be required to engage in new contract negotiations with third parties that aid in processing personal data on our behalf or localize certain personal data. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions also increasingly maintain laws and regulations addressing privacy, data protection, and information security.</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may incur liabilities, expenses, costs, and other operational losses under GDPR and local laws of applicable EU member states, the UK, and other regions in connection with any measures we take to comply with them. Working to comply with the GDPR and other laws and regulations to which we are subject in Europe and other regions outside the United States relating to privacy, data protection, and information security will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our activities in those regions.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in California, the CCPA creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action in data breach situations. While it exempts some data regulated by HIPAA and certain clinical trials data, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA went into effect on January 1, 2020, and the California Attorney General commenced enforcement actions for violations on July 1, 2020. Moreover, the CPRA was approved by California voters in the November 3, 2020 election. The CPRA will significantly modify the CCPA, creating obligations beginning on January 1, 2022, with implementing regulations expected on or before July 1, 2022, and enforcement commencing July 1, 2023. The CPRA creates further uncertainty and may require us to incur additional costs and expenses. The CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States. The CCPA has prompted a number of proposals for federal and state privacy legislation. For example, in March 2021, Virginia enacted the Virginia Consumer Data Protection Act (CDPA), a comprehensive privacy statute that becomes effective on January 1, 2023 and shares similarities with the CCPA. In addition, on July 7, 2021, Colorado enacted the Colorado Privacy Act (CPA), becoming the third state to pass comprehensive consumer privacy legislation in the United States. These and other new laws that may be proposed or enacted could increase our potential liability and adversely affect our business.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Any actual or alleged failure to comply with U.S. or international laws and regulations relating to privacy, data protection, and data security could result in governmental investigations, proceedings and enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity, harm to our reputation, and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information or impose other obligations or restrictions in connection with our use, retention and other processing of information, and we may otherwise face contractual restrictions applicable to our use, retention, and other processing of information. Claims that we have violated individuals privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to obtain services, reimbursement, or funding from the federal government may be impacted by possible reductions in federal spending.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal budget remains in flux and could, among other things, cut Medicare payments to providers. The Medicare program is frequently mentioned as a target for spending cuts. The full impact on our business of any future cuts in Medicare or other programs is uncertain. We cannot predict the extent of legislative, executive, and administrative actions of the Biden administration will have on us and the biopharmaceutical industry as a whole. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve drug research and development, manufacturing, and marketing activities, which may delay our ability to develop, market, and sell any therapeutics we may develop.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our therapeutic candidates receives marketing approval and we or others later identify undesirable side effects caused by the therapeutic product, our ability to market and derive revenue from the therapeutic products could be compromised.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event any of our therapeutic candidates receive regulatory approval and we or others identify undesirable side effects, adverse events, or other problems caused by one of our therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory authorities may withdraw their approval of the product and require us to take the product off the market or seize the product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may need to recall the therapeutic or change the way the therapeutic is administered to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">additional restrictions may be imposed on the marketing and promotion of the particular therapeutic or the manufacturing processes for the therapeutic or any component thereof;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may not be able to secure or maintain adequate coverage and reimbursement for our proprietary therapeutic products from government (including U.S. federal health care programs) and private payors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may lose or see adverse alterations to compendia listings or treatment protocols specified by accountable care organizations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may be subject to fines, restitution, or disgorgement of profits or revenues, injunctions, or the imposition of civil penalties or criminal prosecution;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory authorities may require the addition of labeling statements, such as a black box warning, or equivalent, or a contraindication;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">regulatory authorities may require us to implement a REMS plan, or to conduct post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the therapeutic may become less competitive; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our reputation may suffer.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our therapeutic candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsors own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of our therapeutic candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our therapeutic candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant developments stemming from the United Kingdoms recent withdrawal from the European Union could have a material adverse effect on us.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdoms recent withdrawal from the European Union and ongoing negotiations related to the United Kingdoms trade and other relationships with the European Union continue to create political and economic uncertainty, particularly in the United Kingdom and the European Union. Any business we conduct, now and in the future, in the United Kingdom, the European Union, and worldwide could be affected as a result of this transition and there are multiple ways in which our business could be negatively affected.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brexit is expected to disrupt the operation of pre- and post-authorization clinical trial infrastructure. As of January 1, 2021, European Union law applies only to the territory of Northern Ireland to the extent foreseen in the Protocol on Ireland / Northern Ireland. The rules around GMP and pharmacovigilance in the UK currently remain similar to the EU requirements. However, the Falsified Medicines Directive will not apply in Great Britain though it is likely that the UK will implement a procedure to minimize the risk of falsified medicines. Uncertainty in the regulatory framework and future legislation can lead to disruption in the execution of international multi-center clinical trials, the monitoring of adverse events in through pharmacovigilance programs, and determination of marketing authorization across different jurisdictions. There could also be disruption to the supply and distribution as well as the import/export both of active pharmaceutical ingredients and finished product. Such a disruption could create supply difficulties for ongoing clinical trials and may damage the integrity of the pharmacovigilance database for the safety of new products. The cumulative effects of the disruption to the regulatory framework, uncertainty in future regulation, and changes to existing regulations may add considerably to the development lead time to marketing authorization and commercialization of products in the European Union and/or the United Kingdom and increase our costs. We cannot predict the impact of such changes and future regulation on our business or the results of our operations. Exposure to different and changing regulations in multiple foreign jurisdictions may increase our liabilities, expenses, costs, and other operational losses. </span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_52"></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile, and an active, liquid, and orderly trading market may not develop for our common stock. As a result, stockholders may not be able to resell shares at or above their purchase price.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on Nasdaq, an active trading market for our common stock may not be sustained. The lack of an active market may impair the ability of our stockholders to sell their shares at the time they wish to sell them or at a price that they consider reasonable, which may reduce the fair market value of their shares. Further, an inactive market may also impair our ability to raise capital by selling our common stock should we determine additional funding is required.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our and our collaborators ability to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">issues in manufacturing our approved products, if any, or product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the results of current, and any future, preclinical or clinical trials of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our ability to achieve development milestones and receive associated milestone payments pursuant to the terms of our collaboration agreements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the entry into, or termination of, key agreements, including key licensing, collaboration or acquisition agreements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the initiation or material developments in, or conclusion of, litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">announcements by commercial partners or competitors of new commercial products, clinical progress (or the lack thereof), significant contracts, commercial relationships, or capital commitments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">adverse publicity relating to our markets, including with respect to other products and potential products in such markets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">adverse publicity about our company, employees, therapeutic candidates, and/or therapeutic products in the media or on social media;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the impact of COVID-19 on our company or the economy generally; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the introduction of technological innovations or new therapies competing with our potential products;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the loss of key employees;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in estimates or recommendations by securities analysts, if any, who cover our common stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">general and industry-specific economic conditions potentially affecting our research and development expenditures;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">changes in the structure of health care payment systems;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unanticipated serious safety concerns related to the use of any of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure to meet or exceed financial and development projections we may provide to the public;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure to meet or exceed the financial and development projections of the investment community;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the perception of the pharmaceutical industry by the public, legislators, regulators, and the investment community;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">adverse regulatory decisions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">commencement of, or our involvement in, litigation;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">trading volume of our common stock; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">period-to-period fluctuations in our financial results; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the other factors described in this </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_22" tabindex="18">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a companys securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business and reputation.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our officers and directors, and their respective affiliates, have a controlling influence over our business affairs and may make business decisions with which stockholders disagree and which may adversely affect the value of their investment.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and directors together with their respective affiliates, beneficially own approximately 51% of our common stock as of December&nbsp;31, 2021. As a result, if some of these persons or entities act together, they will have the ability to exercise significant influence over matters submitted to the stockholders for approval, including the election of directors, amendments to the certificate of incorporation and bylaws and the approval of any strategic transaction requiring the approval of the stockholders. These actions may be taken even if they are opposed by other stockholders. This concentration of ownership may also have the effect of delaying or preventing a change of control of our company or discouraging others from making tender offers for our shares, which could prevent our stockholders from receiving a premium for their shares. Some of these persons or entities who make up our principal stockholders may have interests different from other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors perception that conflicts of interest may exist or arise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales, or the perception of future sales, of a substantial amount of our common stock could depress the trading price of our common stock.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in connection with our July 2020 private placement, we entered into a registration rights agreement with the private placement investors that required us to prepare and file a resale registration statement, which was declared effective by the SEC on August 18, 2020 and permits the resale by the private placement investors of approximately 5.1 million shares of our common stock as well as approximately 2.6 million shares of common stock issuable upon the exercise of prefunded warrants and warrants issued in the July 2020 private placement. Additionally, in connection with our September 2021 private placement, we entered into a registration rights agreement with the private placement investors that required us to prepare and file a resale registration statement, which was declared effective by the SEC on November 19, 2021 and permits the resale by the private placement investors of approximately 6.5 million shares of our common stock as well as approximately 3.2 million shares of common stock issuable upon the exercise of prefunded warrants issued in the September 2021 private placement. We have in the past and may again in the future sell shares of our common stock to strategic partners in connection with collaboration agreements, as we did in December 2021 in connection with our agreement with Horizon. The shares subject to outstanding options and warrants, of which options and warrants (including prefunded warrants) to purchase 3.0 million shares and 8.8 million shares, respectively, were exercisable as of December&nbsp;31, 2021, and the shares reserved for future issuance under our equity incentive plans will become available for sale immediately upon the exercise of such options. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also register the offer and sale of all shares of common stock that we may issue under our equity incentive plans. Once we register the offer and sale of shares for the holders of registration rights and option holders, they can be freely sold in the public market upon issuance, subject to any related lock-up agreements or applicable securities laws.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such future issuance, including any issuances pursuant to our at the market equity offering program with Cowen, could result in substantial dilution to our existing stockholders and could cause our stock price to decline.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion over the use of the proceeds to us from our financing activities and may apply the proceeds to uses that do not improve our operating results or the value of your securities.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have broad discretion over the use of proceeds to us from our financing activities and our stockholders rely solely on the judgment of our board of directors and management regarding the application of these proceeds. Our use of proceeds may not improve our operating results or increase the value of our common stock. Any failure to apply these proceeds effectively could have a material adverse effect on our business, delay the development of our product candidates and cause the market price of our common stock to decline.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware or Washington law could discourage, delay or prevent a change in control of our company, limit attempts by our stockholders to replace or remove our current management and may affect the trading price of our common stock.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate documents contain provisions that may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock. Among other things, our certificate of incorporation and bylaws:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">stagger the terms of our board of directors and require 66 and 2/3% stockholder voting to remove directors, who may only be removed for cause;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">provide that the authorized number of directors may be changed only by resolution of the board of directors;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">provide that all vacancies, including newly-created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">authorize our board of directors to issue blank check preferred stock and to determine the rights and preferences of those shares, which may be senior to our common stock, without prior stockholder approval;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">establish advance notice requirements for nominating directors and proposing matters to be voted on by stockholders at stockholders meetings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">prohibit our stockholders from calling a special meeting and prohibit stockholders from acting by written consent;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">require 66 and 2/3% stockholder voting to effect certain amendments to our certificate of incorporation and bylaws; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. Likewise, because our principal executive offices are located in Washington, the anti-takeover provisions of the Washington Business Corporation Act may apply to us under certain circumstances now or in the future. These provisions prohibit a target corporation from engaging in any of a broad range of business combinations with any stockholder constituting an acquiring person for a period of five years following the date on which the stockholder became an acquiring person. These provisions could discourage, delay or prevent a transaction involving a change in control of our company. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and cause us to take other corporate actions our stockholders desire.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of available cash.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that we will indemnify our directors to the fullest extent permitted by Delaware law.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe such persons conduct was unlawful.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may, in our discretion, indemnify other employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless the proceeding was authorized in the specific case by our board of directors or such indemnification is required to be made pursuant to our amended and restated bylaws.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to our directors or officers</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, if we are required to indemnify one or more of our directors or officers, it may reduce our available funds to satisfy successful third-party claims against us, may reduce the amount of available cash and may have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">our stockholders ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our common stock shall be deemed to have notice of and to have consented to this provision of our amended and restated certificate of incorporation. In addition, our amended and restated bylaws provide that the U.S. federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provision may limit our stockholders ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find these choice of forum provisions in our amended and restated certificate of incorporation and amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay any dividends on our common stock for the foreseeable future.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect to retain all future earnings, if any, for future operations and expansion, and have no current plans to pay any cash dividends to holders of our common stock for the foreseeable future. Any decision to declare and pay dividends in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our board of directors may deem relevant. As a result, stockholders may not receive any return on an investment in our common stock unless stockholders sell our common stock for a price greater than that which they paid for it.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq may delist our common stock from its exchange, which could limit investors ability to make transactions in our securities and subject us to additional trading restrictions.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on Nasdaq under the trading symbol ALPN. Our securities may fail to meet the continued listing requirements to be listed on Nasdaq. If Nasdaq delists our common shares from trading on its exchange, we could face significant material adverse consequences, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">significant impairment of the liquidity for our common stock, which may substantially decrease the market price of our common stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a determination that our common stock qualifies as a penny stock which will require brokers trading in our common stock to adhere to more stringent rules and possibly resulting in a reduced level of trading activity in the secondary trading market for our common stock;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a limited amount of news and analyst coverage for our company; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a decreased ability </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to issue additional securities or obtain additional financing in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_55"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Reporting and Disclosure</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a smaller reporting company, and any decision on our part to comply only with reduced reporting and disclosure requirements applicable to such companies could make our common stock less attractive to investors.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act. For as long as we continue to be a smaller reporting company, we may choose to take advantage of exemptions from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">various reporting requirements applicable to other public companies that are not smaller reporting companies, including, but not limited to, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduced</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain a smaller reporting company so long as, as of June 30 of the preceding year, (i) the market value of our common shares held by non-affiliates, or our public float, is less than $250 million; or (ii) we have annual revenues less than $100 million and either we have no public float or our public float is less than $700 million. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we take advantage of some or all of the reduced disclosure requirements available to smaller reporting companies, investors may find our common stock less attractive, which may result in a less active trading market for our common stock and greater stock price volatility. For so long as we are a smaller reporting company and not classified as an accelerated filer or large accelerated filer pursuant to SEC rules, we will continue to be exempt from the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley. </span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of The Nasdaq Stock Market LLC. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. An internal control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the internal control systems objectives will be met. Because of the inherent limitations in all internal control systems, no evaluation of internal controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all internal control issues and instances of fraud will be detected.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by The Nasdaq Stock Market LLC, the SEC, or other regulatory authorities.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disclosure controls and procedures are designed to reasonably ensure that information required to be disclosed by us in reports we file or submits under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures as well as internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are and will be met. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur significant legal, accounting, and other expenses associated with public company reporting requirements. We will also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as new rules implemented by the SEC and The Nasdaq Stock Market LLC. Although our status as a smaller reporting company may for a limited period of time somewhat lessen the cost of complying with these additional regulatory and other requirements, we nonetheless expect that these rules and regulations will increase our legal and financial compliance costs and to make some activities more time-consuming and costlier. Our executive officers and other personnel will need to devote substantial time to oversee our operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it difficult and expensive for us to obtain directors and officers liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers of our company, which may adversely affect investor confidence in us and could cause our business or stock price to suffer.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in accounting rules and regulations, or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting methods and policies for biopharmaceutical companies, including policies governing revenue recognition, research and development and related expenses, and accounting for stock-based compensation, are subject to review, interpretation, and guidance from our auditors and relevant accounting authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate, or otherwise change or revise our financial statements.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock or discontinue existing research coverage, and such lack of research coverage may adversely affect the market price of our common stock. We do not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we entered into a lease for 27,164 square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is 10.8 years with one option to extend the term by 5.0 years. The lease term commenced in June 2019. We </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that our existing facility is adequate for our current needs as the facility has sufficient space to house additional personnel as we expand. </span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not engaged in any material legal proceedings. From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. We believe that there are no claims or actions pending against us currently, the ultimate disposition of which would have a material adverse effect on our consolidated results of operation, financial condition or cash </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_73"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From June 17, 2015 through July 24, 2017, our common stock was traded under the symbol NVLS. On July 24, 2017, in connection with the business combination of Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc., we completed a 1-for-4 reverse stock split. Commencing on July 25, 2017, our common stock began trading on The Nasdaq Global Market under the </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">symbol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ALPN. As of March&nbsp;7, 2022, we have approximately 26 stockholders of record for our common stock, which excludes stockholders whose shares were held in nominee or street name accounts through brokers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our board of directors, subject to applicable laws, and </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> depend on our financial condition, results of operations, capital requirements, general business conditions and other factors that our board of directors considers relevant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> company, as defined by Rule 12b-2 of the Exchange Act, and pursuant to Instruction 6 to Item 201(e) of Regulation S-K we are not required to provide the stock performance graph.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_82"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_148" tabindex="18">consolidated financial statements and the related notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information, some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, future financial performance, expense levels and liquidity sources, includes forward-looking statements that involve risks and uncertainties. You should read </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_22" tabindex="18">Risk Factors</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in Part I, Item 1A of this report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Our approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. We believe our strategies are capable of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meaningfully</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> modulating the human immune system and significantly improving outcomes in patients with serious diseases.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Autoimmune/Inflammatory Diseases</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acazicolcept, is a dual ICOS and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases. Preclinical studies with acazicolcept have demonstrated efficacy in models of SLE, SjS, arthritis, inflammatory bowel disease, multiple </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sclerosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, type 1 diabetes, uveitis, and graft versus host disease. We have evaluated acazicolcept in a Phase 1 healthy volunteer study and initiated patient dosing in Synergy, a global, randomized, double-blind, placebo-controlled Phase 2 study of acazicolcept in adults with moderate-to-severe SLE. In June 2020, we entered into an Option and License Agreement with AbbVie Ireland Unlimited Company, or AbbVie, which grants AbbVie an exclusive option to take an exclusive license to acazicolcept. Through December&nbsp;31, 2021, we have received $105.0&nbsp;million in upfront and pre-option exercise development milestones as part of the AbbVie Agreement.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Engineered using our proprietary directed evolution platform, ALPN-303 potently inhibits BAFF, BLyS and APRIL, which play key roles in B cell development, differentiation, and survival, and together contribute to the pathogenesis </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> multiple autoimmune diseases such as SLE and many other autoantibody-related inflammatory diseases. Data presented at the ACR Convergence 2021 Annual Meeting demonstrated that ALPN-303 inhibits the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as anti-BAFF and anti-APRIL monoclonal antibodies. In addition, ALPN-303 has been well-tolerated in preclinical models and exhibited superior pharmacokinetics and pharmacodynamics over wild-type TACI-Fc counterparts, including superior serum exposure, suppression of T-dependent antibody production, and/or serum immunoglobulins in mice and/or cynomolgus monkeys. A first-in-human, Phase 1 study of ALPN-303 in healthy volunteers began in the fourth quarter of 2021, with top-line results targeted by mid-2022. This randomized, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-303 administered intravenously and subcutaneously. We are planning to initiate patient-based studies in the second half of 2022 including SLE, and possibly other autoantibody-related diseases in other therapeutic areas.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the Horizon Agreement which grants Horizon an exclusive license for the development, manufacture and commercialization of one Existing Program and up to three additional Research Programs generated from our </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">libraries</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of proteins and molecules for research, discovery and identification of additional compounds. Under the terms of the agreement, Horizon made an upfront payment to us of $25.0 million as well as an equity investment for which they paid $15.0 million, a 25 percent premium to the 30-day volume-weighted average share price as of December 9, 2021. In addition, we are eligible to receive up to $381.0 million per program, or approximately $1.5 billion in total, in future success-based payments related to development, regulatory and commercial milestones as well as tiered royalties on global net sales.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immuno-oncology</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead oncology program is davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Preclinical in vivo data have demonstrated monotherapy efficacy in tumor models superior to approved therapies. In June 2020, we initiated NEON-1, a Phase 1 monotherapy dose escalation and expansion study in patients with advanced malignancies. Initial data from NEON-1 were presented at the 2021 ASCO Virtual Meeting demonstrating that davoceticept was well-tolerated as of the cutoff date (April 22, 2021) with evidence of peripheral T cell modulation consistent with CD28 agonism. In addition, although most enrolled participants had tumors considered classically non-responsive to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapies, 61% (14 of 23 evaluable) derived clinical benefit as defined as a best outcome of stable disease or better. Completion of dose escalation for NEON-1 and initiation of expansion cohorts is anticipated in the first half of 2022. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we announced a collaboration and supply agreement with Merck to evaluate the safety and efficacy of davoceticept in combination with Mercks anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase 1 dose escalation and expansion study. The </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> trial, NEON-2, was initiated in June 2021. As discussed above, on March 7, 2022, we announced that the FDA placed a partial clinical hold on the NEON-2 trial in response to the death of a study participant in the NEON-2 trial. The participants death was attributed to cardiogenic shock, considered by the treating physicians as likely related to immune-mediated myocarditis, or possibly infection. Participants who are currently enrolled in the NEON-2 trial may continue to receive davoceticept and pembrolizumab, although no new participants may be enrolled until the partial clinical hold is resolved. This partial clinical hold does not affect the ongoing NEON-1 clinical trial of davoceticept as monotherapy (NCT04186637).</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our scientific platform has also generated immune modulatory proteins with the potential of improving engineered cell therapies, such as CAR-T, TCR-T, and TILs. In May 2019, we signed a collaboration and license agreement with Adaptimmune to </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> next-generation SPEAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cell products which incorporate our secreted and transmembrane immunomodulatory protein (termed SIP and TIP) technology. We intend to continue to leverage our existing pipeline and platform to actively explore and evaluate potential value-creating partnering opportunities. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> discover and develop modern therapies to treat patients with serious conditions such as cancer and autoimmune/inflammatory diseases. To achieve our goals, we intend to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">aggressively move our lead autoimmune/inflammatory program acazicolcept through clinical development as part of the AbbVie Agreement, including conducting Synergy, our Phase 2 study for the treatment of SLE;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">aggressively move our second autoimmune/inflammatory program ALPN-303 through a Phase 1 study in healthy volunteers and into clinical studies for the treatment of B cell mediated autoimmune/inflammatory diseases; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">aggressively move our lead oncology program davoceticept through clinical development for the treatment of cancer; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">maximize the value of our pipeline and platform via potential partnering activities.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been limited to business planning, raising capital, developing our platform technology, identifying potential immunotherapy candidates, clinical studies, and other research and development activities. To date, we have financed operations primarily through private placements of common stock and convertible preferred stock, funds received from license and research agreements, debt financing and assets acquired upon the close of our merger with Nivalis Therapeutics Inc., or Nivalis. We do not have any products approved for sale and have not generated any product sales. Since inception and through December&nbsp;31, 2021, excluding amounts borrowed through debt financing, we have raised an aggregate of $393.1 million to fund operations, of which $170.6 million&nbsp;was from the sale of common stock and warrants, $49.2 million was from the sale of convertible preferred stock, $129.2 million was through our license and collaboration agreements, and $44.1 million in cash, cash equivalents, and marketable securities acquired through the merger with Nivalis. As of December&nbsp;31, 2021, we had cash, cash equivalents, restricted cash, and investments totaling $215.4 million.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net loss was $50.3 million, $27.9 million, and $41.9 million for the years ended December&nbsp;31, 2021, 2020, and 2019, respectively. We expect to continue incurring significant expenses and operating losses for at least the next several years as we:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">initiate and complete nonclinical studies and clinical trials for our product candidates, including acazicolcept, a dual ICOS/CD28 antagonist program targeting autoimmune/inflammatory disorders, davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer, and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">contract to manufacture and perform additional process development for our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">continue research and development efforts to build our pipeline beyond the current product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">maintain, expand, and protect our intellectual property portfolio;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">hire additional clinical, quality control, scientific, and management personnel; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">add operational and financial personnel to support our product development efforts and operational capabilities applicable to operating as a public company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate product revenue unless and until we successfully complete development of, obtain marketing approval for and commercialize our product candidates, either alone or in collaboration with third parties. We expect these activities will take a number of years and our success in these efforts is subject to significant uncertainty. Accordingly, we will need to raise additional capital prior to the regulatory approval and commercialization of any of our product candidates. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our operating activities through equity or debt financings, collaborations or licenses, capital lease transactions, or other available financing transactions. However, additional capital may not be available on reasonable terms, if at all, and if we raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders and increased fixed payment obligations.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our collaboration revenue primarily from our collaboration and licensing agreements. We may generate revenue in the future from milestone payments received pursuant to our collaboration and licensing agreements with AbbVie, Horizon, Adaptimmune, or from payments from future license or collaboration agreements, product sales, or government contracts and grants. We expect revenue we generate, if any, will fluctuate from quarter to quarter.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Horizon </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into the Horizon Agreement which grants Horizon an exclusive license for the development, manufacture and commercialization of one Existing Program and up to three additional Research Programs generated from our libraries of proteins and molecules for research, discovery and identification of additional compounds.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Horizon made an upfront payment to us of $25.0 million as well as an equity investment for which they paid $15.0 million, a 25 percent premium to the 30-day volume-weighted average share price as of December 9, 2021. In addition, we are eligible to receive up to $381.0 million per program, or approximately $1.5 billion in total, in future success-based payments related to development, regulatory and commercial milestones as well as tiered royalties on global net sales. We will conduct our activities under the Existing Program and up to three Research Programs to deliver compounds meeting agreed criteria. In addition, Horizon will pay us for the costs and expenses of conducting such activities under the deliverables plans. Horizon will then assume responsibility for development and commercialization activities and costs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For revenue recognition purposes, we determined that the Existing Program and each Research Program are distinct performance obligations. We allocated revenue to each performance obligation based on its relative stand-alone selling price. The future success-based payments related to development and regulatory milestones are probable of significant revenue reversal as the achievement is highly dependent on factors outside our control. Therefore, these milestone payments are fully constrained and are not initially included in the transaction price. We will continue to re-evaluate the transaction price each reporting period and update as uncertain events are resolved or other changes in circumstances occur. Any consideration related to commercial milestones and royalties will be recognized when the related sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AbbVie</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into the AbbVie Agreement for the development of acazicolcept. The AbbVie Agreement grants AbbVie the exclusive option to purchase an exclusive worldwide license to acazicolcept, or the License Option. The License Option is exercisable by AbbVie at any time and will expire 90 days from the achievement of certain development milestones. If AbbVie exercises the License Option, AbbVie will take over the future development and commercialization. Prior to the exercise of the License Option, we will perform research and development services, including conducting our Phase 2 study in SLE, based on an agreed-upon development plan, or the Development Plan. We will be fully responsible for all costs incurred to conduct the activities under the Development Plan, provided that, AbbVie may be responsible for increased costs under the Development Plan in connection with certain material amendments proposed by AbbVie. We will also be solely responsible, at our sole cost and expense, for manufacturing and regulatory filings for acazicolcept necessary to complete activities under the Development Plan.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, in connection with the execution of the AbbVie Agreement, AbbVie paid us a nonrefundable upfront payment of $60.0 million. Prior to the exercise of the License Option, AbbVie has agreed to make cash payments upon our achievement of certain predefined pre-option development milestones, or the Alpine Development Milestones, up to an aggregate amount of $75.0 million. In the second quarter of 2021, we achieved $45.0 million of the Alpine Development Milestones. If AbbVie exercises the License Option, they will pay a one-time cash payment of $75.0 million. Following the exercise of the License Option, AbbVie has also agreed to make aggregate cash payments of up to $205.0 million upon </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVies achievement of certain development and commercial milestones and additional aggregate cash payments of up to $450.0 million upon AbbVies achievement of certain sales-based cash milestones, collectively referred to as the AbbVie Milestones. Subsequent to commercialization, we are also eligible to receive high single-digit to low double-digit percentage royalties on worldwide net sales of licensed products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For revenue recognition purposes, we determined that our contractual promises in the AbbVie Agreement are not distinct and are interdependent with our performance obligation to provide research and development services under the Development Plan. Thus, all contractual promises related to the upfront payment and Alpines Development Milestones were combined into a single performance obligation. We determined the Alpine Development Milestone payments are probable of significant revenue reversal as the achievement is highly dependent on factors outside our control. Therefore, these milestone payments were fully constrained and were not initially included in the transaction price. In June 2021, we re-evaluated and updated the transaction price to include the achieved portion of the Alpine Development Milestones. We will continue to re-evaluate the transaction price each reporting period and update as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Option and the AbbVie Milestones were not determined to be performance obligations at the inception of the contract as they did not represent material rights. If exercised, the License Option and AbbVie Milestones will be accounted for as a separate contract and will be recognized as revenue if and when triggered. Any consideration related to sales-based royalties and profit-sharing payments will be recognized when the related sales occur.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a cost-based input method to measure progress toward completion of the performance obligation and to calculate the corresponding revenue to recognize each period. In applying the cost-based input, we use actual costs incurred relative to budgeted costs for the combined performance obligation. These costs consist primarily of internal personnel efforts and third-party contract costs relative to the level of patient enrollment in the study. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete our performance obligation. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete our performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from the AbbVie Agreement of $23.4&nbsp;million and $7.0&nbsp;million for the years ended December&nbsp;31, 2021 and 2020, respectively. As of December&nbsp;31, 2021 the remaining balance of the transaction price is $74.5&nbsp;million and is recorded as current and noncurrent deferred revenue on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to recognize the remaining deferred revenue over the remainder of our Development Plan, which began in June 2020 and will end upon the later of the exercise or expiration of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adaptimmune</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into the Adaptimmune Agreement with Adaptimmune, a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to patients, particularly for the treatment of solid tumors, to develop next-generation SPEAR T cell products which incorporate our SIP and TIP technologies. Under the Adaptimmune Agreement, we are to perform certain research services and grant Adaptimmune an exclusive license to programs from our SIP and TIP technologies. In June 2019, under the terms of the Adaptimmune Agreement, we received an upfront license payment of $2.0 million and through December&nbsp;31, 2021 we have received an additional $1.6 million in research support payments to fund ongoing programs. These payments were recorded to deferred revenue upon receipt and were recognized as revenue based on employee hours contributed to each performance obligation. In the fourth quarter of 2020, based on the completion of our initial research and development efforts in connection with our performance obligations, we recognized the remaining balance in deferred revenue associated with Adaptimmune on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the Adaptimmune Agreement, we recognized no revenue for the year ended December&nbsp;31, 2021, and $2.3&nbsp;million and $1.3 million for the years ended December&nbsp;31, 2020 and 2019, respectively. In addition, we are eligible for additional research support payments, one-time payments and downstream development and commercialization milestones of up to $288.0 million, if all pre-specified milestones for each program are achieved. We are also eligible to receive low-single digit percentage royalties on worldwide net sales of the applicable products. In February 2022, Adaptimmune selected an additional research program, triggering a $1.0&nbsp;million upfront payment, which will be recorded as deferred revenue upon receipt and recognized to revenue based on employee hours contributed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus our resources on research and development activities, including the conduct of preclinical studies, product development, regulatory support, and clinical trials for our product candidates. We recognize research and development expenses as they are incurred. Our research and development expenses consist of:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">employee-related expenses, including salaries, benefits, taxes, travel, and stock-based compensation expense for personnel in research and development functions;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expenses related to process development and production of product candidates paid to contract manufacturing organizations;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">costs associated with preclinical activities and regulatory operations, including the cost of acquiring, developing, and manufacturing research material; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">clinical trials and activities related to regulatory filings for our product candidates; and </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">allocation of facilities, overhead, depreciation, and amortization of laboratory equipment and other expenses.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes our research and development expenses for the periods indicated. Our direct research and development expenses consist primarily of expenses incurred pursuant to agreements with third-party manufacturing organizations for our product candidates, CROs, clinical trial sites, collaborators, and consultants. Other direct costs included direct research and development costs incurred before a selected product candidate begins clinical trials. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use our employee and infrastructure resources across multiple research and development programs that we are advancing in parallel, and therefore do not allocate salaries, stock-based compensation, employee benefit expenses or other indirect costs related to our research and development to specific product candidates. These expenses are included in indirect research and development expense by type in the table below.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses are summarized as follows (in thousands): </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct research and development expense by program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acazicolcept (ALPN-101)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,923&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,583&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Davoceticept (ALPN-202)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,640&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,697&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,393&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ALPN-303</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,311&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expense by program</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,389&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,620&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,243&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indirect research and development expense by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,456&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,697&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,169&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development supplies and services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allocated facility, equipment and other expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,064&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,826&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,846&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,353&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,565&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,604&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,742&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,185&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,847&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase for the foreseeable future as we continue to develop our platform and product candidates.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our platform and product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing, or costs of the efforts necessary to finish developing any of our product candidates or the period in which material net cash, if any, from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing therapeutics, including the uncertainty of:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the scope, rate of progress, expense, and results of clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the scope, rate of progress, and expense of process development and manufacturing;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">preclinical and other research activities; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of regulatory approvals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for employees in executive, business development, finance, and administrative functions. Other significant general and administrative expenses include professional fees for accounting and legal services, expenses associated with obtaining and maintaining patents and other intellectual property, and allocation of facility and overhead costs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect general and administrative expenses to increase as we expand infrastructure, headcount, and continue to prosecute our patents and other intellectual property. Other increases could potentially include increased costs for insurance, costs related to the hiring of additional personnel, and increased fees for directors, outside consultants, lawyers, and accountants. We expect to incur significant costs to comply with corporate governance, internal controls, and similar requirements applicable to public companies.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of interest associated with our term loan with Silicon Valley Bank, or SVB, and the amortization of the related debt discount.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash, cash equivalents, and investments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&nbsp;31, 2020 and 2019, other (expense) income consists primarily of research and development tax credits received by our wholly-owned Australian subsidiary and an employee retention tax credit related to COVID-19 relief legislation. Other (expense) income was immaterial for the year ended December 31, 2021.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&nbsp;31, 2021 and 2020 </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&nbsp;31, 2021 and 2020 (in thousands):&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,443&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,335&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,108&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,742&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,185&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,557&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,560&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,661&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,302&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,084&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,218&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,859)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,110)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,474)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,333)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,940)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,393)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&nbsp;Collaboration Revenue</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December 31, 2021 consists of $23.4&nbsp;million recognized under the AbbVie Agreement, an increase from prior year as we execute on our AbbVie Development Plan. Revenue for the year ended December 31, 2020 consists of $7.0 million recognized under the AbbVie Agreement and $2.3 million recognized under the Adaptimmune Agreement. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $31.6 million increase in research and development expenses was primarily attributable to increases of $10.8 million in clinical trial activity primarily related to our Synergy and NEON studies, $10.0 million in contract manufacturing and process development of our product candidates primarily for acazicolcept and ALPN-303, and $4.8 million in preclinical and other research activities. Additionally, we had an increase of $5.7 million related to personnel expenses, which includes $1.2 million in stock-based compensation expense, and an increase of $0.3 million related to overhead and facilities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.7 million increase in general and administrative expenses was primarily attributable to increases of $2.5 million in personnel related expenses, which includes $0.9 million in stock-based compensation expense, $0.8 million related to professional and legal services, and $0.4 million in insurance, facility and other costs to support the growth and expansion of our business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense relates primarily to interest paid on our term loan with SVB and the related non-cash interest expense associated with the amortization of the debt discount. Interest expense during the 2021 period is slightly higher due to additional interest related to the drawdown of the second tranche of our SVB loan in March 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Higher average investment balances during 2021, combined with lower interest rates produced relatively consistent interest income as compared to the 2020 period. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense during 2021 consisted of a loss on an asset disposal. In 2020, other income consisted of a $1.0 million research and development tax credit received by our wholly-owned Australian subsidiary and a $0.3 million employee retention tax credit related to COVID-19 relief legislation. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&nbsp;31, 2020 and 2019 </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&nbsp;31, 2020 and 2019 (in thousands):&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,335&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,595&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,185&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,847&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,899&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,467&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,084&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,314&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,230)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,749)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,574)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,825&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(437)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,906&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,940)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,852)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,912&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the year ended December 31, 2020 consists of $7.0 million recognized under the AbbVie Agreement and $2.3 million recognized under the Adaptimmune Agreement. Revenue for the year ended December 31, 2019 consists of $1.3 million related to the Adaptimmune Agreement and $0.4 million related to the milestone payment from Laurel from the sale of our GSNOR assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $8.7 million decrease in research and development expenses was primarily attributable to decreases of $5.7 million in contract manufacturing and process development of our product candidates and $4.1 million in other research activities. The decreases were partially offset by increases of $0.6 million in clinical trial activity and $0.5 million in stock-based compensation.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.4 million increase in general and administrative expenses was primarily attributable increases of $0.8 million related to professional and legal services, $0.6 million in stock-based compensation and $0.4 million in insurance and facility costs to support the growth and expansion of our business. These increases were partially offset by a decrease of $0.4 million related primarily to personnel expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense relates primarily to interest paid on our term loan with SVB and the related non-cash interest expense associated with the amortization of the debt discount. The $0.4 million increase in interest expense is due to additional interest related to the drawdown of the second tranche of our SVB loan in March 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.0 million decrease in interest income is due primarily to less interest earned on our investments as we maintained a lower average investment balance during the 2020 period.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $0.5 million increase in other (expense) income is attributable a $0.2 million increase in research and development tax credits received by our wholly-owned Australian subsidiary. Additionally, for the 2020 period, we recognized a $0.3 million employee retention tax credit related to COVID-19 relief legislation. </span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our operations primarily through the sale of equity securities, debt, and payments received under our collaboration agreements. As of December&nbsp;31, 2021, we had cash, cash equivalents, restricted cash, and investments totaling $215.4 million. Except for any obligations of our collaborators to make milestone payments under our agreements with them, we do not have any committed external sources of capital. Until such time as we can generate substantial product revenue, if ever, we expect to finance our cash needs through a combination of collaboration agreements and equity or debt financings. </span></div><div style="text-indent:29.25pt"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Equity Financing Agreements</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, in connection with the execution of the Horizon Agreement, we entered into a Stock Purchase Agreement with Horizon, or the Purchase Agreement, in which Horizon made an equity investment in Alpine of 951,980 shares of our common stock for approximately $15.76 per share, for an aggregate purchase price of $15.0&nbsp;million. The purchase price represents a 25% premium to the volume-weighted average share price of our common stock for the 30-day period ended December 9, 2021. The shares are subject to lock-up restrictions, which, subject to certain exceptions, prohibit Horizon from selling the shares for a period of six months after the date of the Purchase Agreement. The shares were recorded at the fair value of our common stock on the effective date of the Horizon Agreement, with the excess of the proceeds recorded to deferred revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a securities purchase agreement, or the 2021 Securities Purchase Agreement, for a private placement with a select group of institutional investors, pursuant to which we sold 6,489,357 shares of our common stock, or the Shares, and prefunded warrants to purchase 3,191,487 Shares, or the Prefunded Warrants. The purchase price for each Share and for each Prefunded Warrant was $9.40 per share, for an aggregate purchase price of approximately $91.0 million. The Prefunded Warrants became fully exercisable upon the closing date and have an exercise price of $0.001 per share. In connection with the 2021 Securities Purchase Agreement approximately 3.7 million of the Shares issued and approximately 2.3 million of the Prefunded Warrants issued, for gross proceeds of approximately $57.0 million, were issued to certain stockholders whose beneficial ownership exceeded 5% prior to completion of the 2021 Securities Purchases Agreement.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we may sell shares of our common stock from time to time through an at the market equity offering for up to $75.0 million in gross cash proceeds. Cowen will act as the sales agent and will be entitled to compensation for services of up to 3.0% of the gross sales price per share of all shares sold through Cowen under the Sales Agreement. The shares would be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-256107). We filed a prospectus supplement, dated July 2, 2021, with the SEC in connection with the offer and sale of the shares pursuant to the Sales Agreement. As of the date of this report, we have made no such sales under the Sales Agreement.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a securities purchase agreement, or the 2020 Securities Purchase Agreement, for a private placement with a select group of institutional investors, pursuant to which we sold 5,139,610 units, or the Common Units, and 790,710 units, or the Prefunded Warrant Units, for an aggregate purchase price of $60.0 million. Each Common Unit consists of one share of our common stock plus a warrant to purchase 0.3 shares of common stock, or the Common Stock Warrants, and each Prefunded Warrant Unit consists of one prefunded warrant to purchase one share of common stock, or the Prefunded Warrants, plus one Common Stock Warrant to purchase 0.3 shares of common stock. The Prefunded Warrant Units and the Common Units are collectively referred to as the Units and each Unit has a purchase price of $10.1175. The Common Stock Warrants have an exercise price of $12.74 and a term of 3.5 years. The Prefunded Warrants became fully exercisable upon the closing date and have an exercise price of $0.001 per share.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a securities purchase agreement, or the 2019 Securities Purchase Agreement, with a limited number of accredited investors, pursuant to which we sold approximately 4.7 million units, or the 2019 Units, for an aggregate purchase price of $25.3 million in a private placement, which we refer to as the Private Placement. Each 2019 Unit has a purchase price of $5.37 and consists of one share of our common stock and a warrant to purchase 0.39 shares of common stock. Pursuant to the terms of the 2019 Securities Purchase Agreement, we issued approximately 4.7 million shares of common stock and warrants to purchase an aggregate of approximately 1.8 million shares of common stock. The warrants have an exercise price of $12.74 and have a term of five years.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Financing Agreements</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into an Amended and Restated Loan and Security Agreement, or the Loan Agreement, with SVB, pursuant to which SVB agreed to extend term loans to us with an aggregate principal amount of up to $15.0 million, or the Term Loans. Borrowings under the Loan Agreement consisted of up to three separate tranches. The initial tranche of $5.0 million was funded in August 2019, $3.0 million of which was used to repay amounts owing under our prior loan and security agreement with SVB. In March 2020, the second tranche of $5.0 million was funded to us. We did not draw down the final tranche of $5.0 million, which expired on July 31, 2020.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans accrue interest at a floating per annum rate of 0.25% above the prime rate, subject to a floor of 5.75%, which interest is payable monthly commencing in September 2019. Upon the occurrence and during the continuance of an event of default, a default interest rate will apply that is 4.0% above the otherwise applicable interest rate. The Term Loans were interest only until September 30, 2020, however, under the Loan Agreement our interest only period automatically extended to June 30, 2021 if we received aggregate new capital of at least $40.0 million no later than June 30, 2020. We met this milestone in June 2020 in conjunction with the execution of the AbbVie Agreement, discussed in detail in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_199" tabindex="18">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the interest only extension, the Term Loans will be payable in 25 equal monthly installments of principal plus interest, with the final installment due and payable on July 1, 2023. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may prepay all, but not less than all, of the Term Loans subject to a prepayment fee equal to $75,000, which represents the deferred portion of the final payment due under the Original Agreement, plus the outstanding principal balance under the Term Loans at the time of such prepayment multiplied by a prepayment fee of 2.0% in the first year, 1.0% in the second year, and 0.0% in the third year and thereafter. Additionally a final payment in the amount of 5.5% of the funded Term Loans is payable to SVB on the date on which the Term Loans are prepaid, paid or become due and payable in full. The final payment fees are recorded in long-term debt with an offsetting reduction to debt discount on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including, among others, covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant liens, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets, engage in any new lines of business, and enter into certain transactions with affiliates, in each case subject to certain exceptions. Among other events, a failure to make a required loan payment, an uncured covenant breach or a material adverse change in our business, operations or condition (financial or otherwise) could lead to an event of default, and in such case, all amounts then outstanding may become due and payable immediately. We were in compliance with our covenants as of December&nbsp;31, 2021. As security for its obligations under the Loan Agreement, we granted SVB a first priority security interest on substantially all of our assets, except intellectual property, and subject to certain other exceptions. As of December&nbsp;31, 2021, we had $8.2 million in outstanding principal and final fees due under our term loan agreement. See </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_193" tabindex="18">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of our Term Loans.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Cash Flows</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our cash flows (in thousands):&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,084&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,346)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,819)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,763&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,764&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,381&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash (used in) provided by operating activities:</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $15.2 million for the year ended December&nbsp;31, 2021 and consisted primarily of our net loss of&nbsp;$50.3 million. This was offset by an increase of $27.3 million in our net operating assets and liabilities. Additionally, we had a $7.8 million increase in our net non-cash adjustments, which primarily relates to stock-based compensation, depreciation and amortization.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $30.1 million for the year ended December&nbsp;31, 2020 and consisted primarily of our net loss of&nbsp;$27.9 million. This was offset by an increase of $52.9 million in our net operating assets and liabilities. This increase was primarily driven by the receipt of a $60.0 million upfront payment from AbbVie, which was recorded as current and noncurrent deferred revenue on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Additionally, we had an increase of $5.1 million in our net non-cash adjustments, which primarily relates to stock-based compensation, depreciation and amortization.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $35.3 million for the year ended December&nbsp;31, 2019 and consisted primarily of our net loss of $41.9 million. This was offset by an increase of $3.2 million in our net operating assets and liabilities and an increase of $3.3 million in our net non-cash adjustments, which primarily relate to stock-based compensation, depreciation and amortization.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities:</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from investing activities primarily reflect cash used to purchase investments and proceeds from the maturities and sales of investments, thus causing a shift between our cash and cash equivalents and investment balances. We manage our cash usage with respect to our total cash, cash equivalents and investments. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $52.5 million for the year ended December&nbsp;31, 2021 and consisted primarily of our purchases and maturities of investments in U.S. Treasury securities, commercial paper, and corporate debt securities, partially offset by purchases of property and equipment, primarily lab equipment, to support our research and development efforts. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $72.8 million for the year ended December&nbsp;31, 2020 and consisted primarily of our purchases and maturities of investments in U.S. Treasury securities, commercial paper, and corporate debt securities, partially offset by purchases of property and equipment, primarily lab equipment, to support our research and development efforts. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $16.8 million during the year ended December&nbsp;31, 2019 and consisted primarily of the maturities, sales and purchases of short-term investments in U.S. Treasury securities, commercial paper, and corporate debt securities, partially offset by purchases of property and equipment, primarily lab equipment, to support our research and development efforts. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities:</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $100.8 million for the year ended December&nbsp;31, 2021 and consisted primarily of the net proceeds of $90.7 million related to the sale of approximately 6.5 million shares of common stock and 3.2 million prefunded warrants under our 2021 Securities Purchase Agreement, $11.9 million in proceeds related to the fair value of our common stock purchased by Horizon in December 2021, and $0.5 million related to the exercise of stock options. These were partially offset by $2.4 million in principal payments on our debt.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $61.4 million for the year ended December&nbsp;31, 2020 and consisted primarily of the net proceeds of $56.3 million related to the sale of approximately 5.9 million Units under our 2020 Securities Purchase Agreement, $5.0 million in proceeds received from the draw down of the second tranche of our Loan Agreement in March 2020, and $0.1 million related to the exercise of stock options.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $24.3 million for the year ended December&nbsp;31, 2019 and consisted primarily of the net proceeds of $23.6 million related to the sale of approximately 4.7 million Units under our 2019 Securities Purchase Agreement and $2.0 million in net proceeds from our debt refinancing, partially offset by $1.3 million in principal payments on our debt.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses since inception. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue our research and preclinical and clinical development of our product candidates; expand the scope of our current studies for our product candidates; initiate additional preclinical, clinical or other studies for our product candidates, including under any collaboration agreements; change or add additional manufacturers or suppliers; seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical studies; seek to identify, evaluate and validate additional product candidates; acquire or in-license other product candidates and technologies; maintain, protect and expand our intellectual property portfolio; attract and retain skilled personnel; and experience any delays or encounter issues with any of the above. Additionally, we have ongoing obligations with respect to our Loan Agreement, as described above, and our Operating Lease and certain contingencies, as described below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Operating Lease</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we entered into a lease with ARE-Seattle No. 28, LLC, or the Landlord, for 27,164 square feet of office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is 10.8 years with one option to extend the term by 5 years. The lease term commenced in June 2019. The Rent Commencement Date began in March 2020, nine months after the commencement date. We were not required to pay base rent from the Rent Commencement Date through November 2020, the last day of the ninth month following the Rent Commencement Date. The annual base rent under the lease is $1.7 million for the first year and will increase by 3.0% each year thereafter. We received a tenant improvement allowance of $5.4 million, which is included in our base rent, and a maximum additional tenant improvement allowance of $1.8 million, which will result in additional rent amortized over the term of the lease at an annual rate of 8.0%. The lease also requires us to pay additional amounts for operating and maintenance expenses. In March 2019, in connection with the lease, we provided a&nbsp;$254,000&nbsp;letter of credit as a security deposit, which is recorded as restricted cash in our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See further discussion of our operating lease in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_196" tabindex="18">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain credits received related to our research and development expenditures and recorded within other income in our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are subject to review by foreign taxing authorities. It is reasonably possible we may incur losses upon the completion of these reviews of up to approximately $1.8&nbsp;million, which we would be required to repay to certain tax authorities.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we can generate substantial product revenue, if ever, we expect to finance our cash needs through a combination of equity or debt financings and collaboration agreements. To the extent that we raise additional capital through the future sale of equity or debt, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through collaboration agreements in the future, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements are difficult to forecast and will depend on many factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the number and characteristics of the future product candidates we pursue either from our internal research efforts or through acquiring or in-licensing other product candidates or technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the scope, progress, results and costs of independently researching and developing any of our future product candidates, including conducting preclinical research and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">whether our existing collaborations generate substantial milestone payments and, ultimately, royalties on future approved products for us;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing of, and the costs involved in, obtaining regulatory approvals for any future product candidates we develop independently;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost of future commercialization activities, if any;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the cost of manufacturing our future product candidates and products, if any;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our ability to maintain our existing collaborations and to establish new collaborations, licensing or other arrangements and the financial terms of such arrangements;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the costs of preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the timing, receipt and amount of sales of, or royalties on, our current or future collaborators product candidates, and our future products, if any.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have considered that our long-term operations anticipate continuing net losses and the need for potential equity or debt financing. We have also considered that new collaborations or selectively partnering our technology or programs may provide other sources of capital. However, there can be no assurances that additional funding or other sources of capital will be available on terms acceptable to us, or at all. Based on our current operating plan, we believe our available cash and cash equivalents and investments, will be sufficient to fund our planned level of operations for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing drug candidates in preclinical and clinical studies is costly, and the timing of progress in these studies remains uncertain. Further, inflation may affect our use of capital resources by increasing our cost of labor and clinical trial expenses. Our long-term funding requirements will consist of operational, capital, and manufacturing expenditures, including those contractual commitments described above. Because of the inherent risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of capital outflows and operating expenditures associated with our long-term anticipated preclinical studies and clinical trials.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our managements discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i75d4456fb1ed409bb59167bcf5c6f56b_172" tabindex="18">Note&nbsp;2</a> to our consolidated financial statements, we believe that the following accounting policies are the most critical to fully understanding and evaluating our financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognition is a critical accounting estimate due to the magnitude and nature of the upfront cash and milestone payments we receive. Our primary sources of revenue is derived from our collaboration and licensing agreements. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&nbsp;(1) identifying the contract,&nbsp;(2) identifying the performance obligations as either distinct or bundled goods and services,&nbsp;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&nbsp;(4) allocating the transaction price to the performance obligations in the contract and&nbsp;(5) recognizing revenue upon satisfaction of performance obligations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreements principally contain multiple performance obligations, which may include (1)&nbsp;grants of, or options to obtain, intellectual property licenses; (2)&nbsp;research and development services; and/or (3)&nbsp;manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our collaboration agreements with Adaptimmune, AbbVie, and Horizon. See further discussion of our collaboration agreements in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_199" tabindex="18">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under our collaboration agreements by using a cost-based input method to measure progress toward completion of the performance obligation, including employee hours contributed to each performance obligation, and to calculate the corresponding revenue to recognize each period.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreements provide for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&nbsp;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&nbsp;relates solely to our past performance; and (3)&nbsp;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the contributed employee hours and progress towards completion for each performance obligation under our collaboration agreements and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. Revenue recognition may be accelerated in the event of early termination of programs or if our expectations change. Alternatively, revenue recognition may be decelerated if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is recognized for all share-based payments based on the estimated fair value as of the date of grant. The fair value of our stock options is calculated using the Black-Scholes option pricing model, which requires us to apply our judgment regarding certain key assumptions including risk-free interest rate, expected term, volatility and dividend yield. For risk-free interest rate, we use the zero-coupon U.S. Treasury instruments security rate with a term equal to the expected life of the option. We use the simplified method for options to determine the expected term of stock options. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. For volatility, we analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price. Our assumed dividend yield is zero as we have never paid cash dividends and have no present intention to pay cash dividends. The fair value of restricted stock units, or RSUs, is based on the closing price of our common stock on the award date. Stock-based compensation expense is recognized over the requisite service period of the awards, usually the vesting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">period, on a straight-line basis. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, the related stock-based compensation is recognized as expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If factors change and we employ different assumptions for estimating stock-based compensation expense in future periods, or if we decide to use a different valuation model, the stock-based compensation expense we recognize in future periods may differ significantly from what we have recorded in the current period and could materially affect our financial statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2019-12, Income Taxes, or Topic 740: Simplifying the Accounting for Income Taxes. This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this standard on January 1, 2021, and concluded that the adoption of the standard did not have a material impact on our consolidated financial statements and related disclosures. </span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K we are not required to provide quantitative and qualitative disclosures about market risk.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding our financial statements and supplementary data, please refer to the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_166" tabindex="18">Notes to Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included elsewhere in this report.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act and pursuant to Article 8, Regulation X and Item 302 of Regulation S-K, we are permitted to provide scaled Item 8 disclosure.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December&nbsp;31, 2021. The term disclosure controls and procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act, means controls and other </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissions rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companys management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&nbsp;31, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Managements Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and Rule 15d-15(f) of the Exchange Act. Our internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.07pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.3pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.53pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute, assurances. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Our management assessed the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2021. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework (2013). Based on our assessment using those criteria, our management has concluded that, as of December&nbsp;31, 2021, our internal control over financial reporting was effective.</span></div><div style="margin-top:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant changes in our internal control over financial reporting occurred during the fiscal quarter ended December&nbsp;31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Auditor Attestation</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ceased to be an emerging growth company under the JOBS Act effective December 31, 2020. However, for so long as we are not classified as an accelerated filer or large accelerated filer pursuant to SEC rules, we will continue to be exempt from the auditor attestation requirements of Section 404(b) of Sarbanes-Oxley.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_1690"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_121"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_124"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 10 of Form 10-K is incorporated by reference to our Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 11 of Form 10-K is incorporated by reference to our Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_130"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 12 of Form 10-K is incorporated by reference to our Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 13 of Form 10-K is incorporated by reference to our Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accounting Fees and Services.</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 14 of Form 10-K is incorporated by reference to our Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2021.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_139"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_142"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The financial statements, schedules and exhibits filed as a part of this Annual Report on Form 10-K are as follows:</span></div><div style="padding-left:60.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Financial statements  The financial statements included in Item 8 are filed as part of this Annual Report on Form 10-K.</span></div><div style="padding-left:60.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement Schedules  All schedules have been omitted because they are not applicable or required, or the information required to be set forth therein is included in the <a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i75d4456fb1ed409bb59167bcf5c6f56b_148" tabindex="18">consolidated financial statements or notes thereto</a> included in Item 8 of this Annual Report on Form 10-K.</span></div><div style="padding-left:60.75pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Exhibits  The exhibits required to be filed as part of this report are listed in the Exhibit List attached hereto and are incorporated herein by reference.</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex31_207.htm" tabindex="18">Amended and Restated Certificate of Incorporation of the Registrant, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-ex32_20201231.htm" tabindex="18">Amended and Restated Bylaws of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex41_205.htm" tabindex="18">Form of Common Stock Certificate of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex45_206.htm" tabindex="18">Warrant to Purchase Shares, dated December 16, 2016, by and between Alpine Immune Sciences, Inc. and Silicon Valley Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex46_203.htm" tabindex="18">Form of Warrant to Purchase Shares of Common Stock issued to certain service providers on April 12, 2017 pursuant to the Amended and Restated 2015 Stock Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312519010606/d673408dex103.htm" tabindex="18">Form of Warrant to Purchase Common Stock issued pursuant to the Securities Purchase Agreement, dated January 15, 2019, by and among the Registrant and the Purchasers party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619919000060/alpinesvbwarranttopurcha.htm" tabindex="18">Warrant to Purchase Common Stock, dated August 26, 2019, by and between Alpine Immune Sciences, Inc. and Silicon Valley Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000037/ex_103x20200724.htm" tabindex="18">Form of Warrant to Purchase Common Stock issued pursuant to the Securities Purchase Agreement, dated July 24, 2020, by and among Alpine Immune Sciences, Inc. and the Purchasers party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 24, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000037/ex_104x20200724.htm" tabindex="18">Form of Prefunded Warrant to Purchase Common Stock issued pursuant to the Securities Purchase Agreement, dated July 24, 2020, by and among Alpine Immune Sciences, Inc. and the Purchasers party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 24, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-ex410_20201231.htm" tabindex="18">Description of Capital Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex103_8xkx2021pipe.htm" tabindex="18">Form of Prefunded Warrant to Purchase Common Stock issued pursuant to the Securities Purchase Agreement, dated September 14, 2021, by and among the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex103_8xkx2021pipe.htm" tabindex="18"> A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex103_8xkx2021pipe.htm" tabindex="18">lpine Immune Scienc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex103_8xkx2021pipe.htm" tabindex="18">es, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex103_8xkx2021pipe.htm" tabindex="18">and the Purchasers party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d4.htm" tabindex="18">Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205220</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d5.htm" tabindex="18">Form of Notice of Stock Option Grant and Stock Option Agreement for Employees under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205220</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d6.htm" tabindex="18">Form of Notice of Stock Option Grant and Stock Option Agreement for Non-Employee Directors under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205220</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000110465915047582/a15-14497_1ex4d7.htm" tabindex="18">Nivalis Therapeutics, Inc. Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-205220</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 25, 2015</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000104746915004723/a2224618zex-10_18.htm" tabindex="18">Form of Indemnification Agreement entered into by and between the Registrant and its directors and officers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-204127</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 13, 2015</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619921000038/alpn-ex106_20201231.htm" tabindex="18">Non-Employee Director Compensation Guidelines</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 18, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517366252/d505987dex101.htm" tabindex="18">Change of Control and Severance Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 11, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1033_212.htm" tabindex="18">Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Mitchell H. Gold, M.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1035_214.htm" tabindex="18">Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Paul Rickey</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex1037_2544.htm" tabindex="18">Employment Agreement, dated as of January 1, 2018, by and between the Registrant and Stanford Peng, M.D., Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619921000100/alpn-ex102_10xqx2021q2.htm" tabindex="18">Employment Agreement, dated as of June 1, 2021, by and between the Registrant and Zelanna Goldberg</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619921000100/alpn-ex101_10xqx2021q2.htm" tabindex="18">Form of Stand-Alone Inducement Stock Option Grant between the Registrant and Zelanna Goldberg</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13*+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex1013_20211231.htm" tabindex="18">Separation Agreement, dated as of October 8, 2021, by and between the Registrant and Zelanna Goldberg</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517281903/d453065dex41.htm" tabindex="18">Alpine Immune Sciences, Inc. (now known as AIS Operating Co., Inc.) Amended and Restated 2015 Stock Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8 POS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-218134</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312517281903/d453065dex42.htm" tabindex="18">Form of Option Agreement under the Alpine Immune Sciences, Inc. (now known as AIS Operating Co., Inc.) Amended and Restated 2015 Stock Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8 POS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-218134</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2017</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000024/alpn-ex101_20200616.htm" tabindex="18">Alpine Immune Sciences, Inc. 2018 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 17, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312518192903/d605617dex102.htm" tabindex="18">Form of Stock Option Agreement under the 2018 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 14, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000003/alpn-ex101_20200127.htm" tabindex="18">Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 27, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000119312519010606/d673408dex101.htm" tabindex="18">Securities Purchase Agreement, dated January 15, 2019, by and among the Company and the Purchasers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619919000019/alpn-ex1001_20190401.htm" tabindex="18">Alpine Immune Sciences, Inc. Executive Incentive Compensation Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619919000040/alpn-ex106_20190331.htm" tabindex="18">Lease Agreement, dated March 14, 2019, by and between the Company and ARE Seattle No. 28, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619919000060/alpinesvbarloan.htm" tabindex="18">Amended and Restated Loan and Security Agreement, dated August 26, 2019, by and among Alpine Immune Sciences, Inc., AIS Operating Co., Inc. and Silicon Valley Bank</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 28, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.23**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000045/alpn-ex10220200630.htm" tabindex="18">Option and License Agreement, dated June 17, 2020, by and between Alpine Immune Sciences, Inc. and AbbVie Ireland Unlimited Company</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.24</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000037/ex_101x20200724.htm" tabindex="18">Securities Purchase Agreement, dated July 24, 2020, by and among Alpine Immune Sciences, Inc. and the Purchasers named therein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 24, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.25</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000037/ex_102x20200724.htm" tabindex="18">Registration Rights Agreement, dated July 24, 2020, by and among Alpine Immune Sciences, Inc. and the Purchasers named therein</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 24, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000091/alpn-ex11_8xk2021atm.htm" tabindex="18">Sales Agreement, dated as of July 2, 2021, between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000045/alpn-ex10220200630.htm" tabindex="18">Alpine Immune Sciences, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000091/alpn-ex11_8xk2021atm.htm" tabindex="18"> and Cowen and Company, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex101_8xkx2021pipe.htm" tabindex="18">Securities Purchase Agreement, dated September 14, 2021, by and among Alpine Immune Sciences, Inc. and the Purchasers thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 14, 2021</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex102_8xkx2021pipe.htm" tabindex="18">Registration Rights Agreement, dated September 14, 2021, by and among Alpine Immune Sciences, Inc. and the Purchasers thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex104_8xkx2021pipe.htm" tabindex="18">Exchange Agreement, dated September 14, 2021, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000162619920000045/alpn-ex10220200630.htm" tabindex="18">Alpine Immune Sciences, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001626199/000162619921000104/alpn-ex104_8xkx2021pipe.htm" tabindex="18"> and Frazier Life Sciences VIII, L.P.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30+**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex1030_20211231.htm" tabindex="18">License and Collaboration Agreement, dated December 15, 2021 by and between Alpine Immune Sciences, Inc. and Horizon Therapeutics Ireland DAC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex1031_20211231.htm" tabindex="18">Stock Purchase Agreement, dated December 15, 2021 by and between Alpine Immune Sciences, Inc. and Horizon Therapeutics Ireland DAC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1626199/000156459018006916/alpn-ex211_2624.htm" tabindex="18">List of subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37449</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 28, 2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex231_20211231.htm" tabindex="18">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_145" tabindex="18">Powers of Attorney (contained on signature page)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex311_20211231.htm" tabindex="18">Certification of Principal Executive Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex312_20211231.htm" tabindex="18">Certification of Principal Financial Officer Required Under Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex321_20211231.htm" tabindex="18">Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1626199/000162619922000032/alpn-ex322_20211231.htm" tabindex="18">Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover page formatted as Inline XBRL and contained in Exhibit 101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or a compensatory plan, contract or arrangement.</span></td></tr></tbody></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></tbody></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.302%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K because they are private, confidential and not material.</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_145"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALPINE IMMUNE SCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 17, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mitchell H. Gold, M.D.</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mitchell H. Gold, M.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ALPINE IMMUNE SCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: March 17, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Paul Rickey</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul Rickey</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mitchell H. Gold, M.D. and Paul Rickey, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file, any and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their and his or her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Mitchell H. Gold, M.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Executive Chairman of the Board of Directors (Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mitchell H. Gold, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Paul Rickey</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul Rickey</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Peter Thomson, M.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Thompson, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">James N. Topper, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">James N. Topper, M.D., Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Jay Venkatesan, M.D.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jay Venkatesan, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Robert Conway</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert Conway</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Natasha Hernday</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Natasha Hernday</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&nbsp;Christopher Peetz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Peetz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Xiangmin Cui, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 17, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Xiangmin Cui, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_148"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_151" tabindex="18">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(PCAOB ID: <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:AuditorFirmId" id="fact-identifier-35" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNDgvZnJhZzoxYmViMjI1YzA3MTM0OWJlYjRlNmEzOWFkMDYwMzMzMC90YWJsZTozZmQ1NjEzNTJjYzU0ZDlmYWQwY2Q5M2ZiYThhNmRkZC90YWJsZXJhbmdlOjNmZDU2MTM1MmNjNTRkOWZhZDBjZDkzZmJhOGE2ZGRkXzAtMC0xLTEtMzYyOTQvdGV4dHJlZ2lvbjoyYzdmYzIxMzMxOTM0MjBhOGY5YmIzMWUyNzA3ZjEwNF8xMDk5NTExNjI4MTIx_1a95cc8b-8219-4e73-9e1e-4c7e49ea7c4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42</ix:nonnumeric></span>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_151" tabindex="18">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_160" tabindex="18">Consolidated Statements of Stockholders Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_160" tabindex="18">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_163" tabindex="18">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_163" tabindex="18">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_166" tabindex="18">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_166" tabindex="18">8</a></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_151"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Alpine Immune Sciences, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Alpine Immune Sciences, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive income (loss), stockholders equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Companys financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current and prior period audits of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.837%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span><br></span></div><div><span><br></span></div><div><span><br></span></div><div><span style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></div><div><span><br></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Accounting for Revenue under the AbbVie Collaboration Agreement</span></div><div><span><br></span></div><div><span style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note 11 to the consolidated financial statements, the Company entered into an option and license agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101 in June 2020. Collaboration revenue recognized from the AbbVie Agreement was $23.4 million and $7.0 million for the year ended December 31, 2021 and 2020, respectively. The Company determined that all contractual promises related to the upfront payment and Alpines Development Milestone represent a single performance obligation and used a cost-based input method to measure progress toward completion of the performance obligation and to calculate the corresponding revenue to recognize each period.</span></div><div><span><br></span></div><div><span style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the Companys estimated measure of progress toward completion of the performance obligation is complex. A cost-based input method of revenue recognition requires management to make estimates of total expected costs to complete the performance obligation. In making such estimates, significant judgment is required to evaluate key assumptions related to cost estimates, including internal personnel efforts and third-party contract costs.</span></div><div><span><br></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As discussed in Note 11 to the consolidated financial statements, the Company entered into an option and license agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101 in June 2020. Collaboration revenue recognized from the AbbVie Agreement was $23.4 million and $7.0 million for the year ended December 31, 2021 and 2020, respectively. The Company determined that all contractual promises related to the upfront payment and Alpines Development Milestone represent a single performance obligation and used a cost-based input method to measure progress toward completion of the performance obligation and to calculate the corresponding revenue to recognize each period.</span></div><div><span><br></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing the Companys estimated measure of progress toward completion of the performance obligation is complex. A cost-based input method of revenue recognition requires management to make estimates of total expected costs to complete the performance obligation. In making such estimates, significant judgment is required to evaluate key assumptions related to cost estimates, including internal personnel efforts and third-party contract costs.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How We Addressed the Matter in Our Audit<br></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test revenue recognized, we performed audit procedures that included, among others, gaining an understanding and testing the Companys estimates of total expected costs including testing the completeness and accuracy of the underlying data, inspecting evidence of actual costs incurred and comparing with previous estimates. We evaluated any changes in the total expected costs, inspected communications between the Company and AbbVie regarding updates to estimated budgeted costs as well as any significant changes in its development plan, performed sensitivity analyses of key assumptions and compared the estimates to actual incurred costs for the same or similar activities. We discussed the basis for key assumptions with the Company's research and development personnel to assess management's key assumptions used in the Company's estimates of total expected costs.</span></td></tr></tbody></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:AuditorName" id="fact-identifier-36" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTEvZnJhZzoyNGM1MmUxMTcyMzM0MmI3Yjg2YjU1OGZhOWQ3ZTlhZi90ZXh0cmVnaW9uOjI0YzUyZTExNzIzMzQyYjdiODZiNTU4ZmE5ZDdlOWFmXzE2NDkyNjc0NDQ1NDI_572de478-117b-45b8-ad7c-a59182a797b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Ernst &amp; Young LLP</ix:nonnumeric></span></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Companys auditor since 2015.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="dei:AuditorLocation" id="fact-identifier-37" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTEvZnJhZzoyNGM1MmUxMTcyMzM0MmI3Yjg2YjU1OGZhOWQ3ZTlhZi90ZXh0cmVnaW9uOjI0YzUyZTExNzIzMzQyYjdiODZiNTU4ZmE5ZDdlOWFmXzE2NDkyNjc0NDQ1NDQ_13b24835-b9f6-4028-aab4-0aa5d557a28b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Seattle, WA</ix:nonnumeric></span></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 17, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_154"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-38" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzQtMi0xLTEtMjY2MzU_dfade804-7b9c-4bad-9d34-f9ea18dab5d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,907</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-39" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzQtNC0xLTEtMjY2MzU_57ee9a2b-6b42-432f-bb68-23c846a38bbd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34,959</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-40" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzUtMi0xLTEtMjY2MzU_4a3fa7e3-cdd1-4155-86ce-f3560e854713" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94,396</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-41" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzUtNC0xLTEtMjY2MzU_8ba5c2f8-78f6-4c57-9cef-cf5f6e530169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,622</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-42" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzYtMi0xLTEtMzE0OTY_08967f7d-f10e-403a-885c-8034ae2663fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-43" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzYtNC0xLTEtMzE0OTY_9e358f06-3b60-478a-82a4-e1c5f2a6ab4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-44" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzctMi0xLTEtMjY2MzU_b3200842-f93b-4b37-8885-d371903bbebe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-45" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzctNC0xLTEtMjY2MzU_9b8cbf1c-0515-4e20-a837-cdd1a34f57b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,520</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-46" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzgtMi0xLTEtMjY2MzU_6e16e0e6-2b36-42f8-96c2-e5b08e04d276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">192,013</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-47" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzgtNC0xLTEtMjY2MzU_5511b491-06b5-4a08-ae64-614b21e52e49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,101</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="fact-identifier-48" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzktMi0xLTEtMjY2MzU_45f6c2f1-39a7-4d4b-b67c-a8e1a2e93650" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">254</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="fact-identifier-49" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzktNC0xLTEtMjY2MzU_169e6c43-96a7-4a61-81f4-b25c7ec64247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">254</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-50" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzEwLTItMS0xLTI2NjM1_00e3b381-118d-42bf-a01d-06e36095b4bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,716</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-51" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzEwLTQtMS0xLTI2NjM1_31703d51-f5b3-4211-82ca-6de96ce19d19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,785</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease, right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-52" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzExLTItMS0xLTI2NjM1_3e385938-ca68-4309-bb69-81b5e287ec4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,837</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-53" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzExLTQtMS0xLTI2NjM1_13183f4c-0d1c-4570-ab87-99aeb131da0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,401</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-54" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzEyLTItMS0xLTI2NjM1_ae41a555-1656-43fc-a8f3-a4f2028ba00e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,866</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-55" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzEyLTQtMS0xLTI2NjM1_9c38bed0-f346-445d-a3a2-e44c99aad936" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,549</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="fact-identifier-56" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE0LTItMS0xLTMxNTA4_ab7e1ac5-11bd-4292-847a-b8ba33ff8e97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">214</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-57" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE0LTQtMS0xLTMxNTA4_f754b3ef-12b3-46fa-9b74-d7a8af2e45e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-58" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzEzLTItMS0xLTI2NjM1_46441b60-8f8a-4b0b-9640-5dd6e81ca70b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,900</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-59" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzEzLTQtMS0xLTI2NjM1_3ecf4c08-321a-43f0-9c55-9e8bd337c6c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,090</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and stockholders equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-60" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE2LTItMS0xLTI2NjM1_91debd4c-2841-4a76-8cd2-b567deba9302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,349</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="fact-identifier-61" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE2LTQtMS0xLTI2NjM1_f5667454-4fb6-4af2-be5f-0fd240ef7f17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">582</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-62" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE3LTItMS0xLTI2NjM1_03598bd6-dab4-46a9-8660-23b33f9cff61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,417</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-63" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE3LTQtMS0xLTI2NjM1_5e1de2fa-b67c-43e7-a133-879b92c3e3ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,777</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-64" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE4LTItMS0xLTI2NjM1_aec3dd82-e3c9-47af-a62c-9747228631ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,773</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-65" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE4LTQtMS0xLTI2NjM1_55f14e97-9604-4d5f-ac5e-f0fa88a84564" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,627</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-66" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE5LTItMS0xLTI2NjM1_5d44027a-a699-4e4c-9e4d-bc4f4803c666" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">617</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-67" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzE5LTQtMS0xLTI2NjM1_8c3a2315-0d5d-42b9-93a9-f5391b57210d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">655</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-68" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIwLTItMS0xLTI2NjM1_b74cb96e-18d9-4050-a931-c29630274112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,622</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-69" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIwLTQtMS0xLTI2NjM1_43ab3f7a-9686-4b10-aca9-7cc880064a08" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,526</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-70" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIxLTItMS0xLTI2NjM1_2a1bdbcc-e1dc-4c75-a2a2-275d365c827b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69,778</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-71" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIxLTQtMS0xLTI2NjM1_9ddaf209-2e8b-4e95-b666-bcba055cfe06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,167</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, noncurrent</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-72" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIyLTItMS0xLTI2NjM1_b8523799-759a-4de6-8bc0-95da57c39ce4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,830</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-73" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIyLTQtMS0xLTI2NjM1_3fc21957-c912-4d79-96c2-4a8684200213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,348</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, noncurrent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-74" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIzLTItMS0xLTI2NjM1_6bd2d2be-3b5f-4ab8-95a4-8064d60a3d39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,009</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-75" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzIzLTQtMS0xLTI2NjM1_afdb1820-e0b5-43e4-ab25-4db8f3e411bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,815</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-76" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI0LTItMS0xLTI2NjM1_23ade2e7-958b-428c-904a-d726cdcb1468" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,380</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-77" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI0LTQtMS0xLTI2NjM1_489b2a16-f287-4e83-955d-53014386c051" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,602</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-78" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI1LTItMS0xLTI2NjM1_711c49db-b5fe-4766-81f9-1423194b6199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,997</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-79" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI1LTQtMS0xLTI2NjM1_be2d2036-a707-4cb0-83aa-9c2007613a79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,932</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-80" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI2LTItMS0xLTI2NjM1_9b8ca766-105e-42b3-8265-eedac0ad7d5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-81" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI2LTQtMS0xLTI2NjM1_f377851f-6a5f-440f-a05e-299e3f0f2045" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="fact-identifier-82" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfMjE_3e9b7ca1-496f-4970-80c0-695489d6bfbd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="fact-identifier-83" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfMjE_e7755926-6bf7-47a2-9929-d7e22aa81d60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span> par value per share; <span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-84" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfNDU_0146deeb-1fc5-423d-9945-49a2644c4373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-85" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfNDU_93ff06ef-2e34-40dc-a463-b82aea982cf7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000,000</ix:nonfraction></span></ix:nonfraction></span> shares authorized at December&nbsp;31, 2021 and 2020; <span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-86" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfODA_2ac24048-e552-4ef9-aea7-08f618fa341d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-87" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfODA_769ea664-cc48-4cc4-9a7f-c1330ef2af1b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="fact-identifier-88" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfODA_a754619a-2663-4f25-a6da-1f2c4aa5b843" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="fact-identifier-89" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MDc4YjQ4N2MzNzg0NDYyMmJmOTJkYTM5ZDEyNDMzNGNfODA_e28b640e-2f93-4c2a-8dca-8fea7231b3c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">zero</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> shares issued and outstanding at December&nbsp;31, 2021 and 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="fact-identifier-90" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTItMS0xLTI2NjM1_f68e6212-726a-4c61-9bad-65f98937f881" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="fact-identifier-91" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI3LTQtMS0xLTI2NjM1_58d212fb-2242-4490-b3b9-3ede4a6af0d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<span><ix:nonfraction unitref="usdPerShare" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-92" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfMTg_a0475da3-7626-4af1-9ab8-edb3f4a0938b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-93" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfMTg_c5032fdc-d31b-4c7c-90ca-49895fe5982a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span> par value per share; <span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-94" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfNDI_8ebdc2de-2da4-49f2-82c8-9acccae77bc8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-95" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfNDI_bf48a9a6-0447-49b9-95f5-fd820529ad41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></ix:nonfraction></span> shares authorized at December&nbsp;31, 2021 and 2020; <span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-96" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfNzc_5f1ad86d-082a-4737-aa0f-49b18354f4cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,444,746</ix:nonfraction></span> shares issued and <span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-97" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfOTg_b0189015-7a10-4f06-8b68-ba7335748635" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,194,279</ix:nonfraction></span> shares outstanding at December&nbsp;31, 2021; <span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-98" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfMTI3_5268a894-d6c6-4591-9164-94f2b5d9b5ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,853,650</ix:nonfraction></span> shares issued and <span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-99" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTAtMS0xLTI2NjM1L3RleHRyZWdpb246MzdkOWQ1ZDY2ZWNmNDhjNGIwMGI1Mjg2MzQ1Yjk3MzZfMTQ4_c26c01af-15b4-4a31-960c-2b7602c7c30c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,803,183</ix:nonfraction></span> shares outstanding at December&nbsp;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="fact-identifier-100" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTItMS0xLTI2NjM1_26db2cc2-5966-4803-9a45-229e0746093f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="fact-identifier-101" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzI5LTQtMS0xLTI2NjM1_89e22cc9-f027-4bcf-b88b-6731af80b79f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-102" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMwLTAtMS0xLTI2NjM1L3RleHRyZWdpb246MGRjMzYyMTNiZTdmNDBlMTkyOTY4NmRhMDE5NDk0NjFfMjk_cdcffaa4-3191-4c61-a53d-28439f3c4012" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,250,467</ix:nonfraction></span> shares and <span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-103" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMwLTAtMS0xLTI2NjM1L3RleHRyZWdpb246MGRjMzYyMTNiZTdmNDBlMTkyOTY4NmRhMDE5NDk0NjFfMTA5OTUxMTYyNzg3MQ_fa7dc637-0ff4-4a1e-bdf0-a3b22a6d0373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,467</ix:nonfraction></span> shares at December&nbsp;31, 2021 and 2020, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:fixed-zero" scale="3" id="fact-identifier-104" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMwLTItMS0xLTI2NjM1_8b91ae8b-f98e-4f65-baf7-42729b377c72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:fixed-zero" scale="3" id="fact-identifier-105" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMwLTQtMS0xLTI2NjM1_15d8616b-9b40-4b5e-a771-bcca2d753527" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-106" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMxLTItMS0xLTI2NjM1_8dddb366-3314-4dfd-aed8-9c938919f8d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">287,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-107" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMxLTQtMS0xLTI2NjM1_e74916f5-0b1b-427b-922f-131dc3b79c7f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">177,947</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) gain</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="fact-identifier-108" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMyLTItMS0xLTI2NjM1_2b8f5112-e4de-4801-8b0f-239077478758" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="fact-identifier-109" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMyLTQtMS0xLTI2NjM1_2f2ba8cb-d0ae-4ee3-b850-d402b1dc946d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-110" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMzLTItMS0xLTI2NjM1_02f67f12-da3c-48f1-afc6-c90998aaab86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166,199</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-111" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzMzLTQtMS0xLTI2NjM1_c11da2e1-87fd-469f-b114-0c2a71d3b1f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,866</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-112" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzM0LTItMS0xLTI2NjM1_be9e8242-c403-4642-98a4-e11950d4fcde" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,903</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-113" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzM0LTQtMS0xLTI2NjM1_d51d8163-e450-4324-84b3-b59e4bb065d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,158</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders equity</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-114" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzM1LTItMS0xLTI2NjM1_4c5c2e68-6444-4ab0-a43e-5b998ffc6a45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,900</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-115" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTQvZnJhZzozNTRmNWMxMzFiMDQ0MGFhYmQwN2M1M2ZjNjcwYmZhOS90YWJsZTo4NDY0OGVjNGIwN2M0ZTk1OGE0YTA5NTVkZWNiMGE5NS90YWJsZXJhbmdlOjg0NjQ4ZWM0YjA3YzRlOTU4YTRhMDk1NWRlY2IwYTk1XzM1LTQtMS0xLTI2NjM1_10170ed9-014a-4d6a-aefc-f369f6627419" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">144,090</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_157"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_091ece9d-39cf-4ec6-b31a-e859f676634f"><span><ix:nonnumeric contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="fact-identifier-116" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_091ece9d-39cf-4ec6-b31a-e859f676634f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_0e8d6efb-e8ab-4715-88e6-68781f569926"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMC0xLTEtMjY2MzU_92f831ac-72b6-420b-a93c-169263491fdc">Collaboration revenue</span></span></ix:nonnumeric></span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-117" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMS0xLTEtMjY2MzU_18c23030-2acb-43a2-8e0c-e5ddf6f4154d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,443</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-118" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItMy0xLTEtMjY2MzU_af2e3152-d1a7-4e22-9ff1-dff2d0081429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,335</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-119" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzItNS0xLTEtMjY2MzU_bfb95cd6-9c39-4d07-ab78-082bd501bb00" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,740</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-120" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzQtMS0xLTEtMjY2MzU_16e50ed0-ec06-469d-b1c6-01c08c345575" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58,742</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-121" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzQtMy0xLTEtMjY2MzU_b8a7b5b6-89e2-4ce0-9fa5-1b45ad09380c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,185</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-122" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzQtNS0xLTEtMjY2MzU_a5c0f7eb-1043-4871-86df-a04fe687f937" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,847</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-123" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzUtMS0xLTEtMjY2MzU_b974f76b-a7b3-4ce7-a89a-55ac01c93c39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,560</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-124" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzUtMy0xLTEtMjY2MzU_f92fc9c3-d0df-438b-acf4-2ccdd52ce61b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,899</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-125" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzUtNS0xLTEtMjY2MzU_fe4fd38d-bb9f-45fd-a6dc-6952fef464f5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,467</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-126" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzctMS0xLTEtMjY2MzU_9a91d361-00d5-48b7-b14d-29068b683a82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,302</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-127" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzctMy0xLTEtMjY2MzU_1d980bf1-68f6-422a-bd70-ad41df3e9d25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,084</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-128" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzctNS0xLTEtMjY2MzU_251a1061-1c8c-46c3-b4c6-8b7e19c44378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,314</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-129" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzgtMS0xLTEtMjY2MzU_7a4240ec-156a-4c0f-9d77-c97e1e27181b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,859</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-130" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzgtMy0xLTEtMjY2MzU_255af3df-03ae-4048-801f-c3175fbf1794" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,749</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-131" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzgtNS0xLTEtMjY2MzU_57ae38f6-d600-410d-907b-44fe5c8021b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,574</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-132" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEwLTEtMS0xLTI2NjM1_2e1f21fa-f012-4757-8001-655c39b9dd78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">816</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-133" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEwLTMtMS0xLTI2NjM1_072d8185-54a4-46c2-8571-0b20ed82c005" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">775</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-134" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEwLTUtMS0xLTI2NjM1_43cb7c3a-38a3-4427-b607-f31cb51c44d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">338</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="fact-identifier-135" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzExLTEtMS0xLTI2NjM1_9c822b82-4129-455d-bc54-2fd715237b36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">259</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" scale="3" id="fact-identifier-136" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzExLTMtMS0xLTI2NjM1_482202b2-0e12-469d-8651-f6daa822843d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-137" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzExLTUtMS0xLTI2NjM1_35c1877c-7bde-4b4d-9147-b29f8646ea21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,248</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="fact-identifier-138" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEyLTEtMS0xLTI2NjM1_07f7766e-449c-438b-b60b-34ca21db96d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-139" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEyLTMtMS0xLTI2NjM1_c17b7f40-a727-4ab3-b35f-919c43b52f5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,333</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="fact-identifier-140" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEyLTUtMS0xLTI2NjM1_278ca5bb-5588-4325-8411-00c102151655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">812</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-141" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEzLTEtMS0xLTI2NjM1_907469f3-d252-4b92-b83e-39286f1a5d8a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,420</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-142" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEzLTMtMS0xLTI2NjM1_4341632d-000a-43e9-b99d-6a375b2ac60a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,946</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-143" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzEzLTUtMS0xLTI2NjM1_9489ed49-120e-4c07-876c-0f050e263b10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,852</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-144" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE0LTEtMS0xLTI2NjM1_428677bf-aa4c-4397-8242-07a1942ae12a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-145" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE0LTMtMS0xLTI2NjM1_78113dbd-d851-4d68-84b1-a9b9a71d62b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-146" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE0LTUtMS0xLTI2NjM1_96b83159-b364-458f-9c3d-8330a0de46d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-147" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE1LTEtMS0xLTI2NjM1_a4e02b16-bfb5-4498-b2a3-3b302092602b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,333</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-148" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE1LTMtMS0xLTI2NjM1_23227ba8-6784-43f3-9bfb-3e6148b1d510" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,940</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-149" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE1LTUtMS0xLTI2NjM1_43073017-14e1-4558-9320-97be4220ffeb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,852</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-150" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE3LTEtMS0xLTI2NjM1_cf5a62df-324e-415d-b611-25ceaa55a820" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">238</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-151" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE3LTMtMS0xLTI2NjM1_f7553fef-a56a-4c77-b4da-a4cf0a1b4095" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-152" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE3LTUtMS0xLTI2NjM1_ddbbcdf3-4a9d-4932-8057-a78cab0a53b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-153" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE4LTEtMS0xLTI2NjM1_604d1c5f-cbe5-42c9-886f-5ad3304dd3cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-154" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE4LTMtMS0xLTI2NjM1_dd021d02-e16f-4e50-9a77-d1717e958df6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-155" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE4LTUtMS0xLTI2NjM1_eea157b9-4fca-44ec-b17a-42dc74e39528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-156" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE5LTEtMS0xLTI2NjM1_64bb5273-a29e-48d0-903b-aed06b7f4443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,659</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-157" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE5LTMtMS0xLTI2NjM1_c969c6e9-3a35-4dc5-8302-60f2d8c58b93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,897</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-158" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzE5LTUtMS0xLTI2NjM1_88004f3d-bdf4-4be4-8c00-b08b5abdc979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,829</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-159" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIwLTEtMS0xLTI2NjM1_8e04757c-e0fb-44c3-a734-241cedd25cad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-160" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIwLTEtMS0xLTI2NjM1_d319ef27-2ed3-4e27-8044-8b32c268e43c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,476,889</ix:nonfraction></span></ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-161" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIwLTMtMS0xLTI2NjM1_80acfeae-4508-40a0-a7b2-d6d316baf81e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-162" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIwLTMtMS0xLTI2NjM1_f1881d96-a96f-46e9-b327-868d3e8d0c94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,826,466</ix:nonfraction></span></ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-163" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIwLTUtMS0xLTI2NjM1_7166dcbc-661b-4f72-9261-4014a3683849" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-164" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIwLTUtMS0xLTI2NjM1_763b7b02-5dcc-4b76-9777-2ce27c5a10f5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,358,864</ix:nonfraction></span></ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-165" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIxLTEtMS0xLTI2NjM1_2178d336-2d90-4f97-9b7e-eb7607d19c38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-166" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIxLTEtMS0xLTI2NjM1_42b86f75-f871-4767-92ed-12b3212696c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.98</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-167" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIxLTMtMS0xLTI2NjM1_72efd41f-17b8-4525-b872-d2c0114a4c69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-168" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIxLTMtMS0xLTI2NjM1_fa76a422-922e-4679-bee0-00709e2b5ef3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.34</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="fact-identifier-169" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIxLTUtMS0xLTI2NjM1_3e1fafe7-2376-421f-a9a5-4cd84c485ba2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="fact-identifier-170" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNTcvZnJhZzo2N2MxNGFjZDdiMDM0N2U2OGUyN2E4YzhjZjIzYzU1Ny90YWJsZTpmYWVlYWRiZWFlYmM0ZGY3OThiZTk5ODZkNDMzZTE1ZC90YWJsZXJhbmdlOmZhZWVhZGJlYWViYzRkZjc5OGJlOTk4NmQ0MzNlMTVkXzIxLTUtMS0xLTI2NjM1_c44e24db-d9f4-42dd-9f70-a0161a22fbe7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.28</ix:nonfraction></span></ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_160"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.433%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.308%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br>Other Comprehensive (Loss) Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br>Stockholders Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i919043086e3049048a17c0e6de073a2f_I20181231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-171" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTYtMS0xLTI2NjM1_6b8fe7da-e631-48cd-8e64-5be60e452d90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,854,205</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i919043086e3049048a17c0e6de073a2f_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-172" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTgtMS0xLTI2NjM1_75646c27-16ba-4089-a808-a9d7d7e2af4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i1c4ce683b38c4ba9a752ad0990e7db31_I20181231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-173" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTEwLTEtMS0yNjYzNQ_85fa3a8a-163b-45dc-9363-cf50a8f6dafc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,467</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1c4ce683b38c4ba9a752ad0990e7db31_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="fact-identifier-174" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTEyLTEtMS0yNjYzNQ_660f813d-26ca-408c-8bc1-7c160fdee2e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2c61c72b207f4822b0f8726675195e4f_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-175" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTE0LTEtMS0yNjYzNQ_a19cf9df-4c43-4870-aeb8-b3bd7b12b426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,664</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ib2ad74a5fab448fa94b0294c0c03a645_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-176" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTE2LTEtMS0yNjYzNQ_c01a4978-4186-4e22-b17e-37032debff8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iaa3867bf696240f9af9d3129e941f0ee_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-177" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTE4LTEtMS0yNjYzNQ_61ec267a-f7c2-4bf1-bff5-a8c7392a8b3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,074</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8071de4bb91440b9adb67a4f284b30fe_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-178" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzI5LTIwLTEtMS0yNjYzNQ_963bcf50-4ded-49db-9b03-4ea5bcca6bd0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44,591</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Units in Private Placement, net of offering costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i99cb38eebbf14566811523dbafb7634d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-179" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMwLTYtMS0xLTI2NjM1_9805e6cd-9018-4bc6-b129-f3891ca15856" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,706,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i99cb38eebbf14566811523dbafb7634d_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-180" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMwLTgtMS0xLTI2NjM1_f6399089-0f31-43f3-8f51-db9b7304d12a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i256db623b464499499272de9a09fe475_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-181" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMwLTE0LTEtMS0yNjYzNQ_f7cdec5a-59a3-4324-a0fd-07c9f0acefc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,593</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-182" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMwLTIwLTEtMS0yNjYzNQ_a1e2eee3-23fe-4dea-9ae9-337e3477cec7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,598</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i99cb38eebbf14566811523dbafb7634d_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-183" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMxLTYtMS0xLTI2NjM1_16a19c8b-a821-4c18-b305-5f1ca4ccbd8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,987</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i256db623b464499499272de9a09fe475_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-184" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMxLTE0LTEtMS0yNjYzNQ_ce355664-5354-49cd-bbb7-4e83fd99bdb3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-185" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMxLTIwLTEtMS0yNjYzNQ_67dbc33b-9824-4570-a53e-850010a64e29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i256db623b464499499272de9a09fe475_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-186" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMyLTE0LTEtMS0yNjYzNQ_d76e8a27-4d05-40d3-9d58-4bcef731159c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,041</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-187" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMyLTIwLTEtMS0yNjYzNQ_8e804369-db66-4c6b-810e-aaeb42bb3057" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,041</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i256db623b464499499272de9a09fe475_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="fact-identifier-188" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMzLTE0LTEtMS0yNjYzNQ_5ca211aa-9e20-48b9-bae3-221977dee6aa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="fact-identifier-189" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzMzLTIwLTEtMS0yNjYzNQ_a2ccf4a6-abad-4db4-98b7-729b706afaa6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i91d44d4b51814547bc7e3b442fcff7b0_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-190" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM0LTE2LTEtMS0yNjYzNQ_5e6a0860-a49d-46a3-955a-8b45ceb55cd9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-191" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM0LTIwLTEtMS0yNjYzNQ_b8cae66d-4df3-43a4-bf96-0a6c95fe3f81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i91d44d4b51814547bc7e3b442fcff7b0_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-192" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM1LTE2LTEtMS0yNjYzNQ_b77786c6-44f4-419c-88a5-ed3b4215dad1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-193" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM1LTIwLTEtMS0yNjYzNQ_27cf23cd-b1d3-458a-abdd-0d2cae0face8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i15d2b0e22559474b8985b59136c58e26_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-194" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM2LTE4LTEtMS0yNjYzNQ_e74130be-5f96-476b-9759-8f3a0d4a0ae2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,852</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-195" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM2LTIwLTEtMS0yNjYzNQ_dce40b99-8b50-49db-8d0e-521fa5505768" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,852</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ie14bab752cfe496c895327a2fcb47e59_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-196" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTYtMS0xLTI2NjM1_4661e70f-278c-4204-8a04-0d3b9d5770a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,587,892</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie14bab752cfe496c895327a2fcb47e59_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-197" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTgtMS0xLTI2NjM1_284989ff-9bb4-4949-a399-07017c9307e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9ed7c537c77e4e78919fdf840dabfb19_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-198" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTEwLTEtMS0yNjYzNQ_c52ffd47-7593-4dab-b2e3-906f0060b5b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,467</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9ed7c537c77e4e78919fdf840dabfb19_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="fact-identifier-199" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTEyLTEtMS0yNjYzNQ_117e45dd-19b1-4079-a21f-d206c26a3505" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0e4b53c25b064cbdb61c73329f9d373d_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-200" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTE0LTEtMS0yNjYzNQ_038fbce2-99c5-4e6f-a475-dfb8ae99e661" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,371</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id40267d2fb5a4cb592c161a53fb6c50a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-201" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTE2LTEtMS0yNjYzNQ_e389ffa9-c9c4-4f8e-b67c-e8239e573e85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9cb34f9836454ee4b95587a80586d219_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-202" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTE4LTEtMS0yNjYzNQ_072677e1-7214-4d68-a333-e8dab188e003" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,926</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-203" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM3LTIwLTEtMS0yNjYzNQ_986a5e8e-20aa-49c7-b783-2c322d2179da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,474</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Units in private offering, net of offering costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i73a21cddc36c40df81368c4056b6ce3b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-204" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM4LTYtMS0xLTI2NjM1_35232ccc-3f67-44df-bfd2-847ea25c26a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,139,610</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i73a21cddc36c40df81368c4056b6ce3b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-205" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM4LTgtMS0xLTI2NjM1_70ea4216-872f-4f09-ac9e-b623d49ae8b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3cc09431f82641ca94d297afdc885945_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-206" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM4LTE0LTEtMS0yNjYzNQ_6f1c16ef-e803-4415-9c13-8a54341a4dfc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,253</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-207" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM4LTIwLTEtMS0yNjYzNQ_c686bdde-d1a5-4795-b1b9-5d560e7f4d09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,258</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3cc09431f82641ca94d297afdc885945_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="fact-identifier-208" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM5LTE0LTEtMS0yNjYzNQ_7024e71e-f6ca-4fe3-8329-03cedf50156e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="fact-identifier-209" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzM5LTIwLTEtMS0yNjYzNQ_7a27872c-edda-4fcb-8df7-e48d42d225f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i73a21cddc36c40df81368c4056b6ce3b_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-210" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQwLTYtMS0xLTI2NjM1_0749788d-a411-4d85-b69e-fdf70f3f6792" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,681</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3cc09431f82641ca94d297afdc885945_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="fact-identifier-211" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQwLTE0LTEtMS0yNjYzNQ_1a286d0c-b721-4219-b87a-6e1d138e3fef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="fact-identifier-212" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQwLTIwLTEtMS0yNjYzNQ_d3b674ef-9118-488d-9aa7-26b57435081d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3cc09431f82641ca94d297afdc885945_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-213" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQxLTE0LTEtMS0yNjYzNQ_cccd600d-bc56-4943-8ca6-3db3e0fe4bc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-214" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQxLTIwLTEtMS0yNjYzNQ_722c3136-9a13-43bc-9a48-f75d2ff3652c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i243f35162d6f4ed7a415269f539b04e5_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-215" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQyLTE2LTEtMS0yNjYzNQ_8314910a-2bd7-40af-95c6-0c5b397b6d6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-216" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQyLTIwLTEtMS0yNjYzNQ_332461a7-ccc8-4c9d-bfdb-96c8d21aad33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i243f35162d6f4ed7a415269f539b04e5_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-217" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQzLTE2LTEtMS0yNjYzNQ_833e2602-e4a3-4ba9-a299-af1b592034cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-218" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQzLTIwLTEtMS0yNjYzNQ_8f5e2181-a583-4c6d-a7fc-5e46277f3a75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id3e587cdd7ab4aa0ab733f9cfbc155fb_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-219" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ0LTE4LTEtMS0yNjYzNQ_d6fb69db-e40a-44e7-b11c-e9e79a67bacf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,940</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-220" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ0LTIwLTEtMS0yNjYzNQ_ab077b6e-47c2-49e9-9c36-66755d5106ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,940</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iba0ddb9b77924e6096476453a17bb2a8_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-221" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTYtMS0xLTI2NjM1_74c8fa02-b64a-4c37-b6a1-9be040883772" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,803,183</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iba0ddb9b77924e6096476453a17bb2a8_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-222" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTgtMS0xLTI2NjM1_8b795bc1-4db0-4408-99d1-33aec8860d68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib4edcf137dc74d3f8eeab9ad1ea23448_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-223" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTEwLTEtMS0yNjYzNQ_91357814-539b-4080-8a32-5b972ea09ea8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,467</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib4edcf137dc74d3f8eeab9ad1ea23448_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="fact-identifier-224" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTEyLTEtMS0yNjYzNQ_af81a633-7ae4-4e50-8ff3-41ded110b6b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6aed5ad924d745e0a110878651454bf4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-225" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTE0LTEtMS0yNjYzNQ_1accbe5f-329f-42a5-a894-bf2fdcd1471c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">177,947</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie0c2b383b84d40e58fa0f67af121be49_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-226" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTE2LTEtMS0yNjYzNQ_de59d837-b05e-4509-aff4-7c241a70f329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ia2648eabdbd140f5974b595477aca5ec_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-227" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTE4LTEtMS0yNjYzNQ_1933cf04-85bf-4878-a73d-0428251ba77d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,866</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-228" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ1LTIwLTEtMS0yNjYzNQ_e7fbb6f3-3ad6-4983-a532-cd14da5ff1ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62,158</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in Private Placement, net of offering costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-229" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ2LTYtMS0xLTI4OTYy_48b1a034-ff8e-45a0-b51d-12bcbe44a438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,489,357</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-230" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ2LTgtMS0xLTI4OTYy_80bb8120-d821-4cc1-a956-4d0db26a0a8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707070799aba47bbbf2bacf54dcf8436_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-231" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ2LTE0LTEtMS0yODk2Mg_433be7c4-5919-4986-93ac-f25f90679a55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,727</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-232" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ2LTIwLTEtMS0yODkzNQ_0802681f-06d3-4fad-aab7-0d28f0c9f634" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,733</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to Horizon</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="INF" name="alpn:StockIssuedDuringPeriodSharesCollaborationAgreement" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-233" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTYtMS0xLTMxNzQz_685c337a-fce2-4194-8a83-6753f1f890cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">951,980</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="-3" name="alpn:StockIssuedDuringPeriodValueCollaborationAgreement" scale="3" id="fact-identifier-234" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTgtMS0xLTMxNzQz_317a6fc6-9db6-4d34-9837-ff1b11a34dea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707070799aba47bbbf2bacf54dcf8436_D20210101-20211231" decimals="-3" name="alpn:StockIssuedDuringPeriodValueCollaborationAgreement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-235" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTE0LTEtMS0zMTc0Mw_444d217e-47a2-45e6-b83a-6330e7531df5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11,928</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="alpn:StockIssuedDuringPeriodValueCollaborationAgreement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-236" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTIwLTEtMS0zMTc0Mw_cee5f69e-2796-4b2e-ba3c-a14cfa44929c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11,929</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange of common stock for prefunded warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="INF" sign="-" name="alpn:StockIssuedDuringPeriodSharesExchangeForPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-237" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTYtMS0xLTI4OTYy_66db1949-9a67-46cd-b11a-8daa328ea8fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,200,000</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="-3" sign="-" name="alpn:StockIssuedDuringPeriodValueExchangeForPrefundedWarrants" scale="3" id="fact-identifier-238" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTgtMS0xLTI4OTYy_61ffe98f-c5d3-4f7e-83b7-3cad9d4c3f07" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i1fe4f6c096224997bdc46005a9f39525_D20210101-20211231" decimals="INF" name="alpn:StockIssuedDuringPeriodSharesExchangeForPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-239" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTEwLTEtMS0yODk2Mg_8d8328f6-037a-4f12-90c6-21f47c811385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,200,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707070799aba47bbbf2bacf54dcf8436_D20210101-20211231" decimals="-3" name="alpn:StockIssuedDuringPeriodValueExchangeForPrefundedWarrants" scale="3" id="fact-identifier-240" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTE0LTEtMS0yODk2Mg_0aa5e579-d8e8-401f-8b6c-aa44b531efa7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="alpn:StockIssuedDuringPeriodValueExchangeForPrefundedWarrants" format="ixt:fixed-zero" scale="3" id="fact-identifier-241" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ3LTIwLTEtMS0yODkzNw_eaa3ab71-ee78-4157-b780-664762db76d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707070799aba47bbbf2bacf54dcf8436_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-242" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ4LTE0LTEtMS0yODk2Mg_f76b9891-a6dd-464d-b238-1b822f8fe3a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,240</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-243" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ4LTIwLTEtMS0yODkzOQ_f4b89ea9-5cf0-4efc-bf6b-f096d9666480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,240</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive plans</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ac18e3c6b3d44de88ee6b0b16fd9c59_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-244" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ5LTYtMS0xLTI4OTY0_fa928c0e-0ac4-4fb4-ab42-cd04a86f3fab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">149,759</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i707070799aba47bbbf2bacf54dcf8436_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="fact-identifier-245" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ5LTE0LTEtMS0yODk2NA_4ff217b3-ddc1-4e58-a7d2-f588ce038776" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">502</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="fact-identifier-246" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzQ5LTIwLTEtMS0yODk0MQ_1ef2ca53-5d51-4361-acd1-2878d5f66537" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">502</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iaec48ff876724e438f733dcf4f37690b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-247" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUwLTE2LTEtMS0yODk2Ng_fa61f52e-e726-40bb-b6d0-4ed14afd85ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">238</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="fact-identifier-248" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUwLTIwLTEtMS0yODk0Mw_05f655c7-e524-4691-b9a0-8966294fb932" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">238</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iaec48ff876724e438f733dcf4f37690b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-249" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUxLTE2LTEtMS0yODk2Ng_cc407c22-505d-4350-bff8-293f527af55f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-250" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUxLTIwLTEtMS0yODk0NQ_c0ff7056-d60a-4d9c-8405-8fb8516de21d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9e466bd5f39940ba920dcf1ddf259781_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-251" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUyLTE4LTEtMS0yODk2Ng_c96bee02-11ba-40d6-9af4-e44d429362e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,333</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-252" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUyLTIwLTEtMS0yODk0Nw_8c95e71f-c9f6-4211-867a-74fc089527c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,333</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i75d81b01f697461cb4c519a3d2969ed3_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-253" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTYtMS0xLTI4OTMw_6257e5f7-0d88-491d-912a-1c214a9d5d3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,194,279</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i75d81b01f697461cb4c519a3d2969ed3_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-254" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTgtMS0xLTI4OTMw_0f98dcd4-7808-41d3-922c-96b7ae344686" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i74040b977c504756ac1b5616db85814d_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-255" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTEwLTEtMS0yODkzMA_6f3b158a-4b66-4712-8620-5c02a9b99ea5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,250,467</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i74040b977c504756ac1b5616db85814d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="fact-identifier-256" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTEyLTEtMS0yODkzMA_46d7a0f3-b629-49df-9cd3-33f84bef8ad8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8ef03a0a954a4cb28f082b2a2bd77dba_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-257" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTE0LTEtMS0yODkzMA_4fa31786-b12b-4ce7-83c7-155a0f73f663" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">287,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i3769092a6f2e4a09bab7b6cb75d25c62_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-258" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTE2LTEtMS0yODkzMA_9ff6addf-3bfa-4258-beb4-c8505c719cc9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0e587f3abecf433193c20c1bb12350a3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-259" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTE4LTEtMS0yODkzMA_42a81d68-0581-42f0-981d-44d37a932572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">166,199</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-260" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjAvZnJhZzpmMDNjM2U3ZDRjMzg0YjNhYmRkZGJjNzkwMDNlNmU2My90YWJsZTplOTUyYTBhMGI0Y2I0YmUyOWQ0ZGI1MDU3NDg4ZGQ2OC90YWJsZXJhbmdlOmU5NTJhMGEwYjRjYjRiZTI5ZDRkYjUwNTc0ODhkZDY4XzUzLTIwLTEtMS0yODkzMA_7457498e-c851-4a6a-8420-8a10eef9b99c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">120,903</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_163"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-261" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMtMS0xLTEtMjY2MzU_fb5bc87c-19aa-4f68-be00-28e6694e0636" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,333</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-262" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMtMy0xLTEtMjY2MzU_fbdcc6fc-b175-44a8-be5e-7668cf3e5428" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,940</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-263" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMtNS0xLTEtMjY2MzU_4388f567-7f01-4c0a-8dc5-858d694acce3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,852</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="fact-identifier-264" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzUtMS0xLTEtMjY2MzU_4ed06bec-c987-4a69-aef6-eb4d98b9031b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="fact-identifier-265" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzUtMy0xLTEtMjY2MzU_56249532-e02f-413b-a1ed-a3029c869dcb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="fact-identifier-266" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzUtNS0xLTEtMjY2MzU_716fc5e3-f50d-4615-b2a6-cabe92553c8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="fact-identifier-267" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzctMS0xLTEtMjY2MzU_9b89df0f-aaa5-4ffd-abae-e8e5ec6e343d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">620</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="fact-identifier-268" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzctMy0xLTEtMjY2MzU_69f307f6-cf0c-4ada-9145-564d36e798b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">578</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="fact-identifier-269" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzctNS0xLTEtMjY2MzU_ab6db4ab-5318-41ca-879d-f5cad5fdb683" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">468</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium/discount on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="fact-identifier-270" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzgtMS0xLTEtMjY2MzU_6c5122b0-7d7b-4993-85c5-58187d2f85ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">906</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="fact-identifier-271" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzgtMy0xLTEtMjY2MzU_5ab174c6-a880-4456-bec4-3881ce41f76f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">103</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="fact-identifier-272" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzgtNS0xLTEtMjY2MzU_77777c03-3cb2-4b89-a71a-1f78f5b577e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">360</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="fact-identifier-273" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzktMS0xLTEtMjY2MzU_68552de5-0e38-48b3-9dce-662a3ac7590a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">274</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="fact-identifier-274" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzktMy0xLTEtMjY2MzU_de2db2f2-881d-4b24-8182-55cecf962b34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">261</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="fact-identifier-275" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzktNS0xLTEtMjY2MzU_f5272cd9-45db-4b36-8e37-adffc0151cbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-276" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzEwLTEtMS0xLTI2NjM1_c5da17a2-ed69-46d0-9cf6-287caf66cb4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">214</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-277" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzEwLTMtMS0xLTI2NjM1_ee9fc8e4-23f5-4464-ba70-26c5d7b7a007" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-278" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzEwLTUtMS0xLTI2NjM1_9a3db4dd-e11a-46c4-a401-d1593026f109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-279" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzExLTEtMS0xLTI2NjM1_0946f9c7-384b-4093-823d-6d9ac9a2b342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,240</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-280" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzExLTMtMS0xLTI2NjM1_36f4c06f-4a92-4f0a-a95e-1f738f22638c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-281" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzExLTUtMS0xLTI2NjM1_87825959-f9bc-4ca7-be51-906a6c73b033" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,041</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-282" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzEzLTEtMS0xLTI2NjM1_ba4d0cda-5bdb-4278-a089-0f9764b490a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,063</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-283" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzEzLTMtMS0xLTI2NjM1_deb4b17b-6ee4-4853-b28d-bf5270485587" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-284" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzEzLTUtMS0xLTI2NjM1_0be7d8ec-0d42-426b-b704-42fe60a59eee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">408</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="alpn:IncreaseDecreaseInRightOfUseAsset" scale="3" id="fact-identifier-285" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE0LTEtMS0xLTI2NjM1_7d7d61ab-ea84-49ee-be2e-dbe66f3210b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">564</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="alpn:IncreaseDecreaseInRightOfUseAsset" scale="3" id="fact-identifier-286" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE0LTMtMS0xLTI2NjM1_4a14630d-646f-4eff-ab61-36b568038479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">592</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="alpn:IncreaseDecreaseInRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-287" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE0LTUtMS0xLTI2NjM1_fa7d27f8-604c-4e78-a984-628c686d5a3f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,553</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-288" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE1LTEtMS0xLTI2NjM1_3c6b9102-ce41-420a-be60-c9c5174db074" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,970</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="fact-identifier-289" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE1LTMtMS0xLTI2NjM1_cd90266e-3b3c-4385-b107-f359a95ddaef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">491</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="fact-identifier-290" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE1LTUtMS0xLTI2NjM1_1d675ece-95a2-4e8e-98fd-e297dd75e17e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">816</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-291" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE2LTEtMS0xLTI2NjM1_675bb5ed-3b16-4713-8164-656132eb2ca3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,628</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-292" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE2LTMtMS0xLTI2NjM1_77fe26c0-08b2-4d04-b558-6b326030b63b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">51,540</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-293" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE2LTUtMS0xLTI2NjM1_156c0596-bb89-47e6-be7a-b0026d98e3c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="alpn:IncreaseDecreaseInLeaseLiabilities" scale="3" id="fact-identifier-294" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE3LTEtMS0xLTI2NjM1_c6879fa9-dacb-4e69-9219-001576729c37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">844</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="alpn:IncreaseDecreaseInLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-295" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE3LTMtMS0xLTI2NjM1_ef4db7cc-6d17-465c-9262-becf871f1ca5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,041</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="alpn:IncreaseDecreaseInLeaseLiabilities" scale="3" id="fact-identifier-296" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE3LTUtMS0xLTI2NjM1_9db7d5d1-4853-4635-87ec-894c3aac7c8c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">195</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-297" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE4LTEtMS0xLTI2NjM1_310dc6af-ea3b-46da-8795-94da11bd4f5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,248</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-298" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE4LTMtMS0xLTI2NjM1_4ebdcb1c-30ac-4829-a5cc-3c7ee0ac3b82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,084</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-299" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzE4LTUtMS0xLTI2NjM1_dc754865-ff1a-4498-8ce7-133914531883" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,346</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-300" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIwLTEtMS0xLTI2NjM1_2c2d4867-7c13-4a32-abab-8e0b614626b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">118</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-301" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIwLTMtMS0xLTI2NjM1_c76abe40-96a4-4d77-b019-088650502a45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">802</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-302" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIwLTUtMS0xLTI2NjM1_1280e88c-0726-4568-ac69-a3e4562648f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">821</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-303" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIyLTEtMS0xLTI2NjM1_27a93b05-90ff-4c90-9fea-b7e104ffb135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">133,518</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-304" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIyLTMtMS0xLTI2NjM1_8dccbb1a-12a3-46ef-bde1-7d04178422c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">101,328</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-305" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIyLTUtMS0xLTI2NjM1_fde2ee28-93af-402b-bf85-5cefcb174016" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,382</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-306" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIzLTEtMS0xLTI2NjM1_d3f8d8cc-e055-4dc1-8217-8d03d93c4b60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">81,156</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-307" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIzLTMtMS0xLTI2NjM1_b50bb570-0925-4343-b202-d42ea9b7f24b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,311</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-308" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzIzLTUtMS0xLTI2NjM1_36fd4983-52cf-47ce-8ece-37ccf83d9fbd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,575</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the sale of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-309" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI0LTEtMS0xLTI2NjM1_735f9fea-b3f6-4244-b13c-36888cda0417" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-310" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI0LTMtMS0xLTI2NjM1_81f38e31-b039-4da8-acfe-ff714bea2f0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-311" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI0LTUtMS0xLTI2NjM1_84c9e4cd-01e8-4ddf-b3e4-c15a90b48df5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,391</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-312" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI1LTEtMS0xLTI2NjM1_adcf022e-0903-4acf-98e0-1bae508b9dc8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,480</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-313" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI1LTMtMS0xLTI2NjM1_464859db-b268-40c2-8219-f8111c94cba3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,819</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-314" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI1LTUtMS0xLTI2NjM1_2dcf520d-10c1-4ba8-9f77-6112bab7ccb5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,763</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock and warrants, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-315" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI3LTEtMS0xLTI2NjM1_72e3710d-8bff-4d65-bd89-62f5477a1d93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,733</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-316" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI3LTMtMS0xLTI2NjM1_410f293b-399d-4089-8bc6-15bf3e04bb5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">56,258</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-317" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI3LTUtMS0xLTI2NjM1_b3f01b58-6191-4805-b790-01af674c62af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,598</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock to Horizon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-318" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI4LTEtMS0xLTMxNjI2_3e2ff794-4a69-4302-b2e7-19da56c5d688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,929</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="fact-identifier-319" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI4LTMtMS0xLTMxNjI2_a2f7bbd3-3c2f-427d-813a-54df7b017b95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="fact-identifier-320" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI4LTUtMS0xLTMxNjI2_e2102996-bbde-4fbd-a2ea-eeae4373105a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-321" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI4LTEtMS0xLTI2NjM1_1048365e-df39-4536-9df3-ba1f2602f02a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-322" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI4LTMtMS0xLTI2NjM1_0b761a52-b3cd-489a-a091-208f145c39ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-323" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI4LTUtMS0xLTI2NjM1_614d2f89-1ee0-4205-ac73-23d9759b2a8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,977</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-324" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI5LTEtMS0xLTI2NjM1_684d430d-e336-402c-a376-1a061c0e85da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,400</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="fact-identifier-325" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI5LTMtMS0xLTI2NjM1_0403c70e-bc04-406b-88ab-6047bc514166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-326" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzI5LTUtMS0xLTI2NjM1_a62c8ccc-f1a6-4247-b9a2-d8a0372962a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,333</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-327" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMwLTEtMS0xLTI2NjM1_3497659e-eb7b-4d60-975e-e7531257f36c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">502</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-328" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMwLTMtMS0xLTI2NjM1_bceb7593-4cfa-4db7-af41-5e67732ac962" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">123</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-329" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMwLTUtMS0xLTI2NjM1_6abad2e3-bee8-4157-86c9-1989b92673f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-330" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMxLTEtMS0xLTI2NjM1_29918993-0779-4d87-b969-d71a93e0c036" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,764</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-331" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMxLTMtMS0xLTI2NjM1_e33619d0-7000-483b-849a-d8313ea81100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61,381</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-332" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMxLTUtMS0xLTI2NjM1_5ba8026b-77e2-4090-b36e-a502e551550e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,255</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-333" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMyLTEtMS0xLTI2NjM1_86171c2a-72e5-4b54-8fde-70c87bfc526f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-334" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMyLTMtMS0xLTI2NjM1_9e16fb8a-01b2-4e66-97c4-14dfa110eb2f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-335" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMyLTUtMS0xLTI2NjM1_d1d87099-411f-4cc0-b408-2862a50c3623" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-336" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMzLTEtMS0xLTI2NjM1_1bfbef6f-b0db-4b30-a4e0-826bfee511a0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,948</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-337" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMzLTMtMS0xLTI2NjM1_8f2c9df0-5e8a-4c6e-a6c3-e7d9b17ff638" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,704</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-338" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzMzLTUtMS0xLTI2NjM1_714eed18-6467-46b5-a979-49b455643a5c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,666</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-339" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM0LTEtMS0xLTI2NjM1_ec787e7d-6840-4cbb-ad75-1645c5f3bd37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,213</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-340" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM0LTMtMS0xLTI2NjM1_4ff06dff-2127-4682-a11a-09cef3fa1eb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,509</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8071de4bb91440b9adb67a4f284b30fe_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-341" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM0LTUtMS0xLTI2NjM1_9d2c80ce-e486-4ef4-8c9f-5bb1850a1ec7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,843</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-342" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM1LTEtMS0xLTI2NjM1_e2d9534c-8833-48c9-b2c2-770ba4b96090" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68,161</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-343" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM1LTMtMS0xLTI2NjM1_040bb1bb-b086-467e-8892-18023c465533" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,213</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-344" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM1LTUtMS0xLTI2NjM1_617152cd-cb52-428c-8dea-fe0dfa8874eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,509</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of right-of-use asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="fact-identifier-345" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM3LTEtMS0xLTI2NjM1_3f0aac02-f26d-4022-abeb-c82446f12282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="fact-identifier-346" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM3LTMtMS0xLTI2NjM1_738ef06a-331a-48dd-9003-9459a5f1f660" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-347" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM3LTUtMS0xLTI2NjM1_e9261298-bd4d-493f-bbad-143cfc05ba15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,173</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="fact-identifier-348" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM4LTEtMS0xLTI2NjM1_e6eb778c-791d-40a1-96b9-28d88dcc20e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">554</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="fact-identifier-349" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM4LTMtMS0xLTI2NjM1_4b4c2c48-6fe9-46d9-80d5-b549616ecabc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">490</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="fact-identifier-350" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM4LTUtMS0xLTI2NjM1_0dfc1114-1360-44d0-8308-113c8a3d0904" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">170</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount in connection with issuance of debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="alpn:IssuanceOfDebtDiscount" format="ixt:fixed-zero" scale="3" id="fact-identifier-351" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM5LTEtMS0xLTI2NjM1_155a69e4-7f42-4774-8896-3350ab511e1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="alpn:IssuanceOfDebtDiscount" scale="3" id="fact-identifier-352" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM5LTMtMS0xLTI2NjM1_2f6de2fc-5888-4a4b-8fbb-9fef63b195fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">334</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="alpn:IssuanceOfDebtDiscount" format="ixt:fixed-zero" scale="3" id="fact-identifier-353" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjMvZnJhZzo2MmJiMWE2ZjViYWI0YTRiYTJhZGY4NTNlNzY2Yjk4Yy90YWJsZToxNmZiNDk0MjA4YzY0ODM0YjE3YzI3YTZiNGU3MTUxMC90YWJsZXJhbmdlOjE2ZmI0OTQyMDhjNjQ4MzRiMTdjMjdhNmI0ZTcxNTEwXzM5LTUtMS0xLTI2NjM1_cae19af7-27dd-41bd-a675-82646c1330a0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_166"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:9pt;text-indent:29.25pt"><span><br></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_169"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="fact-identifier-354" continuedat="i7b93635b73d84e6aa21888174c8bbe94" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNjkvZnJhZzpmNTIzN2U4NTBjODE0MWVkYWY5ZTc5ZTZhMmY4MGRjMi90ZXh0cmVnaW9uOmY1MjM3ZTg1MGM4MTQxZWRhZjllNzllNmEyZjgwZGMyXzE2MDk_c349d4d1-3d96-4130-bfff-96cc3212540c" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Description of Business</ix:nonnumeric></span></span></div><span><ix:continuation id="i7b93635b73d84e6aa21888174c8bbe94" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpine Immune Sciences, Inc. (the Company, Alpine, we, us, or our), together with its consolidated subsidiaries, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Our approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. We believe our strategies are capable of meaningfully modulating the human immune system and significantly improving outcomes in patients with serious diseases. We were incorporated under the laws of the State of Delaware and are headquartered in Seattle, Washington. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A novel strain of coronavirus, SARS-CoV-2 (COVID-19), was first reported in December 2019, and subsequently declared a global pandemic by the World Health Organization in March 2020. As a result of the COVID-19 outbreak, many companies have experienced disruptions in their operations and in markets served. We have implemented some and may take additional temporary precautionary measures intended to help ensure the well-being of our employees and minimize business disruption. We considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts to our results of operations and financial position </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> December&nbsp;31, 2021. The full extent of the future impacts of the continuing COVID-19 outbreak on our operations is uncertain and may adversely impact our business, including our clinical trials.</span></div></ix:continuation></span><div id="i75d4456fb1ed409bb59167bcf5c6f56b_172"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="fact-identifier-356" continuedat="id15fb454661f4d3a96e306fa22bece47" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzIy_f02456a5-7bd1-4b85-ab73-7bdbf2810592" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Summary of Significant Accounting Policies</ix:nonnumeric></span></span></div><span><ix:continuation id="id15fb454661f4d3a96e306fa22bece47" continuedat="iba82ec71d4b24fdb807171aee74be5e3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="fact-identifier-358" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzU1_e96e9522-ee49-4b09-beb1-be5dea1f927a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) and generally accepted accounting principles in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Significant estimates inherent in the preparation of the accompanying consolidated financial statements include those used for revenue recognition, accruals for clinical trial activities and other accruals, and the estimated fair value of equity-based awards. We base our estimates and assumptions on historical experience when available and on various factors we believe to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="fact-identifier-359" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4Mjk2_d063113c-ad31-49dc-8ac9-6812d4411379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include the financial position and results of operations of Alpine Immune Sciences, Inc. and our wholly owned operating company and subsidiary, AIS Operating Co., Inc., and our wholly-owned subsidiary, Alpine Immune Sciences Australia PTY LTD. All inter-company balances and transactions have been eliminated in consolidation.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="fact-identifier-360" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4Mjk3_ed215ef6-449d-46a6-930b-3ad25a4ca473" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as&nbsp;<span><ix:nonfraction unitref="segment" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-361" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE0NjQ_9802fd95-3a7b-45f8-9650-c13c9de3c875" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span>&nbsp;operating segment and use cash flow as the primary financial measure to manage our business.</span></div></ix:nonnumeric></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="fact-identifier-362" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4Mjk0_0a342a79-a17a-4af1-9c23-bc96bf69bcb4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Restricted Cash</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking and interest-bearing accounts, and highly liquid money market funds.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents cash drawn on our line of credit used to establish collateral to support the security deposit on our operating lease to rent office and laboratory space in Seattle, Washington.</span></div></ix:nonnumeric></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="fact-identifier-363" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzE4_6e1a6a37-7d57-4dbb-887b-84c9840e1ad1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Periodically, we maintain deposits in financial institutions in excess of government insured limits. We believe we are not exposed to significant credit risk as our deposits, which are held at financial institutions, are high credit quality securities such as money market funds, U.S. Treasury securities, and commercial paper. To date, we have not realized any losses on these deposits.</ix:nonnumeric></span></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="iba82ec71d4b24fdb807171aee74be5e3" continuedat="ia64eb351d5d04fb98d83524e49abf7ad" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="fact-identifier-365" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzEx_82bfebbe-3e55-457b-9cb0-f82c69fbd2b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments include funds invested in highly liquid money market funds, U.S. Treasury securities, commercial paper, and corporate debt securities with a final maturity of each security of less than <span><ix:nonnumeric contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="fact-identifier-366" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzI2ODQ_117c2143-dd13-4a8f-80bc-3b554189b6e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span>. These investments are classified as available-for-sale debt securities, which are recorded at fair value based on quoted prices in active markets. We classify our investments maturing within one year of the reporting date as short-term investments.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the estimated fair value of a debt security is below its amortized cost basis, we evaluate whether it is more likely than not that we will sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. A credit loss exists if the present value of expected cash flows is less than the amortized cost basis of the security. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in other comprehensive income (loss). Purchase premiums and discounts are recognized as interest income using the interest method over the terms of the securities. Realized gains and losses and declines in fair value deemed to be other than temporary are reflected in the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using the specific-identification method.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="fact-identifier-367" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4Mjg5_ceafdd00-8f05-407d-9660-baaaf8b351d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzQyMzc_f6dd7d1f-e6bd-4216-a7b6-14c223c6ef62"><span><ix:nonnumeric contextref="i3122bde756bb405da9845b0b4487e083_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="fact-identifier-368" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzQyMzc_f6dd7d1f-e6bd-4216-a7b6-14c223c6ef62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">three</ix:nonnumeric></span></span> to <span><ix:nonnumeric contextref="i24fe921914f34cc882da3945c9ad85cc_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="fact-identifier-369" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzQyNDM_f0bef040-2c3a-4047-aa9a-a616dac32ce4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five years</ix:nonnumeric></span>, while leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Maintenance and repairs are expensed as incurred. Major improvements are capitalized as additions to property and equipment.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="fact-identifier-370" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4Mjk5_ecc52ee3-cab8-448a-966f-34cc7ffc6201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-lived Assets</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. If the carrying value exceeds the undiscounted future cash flows estimated to result from the use and eventual disposition of the asset, we write down the asset to its estimated fair value. Impairment is assessed by comparing the undiscounted cash flows expected to be generated by the asset to its carrying value. We did not record any impairments in the years ended December&nbsp;31, 2021, 2020 or 2019.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="alpn:AccruedLiabilitiesPolicyPolicyTextBlock" id="fact-identifier-371" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzAw_21e14b8a-7a29-4e33-9781-b8a024b3c32f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Liabilities</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate accruals for professional services and research and development expenses. This process involves reviewing contracts and vendor agreements and communicating with applicable personnel to identify services that have been performed on our behalf. We estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We estimate accrued liabilities as of each balance sheet date based on known facts and circumstances.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, we have not experienced any significant adjustments to our estimates.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="fact-identifier-372" continuedat="ibb80a137f0484c20b79b7e2ace6ad7ec" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzUx_bfbde895-2055-45d4-bda8-797315866389" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our leases under Accounting Standards Codification (ASC) 842, Leases. Under this guidance, we applied the practical expedients regarding the identification of leases, lease classification, indirect costs, and the combination of lease and non-lease components. Arrangements meeting the definition of a lease are classified as operating or financing leases, and are recorded on the consolidated balance sheet as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or our incremental borrowing rate. As we do not know the lessors implicit rate, we use our incremental borrowing rate at the commencement date of the lease in determining the present value of lease payments. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the right-of-use asset results is front-loaded expense over the lease term. Variable lease expenses are recorded when incurred.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="ia64eb351d5d04fb98d83524e49abf7ad" continuedat="ia7b7c8651da44df3a5fda2528e160255" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ibb80a137f0484c20b79b7e2ace6ad7ec" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In calculating the right-of-use asset and lease liability, we elected to combine lease and non-lease components. We exclude short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognize rent expense on a straight-line basis over the lease term.</ix:continuation></span> </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="fact-identifier-375" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzYw_44a75efc-368e-4b44-a835-1489cf30db76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate all of our financial instruments, including prefunded warrants and warrants to purchase common stock, to determine if such instruments are derivatives or contain&nbsp;features qualifying as embedded derivatives.&nbsp;For derivative financial instruments accounted for as liabilities, the derivative instrument&nbsp;is initially recorded at its fair value and is then re-valued at each reporting date, with changes in&nbsp;the fair value reported in the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We use the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. We do not use derivative instruments to hedge exposures to cash flow, market, or&nbsp;foreign currency risks.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="fact-identifier-376" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzU3_115b3d9f-4cf0-49c3-9d71-89c436f57377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our steps for recognizing revenue consist of;&nbsp;(1) identifying the contract,&nbsp;(2) identifying the performance obligations as either distinct or bundled goods and services,&nbsp;(3) determining the transaction price associated with each performance obligation for which we expect to be entitled in exchange for transferring such goods and services,&nbsp;(4) allocating the transaction price to the performance obligations in the contract and&nbsp;(5) recognizing revenue upon satisfaction of performance obligations.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreements principally contain multiple performance obligations, which may include (1)&nbsp;grants of, or options to obtain, intellectual property licenses; (2)&nbsp;research and development services; and/or (3) manufacturing or supply services. Payments typically received under these arrangements include one or more of the following: non-refundable upfront license fees, option exercise fees, payment for research and/or development efforts, amounts due upon the achievement of specified objectives, and/or royalties on future product sales. Our revenue is primarily derived from our collaboration agreements with Adaptimmune Therapeutics plc (Adaptimmune), AbbVie Ireland Unlimited Company (AbbVie), and Horizon Therapeutics Ireland DAC (Horizon). See further discussion of our collaboration agreements in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_199" tabindex="18">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate revenue to each performance obligation based on its relative stand-alone selling price. We generally determine stand-alone selling prices at the inception of the contract based on our best estimate of what the selling price would be if the deliverable was regularly sold by us on a stand-alone basis. Payments received prior to satisfying the relevant revenue recognition criteria are recorded as deferred revenue in the accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and recognized as revenue when the related revenue recognition criteria are met. We recognize revenue under our collaboration agreements by using a cost-based input method to measure progress toward completion of the performance obligation, including employee hours contributed to each performance obligation, and to calculate the corresponding revenue to recognize each period.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreements provide for non-refundable milestone payments. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved. A milestone is considered substantive when the consideration payable to us for such milestone (1)&nbsp;is consistent with our performance necessary to achieve the milestone or the increase in value to the collaboration resulting from our performance; (2)&nbsp;relates solely to our past performance; and (3)&nbsp;is reasonable relative to all of the other deliverables and payments within the arrangement. In making this assessment, we consider all facts and circumstances relevant to the arrangement, including factors such as the scientific, regulatory, commercial, and other risks that must be overcome to achieve the milestone, the level of effort and investment required to achieve the milestone and whether any portion of the milestone consideration is related to future performance or deliverables.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review the contributed employee hours and progress towards completion for each performance obligation under our collaboration agreements, and adjust the revenue recognized to reflect changes in assumptions relating to the estimated satisfaction of the performance obligation. Revenue recognition may be accelerated in the event of early termination of programs or if our expectations change. Alternatively, revenue recognition may be decelerated if programs are extended or delayed. While such changes to our estimates have no impact on our reported cash flows, the timing of revenue recorded in future periods could be materially impacted.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="fact-identifier-377" continuedat="i53492660a9ef4eb1b5240f23b3729fb3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzQ3_8debbc3b-991b-4bb6-b938-e1f6d4e18899" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs include personnel costs, clinical trials, external contract research and development expenses, raw materials, drug product manufacturing costs and </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="ia7b7c8651da44df3a5fda2528e160255" continuedat="i6f29dd338423493588898653641f4659" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i53492660a9ef4eb1b5240f23b3729fb3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">allocated overhead  including depreciation, rent and utilities. Research and development costs that are paid in advance of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</ix:continuation></span></span></div><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="fact-identifier-380" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzA0_18467c05-0838-416b-9148-0b7be69fdcc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation is recognized for all share-based payments based on the estimated fair value as of the date of grant. The fair value of our stock options is calculated using the Black-Scholes option pricing model, which requires judgmental assumptions including volatility, risk-free interest rate, expected term and dividend yield. The fair value of restricted stock units (RSUs) is based on the closing price of our common stock on the award date. Stock-based compensation is recognized over the requisite service period of the awards, usually the vesting period, on a straight-line basis. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, the related stock-based compensation is recognized as expense when it is probable the milestone will be met. We recognize forfeiture of awards as they occur rather than estimating the expected forfeiture rate.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="fact-identifier-381" continuedat="i960488bc06cb4ee4b7261b021afd5122" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzMz_36b0a63a-71ed-44b3-98a7-12a1aadfe213" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the consolidated financial statement and tax bases of assets and liabilities at the applicable enacted tax rates. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain.</span></div></ix:nonnumeric></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i960488bc06cb4ee4b7261b021afd5122" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">We recognize the tax benefit from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax position is measured based on the largest benefit that has a greater than <span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="alpn:MinimumPercentageOfIncomeTaxBenefitRealizedOnSettlement" scale="-2" id="fact-identifier-383" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE1MDkw_cb231f4c-b55c-489c-b98a-3ed1ea2eacdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% likelihood of being realized upon ultimate settlement. We recognize interest and penalties related to income tax matters in income tax expense if incurred.</ix:continuation></span> </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="fact-identifier-384" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzUy_45013f81-1d58-41a8-ad6f-784cab07c43c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is comprised of net loss and certain changes in equity excluded from net loss. For the years ended December&nbsp;31, 2021, 2020, and 2019, other comprehensive loss consisted of unrealized gains and losses on our investments and unrealized gains and losses on foreign currency translation.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="fact-identifier-385" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4Mjg3_152d5998-d1b9-4c10-b9a5-54baf1dc0401" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly-owned Australian subsidiary uses the Australian dollar as its functional currency. All assets and liabilities related to this subsidiary are translated using period-end exchange rates and revenues and expenses are translated at average exchange rates for the year. Translation adjustments are included as components of comprehensive income (loss) in the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonnumeric></span><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="fact-identifier-386" continuedat="i9bb53c21d14d44f4bce2a055f06a8cdd" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzIvZnJhZzo4ZjYxNTA4NDRhNjA0NTAzYTkyYmRhMzUyNTFjOTdmMi90ZXh0cmVnaW9uOjhmNjE1MDg0NGE2MDQ1MDNhOTJiZGEzNTI1MWM5N2YyXzE4MzA3_54bd0c03-d117-49eb-a18c-a77e6f532add" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Recently Adopted Accounting Pronouncements</ix:nonnumeric></span></span></div></ix:continuation></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i6f29dd338423493588898653641f4659" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i9bb53c21d14d44f4bce2a055f06a8cdd" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also improves consistent application by clarifying and amending existing guidance. The standard is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020. We adopted this standard on January 1, 2021, and concluded that the adoption of the standard did not have a material impact on our consolidated financial statements and related disclosures.</ix:continuation></span></ix:continuation></span> </span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_175"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="fact-identifier-389" continuedat="i0af5b1efb4c14135b27c7b4402060d2e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzk3NQ_84a433f0-99df-4962-9358-159033b8d479" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="fact-identifier-390" continuedat="ia3bb306fdc814065b2808fe442114946" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzk4MQ_c6d3a740-3614-4519-9b93-648c76e8a388" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Net Loss Per Share</ix:nonnumeric></span></ix:nonnumeric></span></span></div><span><ix:continuation id="i0af5b1efb4c14135b27c7b4402060d2e" continuedat="i2abc465c4df54b289d248cf6c6da634d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ia3bb306fdc814065b2808fe442114946" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period.</ix:continuation></span> </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net loss per share for the year ended December 31, 2021 reflects <span><ix:nonfraction unitref="shares" contextref="i364f36976add441091096711347137c1_D20210901-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-393" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzEwOTk1MTE2MjkwMjE_b85a92ee-cb9a-4449-8f74-ebb7d737f489" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,489,357</ix:nonfraction></span> shares of our common stock issued pursuant to a private placement financing completed in September 2021 and <span><ix:nonfraction unitref="shares" contextref="i2e6f753d91fb4814bccc6c4706af2805_D20211201-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-394" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzE2NDkyNjc0NDM5MzA_5d94fde0-f44f-4fa3-8066-7b6693214f6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">951,980</ix:nonfraction></span> shares of our common stock issued in December 2021 pursuant to a private placement financing with Horizon. The net loss per share for the year ended December 31, 2020 reflects <span><ix:nonfraction unitref="shares" contextref="i9d3c61b57ce24a41bdf082b485b48a9e_D20200701-20200731" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-395" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzIzNA_7cec9120-1b22-448b-8659-d4bc80fa4793" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,139,610</ix:nonfraction></span> shares of our common stock issued pursuant to the securities offering completed in July 2020. The net loss per share for the year ended December 31, 2019 reflects <span><ix:nonfraction unitref="shares" contextref="i795c5e13955e498abdbdcd24bf7fc219_D20190101-20190131" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-396" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzQwMA_ad8768d5-8ff5-48c2-b0c7-34dda634c116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,706,700</ix:nonfraction></span> shares of our common stock issued pursuant to a private placement financing completed in January 2019. The increased number of shares issued in these periods has affected the year-over-year comparability of our net loss per share calculations.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i2abc465c4df54b289d248cf6c6da634d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="fact-identifier-398" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90ZXh0cmVnaW9uOmViNGViMmU0MDg5MzRlZDk5MmJiMjUyOGE3MjE0Y2RiXzk4Mw_99627c42-bb57-46b2-8f5a-d706aa114cd8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stock issuable upon the conversion or exercise of the following dilutive securities has been excluded from the diluted net loss per share calculation because their effect would have been anti-dilutive. Diluted net loss per share, therefore, does not differ from basic net loss per share for the periods presented.</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic36dad9700ed425c910c0c97b97eb15c_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="fact-identifier-399" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzMtMS0xLTEtMjY2MzU_a0bfd2fb-e344-4011-a527-3dfafae79371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,666,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i12569b1fee504a8b803f445721db26f3_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-400" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzMtMy0xLTEtMjY2MzU_2fca2790-8495-4444-b25a-cbc790f3b82a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,673,551</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id1ee8e3f455b4c7ab91aba027b3db616_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-401" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzMtNS0xLTEtMjY2MzU_6070c06a-1fac-4a52-8742-b5e7683f2362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,877,094</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prefunded warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id3fed388f6ee430ea4f84b9776b51a5d_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="fact-identifier-402" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzQtMS0xLTEtMzYwODQ_871e83c5-fdcb-44c9-abc3-18e8444fd9aa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,182,197</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic3b02939f14340fdbe39ab5b7f6969ef_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-403" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzQtMy0xLTEtMzYwODQ_7f47efaf-df18-4a45-bacd-cbfbf7c2995d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">790,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i96ba1ec08180409aba13f53843f88603_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="fact-identifier-404" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzQtNS0xLTEtMzYwODQ_2a58445a-1145-4003-81ba-44735afdd4a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options and RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="idccd5aaa47fe4bfa85f50ff3adf5e175_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="fact-identifier-405" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzQtMS0xLTEtMjY2MzU_f26607a2-f9a4-41e7-b3c9-0ac7b630a4f6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,877,309</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i782ef4bf21d14891ac5cb6726bb3f733_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-406" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzQtMy0xLTEtMjY2MzU_e3b13e8b-18c9-4315-b6a2-001557ccf34f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,175,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic227d35d6112472495b45a85c929140e_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-407" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzQtNS0xLTEtMjY2MzU_dc31dbb6-bde9-4520-8a5b-27722bded4b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,252,144</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-408" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzUtMS0xLTEtMjY2MzU_bed91082-6826-4084-9869-09013d6c9ba4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,725,941</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-409" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzUtMy0xLTEtMjY2MzU_8843b215-063b-4275-8e60-0b4f546d4ce0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,639,606</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-410" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzUvZnJhZzplYjRlYjJlNDA4OTM0ZWQ5OTJiYjI1MjhhNzIxNGNkYi90YWJsZTo3NTEwNTM0NmU2OWI0NTRkODk2MzMwNzE1NGFkZWMzMS90YWJsZXJhbmdlOjc1MTA1MzQ2ZTY5YjQ1NGQ4OTYzMzA3MTU0YWRlYzMxXzUtNS0xLTEtMjY2MzU_595ca59f-71e1-47f9-a0a9-e871ae2d2e02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,129,238</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div id="i75d4456fb1ed409bb59167bcf5c6f56b_178"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="fact-identifier-411" continuedat="i2219432db8b94491b1e14a4203dd729b" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzM3NQ_7a806614-b16b-4c3c-8c16-066ac81b7527" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Cash Equivalents and Investments</ix:nonnumeric></span></span></div><span><ix:continuation id="i2219432db8b94491b1e14a4203dd729b" continuedat="i87c0438b55f64cddb0f6cdcfcef5f773" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="fact-identifier-413" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzM3Ng_001a79ca-2545-4495-a641-83c91351cb27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost and fair value of our cash equivalents and investments are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br>unrealized<br>gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br>unrealized<br>losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair market<br>value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i334c78b1bed8469a9dfb31129440ffde_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-414" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzItMS0xLTEtMjY2MzU_79b28ef5-a3ae-4093-b4e7-b0551a703f5c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,277</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i334c78b1bed8469a9dfb31129440ffde_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-415" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzItMy0xLTEtMjY2MzU_171491a2-d88a-4635-9fec-567730c1b44c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i334c78b1bed8469a9dfb31129440ffde_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-416" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzItNS0xLTEtMjY2MzU_7f82d837-bc71-49f5-8baf-c8a5e387fb77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i334c78b1bed8469a9dfb31129440ffde_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-417" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzItNy0xLTEtMjY2MzU_e9394070-c3a3-448c-b754-64f20f41242c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,277</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic1646109f1204cd68f023c88a1e22901_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-418" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzMtMS0xLTEtMjY2MzU_936f6283-937d-497f-9ed6-e390d55d5747" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,006</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic1646109f1204cd68f023c88a1e22901_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="fact-identifier-419" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzMtMy0xLTEtMjY2MzU_7bbaf60f-89c3-499d-a97d-f0eba908741e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ic1646109f1204cd68f023c88a1e22901_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="fact-identifier-420" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzMtNS0xLTEtMjY2MzU_6e5ad261-fe0f-4667-aa86-b1eaf8cd684d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic1646109f1204cd68f023c88a1e22901_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-421" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzMtNy0xLTEtMjY2MzU_27e5bd49-af44-40c0-9de3-c079366a9399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,907</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a34d14730364f2089358509b6c6e251_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-422" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzQtMS0xLTEtMjY2MzU_a1918406-a756-4e95-8add-36b04e24467d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,492</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a34d14730364f2089358509b6c6e251_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="fact-identifier-423" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzQtMy0xLTEtMjY2MzU_4be98c98-9af1-41a6-9574-c0fc6e847f9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i1a34d14730364f2089358509b6c6e251_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="fact-identifier-424" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzQtNS0xLTEtMjY2MzU_f6a3d0c5-8681-4021-a64b-05f670e9908e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">139</ix:nonfraction></span>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a34d14730364f2089358509b6c6e251_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-425" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzQtNy0xLTEtMjY2MzU_53959700-880d-4a9d-a537-1ff596ecea87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,355</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-426" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzUtMS0xLTEtMjY2MzU_1c6884b6-8def-4849-a30f-7c09f39e3e3e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">197,775</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="fact-identifier-427" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzUtMy0xLTEtMjY2MzU_78c974ff-4c85-4c8c-b162-da08bf497c09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="fact-identifier-428" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzUtNS0xLTEtMjY2MzU_62678d3b-66de-4edf-867e-f296804d7eda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">239</ix:nonfraction></span>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-429" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzUtNy0xLTEtMjY2MzU_ee32460e-0846-4e87-aad9-d70c7a802ff5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">197,539</ix:nonfraction></span>&nbsp;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i658455ca7f404340acb649949f14bfb5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-430" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzgtNy0xLTEtMjY2MzU_1bfdd88e-e9f8-4617-ad49-ff2d6ac713f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,277</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if1f44a1b35c14402a0cfb87615de07a2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-431" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzktNy0xLTEtMjY2MzU_9ca94228-6957-4496-a8ca-641dee36c31c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">94,396</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3c7ffc09728149089985212baf293ad7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-432" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzEwLTctMS0xLTI2NjM1_fb4fd4c9-051e-4e10-8d15-4bd61ff34d09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,866</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-433" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTo0Zjc1YWI0ZDM0MWE0NDU5YmNkZGJiNGQyZTE4YWRiNi90YWJsZXJhbmdlOjRmNzVhYjRkMzQxYTQ0NTliY2RkYmI0ZDJlMThhZGI2XzExLTctMS0xLTI2NjM1_c051e48b-007a-41ab-a923-65c038f15d04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">197,539</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br>unrealized<br>gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br>unrealized<br>losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair market<br>value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0d32d5fe12b641829dad30499431b82b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-434" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzItMS0xLTEtMjY2MzU_6b2e218a-4dbc-408c-992c-008a6e8244a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,424</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0d32d5fe12b641829dad30499431b82b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-435" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzItMy0xLTEtMjY2MzU_454ab491-d25d-4bf4-9ee0-c4aa211a21a0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0d32d5fe12b641829dad30499431b82b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-436" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzItNS0xLTEtMjY2MzU_424c1c08-2871-46d8-a504-081e87feb7b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0d32d5fe12b641829dad30499431b82b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-437" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzItNy0xLTEtMjY2MzU_dc9e6e9d-03f3-4f61-8bf9-732ca65df2ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,424</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefb6ee89584f4fd887ae10408d3487f5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-438" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzMtMS0xLTEtMjY2MzU_656cd070-eadd-490e-afa6-762f59c9e4b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,122</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefb6ee89584f4fd887ae10408d3487f5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="fact-identifier-439" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzMtMy0xLTEtMjY2MzU_3597feb7-5ad5-4e97-aabb-4cc3b81b608b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefb6ee89584f4fd887ae10408d3487f5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="fact-identifier-440" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzMtNS0xLTEtMjY2MzU_a2ec5a2f-6f18-4a16-9ca3-51d0891a0400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefb6ee89584f4fd887ae10408d3487f5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-441" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzMtNy0xLTEtMjY2MzU_fab009f0-a18b-4454-be47-03876d862d1e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,130</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if7d64fb4c1544495a5e0a6fcf0b6e8e3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-442" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzQtMS0xLTEtMjY2MzU_d91f164f-e968-44a9-b7cc-f1e594cc4b66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,047</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if7d64fb4c1544495a5e0a6fcf0b6e8e3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="fact-identifier-443" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzQtMy0xLTEtMjY2MzU_e4f0ed90-5669-465f-a233-8c0b61c1d976" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="if7d64fb4c1544495a5e0a6fcf0b6e8e3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="fact-identifier-444" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzQtNS0xLTEtMjY2MzU_a762f556-a2a6-4543-be61-db35abc2de3a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9</ix:nonfraction></span>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if7d64fb4c1544495a5e0a6fcf0b6e8e3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-445" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzQtNy0xLTEtMjY2MzU_ab107685-a4db-46b9-95e8-ed379c4b6b17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,040</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-446" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzUtMS0xLTEtMjY2MzU_bcdd38c7-01b8-4649-adf2-6e27a51d7a2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,593</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="fact-identifier-447" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzUtMy0xLTEtMjY2MzU_7a6cfc93-334d-49dd-8c2e-ffca69ee0143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="fact-identifier-448" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzUtNS0xLTEtMjY2MzU_abbf1736-aad2-40ca-9d81-086c5813add8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-449" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzUtNy0xLTEtMjY2MzU_7991d6ea-1eae-4403-b803-716df083f8b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,594</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibed046730d564d47bb4885ab0051af84_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-450" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzgtNy0xLTEtMjY2MzU_d2e699bf-51c7-4706-8082-ea68113b6fc0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,423</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i48d6a976adc64b91b2621f028a4d3d07_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-451" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzktNy0xLTEtMjY2MzU_571a8051-ca0d-458c-8a39-eb40d1a39cd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,622</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic4807bd0acb44a5b9307c98748f7ef66_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-452" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzEwLTctMS0xLTI5Mzc3_9d0d4fb6-e1bf-496e-935e-1251e6d93eec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,549</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-453" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90YWJsZTplZTc0NjkwM2M5MWM0MzkzYjJlMDMwN2MzMjVhMGZjZC90YWJsZXJhbmdlOmVlNzQ2OTAzYzkxYzQzOTNiMmUwMzA3YzMyNWEwZmNkXzEwLTctMS0xLTI2NjM1_3c0888cf-a421-48c5-b650-9b7207b8641f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,594</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i87c0438b55f64cddb0f6cdcfcef5f773" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">All investments held as of December&nbsp;31, 2021 and 2020 were classified as available-for-sale debt securities and had contractual maturities of less than <span><ix:nonnumeric contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="fact-identifier-455" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzI4NQ_3b93fd9f-774d-448d-8b47-d754bdbc421d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="iefc5e0f908c041b189c9615068048458_I20201231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="fact-identifier-456" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzI4NQ_43f71c0d-d2f9-447f-8243-accdcdcf54ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span></ix:nonnumeric></span>. There were <span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="fact-identifier-457" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzMwMA_667019d0-ef19-474f-ac70-3f9c0e726f90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="fact-identifier-458" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzMwMA_a01d8df4-9b05-4b1b-a4f7-f505829f2fa0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span> realized gains and losses on these securities for the periods presented. The aggregate fair value of available-for-sale debt securities in an unrealized loss position as of December&nbsp;31, 2021 was $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-459" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzEwOTk1MTE2Mjg0Njg_d63fa16a-e48a-4b73-b259-3c201362bbad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83.0</ix:nonfraction></span>&nbsp;million. We did <span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="0" id="fact-identifier-460" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzYwNDczMTM5NTY4Nzk_665ddfc5-c319-459c-9e85-6503fe2c1bf0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span>t have any investments in a continuous unrealized loss position for more than twelve months as of December&nbsp;31, 2021. Our available-for-sale debt securities are invested in highly liquid funds with high credit ratings that have a final maturity of <span><ix:nonnumeric contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="fact-identifier-461" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xNzgvZnJhZzpmYzA2NzlkZmViZTA0YjgxODUzOGZkYjFiZTZhMjZkOC90ZXh0cmVnaW9uOmZjMDY3OWRmZWJlMDRiODE4NTM4ZmRiMWJlNmEyNmQ4XzYwNDczMTM5NTY4ODc_b359cfdb-b3aa-46bf-ae13-cea9582bb0c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">two years</ix:nonnumeric></span> or less on the date of purchase. Unrealized losses on these investments were primarily due to changes in interest rates. We evaluated our investments that are in an unrealized loss position and believe it is more likely than not that we will hold these investments until maturity and will recover the amortized cost basis of these investments.</ix:continuation></span> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_181"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="fact-identifier-462" continuedat="if856a836bd504209abc9356dc4371dcd" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90ZXh0cmVnaW9uOmViOTBiZDRkNGMwODQ4MmM4OWFmODJjZWIyYjlhOWQyXzIwMzM_154dca58-71c4-4fd1-8397-d82ce95d0c24" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="fact-identifier-463" continuedat="i5a8f3c1218f448ecb7e38aed9a78d0f8" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90ZXh0cmVnaW9uOmViOTBiZDRkNGMwODQ4MmM4OWFmODJjZWIyYjlhOWQyXzIwMzY_71d045d9-a8c4-4035-9ce7-a3adde764302" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Fair Value Measurements</ix:nonnumeric></span></ix:nonnumeric></span></span></div><span><ix:continuation id="if856a836bd504209abc9356dc4371dcd" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i5a8f3c1218f448ecb7e38aed9a78d0f8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, restricted cash, receivables, accounts payable and accrued liabilities, which are recorded at invoiced amount or cost, approximate fair value based on the short-term nature of these financial instruments. Fair value is defined as the exchange price received for an asset or paid to transfer a liability, or an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, is as follows:</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&nbsp;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Observable inputs other than Level&nbsp;1 prices, such as quoted prices for similar assets or liabilities, quoted prices in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&nbsp;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Unobservable inputs supported by little or no market activity and significant to the fair value of the assets or liabilities.</span></div></ix:continuation></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021 and 2020, cash of $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-466" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90ZXh0cmVnaW9uOmViOTBiZDRkNGMwODQ4MmM4OWFmODJjZWIyYjlhOWQyXzEzMTA_2d7cf793-84f9-4bc8-b332-523e2907e265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17.6</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-5" name="us-gaap:Cash" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-467" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90ZXh0cmVnaW9uOmViOTBiZDRkNGMwODQ4MmM4OWFmODJjZWIyYjlhOWQyXzEzMTc_b38a8b26-2feb-4812-9327-ad2e5b830b99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.5</ix:nonfraction></span> million, respectively, is excluded from the fair value table below. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="fact-identifier-468" continuedat="i248d03ec9be74a5aa62d469f58e68e09" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90ZXh0cmVnaW9uOmViOTBiZDRkNGMwODQ4MmM4OWFmODJjZWIyYjlhOWQyXzIwMzQ_d22b525e-2324-44ab-921f-caadcacdc787" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonnumeric></span></span></div><span><ix:continuation id="i248d03ec9be74a5aa62d469f58e68e09" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9141ca2bcbe64bfb885d1dfae8aa3439_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-470" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzItMS0xLTEtMjY2MzU_136df301-17df-4982-86f4-8bc7ed0a49ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,277</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibdfb42ef083744e7a20a93a0c8c6ff53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-471" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzItMy0xLTEtMjY2MzU_a5c0ea84-4425-4285-be56-dc8118230072" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic6fd8694e2f04147863afe58bfc4314e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-472" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzItNS0xLTEtMjY2MzU_75fb2a32-d645-4b2c-ad34-45cc46c64b31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i334c78b1bed8469a9dfb31129440ffde_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-473" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzItNy0xLTEtMjY2MzU_359a1697-09ce-473c-8a58-e88675339e70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,277</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6d4d0b6fd1994501b7ce5646ed902dde_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-474" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzMtMS0xLTEtMjY2MzU_00183494-eb87-49c0-ad38-1f27e6e5983d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,907</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ica69f81c0ede414ea292931d80ed1ef8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-475" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzMtMy0xLTEtMjY2MzU_04059509-21b7-4bae-81c3-ee1389469f04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i65ced17734a944d3bd430e2451263ae9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-476" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzMtNS0xLTEtMjY2MzU_7a877695-3e48-4133-ae3b-dd7cada7f412" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i481ddd50b9d64bb695304ca870715b27_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-477" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzMtNy0xLTEtMjY2MzU_416cd3a3-09bd-47e0-8dbd-aabdd04526da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,907</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i77aaca15b9f8439ca646dac552bb0018_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-478" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzQtMS0xLTEtMjY2MzU_6f367000-4d8c-49f0-a804-4f4856a3edf9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6421e10a56a348f0a007ffa6e931a374_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-479" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzQtMy0xLTEtMjY2MzU_8ceb613e-6179-4605-a660-54140b5468fe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,355</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i88591b5adc104f998fe815b011629dcb_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-480" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzQtNS0xLTEtMjY2MzU_754d7602-6ba6-4c87-9ef3-026ef7208c67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a34d14730364f2089358509b6c6e251_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-481" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzQtNy0xLTEtMjY2MzU_57757fb4-3181-43fe-b6b6-b951b63830b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,355</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia663e0df8fd74120a4788d77e90ac526_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-482" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzUtMS0xLTEtMjY2MzU_7a12549f-bcae-44be-bd3e-77b914243d0a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,184</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8fc58f79a169438590808f9b221ae586_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-483" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzUtMy0xLTEtMjY2MzU_e7e0ec88-4a04-43e4-9ef8-91eee98ce8cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">117,355</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia03fa31b49fd4f8a91745ea634c73f08_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-484" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzUtNS0xLTEtMjY2MzU_d5fe36cb-e013-444c-a8a3-d478552fe14c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-485" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTpmYjY4ZDA4MWY5YTA0MWE2ODUyYWQ0OWRhMGJkOGJmYy90YWJsZXJhbmdlOmZiNjhkMDgxZjlhMDQxYTY4NTJhZDQ5ZGEwYmQ4YmZjXzUtNy0xLTEtMjY2MzU_1617f576-3e6e-4c89-84c7-32696168941a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">197,539</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1c8150d9fab84031b0c0f2067c50b126_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-486" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzItMS0xLTEtMjY2MzU_26351cc8-04e0-4148-8a16-fcdc35d8f86a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,424</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib90a98074ae246abb7d17c75e56556e0_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-487" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzItMy0xLTEtMjY2MzU_6b1fb439-bba6-423c-9043-aea5e2bd25e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9ba26f7978ab46908f569d30a877c023_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-488" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzItNS0xLTEtMjY2MzU_4c94622d-9482-43f2-909f-dbe8a75c6e3a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0d32d5fe12b641829dad30499431b82b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-489" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzItNy0xLTEtMjY2MzU_759c50d7-1c06-427a-9835-80529c620971" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,424</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury bills</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85e5dde8cd214c64ae36080fe04efda5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-490" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzMtMS0xLTEtMjY2MzU_9ef130ad-557d-43bb-9bf6-a01383ab517d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,130</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie36b74e37fdd4372a7a5f38e68c38503_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-491" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzMtMy0xLTEtMjY2MzU_486cfa4c-46b5-4707-b1da-54b3b249c71b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic4223d7cb5bc440ba61cd2a7dbd019a9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-492" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzMtNS0xLTEtMjY2MzU_cd4a7d52-5391-4e58-89a7-afe2bceb2c5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6b46f4d303c04132b6c19f6eeb3dd6a1_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-493" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzMtNy0xLTEtMjY2MzU_276c4a4b-c6f2-44eb-b5e5-ce4b3f4c0aa7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,130</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities and commercial paper</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6aff9044035a41e3920e055df6c75993_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-494" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzQtMS0xLTEtMjY2MzU_52d8bd71-1cd0-491c-a979-1ec980152bbc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64252761e6d44205991db3cd2c1470be_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-495" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzQtMy0xLTEtMjY2MzU_e3b39335-82dd-4127-a204-76df17972ec8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,040</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0755487af112435b8d7d8cfac801d1cd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-496" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzQtNS0xLTEtMjY2MzU_a3b69994-8c9c-4111-8ba9-b2717632a057" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if7d64fb4c1544495a5e0a6fcf0b6e8e3_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-497" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzQtNy0xLTEtMjY2MzU_6364d5b9-dfed-4912-8fe3-749fdf5fe7bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,040</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7e6e9f7d4b5342448544c11860e093f6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-498" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzUtMS0xLTEtMjY2MzU_56d1ccbb-e14d-4fc3-aaa2-335d77d05db9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,554</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i390feb44b2ac4712b2fae153aa1e274a_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-499" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzUtMy0xLTEtMjY2MzU_4dc92684-b741-47fd-b1e9-f7e5426a7700" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,040</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie24fdbc2559c481b82a63532a0a82f91_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="fact-identifier-500" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzUtNS0xLTEtMjY2MzU_dcce8c03-9d27-45de-878c-071d3ffee6db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-501" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODEvZnJhZzplYjkwYmQ0ZDRjMDg0ODJjODlhZjgyY2ViMmI5YTlkMi90YWJsZTo1MGE3NzAzMTM4Njk0OWE5ODgzYWM0ZGE5MWYwYmRjYy90YWJsZXJhbmdlOjUwYTc3MDMxMzg2OTQ5YTk4ODNhYzRkYTkxZjBiZGNjXzUtNy0xLTEtMjY2MzU_5a367401-65dc-4559-81cb-11dce97d7f89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,594</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:continuation></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 2 assets consist of commercial paper and corporate debt securities. We review trading activity and pricing for our available-for-sale securities as of the measurement date. When sufficient quoted pricing for identical securities is not available, we use market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.</span></div></ix:continuation></span><div id="i75d4456fb1ed409bb59167bcf5c6f56b_184"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="fact-identifier-502" continuedat="if421cd05d1414f83a8d33d0cb30771e6" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90ZXh0cmVnaW9uOmVlNTI5MjIzZTM4NjQ1NDM5OGJjMWM4Mjk2ZjQ3ZWM1XzE5Mw_d8a9d41f-3d43-483f-8517-7867219b6aab" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Property and Equipment</ix:nonnumeric></span></span></div><span><ix:continuation id="if421cd05d1414f83a8d33d0cb30771e6" continuedat="i3419982573a848d99cba6638520eb779" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="fact-identifier-504" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90ZXh0cmVnaW9uOmVlNTI5MjIzZTM4NjQ1NDM5OGJjMWM4Mjk2ZjQ3ZWM1XzE5MA_19b164f8-ec81-427d-b585-46255ea4b00d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and equipment, net, consists of the following (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia731b73192204033a92ad47db122bf32_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-505" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzItMS0xLTEtMjY2MzU_ec807423-6e21-41ff-b04f-b6ec08ac870d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,132</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i61ddc1e316434e84b1326d82b3e39515_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-506" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzItMy0xLTEtMjY2MzU_f8d8c253-575d-4a46-9f51-c623117362f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,604</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General equipment and furniture</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7e27e9c1efce41d2a4a50ebf8478bc90_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-507" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzMtMS0xLTEtMjY2MzU_be87eb22-add2-4850-ba6a-00bd7c3314db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">479</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ief221263101442d5b984c00cdc0175c4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-508" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzMtMy0xLTEtMjY2MzU_05b1d687-7143-4304-bff6-5e6761417580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">479</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i297ad02942cb436cb66fd0344a78c95b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-509" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzQtMS0xLTEtMjY2MzU_210fb8ad-7045-4c10-9415-47de1be92467" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">211</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i083b717b3e6849a9abad4799efac640c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-510" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzQtMy0xLTEtMjY2MzU_a039ac1b-e4f3-4c9c-918a-265f61ce9046" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">211</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaf472bbf7fde4eaaaaa52bb42e5283d7_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-511" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzUtMS0xLTEtMjY2MzU_9146558d-6c68-4da6-8872-60291271c913" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7a0ddfb5549d426e9d11b7347a03e9b6_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="fact-identifier-512" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzUtMy0xLTEtMjY2MzU_d060d9e8-2899-4a76-a08f-2beb45f9b42b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-513" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzYtMS0xLTEtMjY2MzU_c86dbcc9-c97c-4646-b5e0-b050cde51b22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,907</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-514" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzYtMy0xLTEtMjY2MzU_edf88319-4802-4220-b056-ca26d64ed283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,379</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-515" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzctMS0xLTEtMjY2MzU_cee9dd73-1a3c-4bb9-aabc-98752fd6d69c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,191</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-516" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzctMy0xLTEtMjY2MzU_b4561a52-03b1-4f55-b4dc-6d9dafdb5873" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,594</ix:nonfraction></span>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-517" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzgtMS0xLTEtMjY2MzU_bde209fa-3058-47cf-8f78-c4fff4cb15a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,716</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-518" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90YWJsZTpiOGQ2MzFjMmNjMDY0NWRhYTZmOWU1YTY4YTM5ZjVkYy90YWJsZXJhbmdlOmI4ZDYzMWMyY2MwNjQ1ZGFhNmY5ZTVhNjhhMzlmNWRjXzgtMy0xLTEtMjY2MzU_299062e8-a49f-4ab2-91c2-b3618d448155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,785</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-top:4pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i3419982573a848d99cba6638520eb779" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Depreciation expense was $<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-520" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90ZXh0cmVnaW9uOmVlNTI5MjIzZTM4NjQ1NDM5OGJjMWM4Mjk2ZjQ3ZWM1XzEyNw_bbe33720-64ff-42ba-826a-6ef01ed7f059" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">620,000</ix:nonfraction></span>, $<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-521" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90ZXh0cmVnaW9uOmVlNTI5MjIzZTM4NjQ1NDM5OGJjMWM4Mjk2ZjQ3ZWM1XzEzMQ_97e6084c-46d1-4d4b-a0ab-547bb7231cf4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">578,000</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-522" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODQvZnJhZzplZTUyOTIyM2UzODY0NTQzOThiYzFjODI5NmY0N2VjNS90ZXh0cmVnaW9uOmVlNTI5MjIzZTM4NjQ1NDM5OGJjMWM4Mjk2ZjQ3ZWM1XzEzOA_b869f825-edb1-43b7-b7c0-9658762f2d0a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">468,000</ix:nonfraction></span> for the years ended December&nbsp;31, 2021, 2020 and 2019, respectively.</ix:continuation></span></span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_187"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="fact-identifier-523" continuedat="idd670d3b9f934bb9a228de9dc65bc4cd" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODcvZnJhZzpjZGE2YTM4MjVlYWQ0NTYyYTcwZWIwNzYxMzNjZTZkMS90ZXh0cmVnaW9uOmNkYTZhMzgyNWVhZDQ1NjJhNzBlYjA3NjEzM2NlNmQxXzE3MTM_61ace8cc-93dc-47cb-9dcf-69ad195dd815" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Sale of Intangible Asset</ix:nonnumeric></span></span></div><span><ix:continuation id="idd670d3b9f934bb9a228de9dc65bc4cd" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we entered into an Option License Agreement (Option Agreement) with Laurel Venture Capital Ltd. (Laurel), which granted Laurel a limited license to evaluate the indefinite-life GSNOR inhibitor IPR&amp;D asset acquired as part of the merger with Nivalis in 2017. The IPR&amp;D represents the processes, expertise, and technology employed in the development of GSNOR inhibitors and Nivalis lead product candidate, cavosonstat. Under the Option Agreement, we received an upfront non-refundable payment of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i73042143305f4b2d8eb75ee413683cda_D20180201-20180228" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-525" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODcvZnJhZzpjZGE2YTM4MjVlYWQ0NTYyYTcwZWIwNzYxMzNjZTZkMS90ZXh0cmVnaW9uOmNkYTZhMzgyNWVhZDQ1NjJhNzBlYjA3NjEzM2NlNmQxXzU1OA_4722f203-baad-4298-a96a-7aa4768ec50e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75,000</ix:nonfraction></span>, which was recognized as revenue in our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into an Asset Purchase Agreement (Purchase Agreement) with Laurel and completed the sale of global rights to the GSNOR asset. Upon the sale of the GSNOR assets, we derecognized the full carrying value of the intangible asset. As consideration under the Purchase Agreement, we received a non-refundable closing payment of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="id5a92caa4df7494d86fa7ffb7621152c_D20180601-20180630" decimals="-3" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-526" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODcvZnJhZzpjZGE2YTM4MjVlYWQ0NTYyYTcwZWIwNzYxMzNjZTZkMS90ZXh0cmVnaW9uOmNkYTZhMzgyNWVhZDQ1NjJhNzBlYjA3NjEzM2NlNmQxXzkzMw_7ab7bd49-f601-4d43-a46c-51b01771a193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span>, which was accounted for as a purchase of our intangible asset. In June 2019, we recognized as revenue an additional payment of&nbsp;$<span><ix:nonfraction unitref="usd" contextref="ifa55a2e4dc214bc593f1a6e45e171b1f_D20190601-20190630" decimals="-3" name="alpn:AssetPurchaseAgreementMilestonePayment" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-527" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODcvZnJhZzpjZGE2YTM4MjVlYWQ0NTYyYTcwZWIwNzYxMzNjZTZkMS90ZXh0cmVnaW9uOmNkYTZhMzgyNWVhZDQ1NjJhNzBlYjA3NjEzM2NlNmQxXzEwNjQ_41363f99-b475-483e-ab38-9fb6d50efcd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">425,000</ix:nonfraction></span>, related to the asset purchase. In addition, we are eligible to receive milestone payments of up to&nbsp;$<span><ix:nonfraction unitref="usd" contextref="id9d001249bd54a16b1d98d98076401b0_D20211201-20211231" decimals="-5" name="alpn:AssetPurchaseAgreementPotentialMilestonePaymentsEligibleToBeReceived" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-528" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xODcvZnJhZzpjZGE2YTM4MjVlYWQ0NTYyYTcwZWIwNzYxMzNjZTZkMS90ZXh0cmVnaW9uOmNkYTZhMzgyNWVhZDQ1NjJhNzBlYjA3NjEzM2NlNmQxXzExNjc_db9e3ca0-ec80-4960-9197-3a995f0e1c51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span> million, in the aggregate upon satisfaction by Laurel of certain regulatory approval milestones. We will also be eligible to receive royalty payments equal to a low single-digit percentage rate of worldwide net sales of any approved products.</span></div></ix:continuation></span><div id="i75d4456fb1ed409bb59167bcf5c6f56b_190"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="fact-identifier-529" continuedat="i0ca5438f431542e48402c2f43468bec6" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90ZXh0cmVnaW9uOjkxODg0ZWFmMTJiNTRlMjliZjYxOGJiZjA4ODMzZGE4XzE5NA_e16d6cae-83ad-4e20-b2cb-6b976412bf7d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Additional Balance Sheet Information</ix:nonnumeric></span></span></div><span><ix:continuation id="i0ca5438f431542e48402c2f43468bec6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="fact-identifier-531" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90ZXh0cmVnaW9uOjkxODg0ZWFmMTJiNTRlMjliZjYxOGJiZjA4ODMzZGE4XzIwMA_ceb5e3e6-a658-4f4b-a394-987871ad9124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="alpn:PrepaidResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-532" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzItMS0xLTEtMjY2MzU_576ae017-2ca5-4955-84b8-a13c1df16e15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,315</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="alpn:PrepaidResearchAndDevelopment" scale="3" id="fact-identifier-533" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzItMy0xLTEtMjY2MzU_dd9f1812-b1d0-4613-a81c-291c35c59c87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">517</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="fact-identifier-534" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzMtMS0xLTEtMjY2MzU_7265f2f6-265b-4a2b-a5bb-0ec760b36cfb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">454</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="fact-identifier-535" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzMtMy0xLTEtMjY2MzU_c89de846-c9e8-4653-966f-8595fb7bbdbb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">447</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="fact-identifier-536" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzQtMS0xLTEtMjkzODA_74b3cf07-b240-4fe0-8511-3757fd78eaea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">352</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:fixed-zero" scale="3" id="fact-identifier-537" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzQtMy0xLTEtMjkzODA_6ee9ead2-a4ee-46a2-8be7-1e0783967dec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="alpn:TenantImprovementAllowanceReceivable" format="ixt:fixed-zero" scale="3" id="fact-identifier-538" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzQtMS0xLTEtMjY2MzU_453c01f4-c423-446e-a52c-f89ad27d0bdb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="alpn:TenantImprovementAllowanceReceivable" scale="3" id="fact-identifier-539" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzQtMy0xLTEtMjY2MzU_4f7706c7-d665-4ed4-b17b-dee53d1ce4bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">84</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="fact-identifier-540" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzUtMS0xLTEtMjY2MzU_ec399853-964c-4f95-9f5b-c5499643d2f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">266</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="fact-identifier-541" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzUtMy0xLTEtMjY2MzU_c3b76ae6-be4c-4fee-9e36-29781f05bcc9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="fact-identifier-542" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzYtMS0xLTEtMjY2MzU_decdc884-5692-4e6c-8c23-b76ca81267da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">323</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="fact-identifier-543" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzYtMy0xLTEtMjY2MzU_87e5d8f0-8858-458f-b51d-a95e37410bc9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">304</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-544" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzctMS0xLTEtMjY2MzU_10b253af-26c9-4a67-b8c0-e656f947b92a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-545" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTo2OTM5OWNkN2Y1ZjA0NmViODljMTJiYzViYzAyZGFhYy90YWJsZXJhbmdlOjY5Mzk5Y2Q3ZjVmMDQ2ZWI4OWMxMmJjNWJjMDJkYWFjXzctMy0xLTEtMjY2MzU_b67b7226-3b85-4fce-a4a4-32648800ee96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,520</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="fact-identifier-546" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90ZXh0cmVnaW9uOjkxODg0ZWFmMTJiNTRlMjliZjYxOGJiZjA4ODMzZGE4XzE5Mw_300bcc62-3b79-43a7-b355-a0e28e3cb526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="alpn:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-547" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzItMS0xLTEtMjY2MzU_b999d963-7686-429e-966d-6f947c5237e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5,536</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="alpn:AccruedResearchAndDevelopmentCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-548" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzItMy0xLTEtMjY2MzU_127a04ac-40b9-4149-bf83-9ed9b15bf8ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,571</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-549" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzMtMS0xLTEtMjY2MzU_eea2dc9a-8ec6-4aa2-9a68-9713e1a7ed89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,084</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-550" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzMtMy0xLTEtMjY2MzU_40cbc811-98aa-43d8-9e55-a0c063f2f72c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,619</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-551" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzQtMS0xLTEtMjY2MzU_e763738d-030c-4d14-9633-870a9064a4e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">394</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-552" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzQtMy0xLTEtMjY2MzU_fc32617b-83f2-4c4b-b453-5a55fec9578f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">482</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="fact-identifier-553" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzgtMS0xLTEtMjkzODc_f7e2cb2f-e444-414f-b849-187d3d7f10c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">127</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="fact-identifier-554" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzgtMy0xLTEtMjkzODc_966b9345-4a84-4e00-9a34-aa44a17deb44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-555" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzgtMS0xLTEtMjY2MzU_9f8ef649-d388-4f4b-b581-2d8fafc34518" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">276</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-556" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzgtMy0xLTEtMjY2MzU_7c7cfc38-8154-4513-bb5c-4ef279f0e73e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-557" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzktMS0xLTEtMjY2MzU_536de8e8-8422-4249-81f0-eff5f191b81f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,417</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-558" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTAvZnJhZzo5MTg4NGVhZjEyYjU0ZTI5YmY2MThiYmYwODgzM2RhOC90YWJsZTpkNDVlNzg1OWYxMGM0YjE2YmQzMDM1NWU0ZDBlNTQ5Mi90YWJsZXJhbmdlOmQ0NWU3ODU5ZjEwYzRiMTZiZDMwMzU1ZTRkMGU1NDkyXzktMy0xLTEtMjY2MzU_b5bda10a-7d50-4671-aefd-03cb41766c97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,777</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div></ix:continuation></span><div id="i75d4456fb1ed409bb59167bcf5c6f56b_193"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="fact-identifier-559" continuedat="i26dba06953bc4bf2800cd903bd06017e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU4Mjg_805fdb09-40b5-4257-a4fd-b66d7e9ba034" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Long-term Debt</ix:nonnumeric></span></span></div><span><ix:continuation id="i26dba06953bc4bf2800cd903bd06017e" continuedat="i3c4bfaebc24d4ec09551403ba319f5f3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we entered into a Loan and Security Agreement (the Original Agreement), with Silicon Valley Bank (SVB), under which we borrowed $<span><ix:nonfraction unitref="usd" contextref="ieae2ee4376514631bd2f88324fddebf2_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-561" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzE3Mw_3fd71a0d-726f-4bf3-b7b8-026682eb6d18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span> million. The Original Agreement accrued interest at a floating per annum rate equal to the lenders prime rate minus <span><ix:nonfraction unitref="number" contextref="ib5248356bea14293ab5f6128546160c1_D20161201-20161231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="fact-identifier-562" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzI4NQ_583c5c9f-5b45-4adf-84f7-a91a11a46557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.75</ix:nonfraction></span>%. The Original Agreement had an interest-only period through July 2018.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019 (the Effective Date), we entered into an Amended and Restated Loan and Security Agreement (the Loan Agreement) with SVB, pursuant to which SVB agreed to extend term loans to us with an aggregate principal amount of up to $<span><ix:nonfraction unitref="usd" contextref="i4d1d5568c7fa4b9a87aefbdcd38391ed_I20190831" decimals="INF" name="alpn:DebtInstrumentMaximumBorrowingCapacityAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-563" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU5OQ_01e8089c-78d1-4775-a351-8fde112c293a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15.0</ix:nonfraction></span> million (the Term Loans). Borrowings under the Loan Agreement consisted of up to <span><ix:nonfraction unitref="tranche" contextref="i7b68bced6acb4558a8e16e5a7d47bedb_D20190801-20190831" decimals="INF" name="alpn:DentInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-564" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzY3Nw_7a0d09ba-0eb7-4a7a-ac3e-35b9cc9b578c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> separate tranches. The initial tranche of $<span><ix:nonfraction unitref="usd" contextref="i0f311401c86845e3a26ee4f56456d389_D20190801-20190831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-565" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzcyMg_d5b98c36-082a-4b74-9cbc-c5a96568d4b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span> million was funded in August 2019, $<span><ix:nonfraction unitref="usd" contextref="i2b4a12df2c0b40a2aa808a1c3245ab40_D20190801-20190831" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-566" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3Xzc1Mg_eeae3c59-7aaf-40fb-a5c0-2aea365e8acf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.0</ix:nonfraction></span> million of which was used to repay amounts owing under our Original Agreement. In March 2020, the second tranche of $<span><ix:nonfraction unitref="usd" contextref="idfffa9b897014a0da1f1784b26577c5c_D20200301-20200331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-567" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3Xzg2Mw_055f647f-a6e5-458e-921b-5aa5197f5123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span> million was funded to us. We did not draw down the final tranche of $<span><ix:nonfraction unitref="usd" contextref="i7812e6c89eb44d39911f5e0226410fc4_I20200731" decimals="INF" name="alpn:DebtInstrumentUnusedBorrowingCapacityExpiredAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-568" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzkyNg_030ae0f2-04ab-41c5-b49f-cc28a6aa7964" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.0</ix:nonfraction></span> million, which expired on July 31, 2020. We intend to use the debt proceeds for working capital and other general corporate purposes, including the advancement of our development programs.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i3c4bfaebc24d4ec09551403ba319f5f3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans accrue interest at a floating per annum rate of <span><ix:nonfraction unitref="number" contextref="i7b68bced6acb4558a8e16e5a7d47bedb_D20190801-20190831" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="fact-identifier-570" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzExNzM_cfaefb6f-d4d0-443f-8b5d-33b06d6b070f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span>% above the prime rate, subject to a floor of <span><ix:nonfraction unitref="number" contextref="i238b2644cec24ef2a1b9cef4c5171a1f_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentInterestRateFloor" scale="-2" id="fact-identifier-571" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzEyMjA_bdb2f3b2-949f-4f20-9451-eba8df744b7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.75</ix:nonfraction></span>%, which interest is payable monthly commencing in September 2019. Upon the occurrence and during the continuance of an event of default, a default interest rate will apply that is <span><ix:nonfraction unitref="number" contextref="i7b68bced6acb4558a8e16e5a7d47bedb_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentPercentageOfDefaultInterestRate" scale="-2" id="fact-identifier-572" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzE0MDI_b85eb344-8d74-43ca-8d54-77d9831fd0f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4.0</ix:nonfraction></span>% above the otherwise applicable interest rate. The Term Loans were interest only until September 30, 2020, however, under the Loan Agreement our interest only period automatically extended to June 30, 2021 if we received aggregate new capital of at least $<span><ix:nonfraction unitref="usd" contextref="i4d1d5568c7fa4b9a87aefbdcd38391ed_I20190831" decimals="INF" name="alpn:DebtInstrumentAggregateNewCapitalMilestoneForContinuationOfInterestOnlyPaymentPeriod" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-573" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzE2NjU_cd279be0-3a0d-4fd7-b75e-725b52df900f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">40.0</ix:nonfraction></span>&nbsp;million no later than June 30, 2020. We met this milestone in June 2020 in conjunction with the execution of the AbbVie agreement, discussed in detail in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_199" tabindex="18">Note 11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result of the interest only extension, the Term Loans will be payable in <span><ix:nonfraction unitref="installment" contextref="i7b68bced6acb4558a8e16e5a7d47bedb_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentNumberOfEqualMonthlyInstallmentsPayable" scale="0" id="fact-identifier-574" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzE5MDE_39850a1d-514c-49a7-9a8d-9fb40ff0bbfc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span> equal monthly installments of principal plus interest, with the final installment due and payable on July 1, 2023.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may prepay all of the Term Loans subject to a prepayment fee equal to $<span><ix:nonfraction unitref="usd" contextref="i623358c6ce04441781af218ea4ed34db_I20190831" decimals="-3" name="alpn:DebtInstrumentPrepaymentFeeRepresentingDeferredPortionOfFinalPayment" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-575" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzIwOTI_043cc972-b086-4590-80a7-191b3ddeeb66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75,000</ix:nonfraction></span>, which represents the deferred portion of the final payment due under the Original Agreement, plus the outstanding principal balance under the Term Loans at the time of such prepayment multiplied by a prepayment fee of <span><ix:nonfraction unitref="number" contextref="iebe8391caf35418db8897242b7f86588_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="fact-identifier-576" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzIzMTQ_73d54ad5-168e-40cd-b854-80f8f86c0e41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.0</ix:nonfraction></span>% in the first year, <span><ix:nonfraction unitref="number" contextref="idf5e45b2c94e4166b9a05797103db792_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="fact-identifier-577" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzIzMzY_c55e6d9e-2024-447d-bd7c-b4530e066c5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.0</ix:nonfraction></span>% in the second year, and <span><ix:nonfraction unitref="number" contextref="ia5477c8a4eb6487d9f392c189830c10d_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="fact-identifier-578" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzIzNjM_1fb50ef9-4796-40fd-9278-7255f5ffc395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0</ix:nonfraction></span>% in the third year and thereafter. Additionally, a final payment in the amount of <span><ix:nonfraction unitref="number" contextref="i7b68bced6acb4558a8e16e5a7d47bedb_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentFinalPaymentPercentage" scale="-2" id="fact-identifier-579" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzI0NDc_19463fc3-62c4-4b85-9bab-c62b34a3e1b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.5</ix:nonfraction></span>% of the funded Term Loans is payable to SVB on the date on which the Term Loans are prepaid, paid or become due and payable in full. The final payment fees are recorded in long-term debt with an offsetting reduction to debt discount on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including, among others, covenants that limit or restrict our ability to, among other things, incur additional indebtedness, grant liens, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets, engage in any new lines of business, and enter into certain transactions with affiliates, in each case subject to certain exceptions. We assessed the likelihood of the lender accelerating payment of the loan due to a material adverse change in our business, operations, financial, or other condition as remote. We were in compliance with our covenants as of December&nbsp;31, 2021. As such, as of December&nbsp;31, 2021, the classification of the loan is split between current and noncurrent based on the timing of payment obligations. As security for its obligations under the Loan Agreement, we granted SVB a first priority security interest on substantially all of our assets, except intellectual property, and subject to certain other exceptions.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Loan Agreement, we issued a warrant to SVB to purchase up to <span><ix:nonfraction unitref="shares" contextref="ia3a982b848ef4abcbd8740c7c00cb8a6_I20190831" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-580" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzM5Mjk_bb9ecb93-912a-435f-ac84-54f04d2d967b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,083</ix:nonfraction></span> shares of our common stock at a price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i89214fd22b344936ab289722a0c30e0e_I20190831" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-581" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzM5NzM_86ba7fc2-a833-4d48-b715-a81eeb40261b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.32</ix:nonfraction></span> per share, <span><ix:nonfraction unitref="shares" contextref="i89214fd22b344936ab289722a0c30e0e_I20190831" decimals="INF" name="alpn:ClassOfWarrantOrRightNumberOfSharesExercisable" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-582" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzM5ODc_3a505255-f8a2-47ac-8724-ed549c84911f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,361</ix:nonfraction></span> shares of which became exercisable in August 2019 after we drew down the initial tranche. In March 2020, after we drew down the second tranche of our Term Loan, an additional <span><ix:nonfraction unitref="shares" contextref="ibbef58a54523456282dba402b270de92_I20200330" decimals="INF" name="alpn:ClassOfWarrantOrRightNumberOfSharesExercisable" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-583" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzQxNjU_750df0a9-ad2b-48ef-908e-85be70a6c519" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,361</ix:nonfraction></span> shares became exercisable. The remaining warrants did not vest and expired on July 31, 2020, upon the expiration of the third tranche of our Term Loan. The fair value of the warrants on the date of issuance for the initial tranche and second tranche was&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i2cad8f970b62489086fb35513bc32430_I20190831" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-584" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzQ0MjI_c8a6a2b9-6424-4a41-b055-5fbd12d07399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,000</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="i06fbdb85dd6245d6b21ed18d69c3e19b_I20200330" decimals="-3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-585" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzQ0Mjk_a74b99b8-595f-4fd2-9654-aacb2bec70b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,000</ix:nonfraction></span>, respectively, determined using the Black-Scholes option-pricing model, and was recorded as a component of equity and as a debt discount on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with Original Agreement, SVB also holds <span><ix:nonfraction unitref="shares" contextref="i596b561952cf4ea4be7acd5e19c607d7_I20161231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-586" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzQ2NzI_36cc19a7-e137-4eee-94c5-f54ac9a876de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,069</ix:nonfraction></span> fully vested common stock warrants at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i596b561952cf4ea4be7acd5e19c607d7_I20161231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-587" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzQ3MzQ_e9d061a4-6831-4c9f-be64-8ec98e1a767e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.38</ix:nonfraction></span> per share.&nbsp;</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan was accounted for as a debt modification in a non-troubled debt restructuring, rather than a debt extinguishment, based on a comparison of the present value of the cash flows under the terms of the debt immediately before and after the Effective Date of&nbsp;the&nbsp;Term Loan, which resulted in a change of less than <span><ix:nonfraction unitref="number" contextref="i8b2d9c5c1a524d7ab30e7127baa2a19b_D20190801-20190831" decimals="INF" name="alpn:DebtInstrumentPercentageChangeinNonTroubledDebtRestructuringBasedOnComparisonOfPresentValueOfCashFlows" scale="-2" id="fact-identifier-588" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzUwNzI_6fe1083f-0d38-4594-a4f1-d8a3e84cce61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span>%. As a result, the remaining unamortized debt discount recorded in connection with the Original Agreement will be amortized to interest expense over the repayment term of Loan Agreement. In connection with the initial and second tranches of the Loan Agreement, we recorded a total debt discount of $<span><ix:nonfraction unitref="usd" contextref="i9318da7258ad48f9ac24e4a77fd86292_I20200330" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-589" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzUzNzI_e12957f2-b574-4bb3-aa40-b146db9e82b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">812,000</ix:nonfraction></span>, which is being amortized to interest expense using the effective interest method over the repayment term of the loan. Non-cash interest expense associated with the amortization of the discount was $<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-590" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU1NzM_594273e2-b452-401f-994e-f61869aaeb20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">274,000</ix:nonfraction></span>, $<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-591" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU1Nzc_55eae501-bf30-41b3-984b-ee67bba90a36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">261,000</ix:nonfraction></span>, and $<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-592" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU1ODU_074493bb-da05-4e1e-9ae7-0f151944bd73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">140,000</ix:nonfraction></span>, for years ended December&nbsp;31, 2021, 2020, and 2019, respectively. The unamortized discount was $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-593" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU2NjQ_6d282edf-30ef-4be8-912f-75a562394826" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">223,000</ix:nonfraction></span> as of December&nbsp;31, 2021.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="fact-identifier-594" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90ZXh0cmVnaW9uOjUzMzExODA2NTIwYjRkZTliNjQ1MzUwMTAzNmQwNjQ3XzU4Mjk_e26dcaea-18f1-45a0-be76-f6b89eab59ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled principal payments on our outstanding debt as of December&nbsp;31, 2021 under our Loan Agreement, excluding final fee amounts, are as follows (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:86.015%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ending December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-595" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90YWJsZTpiZmNjZDhkYmQwYjA0N2U3OGNiODgxMTYwNjg2YTVhYS90YWJsZXJhbmdlOmJmY2NkOGRiZDBiMDQ3ZTc4Y2I4ODExNjA2ODZhNWFhXzItMi0xLTEtMjY2MzU_96482c8d-fd16-4920-b75f-8d07aeaa423c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,800</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-596" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90YWJsZTpiZmNjZDhkYmQwYjA0N2U3OGNiODgxMTYwNjg2YTVhYS90YWJsZXJhbmdlOmJmY2NkOGRiZDBiMDQ3ZTc4Y2I4ODExNjA2ODZhNWFhXzMtMi0xLTEtMjY2MzU_086fc5d1-c716-42ce-b7ff-bc8fa500c06d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,800</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-597" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTMvZnJhZzo1MzMxMTgwNjUyMGI0ZGU5YjY0NTM1MDEwMzZkMDY0Ny90YWJsZTpiZmNjZDhkYmQwYjA0N2U3OGNiODgxMTYwNjg2YTVhYS90YWJsZXJhbmdlOmJmY2NkOGRiZDBiMDQ3ZTc4Y2I4ODExNjA2ODZhNWFhXzQtMi0xLTEtMjY2MzU_5c856f4d-29bb-49c5-8158-e43f2c2dfa58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,600</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_196"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="fact-identifier-598" continuedat="i60ca8e769ab741e990ecf1df2c89589f" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzI3NTg_24919fb3-a2fc-439d-ba22-db945c0ccebe" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Commitments and Contingencies</ix:nonnumeric></span></span></div><span><ix:continuation id="i60ca8e769ab741e990ecf1df2c89589f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leased office and laboratory space located at 201 Elliott Avenue West, in Seattle, Washington, under an agreement classified as an operating lease that expired on December 31, 2019. In May 2017, as required by the terms of the lease, we entered into a line of credit to establish collateral to support the security deposit in an amount of $<span><ix:nonfraction unitref="usd" contextref="i678d4957aa5b4bb89cfb502af5f764d5_I20170531" decimals="-3" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-600" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzM4Mw_32035926-c19c-4af4-9c57-63091068c0e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">132,000</ix:nonfraction></span>, which was recorded as current restricted cash in our Consolidated Balance Sheets for the year ended December 31, 2019. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we entered into a lease for office and laboratory space located at 188 East Blaine Street, Seattle, Washington. The term of the lease is <span><ix:nonnumeric contextref="i2c21bce11c2749e2aab827f627b0abcb_I20190331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="fact-identifier-601" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzY3Mg_9962fc91-5d9d-4f07-b350-0196175e1f71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.8</ix:nonnumeric></span> years with <span><ix:nonfraction unitref="lease_term_type" contextref="i2c21bce11c2749e2aab827f627b0abcb_I20190331" decimals="INF" name="alpn:NumberOfOptionsToExtendTermLease" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-602" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzY4MA_cfac276f-0e8a-4f05-a63c-a1f3faf62bfe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> option to extend the term by <span><ix:nonnumeric contextref="i2c21bce11c2749e2aab827f627b0abcb_I20190331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="fact-identifier-603" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzcxMg_847c7a99-a87b-480d-8618-cabc02163769" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonnumeric></span> years. Our option to extend the rental term of our lease was not considered reasonably certain as of December&nbsp;31, 2021. The lease term commenced in June 2019. The Rent Commencement Date began in March 2020, nine months after the commencement date. The annual base rent under the lease is $<span><ix:nonfraction unitref="usd" contextref="i72e961c3079340f8a18bd09a4f4e2b08_D20190301-20190331" decimals="-5" name="alpn:OperatingLeaseAnnualBaseRent" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-604" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2Xzk4NA_fe8c786d-11ce-4ac7-b845-0ce42b1f8655" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.7</ix:nonfraction></span> million for the first year and will increase by <span><ix:nonfraction unitref="number" contextref="i2c21bce11c2749e2aab827f627b0abcb_I20190331" decimals="INF" name="alpn:OperatingLeaseAnnualBaseRentIncreasingPercentage" scale="-2" id="fact-identifier-605" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzEwMjc_2d49f124-2f61-4390-85b0-348c8cf0854d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span>% each year thereafter. We were not required to pay base rent from the Rent Commencement Date through November 2020, the last day of the ninth month following the Rent Commencement Date. We received a tenant improvement allowance of $<span><ix:nonfraction unitref="usd" contextref="i72e961c3079340f8a18bd09a4f4e2b08_D20190301-20190331" decimals="-5" name="us-gaap:PaymentsForProceedsFromTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-606" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzEyNjE_ddadea85-573c-4d55-9eed-b60d88f3c39d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.4</ix:nonfraction></span> million, which is included in our base rent, and a maximum additional tenant improvement allowance of $<span><ix:nonfraction unitref="usd" contextref="i72e961c3079340f8a18bd09a4f4e2b08_D20190301-20190331" decimals="-5" name="alpn:AdditionalMaximumTenantAllowanceToBeReceived" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-607" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzEzNTg_0d3e2be9-05df-4873-bfff-6616e23e807c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.8</ix:nonfraction></span> million, which will result in additional rent amortized over the term of the lease at an annual rate of <span><ix:nonfraction unitref="number" contextref="i72e961c3079340f8a18bd09a4f4e2b08_D20190301-20190331" decimals="INF" name="alpn:OperatingLeaseAdditionalMaximumTenantImprovementAllowanceAmortizationRate" scale="-2" id="fact-identifier-608" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzE0NTc_5b5e3a81-e43f-4c21-9fb7-37877d6a7e1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8.0</ix:nonfraction></span>%. The lease also requires us to pay additional amounts for operating and maintenance expenses. In March 2019, in connection with the lease, we provided a&nbsp;$<span><ix:nonfraction unitref="usd" contextref="i21a965cf6f0d416a99915433235d717d_I20190331" decimals="-3" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-609" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzE2MTM_c3b22f46-6fae-4a9e-a596-b64c4bde4c39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">254,000</ix:nonfraction></span>&nbsp;letter of credit as a security deposit, which is recorded as noncurrent restricted cash in our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&nbsp;31, 2021</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our operating lease right-of-use assets and operating lease liability associated with our leases were $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-610" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzE4NjY_1b8769f0-fde9-4ab1-8295-9231269690c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.8</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-611" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzE4NzM_0429460f-2db5-4faf-bf00-90f22775a37b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.6</ix:nonfraction></span> million, respectively. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="fact-identifier-612" continuedat="i882ec7059ce34811b5cd530a9ae64c11" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzI3NjA_1006fee6-9fc6-4541-97c7-a0710b656743" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Supplemental operating lease information for the year ended December&nbsp;31, 2021 was as follows (in thousands): </ix:nonnumeric></span></span></div><div style="margin-top:14pt"><span><ix:continuation id="i882ec7059ce34811b5cd530a9ae64c11" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-614" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzItMS0xLTEtMjY2MzU_d41bfa36-b52f-4237-8569-824905748b36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,837</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-615" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzItMy0xLTEtMjY2MzU_6c9e5cc0-b239-4662-a75f-5a8c7522586e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,872</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="fact-identifier-616" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzMtMS0xLTEtMjY2MzU_d015aba2-18de-42e2-b1df-5fa1b18686e6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">603</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="fact-identifier-617" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzMtMy0xLTEtMjY2MzU_bba879dc-5242-4bfe-b53f-c74dfc435098" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">475</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-618" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzQtMS0xLTEtMjY2MzU_d031a376-f415-4c07-88fe-e9ee23d89dfa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,440</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-619" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzQtMy0xLTEtMjY2MzU_bbdfad9f-2372-4462-b52d-f77962f46958" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,347</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-620" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzYtMS0xLTEtMjY2MzU_74f5b9ac-5550-4bc8-a36a-9caefe191aa9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,117</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-621" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzYtMy0xLTEtMjY2MzU_fa499bdc-c52d-4f06-af38-d67b9f1e7528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">213</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-622" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzgtMS0xLTEtMjY2MzU_899c83b5-b3fb-4bab-88fc-6399fdcd23bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.2</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="iefc5e0f908c041b189c9615068048458_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="fact-identifier-623" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzgtMy0xLTEtMjY2MzU_3e0e08d8-26da-45db-ab42-45f5216dad31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.2</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-624" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzktMS0xLTEtMjY2MzU_c0f714d0-81be-4286-9e57-7271ae0f0030" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.7</ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-625" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZTowYWIyNTNmMWQ4Y2Q0ZGI1OWE1ZjZkZDJhNGM3MjAyMi90YWJsZXJhbmdlOjBhYjI1M2YxZDhjZDRkYjU5YTVmNmRkMmE0YzcyMDIyXzktMy0xLTEtMjY2MzU_bb18b985-b0f2-4440-aaed-1524585f7a33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.7</ix:nonfraction></span>%</span></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs represent our share of the landlords operating expenses. We do not act as a lessor or have any leases classified as financing leases. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="fact-identifier-626" continuedat="i96418506751945b79bbaf2044382bf98" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzI3NjE_fbd3553b-97ba-41c5-9d15-655d2ba23aed" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Maturities of our operating lease liabilities as of December&nbsp;31, 2021 are as follows (in thousands):</ix:nonnumeric></span></span><span><ix:continuation id="i96418506751945b79bbaf2044382bf98" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-628" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzEtMS0xLTEtMjY2MzU_305ea965-46f7-4b5b-8ae8-6f992708c3a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,841</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-629" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzItMS0xLTEtMjY2MzU_1401a3e9-b635-4f45-90ab-23b9cd086e6f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,057</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-630" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzMtMS0xLTEtMjY2MzU_07f72b8e-32ec-42ff-a75d-423e8d4c508a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,111</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-631" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzQtMS0xLTEtMjY2MzU_9f98ce17-b296-4c49-93d6-67cdf2563729" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,167</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-632" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzUtMS0xLTEtMjY2MzU_6605d480-0fe0-436e-bf0d-4d1ca952a85c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,224</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-633" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzYtMS0xLTEtMjY2MzU_8f034aba-f5f0-42fe-ac52-a9ec33d8e6f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,438</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-634" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzctMS0xLTEtMjY2MzU_13da9d71-f316-4ceb-9171-c4323d6136e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,838</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-635" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzgtMS0xLTEtMjY2MzU_70fcd7ea-ae87-43fa-8f10-3934805ea36a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,212</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-636" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90YWJsZToyOWJmMWU1OWQ0ZGI0Y2FhYmMxZWE1MmE4NjkyMThiMC90YWJsZXJhbmdlOjI5YmYxZTU5ZDRkYjRjYWFiYzFlYTUyYTg2OTIxOGIwXzktMS0xLTEtMjY2MzU_6a341d66-0d07-4681-9c19-8be02736045f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,626</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain credits received related to our research and development expenditures and recorded within other income in our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are subject to review by foreign taxing authorities. It is reasonably possible we may incur losses upon the completion of these reviews ranging from $<span><ix:nonfraction unitref="usd" contextref="i3122bde756bb405da9845b0b4487e083_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" scale="0" id="fact-identifier-637" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzI2ODQ_36830c1b-f56d-4896-b538-f85435645525" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usd" contextref="i18d55851d588457b8af381d6826d0e52_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-638" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTYvZnJhZzplZTZmNDkzY2I1MGU0OGVhYWQ3NDhjYTgyZGQ2ZDhlNi90ZXh0cmVnaW9uOmVlNmY0OTNjYjUwZTQ4ZWFhZDc0OGNhODJkZDZkOGU2XzI2OTA_7ebb7a3a-7b1b-4219-9f6d-bdf9a3e3f239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.8</ix:nonfraction></span>&nbsp;million, which we could be required to repay to certain tax authorities.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_199"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="fact-identifier-639" continuedat="i9d82401ee57e49268a4b2334df47c68f" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzgwNzI_78c07e59-6807-4a84-ad9c-351e7dd015d0" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">License and Collaboration Agreements</ix:nonnumeric></span></span></div><span><ix:continuation id="i9d82401ee57e49268a4b2334df47c68f" continuedat="i14c824c4ea1d4ab3bb38120aaa7f40b0" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we entered into an exclusive license and collaboration agreement with Horizon (the Horizon Agreement) for the development and commercialization of up to <span><ix:nonfraction unitref="candidate" contextref="i2e6f753d91fb4814bccc6c4706af2805_D20211201-20211231" decimals="INF" name="alpn:NumberOfPreclinicalCandidates" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-641" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE1NTQ_ac87d6cd-9844-4846-86fa-59045d5698f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">four</ix:nonfraction></span> preclinical candidates generated from our unique discovery platform. The agreement includes licensing of <span><ix:nonfraction unitref="program" contextref="i2e6f753d91fb4814bccc6c4706af2805_D20211201-20211231" decimals="INF" name="alpn:NumberOfExistingPrograms" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-642" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE1NzE_a2826237-cd04-49c0-a5a5-05acf19c800e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> of our existing preclinical biologic therapeutic programs (the Existing Program), as well as a research partnership to jointly develop candidates for up to <span><ix:nonfraction unitref="program" contextref="i2e6f753d91fb4814bccc6c4706af2805_D20211201-20211231" decimals="INF" name="alpn:NumberOfAdditionalPrograms" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-643" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE1ODE_8fe3274a-f43a-4187-ae83-bc32305706e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> additional autoimmune and inflammatory disease programs for other designated biological targets, (the Research Programs). These candidates include previously undisclosed multi-specific fusion protein-based therapeutic candidates for autoimmune and inflammatory diseases. We will advance candidate molecules to predefined preclinical milestones while Horizon will be responsible for the respective costs and, ultimately, Horizon will assume responsibility for development and commercialization activities and costs.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Horizon Agreement in December 2021, we entered into a stock purchase agreement under which Horizon purchased <span><ix:nonfraction unitref="shares" contextref="i22b150e5f4b549dca8129cd7c110db03_D20211201-20211231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-644" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE1NTg_b8bf5e38-2a3e-439a-85a8-b2d2709c6db2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">951,980</ix:nonfraction></span> shares of our common stock in a private placement for approximately $<span><ix:nonfraction unitref="usdPerShare" contextref="i5251479cf79c49749c959a3b7df6aca3_I20211231" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-645" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MzgwNjk_469c0572-7637-4acd-b4fb-8819c13aac54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.76</ix:nonfraction></span> per share and aggregate proceeds of $<span><ix:nonfraction unitref="usd" contextref="i151315902722437a8ad49cfe34610af5_D20210101-20211231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-646" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MzgwNzc_55d30acd-18af-477d-b312-23e1c31ed26a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.0</ix:nonfraction></span>&nbsp;million. The shares were sold at a <span><ix:nonfraction unitref="number" contextref="i22b150e5f4b549dca8129cd7c110db03_D20211201-20211231" decimals="2" name="alpn:SaleOfStockPremiumOnPricePerSharePercent" scale="-2" id="fact-identifier-647" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MzgwOTI_9aa47e69-dbf8-4ac1-930a-ec284241868e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25</ix:nonfraction></span>% premium to the volume-weighted average share price of our common stock for a specified <span><ix:nonnumeric contextref="ibcd9d7ab1c6244d2b2c93079e85f636b_D20210101-20211231" name="alpn:SaleOfStockPremiumOnPricePerShareStockPricePeriod" format="ixt-sec:durwordsen" id="fact-identifier-648" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MzgxMDQ_8c3c3be6-8cdc-40ce-b32c-592327ce415b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30-day</ix:nonnumeric></span> period prior to entering into the agreement. The fair value of the common stock issued to Horizon of $<span><ix:nonfraction unitref="usd" contextref="i151315902722437a8ad49cfe34610af5_D20210101-20211231" decimals="-5" name="alpn:SaleOfStockConsiderationReceivedOnTransactionFairValuePortion" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-649" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzM4NDgyOTA4MDAwNzc_aa16ac3c-7f4e-41ca-a88d-332a15f69a19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">11.9</ix:nonfraction></span>&nbsp;million was recorded to equity, based on the closing price of common stock on the effective date of the Horizon Agreement. For accounting purposes, the $<span><ix:nonfraction unitref="usd" contextref="i151315902722437a8ad49cfe34610af5_D20210101-20211231" decimals="-5" name="alpn:SaleOfStockConsiderationReceivedOnTransactionAdditionalConsiderationPortion" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-650" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzM4NDgyOTA4MDAxMTU_775417d8-cba7-4630-a771-a922bf486fe7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.1</ix:nonfraction></span>&nbsp;million difference between the cash proceeds and the fair value of the common stock was treated as additional consideration attributable to the Horizon Agreement.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreements, Horizon also paid us a non-refundable upfront payment of $<span><ix:nonfraction unitref="usd" contextref="i3454a020ba504a65bb403cbb8792e1de_I20220131" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-651" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE2MTE_eb818f1a-963b-4806-a843-6dfaa35d1d9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span>&nbsp;million in the first quarter of 2022. In addition, we are eligible to receive up to $<span><ix:nonfraction unitref="usd" contextref="i152d7cb06f574ef185e7df19b538c207_I20211231" decimals="-5" name="alpn:PotentialFutureRevenueRecognitionMilestonesReceivablePerProgram" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-652" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE2MjY_e9ed4e8b-92f7-4d4c-ac35-3c3b6127ad6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">381.0</ix:nonfraction></span>&nbsp;million per program, or up to approximately $<span><ix:nonfraction unitref="usd" contextref="i152d7cb06f574ef185e7df19b538c207_I20211231" decimals="-8" name="alpn:PotentialFutureRevenueRecognitionMilestonesReceivable" format="ixt:num-dot-decimal" scale="9" id="fact-identifier-653" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE2NDI_761e3e44-40c6-41a9-8fb1-64fb18b701ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.5</ix:nonfraction></span>&nbsp;billion in total, in future success-based payments related to development, regulatory and commercial milestones. Furthermore, we are eligible to receive tiered royalties from a mid-single digit percentage to a low double-digit percentage on global net sales. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, we recorded on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<span><ix:nonfraction unitref="usd" contextref="i152d7cb06f574ef185e7df19b538c207_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-654" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE2NTc_4504d2e9-94a6-4c57-9900-41ea2fe86c28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28.1</ix:nonfraction></span>&nbsp;million in current and noncurrent deferred revenue, of which $<span><ix:nonfraction unitref="usd" contextref="i020be8c887b846768ee393edf4d0af2e_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-655" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE2NzI_8cf29c25-495d-44e0-8021-068a2e15b426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span>&nbsp;million relates to accounts receivable for the up-front payment and $<span><ix:nonfraction unitref="usd" contextref="idf5cdcf2ae8e447ea4ff3d9c718d0caa_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-656" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE2ODc_c925f651-3362-44ab-b4f4-893319d48f63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.1</ix:nonfraction></span>&nbsp;million relates to the premium paid by Horizon on the stock issuance. As work under the Horizon license and collaboration agreement did not begin until 2022, we did <span><ix:nonfraction unitref="usd" contextref="ia84b2b262f0c4ee2bae1e3ecff18cadd_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="fact-identifier-657" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2NDkyNjc1MjE3MDQ_521a3da1-1fde-4fb4-9b3e-185461b108ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span>t recognize any related revenue for the year ended December 31, 2021.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For revenue recognition purposes, we determined that the Existing Program and each Research Program are distinct performance obligations. We allocated revenue to each performance obligation based on its relative stand-alone selling price. The future success-based payments related to development and regulatory milestones are probable of significant revenue reversal as the achievement is highly dependent on factors outside our control. Therefore, these milestone payments are fully constrained and are not initially included in the transaction price. We will continue to re-evaluate the transaction price each reporting period and update as uncertain events are resolved or other changes in circumstances occur. Any consideration related to commercial milestones and royalties will be recognized when the related sales occur.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into an option and license agreement with AbbVie (the AbbVie Agreement) for the development of ALPN-101 (acazicolcept). The AbbVie Agreement grants AbbVie the exclusive option to purchase an exclusive worldwide license to acazicolcept (the License Option). The License Option is exercisable by AbbVie at any time and will expire 90 days from the achievement of certain development milestones. If AbbVie exercises the License Option, AbbVie will take over the future development and commercialization. Prior to the exercise of the License Option, we will perform research and development services, including conducting a Phase 2 study in systemic lupus erythematosus, based on an agreed-upon development plan (the Development Plan). We will be fully responsible for all costs incurred to conduct the activities under the Development Plan, provided that, AbbVie may be responsible for increased costs under the Development Plan in connection with certain material amendments proposed by AbbVie. We will also be solely responsible, at our sole cost and expense, for manufacturing and regulatory filings for acazicolcept necessary to complete activities under the Development Plan.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, in connection with the execution of the AbbVie Agreement, AbbVie paid us a nonrefundable upfront payment of $<span><ix:nonfraction unitref="usd" contextref="i062134b2fef643f594d8f17b4a7c78e9_I20200630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-658" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzEzNjA_a796c3c5-b261-4d41-b2a1-766b851f68de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60.0</ix:nonfraction></span> million. Prior to the exercise of the License Option, AbbVie has agreed to make cash payments upon our achievement of certain predefined pre-option development milestones (the Alpine Development Milestones) up to an aggregate amount of $<span><ix:nonfraction unitref="usd" contextref="i2dddb55d8ff54aae89296bb009468029_I20200630" decimals="INF" name="alpn:PotentialFutureRevenueRecognitionMilestonesReceivable" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-659" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE1OTM_f96c72a4-a5b2-408e-bb88-174d077b1c0a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75.0</ix:nonfraction></span> million. In the second quarter of 2021, we achieved $<span><ix:nonfraction unitref="usd" contextref="i6a691e7bc9e346ee9c27fcfc724ebecb_I20210630" decimals="INF" name="alpn:PotentialFutureRevenueRecognitionMilestonesReceivable" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-660" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzEwOTk1MTE2MzY4NDI_13a19189-5809-47ea-a0d4-45b1b8186416" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">45.0</ix:nonfraction></span>&nbsp;million of the Alpine Development Milestones. If AbbVie exercises the License Option, they will pay a <span><ix:nonfraction unitref="payment" contextref="iea9a7edca16b44cab64b32238668d6a8_I20200630" decimals="INF" name="alpn:PotentialFutureRevenueRecognitionMilestonesReceivableNumberOfPayments" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-661" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzcxNDY4MjU1ODg2Nzc_89d39d9b-c1b8-4c5a-90b4-e646419129ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span>-time cash payment of $<span><ix:nonfraction unitref="usd" contextref="iea9a7edca16b44cab64b32238668d6a8_I20200630" decimals="-5" name="alpn:PotentialFutureRevenueRecognitionCashPaymentUponLicenseOptionExercise" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-662" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE2Nzg_2f6a4750-4663-4e89-9261-cba4660191ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75.0</ix:nonfraction></span> million. Following the exercise of the License Option, AbbVie has also agreed to make aggregate cash payments of up to $<span><ix:nonfraction unitref="usd" contextref="iea9a7edca16b44cab64b32238668d6a8_I20200630" decimals="-5" name="alpn:PotentialFutureRevenueRecognitionCashPaymentUponAchievementOfCertainDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-663" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE3OTI_e2a23571-bdd8-468a-a298-cdb0c889ba52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">205.0</ix:nonfraction></span> million upon AbbVies achievement of certain development and commercial milestones and additional aggregate cash payments of up to $<span><ix:nonfraction unitref="usd" contextref="iea9a7edca16b44cab64b32238668d6a8_I20200630" decimals="-5" name="alpn:PotentialFutureRevenueRecognitionCashPaymentUponAchievementOfCertainSalesBasedCashMilestones" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-664" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzE5MTg_d890189c-5f2c-4748-a662-5937028b83bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">450.0</ix:nonfraction></span> million upon AbbVies achievement of certain sales-based cash milestones, collectively referred to as (the AbbVie </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i14c824c4ea1d4ab3bb38120aaa7f40b0" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestones). Subsequent to commercialization, we are also eligible to receive high single-digit to low double-digit percentage royalties on worldwide net sales of licensed products.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For revenue recognition purposes, we determined that our contractual promises in the AbbVie Agreement are not distinct and are interdependent with our performance obligation to provide research and development services under the Development Plan. Thus, all contractual promises related to the upfront payment and Alpines Development Milestones were combined into a single performance obligation. We determined the Alpine Development Milestone payments are probable of significant revenue reversal as the achievement is highly dependent on factors outside our control. Therefore, these milestone payments were fully constrained and were not initially included in the transaction price. In June 2021, we re-evaluated and updated the transaction price to include the achieved portion of the Alpine Development Milestones. We will continue to re-evaluate the transaction price each reporting period and update as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The License Option and the AbbVie Milestones were not determined to be performance obligations at the inception of the contract as they did not represent material rights. If exercised, the License Option and AbbVie Milestones will be accounted for as a separate contract and will be recognized as revenue if and when triggered. Any consideration related to sales-based royalties and profit-sharing payments will be recognized when the related sales occur.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a cost-based input method to measure progress toward completion of the performance obligation and to calculate the corresponding revenue to recognize each period. In applying the cost-based input, we use actual costs incurred relative to budgeted costs for the combined performance obligation. These costs consist primarily of internal personnel efforts and third-party contract costs relative to the level of patient enrollment in the study. Revenue will be recognized based on the level of costs incurred relative to the total budgeted costs for the performance obligation. A cost-based input method of revenue recognition requires management to make estimates of costs to complete our performance obligation. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete our performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from the AbbVie Agreement of $<span><ix:nonfraction unitref="usd" contextref="i093ea9e497144471b54a7dc0652275ca_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-666" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzM4NDgyOTA3MDc2MjU_041022e9-f739-451f-ac67-d0dd3e882f66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23.4</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="id7db5daf1ecb4d9a9ea71684f2be918e_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-667" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzQ3MTk_4b5fff59-e778-4e15-af69-c9cc54e010b0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.0</ix:nonfraction></span>&nbsp;million for the years ended December&nbsp;31, 2021 and 2020, respectively. As of December&nbsp;31, 2021 the remaining balance of the transaction price is $<span><ix:nonfraction unitref="usd" contextref="i9b719a349b5747a8834254f8d6fffb75_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-668" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzQ4MDQ_2ee99223-3800-4359-aa76-162b3b666632" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74.5</ix:nonfraction></span>&nbsp;million and is recorded as current and noncurrent deferred revenue on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect to recognize the remaining deferred revenue over the remainder of our Development Plan, which began in June 2020 and ends upon the later of the exercise or expiration of the option.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adaptimmune</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a collaboration and licensing agreement with Adaptimmune (the Adaptimmune Agreement) to develop next-generation SPEAR T cell products. Under the Adaptimmune Agreement, we are to perform certain research services and grant Adaptimmune an exclusive license to programs from our secreted immunomodulatory protein (SIP) and transmembrane immunomodulatory protein (TIP) technologies. In June 2019, under the terms of the Adaptimmune Agreement, we received an upfront license payment of $<span><ix:nonfraction unitref="usd" contextref="iac0cfe61a076402a941cf3ce5b7540a0_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-669" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzU2MzY_d2f5af7c-12a6-4c05-994a-d7c5f49a934e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i779979eacbe54b72937d4fab02c71731_D20190701-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-670" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzU2MzY_dea397d1-f5c2-4454-a05f-a81f001b4948" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.0</ix:nonfraction></span></ix:nonfraction></span> million, and through December&nbsp;31, 2021 we have received an additional $<span><ix:nonfraction unitref="usd" contextref="ifa5fddd88c3e48fe8ff8dbe605960a7f_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-671" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzU2ODY_06da8779-e25e-4525-85dc-c9d780b98318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i5500833b9eaf473abf2f636d5c30f7af_D20190701-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-672" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzU2ODY_d870f901-9a06-4616-8d9a-97c84c35cebd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonfraction></span></ix:nonfraction></span> million in research support payments to fund ongoing programs. These payments were recorded as deferred revenue upon receipt and were recognized to revenue based on employee hours contributed to each performance obligation. In the fourth quarter of 2020, based on the completion of our initial research and development efforts in connection with our performance obligations, we recognized the remaining balance in deferred revenue associated with Adaptimmune on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the Adaptimmune Agreement we recognized <span><ix:nonfraction unitref="usd" contextref="i345f1436aeb944a782c69c7d697fb4d5_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="fact-identifier-673" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzEwOTk1MTE2MzgyMjg_2ce50cb4-9cfa-4da9-afbb-7d60104000ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> revenue for the year ended December&nbsp;31, 2021, and $<span><ix:nonfraction unitref="usd" contextref="i0a75c47adacc45d1bf2c0a53c190fe55_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-674" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzYyNTI_e0e639b9-7381-4c0f-93a2-eddd2d333b96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="if536e7e2d9ca4f7a8557f2c51d4e5f08_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-675" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzYyNTk_73787bd2-f862-4dcc-97ec-33f31e459fe2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span>&nbsp;million for the years ended December&nbsp;31, 2020, and 2019, respectively. In addition, we are eligible for additional research support payments, one-time payments and downstream development and commercialization milestones of up to $<span><ix:nonfraction unitref="usd" contextref="i6f141abe10344389a58347647e70766b_I20211231" decimals="INF" name="alpn:PotentialFutureRevenueRecognitionMilestonesReceivable" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-676" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzY0NjU_364a5421-8298-4336-a977-c3e151d0c8af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">288.0</ix:nonfraction></span> million, if all pre-specified milestones for each program are achieved. We are also eligible to receive low-single digit royalties on worldwide net sales of the applicable products. In February 2022, Adaptimmune selected an additional research program, triggering a $<span><ix:nonfraction unitref="usd" contextref="i5dec84da2bb344a08dd21b61ee6a2864_I20220228" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-677" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8xOTkvZnJhZzo2NTExZjFmYTdjZTk0YjIxYTdjZTI5NTg4MGUxNjMxNS90ZXh0cmVnaW9uOjY1MTFmMWZhN2NlOTRiMjFhN2NlMjk1ODgwZTE2MzE1XzcxNDY4MjU2MzE5MzA_f5263e02-ce9d-4feb-b1cd-b2b80954ab0c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span>&nbsp;million upfront payment, which will be recorded as deferred revenue upon receipt and recognized to revenue based on employee hours contributed.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_202"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="fact-identifier-678" continuedat="if77c7ff998154f97bd30ee172738ed36" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNTI_cf3cf570-0371-4f75-b7f0-3ba54ab7125a" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Stockholders Equity </ix:nonnumeric></span></span></div><span><ix:continuation id="if77c7ff998154f97bd30ee172738ed36" continuedat="i3b73d4ffcade474a88af1f8e1f1e7823" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="fact-identifier-680" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNTQ_e5132df4-3a59-446c-a47d-def043fa0ff0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock reserved for future issuance were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares to be issued upon exercise of outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-681" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzMtMS0xLTEtMjY2MzU_e20260f5-3ddd-4586-a2a7-8dbc9b279532" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,611,743</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib88192ff637346c6adfd814116ed19aa_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-682" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzMtMy0xLTEtMjY2MzU_1aa7f792-1772-46ed-ae32-197602684d1c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,175,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares to be issued upon release of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i89883447444d43b880147da6b2fd98ce_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-683" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzMtMS0xLTEtMzI1NDM_940150c4-dd3b-45f2-b1b9-f9e21898e0f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,566</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i1aca4a3f0af543bdb4d112a177a7741c_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:fixed-zero" scale="0" id="fact-identifier-684" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzMtMy0xLTEtMzI1NDM_0f2e27ad-bb4a-4270-8a3e-e324933586ed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares to be issued upon conversion of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0a1f3650c42a4d00908cfbed80c1ee4b_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-685" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzQtMS0xLTEtMjY2MzU_0c9e1107-f9ee-4e61-b5c4-53e5a81c908c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,666,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i74f983a058be47afbb58ce562b1c4d6c_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-686" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzQtMy0xLTEtMjY2MzU_3ca25426-a4e7-4a11-812e-60005ac2425f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,673,551</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares to be issued upon conversion of prefunded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia5a15a858b3243bfbb2174b597e839b8_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-687" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzUtMS0xLTEtNDAxNTE_34ab76c5-f7eb-4e07-a1d1-b02aad8931ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,182,197</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5b626fbf80d34ac084167087599ad148_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-688" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzUtMy0xLTEtNDAxNTE_1f52e3f7-91d2-4bbf-95df-313b20b8b8e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">790,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for future stock grants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia37a014b4a1643b5a5b9a82861705114_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-689" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzUtMS0xLTEtMjY2MzU_f415ddd6-146e-47ae-9a0d-add86413ed9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">284,906</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ida43dc13312a46108b9a1cc6ec681ffa_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-690" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzUtMy0xLTEtMjY2MzU_19269324-7082-4c17-878c-76b9348fbabe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">887,901</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares to be issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib9d0ebb9da1143a2aff58659fd34ff3f_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-691" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzYtMS0xLTEtMjY2MzU_740fa750-3b68-4ebe-aacc-5806dffe3b72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,211</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id3def57b944b455183938bc50142ac8e_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-692" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzYtMy0xLTEtMjY2MzU_edf95764-d29c-4d66-acdd-dbbae693502f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,211</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-693" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzctMS0xLTEtMjY2MzU_91ddaf6a-17e7-4d23-a0c9-02f42cb7622c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,056,058</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-694" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkNDMzMGQ3ZGUyYzk0NDhlYmY1NjRkMmRhMDU3YmVjZi90YWJsZXJhbmdlOmQ0MzMwZDdkZTJjOTQ0OGViZjU2NGQyZGEwNTdiZWNmXzctMy0xLTEtMjY2MzU_a1f3bc72-7f54-4f86-b82e-a33dac1136f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,572,718</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Offerings</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into a securities purchase agreement (the 2021 Securities Purchase Agreement) for a private placement with a select group of institutional investors, pursuant to which we sold <span><ix:nonfraction unitref="shares" contextref="i0b327bcfa98a40eb91977c3449fc1f7a_D20210901-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-695" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI2OTY_320aba58-0661-4ad7-ba20-85183b12b3eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,489,357</ix:nonfraction></span> shares of our common stock (the Shares) and prefunded warrants to purchase <span><ix:nonfraction unitref="shares" contextref="i4519e0cf9f5a4d29831defb5a0bdf860_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-696" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3MDc_82735803-b555-4a7b-a968-f80645405d57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,191,487</ix:nonfraction></span> Shares (the Prefunded Warrants). The purchase price for each Share and for each Prefunded Warrant was $<span><ix:nonfraction unitref="usdPerShare" contextref="ib7147d6c86994e1c9b650f6ee79fcd0d_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-697" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3MTg_b41da42e-b0bf-4000-bc31-fc07d2d5c421" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.40</ix:nonfraction></span> per share, for an aggregate purchase price of approximately $<span><ix:nonfraction unitref="usd" contextref="i6a05e8d545af4e86a1a2bfe82cb175ef_D20210901-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-698" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3MjU_64b26769-32e9-47ea-914d-2f0c9fd8b8a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91.0</ix:nonfraction></span>&nbsp;million. The Prefunded Warrants became fully exercisable upon the closing date and have an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i4519e0cf9f5a4d29831defb5a0bdf860_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-699" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3NDA_0d971242-6147-457a-b232-691dfa53d4a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> per share. We incurred $<span><ix:nonfraction unitref="usd" contextref="i6a05e8d545af4e86a1a2bfe82cb175ef_D20210901-20210930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-700" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3NDg_69f0b1b6-2b43-4de8-94b7-34bc1687cfaf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">266,000</ix:nonfraction></span> in financing costs associated with the 2021 Securities Purchase Agreement, which was netted against the proceeds within additional-paid-in-capital on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, we entered into an exchange agreement (the Exchange Agreement) with Frazier Life Sciences VIII, L.P. (the Exchanging Stockholder), which Exchanging Stockholder is affiliated with a member of our board of directors, pursuant to which we exchanged an aggregate of <span><ix:nonfraction unitref="shares" contextref="ib35141db54104f6d85ffff605e75fe41_D20210901-20210930" decimals="INF" sign="-" name="alpn:StockIssuedDuringPeriodSharesExchangeForPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-701" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3NjA_862e798c-d02d-45bc-bc95-1cfb396b23f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,200,000</ix:nonfraction></span> shares of common stock held by the Exchanging Stockholder for Prefunded Warrants (the Exchange Warrants) to purchase an aggregate of <span><ix:nonfraction unitref="shares" contextref="ieebacfd44c9b4102a8eb72c9991f2e71_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-702" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3NzE_2056090e-84db-492c-a07a-2c63b44f8d56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span> shares of common stock. Upon the closing of the exchange, we reclassified <span><ix:nonfraction unitref="shares" contextref="i29eb1f5a55ba460d93ee7d27fba0bb17_D20210901-20210930" decimals="INF" name="alpn:StockIssuedDuringPeriodSharesExchangeForPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-703" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDI3ODI_ef153e92-b9c4-4507-a755-457d1ed7db2d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,200,000</ix:nonfraction></span> shares of common stock into treasury stock on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a securities purchase agreement (the 2020 Securities Purchase Agreement) for a private placement with a select group of institutional investors, pursuant to which we sold <span><ix:nonfraction unitref="shares" contextref="ifcefc03f1e124d9bbe7d55bffac1f72a_D20200701-20200731" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-704" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzMzNA_3c35a2ec-4df2-4f3f-ae49-571fa98a2957" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,139,610</ix:nonfraction></span> units (the Common Units) and <span><ix:nonfraction unitref="shares" contextref="i91a19ea89ef747edb76c57033ac240ce_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-705" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzM2OA_4e105a0e-760e-4b85-9797-943044d3e4cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">790,710</ix:nonfraction></span> units (the Prefunded Warrant Units), for an aggregate purchase price of $<span><ix:nonfraction unitref="usd" contextref="i9d3c61b57ce24a41bdf082b485b48a9e_D20200701-20200731" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-706" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQ0NQ_d66e4580-fcb5-48f6-ba9a-3f56a8b079ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60.0</ix:nonfraction></span>&nbsp;million. Each Common Unit consists of <span><ix:nonfraction unitref="shares" contextref="i6a12320f064d4eb7ad11d98b1d6406ff_I20200731" decimals="INF" name="alpn:NumberOfSharesOfCommonStockPerUnitSoldInPurchaseAgreement" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-707" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQ3OA_59f49bd1-d73f-4a01-8741-9a9664200138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of our common stock plus a warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i2b02509e21fe45ef8444933f3cf33999_D20200701-20200731" decimals="1" name="alpn:PurchaseAgreementRatioOfCommonStockToCommonStockWarrants" scale="0" id="fact-identifier-708" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzUzNA_e0f00db4-b91f-43f5-9bc6-8ffc27c9574d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.3</ix:nonfraction></span> shares of common stock (the Common Stock Warrants), and each Prefunded Warrant Unit consists of <span><ix:nonfraction unitref="warrant" contextref="i101c599b3b8246bdbc84e94f5abf0fbd_I20200731" decimals="INF" name="alpn:NumberOfPrefundedWarrantsPerUnitSoldInPurchaseAgreement" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-709" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNDg_a73b8e68-a886-49b9-8be4-4019a66710b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> prefunded warrant to purchase <span><ix:nonfraction unitref="shares" contextref="i293473c00f0f4e6b8f7c85b5b0dec6de_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-710" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY2OQ_23e3b00f-bb5c-4e36-ab80-311472a64dbc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span> share of common stock plus <span><ix:nonfraction unitref="shares" contextref="i5f3968ad1b82430eaa805a7b7154b755_D20200701-20200731" decimals="1" name="alpn:PurchaseAgreementRatioOfPrefundedWarrantsToCommonStockWarrants" scale="0" id="fact-identifier-711" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzcyNg_5c382582-600b-4abf-90b9-836ebc90f0e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.3</ix:nonfraction></span> Common Stock Warrants. The Prefunded Warrant Units and the Common Units are collectively referred to as the Units and each Unit has a purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i9d3c61b57ce24a41bdf082b485b48a9e_D20200701-20200731" decimals="INF" name="alpn:PurchaseAgreementAggregatePurchasePricePerUnit" scale="0" id="fact-identifier-712" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1Xzg4Mw_edd86d63-61f2-4040-ad35-d92d03058ff2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10.1175</ix:nonfraction></span>. Pursuant to the terms of the 2020 Securities Purchase Agreement, we issued warrants to purchase <span><ix:nonfraction unitref="shares" contextref="i794d5118016b40dbbd0610e5dd3e4ecf_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-713" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1Xzk3OA_489050fa-f2bc-41ba-8625-2b05025b35e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,779,096</ix:nonfraction></span> shares of common stock with an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i794d5118016b40dbbd0610e5dd3e4ecf_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-714" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwMzA_9e98c63e-a3aa-4ddc-8adb-8b136fa26c0b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.74</ix:nonfraction></span> and a term of <span><ix:nonnumeric contextref="i794d5118016b40dbbd0610e5dd3e4ecf_I20200731" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="fact-identifier-715" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwNDc_b11b5281-c053-4527-a8f5-c1148a4807c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.5</ix:nonnumeric></span> years. Additionally, we issued <span><ix:nonfraction unitref="shares" contextref="i91a19ea89ef747edb76c57033ac240ce_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-716" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwNzU_7cbb86bd-dd3c-4152-9bfc-8d0fd8ee072b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">790,710</ix:nonfraction></span> prefunded warrants, which became fully exercisable upon the closing date and have an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i91a19ea89ef747edb76c57033ac240ce_I20200731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-717" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzExODE_dd556f86-56bd-4b90-910a-20a26d1994a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span> per share. We incurred $<span><ix:nonfraction unitref="usd" contextref="i9d3c61b57ce24a41bdf082b485b48a9e_D20200701-20200731" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-718" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEyMDc_646e1ba0-fd2f-4d2f-9e42-0ba21dcdfcda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.7</ix:nonfraction></span>&nbsp;million in financing costs associated with the 2020 Securities Purchase Agreement, which was netted against the proceeds within additional-paid-in-capital on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a securities purchase agreement (the 2019 Securities Purchase Agreement) with a limited number of accredited investors, pursuant to which we sold <span><ix:nonfraction unitref="shares" contextref="i80adb87431ed4df1ac1d1748f2389a3a_D20190101-20190131" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-719" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE1NjY_c239a3de-67bf-460e-8045-f7fe62e10500" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,706,700</ix:nonfraction></span> units (the 2019 Units) for an aggregate purchase price of $<span><ix:nonfraction unitref="usd" contextref="i795c5e13955e498abdbdcd24bf7fc219_D20190101-20190131" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-720" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE2Mjk_cbefc414-b399-4a1f-a316-7d4401b68ad4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.3</ix:nonfraction></span> million in a private placement (the Private Placement). Each 2019 Unit has a purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i795c5e13955e498abdbdcd24bf7fc219_D20190101-20190131" decimals="INF" name="alpn:PurchaseAgreementAggregatePurchasePricePerUnit" scale="0" id="fact-identifier-721" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE3MjE_aea07196-c040-414f-9e6c-2d7b822bc9c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.37</ix:nonfraction></span> and consists of <span><ix:nonfraction unitref="shares" contextref="i7376a713e8824a83b2c48abf564c1be2_I20190131" decimals="INF" name="alpn:NumberOfSharesOfCommonStockPerUnitSoldInPurchaseAgreement" format="ixt-sec:numwordsen" scale="0" id="fact-identifier-722" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE3NDA_6aa65554-bd48-4142-aa33-1297089453d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> share of our common stock and a warrant to purchase <span><ix:nonfraction unitref="shares" contextref="ic0f4be439d1e42caba8e3d7a6219cab6_D20190101-20190131" decimals="2" name="alpn:PurchaseAgreementRatioOfCommonStockToCommonStockWarrants" scale="0" id="fact-identifier-723" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE3OTU_2869e130-e174-4e11-8540-16af389451b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.39</ix:nonfraction></span> shares of common stock. Pursuant to the terms of the 2019 Securities Purchase Agreement, we issued <span><ix:nonfraction unitref="shares" contextref="i9b418204263c4b8ea69d175de06bb545_D20190101-20190131" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-724" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE4ODE_1c9926ef-66ad-4b58-aca3-8328fda51a02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,706,700</ix:nonfraction></span> shares of common stock and warrants to purchase an aggregate of <span><ix:nonfraction unitref="shares" contextref="ie30e212db6cb40799cad98f14bc8696d_I20190131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-725" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE5NDg_d4eeb72c-5abf-4322-a92b-2a03352ada7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,835,610</ix:nonfraction></span> shares of common stock. The warrants have an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="ie30e212db6cb40799cad98f14bc8696d_I20190131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-726" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzIwMTQ_572f2d0b-2528-46f7-8ddb-a9cfac5121b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.74</ix:nonfraction></span> and have a term of <span><ix:nonnumeric contextref="ie30e212db6cb40799cad98f14bc8696d_I20190131" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="fact-identifier-727" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzIwMzY_08302a71-768a-41ed-921d-ab287d60b716" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five years</ix:nonnumeric></span>. We incurred $<span><ix:nonfraction unitref="usd" contextref="i795c5e13955e498abdbdcd24bf7fc219_D20190101-20190131" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-728" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzIwNTI_06c639ec-5ce0-4313-819c-f4e049bdae4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.7</ix:nonfraction></span> million in financing costs associated with the 2019 Securities Purchase Agreement, which was netted against the proceeds within additional-paid-in-capital on our accompanying </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_154" tabindex="18">Consolidated Balance Sheets</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of the securities sold under the 2021, 2020, and 2019 Securities Purchase Agreements have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. We filed registration statements for the 2021, 2020 and 2019 Securities Purchase Agreements with the SEC, which were declared effective by the SEC in November 2021, August 2020 and April 2019, respectively, which cover the resale of the shares of common stock issuable in connection with the private placements and upon exercise of the warrants. In May 2021, the registration statement </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i3b73d4ffcade474a88af1f8e1f1e7823" continuedat="i15e76c3eb3cf4cf9877de34e7de97974" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the 2019 Securities Purchase Agreement was deactivated following the expiration of our obligation to maintain its effectiveness under the related registration rights agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Agreements</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a sales agreement (the Sales Agreement) with Cowen and Company, LLC (Cowen) pursuant to which we may sell shares of our common stock from time to time through an at the market equity offering for up to $<span><ix:nonfraction unitref="usd" contextref="i007148e03dd84205a1a6b6b3bbe00984_D20210701-20210731" decimals="-5" name="alpn:MaximumAmountOfCommonStockEligibleToBeSold" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-730" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDQ3MTA_5a9ac948-3bd5-4192-80ee-c8301878d63f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">75.0</ix:nonfraction></span>&nbsp;million in gross cash proceeds. Cowen will act as the sales agent and will be entitled to compensation for services of up to <span><ix:nonfraction unitref="number" contextref="i007148e03dd84205a1a6b6b3bbe00984_D20210701-20210731" decimals="3" name="alpn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfCompensationForServices" scale="-2" id="fact-identifier-731" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzEwOTk1MTE2NDQ3MjU_443339e0-6b19-479e-a6fb-840b56248450" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.0</ix:nonfraction></span>% of the gross sales price per share of all shares sold through Cowen under the Sales Agreement. The shares would be issued pursuant to our effective shelf registration statement on Form S-3 (File No. 333-256107). We filed a prospectus supplement, dated July 2, 2021, with the SEC in connection with the offer and sale of the shares pursuant to the Sales Agreement. As of December&nbsp;31, 2021, no sales have been made under the Sales Agreement.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued warrants in connection with our securities offerings, SVB loans, and to certain non-employee professional advisers. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="fact-identifier-732" continuedat="i2d25cd6e43c04345940db8d3507cfbd4" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNDI_a42df52f-60b3-45ae-9fb0-ca92d37c0eb4" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Excluding the prefunded warrants we issued in connection with our securities offerings discussed above, the table below summarizes our warrant activity:</ix:nonnumeric></span></span><span><ix:continuation id="i2d25cd6e43c04345940db8d3507cfbd4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:61.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants<br>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>average<br>Exercise<br>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>average<br>Remaining<br>Contract<br>Term<br>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-734" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzEtMS0xLTEtMjY2MzU_598b0ddc-7ba7-4307-9737-44468dc61d3e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,673,551</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="2" name="alpn:ClassOfWarrantOrRightWeightedAverageExercisePriceOutstanding" scale="0" id="fact-identifier-735" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzEtMy0xLTEtMjY2MzU_776c182e-1d96-4c61-b704-d16dc1792eb6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12.74</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" name="alpn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOutstanding" format="ixt-sec:duryear" id="fact-identifier-736" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzEtNS0xLTEtMjY2MzU_171ca1cd-b521-4012-b224-20beb07b0019" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.12</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="alpn:ClassOfWarrantOrRightExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-737" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtMS0xLTEtMzEzMTI_7f867ef0-919c-4cbe-8a81-61570427b7a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,484</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" name="alpn:ClassOfWarrantOrRightWeightedAveragePriceExercised" scale="0" id="fact-identifier-738" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtMy0xLTEtMzEzMTI_4bec1767-fde1-454a-8ef1-88f8d8e68554" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.02</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="alpn:ClassOfWarrantOrRightExpired" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-739" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtMS0xLTEtMzAyMTY_b895d9d7-0180-4b00-8f8a-b45edec106b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,632</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" name="alpn:ClassOfWarrantOrRightWeightedAveragePriceExpired" scale="0" id="fact-identifier-740" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtMy0xLTEtMzAyMTY_5108a4f4-1f25-4696-b66e-1986aa4310ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">97.12</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-741" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtMS0xLTEtMjY2MzU_80c0f462-207e-45d6-b495-aada8e611ec3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,666,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="2" name="alpn:ClassOfWarrantOrRightWeightedAverageExercisePriceOutstanding" scale="0" id="fact-identifier-742" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtMy0xLTEtMjY2MzU_acd3c39c-852e-4992-9a0c-2f82a20b1a14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12.64</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="alpn:ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOutstanding" format="ixt-sec:duryear" id="fact-identifier-743" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzMtNS0xLTEtMjY2MzU_571a75b4-98ed-4e9b-a093-6bcdd6136f42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.12</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="alpn:NumberOfWarrantsAvailableToBeExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-744" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzQtMS0xLTEtMjY2MzU_c3e78c0f-7c7e-422a-b053-b0cb3235c68d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,666,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="2" name="alpn:ClassOfWarrantOrRightWeightedAveragePriceExercisable" scale="0" id="fact-identifier-745" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzQtMy0xLTEtMjY2MzU_a50f66f6-bb98-460e-b6bd-5aac63899a97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12.64</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="alpn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermExercisable" format="ixt-sec:duryear" id="fact-identifier-746" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTo4YWQzYzZmNWRmZjY0MmYyYWUyMzI0MGI0ZGNiZDU4Yy90YWJsZXJhbmdlOjhhZDNjNmY1ZGZmNjQyZjJhZTIzMjQwYjRkY2JkNThjXzQtNS0xLTEtMjY2MzU_8b476c7a-8446-4011-94e7-20fa0c0a3441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.12</ix:nonnumeric></span></span></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018 our stockholders approved, the 2018 Equity Incentive Plan (2018 Plan). Upon adoption, we ceased granting stock awards under the Nivalis Therapeutics, Inc. 2015 Equity Incentive Plan (the 2015 EIP) and the Amended and Restated 2015 Stock Plan (the 2015 Plan), collectively, the Legacy Plans. All shares of common stock subject to awards under the Legacy Plans that expire or terminate without having been exercised in full, or are forfeited to or repurchased by the company, will be added to the 2018 Plan, up to a maximum of <span><ix:nonfraction unitref="shares" contextref="i92f975219deb422cab650fbc8f47a58a_I20180630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-747" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQ0MTc_e3cb727c-6487-4bbe-9780-ffd7510e157b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,972,784</ix:nonfraction></span> shares. In June 2020, in conjunction with our annual meeting of stockholders, our stockholders approved an additional increase of <span><ix:nonfraction unitref="shares" contextref="i319952407da944169e6a39afab11abb1_D20200601-20200630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-748" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQ1NTA_68c81a0a-6f6f-4919-bb6a-5a516b44bb23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">743,515</ix:nonfraction></span> shares authorized under our 2018 Plan.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our 2018 Plan we may issue stock options, stock appreciation rights, restricted stock, RSUs or performance shares. As of December&nbsp;31, 2021 we have only issued stock options and RSUs. Our 2018 Plan provides for an annual increase in the number of shares reserved for insurance equal to the lesser of (1) <span><ix:nonfraction unitref="number" contextref="i3b6d3569bb984c1b81f2fb89e7012f6f_D20180601-20180630" decimals="2" name="alpn:SharebasedCompensationArrangementbySharebasedPaymentAwardAnnualAdditionalSharesAuthorizedPercent" scale="-2" id="fact-identifier-749" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQ5MTM_5c1beaa3-9fea-449f-9f1b-66d9fb9efbf5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5</ix:nonfraction></span>% of the number of shares of common stock outstanding as of the last day of the preceding calendar year or (2) <span><ix:nonfraction unitref="shares" contextref="i68fc51cabc7a4b9f9a3c96c70ed15458_D20180601-20180630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-750" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzUwMjU_b1b8b035-a6c9-4fa8-af95-28784ca55762" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span>. However, our board of directors may act prior to January 1 of a given year to provide that there will be no January 1 increase for such year or that the increase for such year will be a lesser number of shares. On January 1, 2022, a total of <span><ix:nonfraction unitref="shares" contextref="i76e8d3957f4e470691a8e3f87306f2b9_D20220101-20220101" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-751" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzUyNzE_f98ef670-7b36-43af-8a19-fc3715793c71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,500,000</ix:nonfraction></span> additional shares were automatically added to the shares authorized under the 2018 Plan.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, in connection with the merger, we assumed Nivalis Employee Stock Purchase Plan (the ESPP) and the 2015 EIP. Upon assumption of the ESPP, there were <span><ix:nonfraction unitref="shares" contextref="ib8be91d9d31c487bb0337b4b034a9e7c_I20170731" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-752" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzU1Mjg_22fe7887-4f92-43ca-b64c-2be5ed5f43c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">45,211</ix:nonfraction></span> shares available for issuance under the ESPP. As of December&nbsp;31, 2021, we have not activated the ESPP. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under our equity plans generally vest within <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="fact-identifier-753" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzU2ODc_f6444dc1-8099-40e4-b221-e2204ac2d136" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four years</ix:nonnumeric></span> and vested options are exercisable from the grant date until <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="fact-identifier-754" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzU3NTE_cd3a0765-761e-40af-a439-643392eb2826" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span> after the date of grant. Vesting of certain employee options may be accelerated in the event of a change in control of the Company. We grant stock options to employees with exercise prices equal to the fair value of our common stock on the date of grant. The term of incentive stock options may not exceed <span><ix:nonnumeric contextref="i94bbbbf5ff2445589142fe551b2539c4_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="fact-identifier-755" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzYwNjA_a072e049-5389-4b76-bfe6-cc7b73911a41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ten years</ix:nonnumeric></span> from the date of grant. </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i15e76c3eb3cf4cf9877de34e7de97974" continuedat="i4fe357f1c51d42089b7a395319c62bfa" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&nbsp;31, 2021, a total of <span><ix:nonfraction unitref="shares" contextref="i2e5aa97b39d04aae95d242dd56165164_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-757" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzYxNjg_b8eafc90-3960-41af-b46e-db459525666e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,616,862</ix:nonfraction></span> shares of common stock were authorized for issuance under our 2018 Plan, 2015 Plan and 2015 EIP. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="fact-identifier-758" continuedat="i642149d6ff8548e191dd2ddcc7f7a719" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNDM_e025b4d6-a880-46f6-81be-3778de7fcdb7" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">A summary of stock option activity under our plans is presented below:</ix:nonnumeric></span></span></div><div style="margin-top:14pt"><span><ix:continuation id="i642149d6ff8548e191dd2ddcc7f7a719" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>average<br>Exercise<br>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>average<br>Remaining<br>Contract<br>Term<br>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br>Intrinsic<br>Value<br>(in&nbsp;thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib88192ff637346c6adfd814116ed19aa_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-760" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzExLTEtMS0xLTI2NjM1_62bdc5e7-5ef5-4d59-b776-24e1b824e460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,175,345</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ib88192ff637346c6adfd814116ed19aa_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-761" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzExLTMtMS0xLTI2NjM1_59c8badb-455d-4756-8255-4f14f15c8daa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.30</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-762" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzEyLTEtMS0xLTI2NjM1_f488fbd4-f68c-41dc-a0b4-a25f9c05e8f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,940,518</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-763" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzEyLTMtMS0xLTI2NjM1_d39a2d52-36e4-4d22-a473-3fee2321ceaa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.38</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-764" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzEzLTEtMS0xLTI2NjM1_05d193ca-5b79-4bc1-a39c-2bec7a77cf36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,190</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-765" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzEzLTMtMS0xLTI2NjM1_1dc194c4-4ec7-4d7a-a1eb-0a8b81f56f61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.37</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-766" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE0LTEtMS0xLTI2NjM1_d9c5e069-9e5c-4996-b92e-154163a2f8f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">412,930</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-767" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE0LTMtMS0xLTI2NjM1_91e0fd8e-311e-41e2-8aa8-9bb177ce8a5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.88</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-768" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE2LTEtMS0xLTI2NjM1_58d7e6ec-d01a-4287-9f20-5ee6bc80a444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,611,743</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-769" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE2LTMtMS0xLTI2NjM1_2708963a-0a71-4e6e-b696-e596efacd16a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.41</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="fact-identifier-770" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE2LTUtMS0xLTI2NjM1_215dae8e-1c1c-44df-9f3b-cdd0640092a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.41</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-771" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE2LTctMS0xLTI2NjM1_8e0fd264-4256-4202-9858-2e82409baf27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,465</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-772" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE3LTEtMS0xLTI2NjM1_2c3d7d18-4a18-4699-a933-2ba2d30ded04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,471,743</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-773" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE3LTMtMS0xLTI2NjM1_27fdf439-9500-4fae-83b1-29f8772f680f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.38</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="fact-identifier-774" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE3LTUtMS0xLTI2NjM1_13bc6295-b27e-440b-b67f-54eaf3244e8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.37</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-775" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE3LTctMS0xLTI2NjM1_169340ec-88cc-4f72-9be5-2af12ff57b77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">35,685</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-776" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE4LTEtMS0xLTI2NjM1_73d7b650-d828-47f5-98aa-d75b570fd166" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,944,273</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-777" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE4LTMtMS0xLTI2NjM1_53bc1213-abd6-44a1-ae19-188e55fcfefe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="fact-identifier-778" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE4LTUtMS0xLTI2NjM1_16b241a7-7bd3-42cd-aa2c-ba9a46f7d9a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.31</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19b0351e1cc9486ba9a330f995a8dc4e_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-779" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpiNjk2YmQ2MzFlZTM0NmIzYmVlMGYxMjVjMjU2MDQ4ZC90YWJsZXJhbmdlOmI2OTZiZDYzMWVlMzQ2YjNiZWUwZjEyNWMyNTYwNDhkXzE4LTctMS0xLTI2NjM1_b3478611-e73a-428f-b935-b15202bcdab2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26,053</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of stock options exercised during the years ended December&nbsp;31, 2021, 2020 and 2019 was $<span><ix:nonfraction unitref="usd" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-780" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY2Mjk_0d55c1a4-3515-484d-952f-0da6643bcb84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">546,000</ix:nonfraction></span>, $<span><ix:nonfraction unitref="usd" contextref="i4f7052f9f1934696b3a10648c61ff1d0_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-781" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY2MzM_914461e4-e97c-4427-91e8-fcd3fed8bfc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">104,000</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="i8896a776a6e944f6a4c6f4ffd48be081_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-782" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY2NDA_efa1030f-a63f-4fd7-bc6d-ded8a7c54492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">155,000</ix:nonfraction></span>, respectively. The fair value of stock options vested during the years ended December&nbsp;31, 2021, 2020 and 2019 was $<span><ix:nonfraction unitref="usd" contextref="i5268b61f1dc84b8487b8dab9207034c2_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-783" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY3OTg_138f81c2-d44b-44ca-bb19-7472d2fa6809" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.4</ix:nonfraction></span> million, $<span><ix:nonfraction unitref="usd" contextref="i4f7052f9f1934696b3a10648c61ff1d0_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-784" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY4MDI_18e1a4ad-1bd7-403e-9f97-aff007d32e13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.2</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i8896a776a6e944f6a4c6f4ffd48be081_D20190101-20191231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-785" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzY4MDk_23f1ed68-b0b4-44e7-aa60-ed2b1bbded6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.0</ix:nonfraction></span> million, respectively.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="fact-identifier-786" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzcxNDY4MjU2MDg3Njk_3a5915bc-ecc0-4ab2-8f4a-24a62767b992" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSU activity under our plans is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>Average<br>Grant Date Fair Value <br>(per share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br>average<br>Remaining<br>Contract<br>Life<br>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br>Intrinsic<br>Value<br>(in&nbsp;thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i1aca4a3f0af543bdb4d112a177a7741c_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="fact-identifier-787" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzExLTEtMS0xLTM0MTMz_393f604e-2d01-4638-9975-99f8510c4d9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i1aca4a3f0af543bdb4d112a177a7741c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-788" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzExLTMtMS0xLTM0MTMz_57141057-cc27-4683-b81e-a09eeab28124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id0b9f3a08f6e445e807288f2baa56edb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-789" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzEyLTEtMS0xLTM0MTMz_8129052b-ca7c-4132-858f-6fd4ab360af3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,566</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id0b9f3a08f6e445e807288f2baa56edb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-790" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzEyLTMtMS0xLTM0MTMz_fdeeacd9-d88a-4481-a282-e00352469114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.00</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i89883447444d43b880147da6b2fd98ce_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-791" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzEzLTEtMS0xLTM0MTMz_68fb334d-7f83-42bd-a7a2-87b1958afa4b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">265,566</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i89883447444d43b880147da6b2fd98ce_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-792" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzEzLTMtMS0xLTM0MTMz_dd5a87fc-5f94-40f5-a4ed-9a05c98962a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.00</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="id0b9f3a08f6e445e807288f2baa56edb_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="fact-identifier-793" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzEzLTUtMS0xLTM0MTMz_10d3036c-4b51-4a98-82b8-a281c96e6e5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.95</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i89883447444d43b880147da6b2fd98ce_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="fact-identifier-794" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTozMDY5YzU1MTM2OTY0YWJlYTFlNTdlYjQyMDFkODlhYy90YWJsZXJhbmdlOjMwNjljNTUxMzY5NjRhYmVhMWU1N2ViNDIwMWQ4OWFjXzEzLTctMS0xLTM0MTMz_abfa9892-547e-4507-b24f-731bd16496c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">491</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of RSUs released during the years ended December&nbsp;31, 2021 and 2020 was $<span><ix:nonfraction unitref="usd" contextref="id0b9f3a08f6e445e807288f2baa56edb_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="0" id="fact-identifier-795" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1MzgxMTY_a226e814-55aa-4eeb-b8b9-b1fb0e263e2f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="i74885c002f184c33b1b02b9b2e01ebee_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-796" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1Mzc5OTI_2e2bea66-159a-48f5-a207-cbd5f76748cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonfraction></span>&nbsp;million, respectively. The fair value of RSUs vested during the years ended December&nbsp;31, 2021 and 2020 was $<span><ix:nonfraction unitref="usd" contextref="id0b9f3a08f6e445e807288f2baa56edb_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="fact-identifier-797" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1MzgxMjA_680a857a-5700-421d-93c8-0e0fdca771af" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="i74885c002f184c33b1b02b9b2e01ebee_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-798" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1MzgwNzU_9002f60a-ce4a-42bb-8d9d-10c58e459c2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">461,000</ix:nonfraction></span>, respectively. We had <span><ix:nonfraction unitref="usd" contextref="i1eaf7070bec4465887796348dc4e160e_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:fixed-zero" scale="0" id="fact-identifier-799" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE2NDkyNjc0NzE1NTQ_a0f7895d-e60b-46b8-8420-5d6e9383c874" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i1eaf7070bec4465887796348dc4e160e_D20190101-20191231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:fixed-zero" scale="0" id="fact-identifier-800" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzE2NDkyNjc0NzE1NTQ_d17373b8-3c17-4c60-8ea8-507f7667b5ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span> RSU activity for the year ended December 31, 2019.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize newly issued shares to satisfy option exercises and RSU releases. As of December&nbsp;31, 2021, there was $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-801" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1MzY1OTA_97d74ccf-db64-47df-b8be-ed0bfaa8b5b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.4</ix:nonfraction></span> million of unrecognized stock-based compensation expense related to approximately <span><ix:nonfraction unitref="shares" contextref="i15197c79e7fc4158aca6c067db846ed1_I20211231" decimals="-5" name="alpn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-802" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1MzY2Njg_d73fae7d-35e9-46b6-b19f-5f866c96963d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.9</ix:nonfraction></span> million nonvested stock options and RSU awards that are expected to be recognized over a weighted-average period of <span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="fact-identifier-803" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzQzOTgwNDY1MzY3ODA_64f76319-2989-4697-82a0-f1e1820f11ae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.7</ix:nonnumeric></span> years. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs is equal to the closing stock price on the date of grant. We use the Black-Scholes option pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes option pricing model requires us to make certain estimates and assumptions, including assumptions related to the expected price volatility of our stock, the period during which the options will be outstanding, the rate of return on risk-free investments, and the expected dividend yield of our stock. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="fact-identifier-804" continuedat="icf2c626dbb1042f281e1c2497462d0f5" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNTk_68325e17-3fb9-4911-840a-c2374dc56b73" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The fair values of stock options granted to employees were calculated using the following assumptions:</ix:nonnumeric></span></span><span><ix:continuation id="icf2c626dbb1042f281e1c2497462d0f5" continuedat="i6822bf3e365f4193835936e14fa13182" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average estimated fair value at grant</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-806" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzItMS0xLTEtMjY2MzU_78367ad4-2d6f-4fcc-ac5a-9f7f9f38ed29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.44</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-807" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzItMy0xLTEtMjY2MzU_029ba230-13c5-45f4-98d1-e7c169e419a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.03</ix:nonfraction></span></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<span><ix:nonfraction unitref="usdPerShare" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-808" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzItNS0xLTEtMjY2MzU_882fad7d-1ed3-4b3c-8a1a-036d52cba52c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.14</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate (1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="fact-identifier-809" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzMtMS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjoyMjU4ZGY4MmQwMTg0ZTExOGJmMDNlMzA4MjdiNjYxZV80_cf28565e-1250-4a36-b997-86aebe42ff48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.25</ix:nonfraction></span>% - <span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="fact-identifier-810" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzMtMS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjoyMjU4ZGY4MmQwMTg0ZTExOGJmMDNlMzA4MjdiNjYxZV85_9e369fa9-2ad2-4448-a5d4-3895c50b9b5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="fact-identifier-811" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzMtMy0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpiZDIzM2MzMTYxZjU0M2M4YjFiOTZlNjFlMWNhMzE3MF80_d0b37064-f2f9-4896-9b10-cfc396a56063" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.38</ix:nonfraction></span>% - <span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="fact-identifier-812" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzMtMy0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpiZDIzM2MzMTYxZjU0M2M4YjFiOTZlNjFlMWNhMzE3MF85_a119b212-5849-4524-aa9a-83bdc6587976" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.68</ix:nonfraction></span>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="fact-identifier-813" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzMtNS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo4Y2Q4YjI2NjdmZjM0MTczODdhZWY1MjVlY2VhZWVhOV80_e6f1c356-aeaa-468a-a4f3-62fb6f04abe2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.42</ix:nonfraction></span>% - <span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="fact-identifier-814" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzMtNS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo4Y2Q4YjI2NjdmZjM0MTczODdhZWY1MjVlY2VhZWVhOV85_6d028615-7f8c-4938-8532-d2ee72015594" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.63</ix:nonfraction></span>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (in years) (2)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i3122bde756bb405da9845b0b4487e083_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-815" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzQtMS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpmNzgwMzJhMmVhMjE0MTlmYjI5YmZjMTU0OTZjZTg1Ml80_f4b94ed3-9edd-4c6f-8539-7ae38a1ee12d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.49</ix:nonnumeric></span> - <span><ix:nonnumeric contextref="i24fe921914f34cc882da3945c9ad85cc_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-816" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzQtMS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjpmNzgwMzJhMmVhMjE0MTlmYjI5YmZjMTU0OTZjZTg1Ml85_c56f9aca-fba6-4455-902a-1ebbe2ac3751" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.08</ix:nonnumeric></span></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="ie62ad91d10bc4fe4a4e201b2525409b3_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-817" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzQtMy0xLTEtMjY2MzUvdGV4dHJlZ2lvbjozM2EwMWM4ZThkNWE0YTM2YTEzODE3MDI1YWFmYmFkOF80_93d8900d-d69f-4320-8ef7-32ec1a4db2db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.27</ix:nonnumeric></span>  <span><ix:nonnumeric contextref="i340c17cd1eea4f6a995433fc3a407d0c_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-818" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzQtMy0xLTEtMjY2MzUvdGV4dHJlZ2lvbjozM2EwMWM4ZThkNWE0YTM2YTEzODE3MDI1YWFmYmFkOF85_10d05a14-8509-49f4-aa4b-3fd19915000a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.90</ix:nonnumeric></span></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i20e72b63f886405e9244810f0fabe4c0_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-819" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzQtNS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo1ZWU2YmI0MDUyOWQ0MjhlYTE5ZDM2OGQxMDc5OTJjMF80_401f4985-6e7c-438e-bab8-8d4a9dce53ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.27</ix:nonnumeric></span>  <span><ix:nonnumeric contextref="i22001bdad5d845b79c4c231a67c25caf_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="fact-identifier-820" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzQtNS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo1ZWU2YmI0MDUyOWQ0MjhlYTE5ZDM2OGQxMDc5OTJjMF85_e3cf1baa-7e1c-41b1-a83c-ce636c39cc77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.08</ix:nonnumeric></span></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock price volatility (3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="fact-identifier-821" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzUtMS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo1OGVjNjEyYmQ1NDg0YTdlOTJjYjIzMTNlNDRmNTJkNl80_956ced04-9b36-4978-84bc-ecf55d09b1de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79</ix:nonfraction></span>% - <span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="fact-identifier-822" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzUtMS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo1OGVjNjEyYmQ1NDg0YTdlOTJjYjIzMTNlNDRmNTJkNl85_e27fddc9-e6fd-418d-8762-d0d4abc8baa7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83</ix:nonfraction></span>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="fact-identifier-823" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzUtMy0xLTEtMjY2MzUvdGV4dHJlZ2lvbjoyNTRjYTdhNzZjMmQ0ZjNmOWU1ZjkxNjY0NDc5M2E5ZF80_f94a1aae-85e9-431a-a762-c10376ded9ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73</ix:nonfraction></span>% - <span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="fact-identifier-824" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzUtMy0xLTEtMjY2MzUvdGV4dHJlZ2lvbjoyNTRjYTdhNzZjMmQ0ZjNmOWU1ZjkxNjY0NDc5M2E5ZF85_417a1f8a-6a1c-4e40-a42c-7047b60c760a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82</ix:nonfraction></span>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="fact-identifier-825" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzUtNS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo4NWY0NDJiOWIwMzI0MTk1ODY5OTZlY2YzOWY4NGY4N180_d853d076-1b6b-46ec-a9dc-f6c4250366f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70</ix:nonfraction></span>% - <span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="fact-identifier-826" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzUtNS0xLTEtMjY2MzUvdGV4dHJlZ2lvbjo4NWY0NDJiOWIwMzI0MTk1ODY5OTZlY2YzOWY4NGY4N185_ca598bb9-3feb-4580-8734-f75dbdc3069d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">77</ix:nonfraction></span>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield (4)</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-827" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzYtMS0xLTEtMjY2MzU_c8f0b5a5-9b9d-491b-b35d-41a73a74dd51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-828" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzYtMy0xLTEtMjY2MzU_5e189de5-a682-4a06-9368-fbd2d2ec6c9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="fact-identifier-829" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTpkYjdkZmFkMWJlZWQ0YjJlYjVlNjcyOTk2ODY2YmU4Zi90YWJsZXJhbmdlOmRiN2RmYWQxYmVlZDRiMmViNWU2NzI5OTY4NjZiZThmXzYtNS0xLTEtMjY2MzU_ab4d97e5-97a8-4524-b0ff-0d5ced26aa9d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>%</span></td></tr></tbody></table></ix:continuation></span></div><span><ix:continuation id="i6822bf3e365f4193835936e14fa13182" continuedat="i86fc534a384c4fc38dd3ff250cd55cc6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The risk-free interest rate assumption was based on zero-coupon U.S. Treasury instruments that had terms consistent with the expected term of our stock option grants.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We used the simplified method for options to determine the expected term of stock options granted, since we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the </span></div></ix:continuation></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i4fe357f1c51d42089b7a395319c62bfa" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i86fc534a384c4fc38dd3ff250cd55cc6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limited time our shares have been publicly traded. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Volatility is a measure of the amount by which a financial variable, such as share price, has fluctuated or is expected to fluctuate during a period. We analyzed the stock price volatility of companies at a similar stage of development to estimate expected volatility of our stock price.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="fact-identifier-833" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90ZXh0cmVnaW9uOmQ3OGIyMWMwM2M1MzQ5NTlhYWE5M2Q4NDBmYWM0ZTY1XzkwNTE_d3ba14ce-7c35-4946-9645-74aebf51ca6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i75d4456fb1ed409bb59167bcf5c6f56b_157" tabindex="18">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows (in thousands):</span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i77ab615ab1bb47629a6c3ef4f7221a13_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-834" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzMtMS0xLTEtMjY2MzU_ffff7f72-ccec-45e8-867d-cdd34fb33771" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,323</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i09e5e8720481494d800c23fb60f91e5e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-835" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzMtMy0xLTEtMjY2MzU_4d7ac9a9-43c0-4198-9d2d-75ddfbc393ba" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,145</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1a3777ec15ed4679ab515eeddca493ef_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-836" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzMtNS0xLTEtMjY2MzU_7bab4663-906d-4755-a975-660d429920a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,608</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia2d270ec08c748fa85ed7d59442baec1_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-837" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzQtMS0xLTEtMjY2MzU_f7558950-64c5-410c-be25-87fb178f63ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,891</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i22cbaa79a99e44f28f042370da6cdcf2_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-838" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzQtMy0xLTEtMjY2MzU_1a59e13e-226a-40f4-b1c0-48fcd440d125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,955</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if44ed21dacff4c85827cdfea8ea78958_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-839" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzQtNS0xLTEtMjY2MzU_5b01b718-0a9a-450e-8d65-f96b4f294e66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,359</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Employee:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9bb1471e612840b880517cee850835a2_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-840" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzYtMS0xLTEtMjY2MzU_89447afd-cc5e-4ecd-91b7-f1e4e7107805" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i97eab3dab8ef46fea30ead9b87fcff96_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-841" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzYtMy0xLTEtMjY2MzU_7e9f4269-7513-4f89-ae28-dcb055de7e72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">34</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia832c77a80ba48e6baa3930ff9c1d7f9_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-842" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzYtNS0xLTEtMjY2MzU_4ba143cd-fcbe-462c-ae45-63a8ba20fa61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">68</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id2151a39d8864da591888605c608654d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-843" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzctMS0xLTEtMjY2MzU_2e8f9a43-fbd1-4642-af06-a4600b018515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i367ab12b77d04395a7f2a515b8c68b0c_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-844" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzctMy0xLTEtMjY2MzU_54ad5673-8f44-4c58-babf-b02dbdc3f248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i79aaff2fa4d84a01ab4feb086666d7e7_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-845" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzctNS0xLTEtMjY2MzU_cfb9e823-be92-4be2-866a-f173d0585684" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-846" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzgtMS0xLTEtMjY2MzU_89634bb7-478d-4253-a772-d702b8c3a960" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,240</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-847" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzgtMy0xLTEtMjY2MzU_65b29101-0a97-482c-bd42-643952008a64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,140</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-848" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDIvZnJhZzpkNzhiMjFjMDNjNTM0OTU5YWFhOTNkODQwZmFjNGU2NS90YWJsZTplMDE2NDAyZGJlZWY0ZTFlYWJkMjY5ODI2NjUxN2EyMC90YWJsZXJhbmdlOmUwMTY0MDJkYmVlZjRlMWVhYmQyNjk4MjY2NTE3YTIwXzgtNS0xLTEtMjY2MzU_7062fd9d-ac7e-47f7-bd41-7b5400af3873" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,041</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div id="i75d4456fb1ed409bb59167bcf5c6f56b_205"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="fact-identifier-849" continuedat="ia687201e005740aaa8d3e27b9fdee37e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNjE_cae677c1-0e48-4ed5-8ee9-f942dc911e1a" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Income Taxes </ix:nonnumeric></span></span></div><span><ix:continuation id="ia687201e005740aaa8d3e27b9fdee37e" continuedat="i96aff61adb0e4c858b9725f98156c02d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="fact-identifier-851" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNDA_b1035587-1ca1-4da3-8cdb-b5c186c3b460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss before taxes is derived from domestic (United States) and foreign (Australian) sources as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-852" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzItMS0xLTEtMjY2MzU_6981cd08-c79f-4dc8-a63a-d356a8e6488a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,932</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-853" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzItMy0xLTEtMjY2MzU_208b0e11-415a-4fae-b19d-95c74d69cfd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">28,356</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-854" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzItNS0xLTEtMzUyMTY_c5893baf-560b-4b2c-9f9f-3fecf3b32363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,234</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-855" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzMtMS0xLTEtMjY2MzU_e9a83af9-0fc4-4f8d-8121-ac95196d9748" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,488</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-856" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzMtMy0xLTEtMjY2MzU_23d9a283-916b-4cfb-bcb7-2f81619e964e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">410</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-857" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzMtNS0xLTEtMzUyMTY_a2be5431-395c-40d7-9bef-d9a60deae7c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,618</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-858" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzQtMS0xLTEtMjY2MzU_3b8d13ce-8763-4b00-ad6f-a3f17d42a183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,420</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-859" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzQtMy0xLTEtMjY2MzU_f6b27e84-03a6-4139-bc5a-60376da0a35c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,946</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-860" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTo3NzRiNmQ2ZjVjNjc0ODFjODNjNzVhN2FhYWNjNjUxYi90YWJsZXJhbmdlOjc3NGI2ZDZmNWM2NzQ4MWM4M2M3NWE3YWFhY2M2NTFiXzQtNS0xLTEtMzUyMTY_9fba300c-2aaf-4d22-9913-408e82b28483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,852</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="fact-identifier-861" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNDE_83e9343d-23c2-4335-b70d-7c0672d8562b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is composed of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. - Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-862" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzMtMS0xLTEtMjY2MzU_5a3c8df6-8469-452b-8eb1-c44058a8d3ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-863" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzMtMy0xLTEtMjY2MzU_c39670e9-1838-410d-9c3a-ab517311ec6c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-864" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzMtNS0xLTEtMzUyMTg_d346272f-8e09-431f-a730-6a82645b5ab1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-865" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzQtMS0xLTEtMjY2MzU_5bf92a06-4597-4f0b-b0f8-f85ac617a1e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="fact-identifier-866" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzQtMy0xLTEtMjY2MzU_46ec2652-0316-44ed-abaa-921cd6454332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-867" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzQtNS0xLTEtMzUyMTg_bd711c3d-3a6d-4555-89e0-e1c09e4a5f89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-868" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzUtMS0xLTEtMjY2MzU_23d04905-46e5-4673-a35e-8e05495fcdf9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-869" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzUtMy0xLTEtMjY2MzU_c2084762-c8aa-4ab3-900f-450c7bd7feea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-870" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzUtNS0xLTEtMzUyMTg_3a3b40d4-82db-477e-9e7c-65413339e3a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-871" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzYtMS0xLTEtMjY2MzU_f53fe850-65db-4446-b5ce-5bbd5c56878d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-872" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzYtMy0xLTEtMjY2MzU_b46f5541-994e-4f5f-be73-7420230a8a84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-873" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzYtNS0xLTEtMzUyMTg_c4334de3-4e27-495c-b24f-d8cb5bf742ee" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. - Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-874" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzgtMS0xLTEtMjY2MzU_8dbb4276-3783-450a-bace-ae2aac935e45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-875" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzgtMy0xLTEtMjY2MzU_852f225c-1b9c-48ca-9024-e5baf89389e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-876" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzgtNS0xLTEtMzUyMTg_db734760-9ae8-4140-b044-c4be2c5bc9e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-877" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzktMS0xLTEtMjY2MzU_f67ec48c-41d2-42a0-b310-14f135a9e138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-878" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzktMy0xLTEtMjY2MzU_34c92dd7-0a5b-4c73-b18d-b623bbaf7cc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-879" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzktNS0xLTEtMzUyMTg_0a71231e-ea94-46ec-bd48-bf86f163a492" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-880" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzEwLTEtMS0xLTI2NjM1_4b7d0b87-6391-4c2b-b0c0-eefb1ac60c35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">216</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-881" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzEwLTMtMS0xLTI2NjM1_fe318750-e2ae-4edc-9860-b906856ec9a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-882" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzEwLTUtMS0xLTM1MjE4_13dff92d-7e96-4538-91be-49632d214cae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="fact-identifier-883" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzExLTEtMS0xLTI2NjM1_b2e460e7-fc7b-453e-8530-f7965e13fb70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">216</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-884" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzExLTMtMS0xLTI2NjM1_7e9bcae1-8beb-41f7-95d2-47aeb0e37a23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-885" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzExLTUtMS0xLTM1MjE4_caec6ce3-9ea5-4e9e-814a-0dd2f7223b11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-886" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzEyLTEtMS0xLTI2NjM1_1b8c9866-9dfb-4e34-8f37-52f4e411d84c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-887" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzEyLTMtMS0xLTI2NjM1_d6d1b187-1dc9-415d-8b57-b7bce2d430ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="fact-identifier-888" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozNWFmY2E4ODYyOTg0YjY2YTk5NzIwNjdjYzViNjhjNi90YWJsZXJhbmdlOjM1YWZjYTg4NjI5ODRiNjZhOTk3MjA2N2NjNWI2OGM2XzEyLTUtMS0xLTM1MjE4_6d993d0e-5e0c-432d-91ef-2205b8a007bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="i96aff61adb0e4c858b9725f98156c02d" continuedat="ia9081b8c95244b7da05302857e6523d8" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="fact-identifier-890" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNDI_88eb95c0-7d61-475a-9ae7-9c0ca7cdd085" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-891" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzItMS0xLTEtMjY2MzU_904ff3fb-cb89-4c93-b832-1b8302039ef8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-892" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzItMy0xLTEtMjY2MzU_4cf4f649-be77-42b4-a7da-0b207d154d11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-893" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzItNS0xLTEtMzUyMjA_821f70f2-2145-44ba-a542-05635ce5b8e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" name="alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="fact-identifier-894" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzUtMS0xLTEtMjY2MzU_c909ee22-1081-46f9-842e-c529cbbf495b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.4</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" sign="-" name="alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="fact-identifier-895" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzUtMy0xLTEtMjY2MzU_8ac0f385-bdff-4fed-8468-41f740d18dbc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="alpn:EffectiveIncomeTaxRateReconciliationPermanentDifferences" scale="-2" id="fact-identifier-896" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzUtNS0xLTEtMzUyMjA_5f48617f-20c6-4646-9daa-56a14fce9485" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="fact-identifier-897" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzYtMS0xLTEtMjY2MzU_9712bb97-1535-4ea0-ac50-2caa42b7d5b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="fact-identifier-898" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzYtMy0xLTEtMjY2MzU_e377ebb2-8f3a-48b6-b377-807e383f6c58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="fact-identifier-899" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzYtNS0xLTEtMzUyMjA_f7ece36b-9690-4331-aef4-56e5af38f156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-900" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzctMS0xLTEtMjY2MzU_099e5c80-9ab8-4b63-9873-56f16e2756eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.4</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-901" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzctMy0xLTEtMjY2MzU_26963b30-e414-47ae-8f73-2398cb52831d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.7</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-902" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzctNS0xLTEtMzUyMjA_b7ca2ec2-3d80-4252-8a55-f2a874b20d31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19.8</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income recapture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" sign="-" name="alpn:EffectiveIncomeTaxRateReconciliationIncomeRecapturePercent" scale="-2" id="fact-identifier-903" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzctMS0xLTEtMzc2MjA_8aa44a3e-7ed7-4353-b3b8-2213f884f18e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.4</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" name="alpn:EffectiveIncomeTaxRateReconciliationIncomeRecapturePercent" format="ixt:fixed-zero" scale="-2" id="fact-identifier-904" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzctMy0xLTEtMzc2MjM_07ca015b-16b1-40ea-aeb6-2795089c3356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="alpn:EffectiveIncomeTaxRateReconciliationIncomeRecapturePercent" format="ixt:fixed-zero" scale="-2" id="fact-identifier-905" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzctNS0xLTEtMzc2MjQ_030f8e61-3d81-4d3f-aa01-38a92b57aebc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="fact-identifier-906" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzktMS0xLTEtMjY2MzU_5d9acec9-4efa-4347-bc79-f8683c7cf317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.8</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="fact-identifier-907" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzktMy0xLTEtMjY2MzU_2675b836-7e2b-47db-9c5f-b61cd3a7879b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.8</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="fact-identifier-908" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzktNS0xLTEtMzUyMjA_6be36f7e-3e91-44a7-8a10-bb04b827200c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-909" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzEzLTEtMS0xLTI2NjM1_6ca21004-29ca-4f44-80a1-38d9ffe9adb7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-910" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzEzLTMtMS0xLTI2NjM1_b47f2e0e-cbb3-4ef5-9e20-4a6eb8c2d5a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-911" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzEzLTUtMS0xLTM1MjIw_e86aa109-0aa7-459e-a535-f43d73669970" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="fact-identifier-912" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzE0LTEtMS0xLTI2NjM1_7c1feaa3-fb47-49a8-994f-593ca78db58e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="fact-identifier-913" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzE0LTMtMS0xLTI2NjM1_49306404-4bd8-49b3-a413-ff2a4cbd8531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="fact-identifier-914" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzE0LTUtMS0xLTM1MjIw_4068a070-af74-4d98-bfd4-cc005f483480" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-915" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzE1LTEtMS0xLTI2NjM1_080ca1bf-89aa-47e7-a3b7-81026bded9dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="fact-identifier-916" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzE1LTMtMS0xLTI2NjM1_0a42c63d-0e41-4482-8892-117224daaf51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="fact-identifier-917" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTpmMmNiMTNlYTgxYjY0Mzc1OTU5NGY2ODJhYzU5YmM4MS90YWJsZXJhbmdlOmYyY2IxM2VhODFiNjQzNzU5NTk0ZjY4MmFjNTliYzgxXzE1LTUtMS0xLTM1MjIw_f4645492-ba99-4caf-ab2c-d68c8252f089" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded tax benefits of $<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-918" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzEwOTk1MTE2MzMyMzM_61ed3fb8-1bb7-4593-a94d-176c2bee97cd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,000</ix:nonfraction></span>, $<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-919" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzEwMjM_7b5310df-b6f0-4f1f-83e9-0431e929d992" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,000</ix:nonfraction></span>, and $<span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="fact-identifier-920" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzEwOTk1MTE2MzM0NzA_51367277-65a8-4fe6-bf93-5d9608d6dc16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span>, representing effective tax rates of <span><ix:nonfraction unitref="number" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-921" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzEwOTk1MTE2MzM0OTY_8178eb1d-2b86-4d7c-a3e0-4537c9ad2c41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span>% for the year ended December&nbsp;31, 2021, and <span><ix:nonfraction unitref="number" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-922" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzExMjk_163b9841-855c-4283-a8ab-f94250136204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="number" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-923" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzExMjk_cf0923f7-0b70-43cb-b42d-98c572df569f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.0</ix:nonfraction></span></ix:nonfraction></span>%, for the years ended December&nbsp;31, 2020 and 2019, respectively. The $<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-924" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzEwOTk1MTE2MzQ1MDc_69525e67-906d-4a4b-b481-739b7ee70373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,000</ix:nonfraction></span> tax benefit for the year ended December&nbsp;31, 2021 represents deferred tax benefits from true-ups and the removal of the valuation allowance in place against our foreign deferred tax assets, partially offset by income tax expense for current year activity.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the U.S. federal statutory tax rates of 21% and our effective tax rate in all periods is primarily due to changes in our valuation allowance related to our deferred tax assets and the generation and consumption of federal research and development tax credits. We have elected to treat taxes due on future U.S. inclusions in taxable income under the global intangible low-taxed income (GILTI) provision as a current-period expense when incurred. As such, expected future GILTI inclusions have not been factored into the measurement of our deferred taxes.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="fact-identifier-925" continuedat="i75da54e3a9dd49a1ae780bfe1a06e1a6" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNDY_7ef403db-f051-4f1b-b767-b6fb97bbcb82" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table represents the significant components of our deferred tax assets and liabilities for the periods presented (in thousands):</ix:nonnumeric></span></span><span><ix:continuation id="i75da54e3a9dd49a1ae780bfe1a06e1a6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-927" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzMtMS0xLTEtMjY2MzU_6c028a56-12a4-4631-aaa6-257e4c460af1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,054</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-928" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzMtMy0xLTEtMjY2MzU_22d4573c-fee2-4dc4-ba95-9043882c5430" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,992</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-929" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzUtMS0xLTEtMjY2MzU_af965ad1-3c9f-4d6a-98c4-b90c3ec1617d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,297</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-930" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzUtMy0xLTEtMjY2MzU_672d6c01-2ad3-48c5-a096-4973f3463e8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,044</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="alpn:DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" scale="3" id="fact-identifier-931" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzYtMS0xLTEtMjY2MzU_7495fd51-0a51-49ac-add7-e72aa58beb75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">13</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="alpn:DeferredTaxAssetsAttributableToDeductibleAndNonDeductibleGoodwillAndIntangibleAssets" scale="3" id="fact-identifier-932" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzYtMy0xLTEtMjY2MzU_729191b1-dc3a-4b96-88e2-766c2b1d6959" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">24</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="alpn:DeferredTaxAssetLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-933" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzctMS0xLTEtMjY2MzU_ef36beec-90cb-4576-82da-62ae4da019db" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="alpn:DeferredTaxAssetLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-934" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzctMy0xLTEtMjY2MzU_16876053-9ed6-4ec3-9537-647cb5907823" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,619</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-935" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzgtMS0xLTEtMzc2MzU_12db49f1-8c70-41eb-b5bd-4675db13f426" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,333</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:fixed-zero" scale="3" id="fact-identifier-936" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzgtMy0xLTEtMzc2MzY_f0e651f6-c213-4b23-ad50-55843f7e30b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-937" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzEwLTEtMS0xLTI2NjM1_b7a4377e-fc3c-4816-b445-292b15675a1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,672</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-938" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzEwLTMtMS0xLTI2NjM1_6ba74626-f354-47d1-9a4b-86243e134b0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,337</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-939" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzExLTEtMS0xLTI2NjM1_1c4b8545-982f-49f6-bd16-20f5168fac46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">217</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-940" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzExLTMtMS0xLTI2NjM1_7e49bbc7-4c3c-4551-adab-e55916cf6d3c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-941" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzEyLTEtMS0xLTI2NjM1_7c8dd299-da99-4bec-8b79-fac4222d58e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41,062</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-942" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzEyLTMtMS0xLTI2NjM1_5a75f25c-534a-4467-a643-eeb3ea9432e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">30,088</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-943" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzEzLTEtMS0xLTI2NjM1_f1ce5752-fc40-4fae-8ace-b0c8d785cad7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,752</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-944" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzEzLTMtMS0xLTI2NjM1_13cc53f6-bdcd-415a-aae2-2eb886478be7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,851</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-945" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE0LTEtMS0xLTI2NjM1_a7e5955a-875a-4572-9edc-0c6dfa066e0d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,310</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-946" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE0LTMtMS0xLTI2NjM1_fcfaf2c1-c46c-4fea-b63d-a2e4e48d169d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,237</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="fact-identifier-947" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE2LTEtMS0xLTI2NjM1_16a23845-4374-4eb5-93ce-5733a80d9d23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">147</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="fact-identifier-948" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE2LTMtMS0xLTI2NjM1_82e372a9-f198-453d-b279-4863a21b7d63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">125</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset basis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="fact-identifier-949" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE3LTEtMS0xLTI2NjM1_fca537a2-e3e2-48ad-805b-5beddd8c1736" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">93</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="fact-identifier-950" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE3LTMtMS0xLTI2NjM1_0c683b19-2b5f-4959-a839-6cbd3599a7b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-951" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE4LTEtMS0xLTI2NjM1_2584b6c8-97e5-4252-8329-67e7df690949" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,856</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-952" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzE4LTMtMS0xLTI2NjM1_f20a4519-7cde-415e-b69d-242e753c7763" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,975</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-953" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzIwLTEtMS0xLTI2NjM1_8f1f2a2e-f5b5-452a-a4ad-265852317730" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,096</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-954" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzIwLTMtMS0xLTI2NjM1_faf5b9ad-2c26-4124-bda8-3a1120f85cac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,237</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets and liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="fact-identifier-955" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzIxLTEtMS0xLTI2NjM1_ecb0aca5-257f-4762-b16e-37bf9b78286f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">214</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="fact-identifier-956" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZToxZDVlMTM4YzVkY2Y0NDUwYmUxNDI5MTBmMGUyNzczYS90YWJsZXJhbmdlOjFkNWUxMzhjNWRjZjQ0NTBiZTE0MjkxMGYwZTI3NzNhXzIxLTMtMS0xLTI2NjM1_f58b07ce-e9fa-419a-8643-ca6032b65dbb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is provided for deferred tax assets where the recoverability of the assets is uncertain. The determination to provide a valuation allowance is dependent upon the assessment of whether it is more likely than not that sufficient taxable income will be generated to utilize the deferred tax assets. For the year ended December&nbsp;31, 2021, we determined that based on an evaluation of the four sources of income and all available evidence, both positive and negative, including our latest forecasts and cumulative losses in recent years, it was more likely than not that none of our domestic deferred tax assets would be realized and therefore we continued to record a full valuation allowance. For the year ended </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><span><ix:continuation id="ia9081b8c95244b7da05302857e6523d8" continuedat="i742cae0c4f7046d18a5dc612934d4614" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&nbsp;31, 2021, we determined that it was more likely than not that our foreign deferred tax assets would be realized. As such, we removed the valuation allowance previously in place against our foreign deferred tax assets as we have generated sufficient foreign taxable income to utilize all historical operating losses and are expecting future foreign taxable income. The valuation allowance increased by $<span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-958" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzIzNjA_5a685c30-921c-4f42-b306-deec8b1fe59f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.9</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-959" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzIzNjc_5d786b47-c616-4f20-99a2-6452ce650b4f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.8</ix:nonfraction></span> million during the year ended December&nbsp;31, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="fact-identifier-960" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNjM_bff2e0b3-0359-4b45-a174-cfc5e7f57041" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have net operating loss (NOL) carryforwards as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal (before January 1, 2018)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i577d5843a4f74cb2bbcec261be5d6d4f_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-961" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzItMS0xLTEtMjY2MzU_c96d1f2f-a53d-409f-ac0a-93beaf4abf67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,094</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iadf8aefc9b9a4e28bae5dccfc69dd77e_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-962" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzItMy0xLTEtMjY2MzU_febfd637-c172-4e33-86fa-db7af851025e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,094</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibe1f107ab72d4110a5e915a7f041b1f9_I20191231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-963" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzItNS0xLTEtMzc2NDE_f57baf02-75f2-4347-9d0e-3fdd1e1d662a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,094</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal (after January 1, 2018)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i585c2562ce674120b62d30847e189adc_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-964" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzMtMS0xLTEtMjY2MzU_6ff86e4f-ee90-4fcd-b5f1-ce3a031b58ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,592</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9ce1e29137a74b5bafb32effd358f488_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-965" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzMtMy0xLTEtMjY2MzU_38f65e19-5735-491d-882d-130693e5831a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,868</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i66d2f911cf0e487dab40fd6658396735_I20191231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-966" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzMtNS0xLTEtMzc2NDE_eb5c1927-6d55-4dd9-b60c-27fb40bde7f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">67,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i43fa42d2304d44a58722229d29c67a48_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-967" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzQtMS0xLTEtMjY2MzU_dd23329f-bfbb-4167-8e3a-bfea8cfd195c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,433</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i48656f99e5a945c1857a4e605d7f5e2c_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-968" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzQtMy0xLTEtMjY2MzU_902dec3d-7e34-4232-a9bd-d4bbb2839f9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,433</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i83c91e71c8fc454dbca0620bea64ea0c_I20191231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-969" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzQtNS0xLTEtMzc2NDE_12a7cd36-474b-4214-93f5-d78e415502d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,433</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iee75049cfece4bb491b857c973622337_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-970" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzUtMS0xLTEtMjY2MzU_2dacab86-7f15-4d6d-9688-ead5d99a94eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6a5e81dc1b884809b82fecca810b65fa_I20201231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="3" id="fact-identifier-971" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzUtMy0xLTEtMjY2MzU_a05a12f0-46e7-4b69-b44d-9b26e3b6236c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3c40c23209da440fac6f64dc973f7914_I20191231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" scale="3" id="fact-identifier-972" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTozYTZjOGNjMGUxZmE0ZmVhYjQxY2I3YmQ1YjgzNGJjMi90YWJsZXJhbmdlOjNhNmM4Y2MwZTFmYTRmZWFiNDFjYjdiZDViODM0YmMyXzUtNS0xLTEtMzc2NDE_9b7d3df1-9045-4626-8e71-3efe51de6814" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">787</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal NOL carryforwards created before January 1, 2018 begin to expire in 2037. Federal NOL carryforwards created after January 1, 2018 carryforward indefinitely. State NOL carryforwards begin to expire in 2038. Foreign NOLs carryforward indefinitely. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="fact-identifier-973" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNDg_61313591-242e-4b9d-b297-12ad158ca67a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have net research and development tax credit carryforwards as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0184f3a0824e486d8c8bb1c1dcf3ee8d_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-974" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTowNGJkODQ2MGFkZmU0ODEyYmY5MTg0NzUxODQxZmNjZC90YWJsZXJhbmdlOjA0YmQ4NDYwYWRmZTQ4MTJiZjkxODQ3NTE4NDFmY2NkXzItMS0xLTEtMjY2MzU_d154c442-c651-4625-9687-60ee06712e4f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,880</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id7372e514e8e45f19127e257f82cbd72_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-975" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTowNGJkODQ2MGFkZmU0ODEyYmY5MTg0NzUxODQxZmNjZC90YWJsZXJhbmdlOjA0YmQ4NDYwYWRmZTQ4MTJiZjkxODQ3NTE4NDFmY2NkXzItMy0xLTEtMjY2MzU_02d0b3d5-eba2-4a16-896e-b7fbdbc2211e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,063</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iafcf19971b8d49fbaf8dcd14cb3233d6_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-976" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTowNGJkODQ2MGFkZmU0ODEyYmY5MTg0NzUxODQxZmNjZC90YWJsZXJhbmdlOjA0YmQ4NDYwYWRmZTQ4MTJiZjkxODQ3NTE4NDFmY2NkXzItNS0xLTEtMzc2NDQ_cadd881e-4bea-41de-a663-c5170d36e3d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,986</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal research and development tax credit carryforwards begin to expire in 2035.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current tax laws impose substantial restrictions on the utilization of research and development credit and NOL carryforwards in the event of an ownership change, as defined by the Internal Revenue Code Section 382 and 383. Such an event may limit our ability to utilize NOLs and research and development tax credit carryforwards. Under Internal Revenue Code Section 382 and 383, the 2017 merger with Nivalis is likely considered an ownership change with respect to the potential limitation of the Nivalis federal tax credits and NOLs. As such, it is likely that any future utilization of Nivalis federal tax credits and NOLs is substantially limited. Therefore, as of December 31, 2018, all Nivalis tax credit and NOL carryforwards have been reduced to <span><ix:nonfraction unitref="usd" contextref="i4a59584cefcd451891ad490590ce1e9e_I20181231" decimals="INF" name="alpn:TaxCreditAndNetOperatingLossCarryforwards" format="ixt:fixed-zero" scale="0" id="fact-identifier-977" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzM2MzU_0e1a5c7e-0c88-4d01-9f86-db03f809965b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">zero</ix:nonfraction></span>.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertainty in income taxes in accordance with ASC 740. Tax positions are evaluated in a two-step process, whereby we first determine whether it is more likely than not that a tax position will be sustained upon examination by the tax authority, including resolutions of any related appeals or litigation processes, based on technical merit. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="fact-identifier-978" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzUzNTM_c7225e38-c8d6-4a4f-b29c-71759c110d58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&nbsp;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized benefits  beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-979" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzItMS0xLTEtMjY2MzU_ff270833-4e82-404a-88c2-1f2e31873746" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">990</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-980" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzItMy0xLTEtMjY2MzU_6f6fe987-52e3-4aa1-b516-11894a867a16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">775</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8071de4bb91440b9adb67a4f284b30fe_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-981" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzItNS0xLTEtNDA3MTI_b8c9e7fe-9906-4280-8fb1-285fe8cb8d42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">469</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases (decreases)  prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="fact-identifier-982" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzMtMS0xLTEtMjY2MzU_3bdac215-7402-4648-be96-937a90bf3091" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-983" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzMtMy0xLTEtMjY2MzU_616dc87b-be1e-41cd-8500-fb68b494d700" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="fact-identifier-984" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzMtNS0xLTEtNDA3MTI_5e03883f-e628-4976-adef-b52ab8c64cc9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases  current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="fact-identifier-985" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzQtMS0xLTEtMjY2MzU_7758e728-9c7e-4087-b6bd-e027031af853" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">563</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04ddeb4f6b044879bee7334fa92c50e7_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="fact-identifier-986" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzQtMy0xLTEtMjY2MzU_f426a380-0013-4996-957c-cc024a5e0d84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">222</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9299e82dfae4c4cae91d97f273d7db6_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="fact-identifier-987" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzQtNS0xLTEtNDA3MTI_ab0866cb-6f7c-4d7d-b1d7-ce3a5fe1d1dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">306</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized benefit  end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="fact-identifier-988" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzUtMS0xLTEtMjY2MzU_d408aad0-6aa3-4ac9-8a30-46476304225f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,553</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-989" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzUtMy0xLTEtMjY2MzU_bd97a350-eafa-43e9-92a5-3ab1f8d288ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">990</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-990" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90YWJsZTphZmVhYjViYjFkZDQ0MWQ0YmQ2YjdhZjZkMDI4OWJkZS90YWJsZXJhbmdlOmFmZWFiNWJiMWRkNDQxZDRiZDZiN2FmNmQwMjg5YmRlXzUtNS0xLTEtNDA3MTI_2dd1aaff-937e-449a-a848-60701876d7f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">775</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the unrecognized tax benefits as of December&nbsp;31, 2021 are accounted for as a reduction in our deferred tax assets. Due to our valuation allowance, <span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:fixed-zero" scale="0" id="fact-identifier-991" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzE2NDkyNjc0NTg4OTE_d29b5fb2-f141-419e-b6c8-84efd9c8c351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">none</ix:nonfraction></span> of the $<span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-992" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzQ1NTI_e0ef4416-d783-4a40-abe2-d9a9d212c70e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonfraction></span> million of unrecognized tax benefits would affect our effective tax rate, if recognized. We do not believe it is reasonably possible that our unrecognized tax benefits will significantly change in the next twelve months.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to unrecognized tax benefits as income tax expense. There were <span><ix:nonfraction unitref="usd" contextref="i34c6dea4e05b47c3bbfc5b38122ed075_I20191231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="fact-identifier-993" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzQ4NzU_77cb2fe4-77a6-420d-a64f-6e7a92c90d8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="iefc5e0f908c041b189c9615068048458_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="fact-identifier-994" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzQ4NzU_e9dd20e4-2493-45ac-b218-57558dac5979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i963ab54fb1c14a5c9f6b44f38e016825_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="fact-identifier-995" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDUvZnJhZzoyZTAyYmNhZTAwYzc0MWJhODI2ZjNhMjkzYzc4OTY5NC90ZXh0cmVnaW9uOjJlMDJiY2FlMDBjNzQxYmE4MjZmM2EyOTNjNzg5Njk0XzQ4NzU_fcb88405-b598-4ae1-9897-082b29b949ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span> accrued interest or penalties related to unrecognized tax benefits for 2021, 2020 and 2019.</span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect any significant change in our unrecognized tax benefits during the next twelve months.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALPINE IMMUNE SCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)</span></div></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i742cae0c4f7046d18a5dc612934d4614" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Our material income tax jurisdictions are the United States (federal), California (state), and Australia (foreign). We are subject to audit for tax years 2012 and forward for federal purposes, 2017 and forward for California purposes, and 2019 and forward for foreign purposes.</ix:continuation></span></span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_208"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="fact-identifier-997" continuedat="ief18fd1e1bbc457ca5a45735bdc9e6c6" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzUyNg_bf60c4a7-a520-4a44-8dbc-f26e85aa1b9f" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Related Party Transactions</ix:nonnumeric></span></span></div><span><ix:continuation id="ief18fd1e1bbc457ca5a45735bdc9e6c6" continuedat="i4a6dde77962f43c7b1d4e0ce871265c5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, in connection with our 2021 Securities Purchase Agreement we issued <span><ix:nonfraction unitref="shares" contextref="i1d8decf993a445a1b3d01f6914b305e0_D20210901-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-999" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzE2NDkyNjc0NDQyOTA_3fab9931-4a89-402a-9de7-af1b6403b6f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,723,402</ix:nonfraction></span> shares of common stock and <span><ix:nonfraction unitref="shares" contextref="i68b5b7144bc845a7b7e702990f1139fd_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1000" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzE2NDkyNjc0NDQyNTY_9863d0cc-5cee-4bee-8302-02a15d7a46de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,340,424</ix:nonfraction></span> prefunded warrants to purchase shares of common stock for gross proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="i7f1ad68d3fab4425afdbf0d151e4af91_D20210901-20210930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1001" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzE2NDkyNjc0NDQyNTU_f8591b95-e514-445c-90b0-80a841c3bb29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">57.0</ix:nonfraction></span>&nbsp;million to certain of our stockholders whose beneficial ownership exceeded <span><ix:nonfraction unitref="number" contextref="i466a64b6d0a7497e9142d4a02fd6c42c_I20210930" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="fact-identifier-1002" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzEwOTk1MTE2MzAzMDk_899dfe5d-cf28-44e4-8283-2a1d314cc9bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>% prior to the completion of the 2021 Securities Purchases Agreement. Also in September 2021, we exchanged an aggregate of <span><ix:nonfraction unitref="shares" contextref="i433869c2192449498bb8e2059fa6ee05_D20210901-20210930" decimals="INF" sign="-" name="alpn:StockIssuedDuringPeriodSharesExchangeForPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1003" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzE2NDkyNjc0NTAzMzQ_e991b922-2c86-4005-833d-f662b8d8fbb6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,200,000</ix:nonfraction></span> shares of common stock held Frazier Life Sciences VIII, L.P. for Prefunded Warrants to purchase an aggregate of <span><ix:nonfraction unitref="shares" contextref="i06c6336b2fd648c58cb6ff26ceb0bec0_I20210930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1004" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzE2NDkyNjc0NTAzNTU_bb1528ab-8854-41f2-a1eb-6bed038d3566" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,200,000</ix:nonfraction></span> shares of common stock. </span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the purchasers in the July 2020 private placement was a greater than <span><ix:nonfraction unitref="number" contextref="id10fcca6dd424b65a308430ebbc6a412_I20200731" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="fact-identifier-1005" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzM4NDgyOTA2OTc5NTE_1d4bac44-04bf-4d3e-9e2f-f152fc4e9a24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>% holder of our outstanding capital stock prior to the July 2020 private placement. </span></div></ix:continuation></span><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i4a6dde77962f43c7b1d4e0ce871265c5" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In January 2019, in connection with our 2019 Securities Purchase Agreement we sold an aggregate of <span><ix:nonfraction unitref="shares" contextref="i9be77689b7604ed0a6842a08b5bc1cea_D20190101-20190131" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1007" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzExOQ_7728045f-4045-418e-b829-2a30d85fd45b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">935,753</ix:nonfraction></span> shares of common stock and issued warrants to purchase an aggregate of <span><ix:nonfraction unitref="shares" contextref="i2e8a974826dd41e1bcdbabb957b91c43_I20190131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="fact-identifier-1008" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzE5Mw_c00d0fc0-2d6e-40df-8e64-0cc30942542b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">364,943</ix:nonfraction></span> shares of common stock for gross proceeds of approximately $<span><ix:nonfraction unitref="usd" contextref="ic061b92b614844538355b5488516f87d_D20190101-20190131" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="fact-identifier-1009" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzI1NQ_f370afe9-3f53-4e6c-b48e-9b84ef0eb1a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span> million to certain of our <span><ix:nonfraction unitref="number" contextref="i9cd1403bd64f4ad1bf977722324b29fb_I20190131" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="fact-identifier-1010" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMDgvZnJhZzoyNzM0YmY0ZTBmYzE0Mjc3YWI3NjU1NWNmNzUwMTU3ZS90ZXh0cmVnaW9uOjI3MzRiZjRlMGZjMTQyNzdhYjc2NTU1Y2Y3NTAxNTdlXzI3Ng_0ad2a1b7-6681-4bd4-8307-09d7f6b35c9d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>% stockholders.</ix:continuation></span> </span></div><div id="i75d4456fb1ed409bb59167bcf5c6f56b_211"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i5d424f18d33b43e3bcd1251e8055a555_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="fact-identifier-1011" continuedat="i77c7a254345c487197785960b25ad82e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOjc1ZDQ0NTZmYjFlZDQwOWJiNTkxNjdiY2Y1YzZmNTZiL3NlYzo3NWQ0NDU2ZmIxZWQ0MDliYjU5MTY3YmNmNWM2ZjU2Yl8yMTEvZnJhZzphODdlODM4M2U4YjY0ZDhmYWM3ZmY3NDg4YWU4OTNmYi90ZXh0cmVnaW9uOmE4N2U4MzgzZThiNjRkOGZhYzdmZjc0ODhhZTg5M2ZiXzIxOQ_00d054d6-6c6f-4f67-a761-f5b96ee008aa" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">401(k) Retirement Plan</ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i77c7a254345c487197785960b25ad82e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">We have adopted a 401(k) plan. All employees are eligible to participate, provided they meet the requirements of the plan. Through December&nbsp;31, 2021, we have not matched employee contributions to the plan. Beginning in 2022, we will match the employees 401(k) contributions, at our discretion and not to exceed a prescribed annual limit.</ix:continuation></span> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div>

</body>
</html>